WO2008043857A2 - Novel method of treatment of male sub-fertility - Google Patents

Abstract

There is provided a method of treatment of male sub-fertility by using a vitamin D compound. Compositions and uses are also provided.

Description

NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY

Field of the Invention

The present invention relates to novel uses and methods, and compounds for use therein, specifically the use of vitamin D compounds for treating male sub- fertility.

Background of the Invention

Male infertility or sub-fertility is a significant problem which can be a cause of distress and anguish amongst couples and may have a deleterious effect on society and economic wellbeing of nations generally.

It has been estimated that the prevalence of infertility in industrialized countries is approximately 15% (Bruckert et al. 1991; Forti and Krausz 1998, Juul et al. 1999). As male causes for infertility are found in half of involuntarily childless couples, it must be assumed that about 7% of all men are confronted with the problem of disturbed fertility in the course of their lives (Nieschlag and Behre, 2000). This means that the prevalence of infertility in men clearly exceeds that of diabetes mellitus, which is often considered almost endemic.

Male infertility can be divided into three major categories: i) pretesticular (mainly endocrine causes); ii) testicular (mainly cryptochidism, varicocele, genetic causes) and iii) post- testicular causes. This last category (which account about 15-20% of cases) includes accessory gland infections, prostate gland pathologies such as prostatitis and benign prostatic hyperplasia, immunological infertility of autoimmune origin (characterized by the presence of Anti Sperm Antibody (Naz and Menge (1994) Fertil Steril 61, 1001-1013), and infertility characterized by the presence in the seminal plasma of pro -inflammatory molecules with no sign of concomitant infection. The World Health Organisation (1992) has laid down certain criteria for the determination of key parameters relevant to male fertility. These include measurement of ejaculate volume, pH, sperm density, motility, morphology and viability, and concentration of certain factors within seminal fluid, partcularly energy sources such as fructose.

Sub-optimal readings in these parameters, and especially sperm density, motility, morphology and viability, can be expected to have a negative impact on the fertility of the individual.

IL-8 is an inflammatory chemokine functioning primarily as a neutrophil chemoattractant and activating factor, but can also recruit basophils and T cells, and is a potent angiogenic factor (Baggiolini et al, 1995). IL-8 is secreted by multiple cell types and exerts its effects by binding with high affinity to two cell surface receptors, the chemokine receptors CXCRl and CXCR2 (Baggiolini et al, 1995). IL-8 plays an important role in different inflammatory diseases, like rheumatoid arthritis (DeBenedetti et al, 1999), gastritis (Shimada et al, 1998), inflammatory bowel disease (McCormack et al, 2001) atherosclerosis (Boisvert et al, 2000) and inflammatory lung disease (Pease et al, 2002).

Infections/inflammation of the seminal ducts can lead to male infertility by different mechanisms. Direct damage is caused by microorganisms or their secretory products, while secondary inflammation is produced by increased numbers of activated leucocytes and an elevated secretion of cytokines and chemokines. In addition, increased formation of reactive oxygen species (ROS) can reduce the fertilization capacity of the spermatozoa (De Geyter et al. 1994, Krausz et al. 1994, Comhaire et al. 1999a)

Whilst the presence of IL-8 in human seminal plasma has been largely demonstrated, the correlation between the levels of this chemokine in the seminal plasma and semen parameters is controversial: Eggert-Kruse et al. 2001 and Sanocka et al. 2003, describe that individuals presenting high concentration of IL-8 in seminal plasma have significantly lower progressive motility and total sperm count per ejaculate, Maegawa et al.2002 and Shimoya et al. 1993 report a correlation between IL8 levels and leukocyte presence in the seminal plasma. However, Comhaire et al. 1994, Dousset et al. 1997, Koumentakis et al. 1998, Furuya et al. 2003, Friebe et al. 2003, Matalliotakis et al. 1998 report that IL-8 levels are not correlated with semen parameters.

Apart from antibiotics, largely used in case of urogential infections (both acute or chronic), there is no successful therapy for chronic abacteric inflammation of the urogential tract. Similarly, there is no validated therapy for reduced sperm motility associated with high ROS or to high levels of proinflammatory chemo/cytokines. Antioxidant therapy with Vitamin C and E and carnitine gave inconsistent results (Mahmoud et al. 1999; Comhaire 1999b). The same situation has been observed for symptomatic therapies with anti-inflammatory drugs.

The immunomodulatory treatment of infertile men with anti-sperm antibodies with Vitamin D3 in association with dexamethasone has been proposed (Bubanovic et al (2004), but the therapeutic potential of Vitamin D3 and related compounds by themselves has never been tested.

Reproductive capacity of animals with vitamin D deficiency has been studied: a vitamin D deficient state leads to reduced fertility both in male and female rodents. Diet supplementation with calcium, as well as vitamin D, restores fertility in the tested animals. Thus, low calcium rather than low vitamin D per se, has been said to be responsible for reproductive failure in such animals (see Uhland et al (1991) J Nutrition 122, 1338-1344 and Johnson et al (2001) J Nutrition 131, 1787-1791). In particular, in the male reproductive system, calcium is a well known mediator of maturation and capacitation of sperm cells. Also, calcium is involved in the acrosome reaction of the sperm cell and in the sperm-egg interaction.

US4970203 A (Deluca et al) discloses a method of improving the fertility and reproductive capacity of male and female mammals by administering a vitamin D compound. This document discusses fertility from a very general perspective, without any focus on males and does not teach any impact of vitamin D compounds on semen quality.

US2003/0166622A1 (Steinmeyer et al) discloses vitamin D derivatives, process for production and the use for production of pharmaceutical agents. The document discusses a range of inidications, without any particular focus on fertility, nor specifically on male fertility, and does not teach any impact of vitamin D compounds on semen quality

The inventors have discovered that elevated levels of IL-8 in seminal plasma are correlated with prostatic disease, and IL-8 levels correlate with semen parameters in individuals with subfertility. Furthermore, the inventors have discovered that levels of IL-8 in benign prostatic hyperplasia (BPH) cells can in vitro be decreased by treatment with vitamin D compounds. The inventors have also discovered that in CP patients levels of IL-8 (as well as levels of other inflammatory markers) in seminal plasma can be decreased by treatment with vitamin D compounds. In particular, the inventors have invented a new treatment for male sub-fertility based on treatment of males with vitamin D compounds to lower inflammatory markers such as IL-8 in seminal plasma and improve semen quality. Summary of the Invention

The present inventors have developed a new method of treating male sub- fertility, with a view to mitigating or alleviating the aforementioned disadvantages. The method is based on the use of calcitriol and analogues thereof, collectively referred to herein as "vitamin D compounds". The importance of vitamin D (cholecalciferol) in the biological systems of higher animals has been recognized since its discovery by Mellanby in 1920 (Mellanby, E. (1921) Spec. Rep. Ser. Med. Res. Council (GB) SRS 61 :4). It was in the interval of 1920-1930 that vitamin D officially became classified as a "vitamin" that was essential for the normal development of the skeleton and maintenance of calcium and phosphorus homeostasis. Studies involving the metabolism of vitamin D₃ were initiated with the discovery and chemical characterization of the plasma metabolite, 25-hydroxyvitamin D₃ [25(OH) D₃] (Blunt, J. W. et al. (1968) Biochemistry 6:3317-3322) and the hormonally active form, 1- alpha,25(OH)₂D₃ (Myrtle, J.F. et al. (1970) J. Biol. Chem. 245:1190-1196; Norman, A.W. et al. (1971) Science 173:51-54; Lawson, D.E.M. et al. (1971) Nature 230:228-230; Holick, M.F. (1971) Proc. Natl. Acad. Sci. USA 68:803-804). The formulation of the concept of a vitamin D endocrine system was dependent both upon appreciation of the key role of the kidney in producing l-alpha,25 (OH)₂Ds in a carefully regulated fashion (Fraser, D. R. and Kodicek, E (1970) Nature 288:764-766; Wong, R.G. et al. (1972) J. Clin. Invest. 51 :1287-1291), and the discovery of a nuclear receptor for l-alpha,25(OH)₂D₃ (VD₃R) in the intestine (Haussler, M. R. et al. (1969) Exp. Cell Res. 58:234-242; Tsai, H.C. and Norman, A.W. (1972) J. Biol. Chem. 248:5967-5975).

The operation of the vitamin D endocrine system depends on the following: first, on the presence of cytochrome P450 enzymes in the liver (Bergman, T. and Postlind, H. (1991) Biochem. J. 276:427-432; Ohyama, Y and Okuda, K. (1991) J. Biol. Chem. 266:8690-8695) and kidney (Henry, HX. and Norman, A.W. (1974) J. Biol. Chem. 249:7529-7535; Gray, R.W. and Ghazarian, J. G. (1989) Biochem. J. 259:561-568), and in a variety of other tissues to effect the conversion of vitamin D₃ into biologically active metabolites such as l-alpha,25 (OH)₂D₃ and 24R,25 (OH)₂Ds; second, on the existence of the plasma vitamin D binding protein (DBP) to effect the selective transport and delivery of these hydrophobic molecules to the various tissue components of the vitamin D endocrine system (Van Baelen, H. et al. (1988) Ann NY Acad. Sci. 538:60-68; Cooke, N.E. and Haddad, J.G. (1989) Endocr. Rev. 10:294-307; Bikle, D.D. et al. (1986) J. Clin. Endocrinol. Metab. 63:954-959); and third, upon the existence of stereoselective receptors in a wide variety of target tissues that interact with the agonist 1- alpha,25(OH)₂D3 to generate the requisite specific biological responses for this secosteroid hormone (Pike, J.W. (1991) Annu. Rev. Nutr. 11 :189-216). To date, there is evidence that nuclear receptors for 1 -alp ha,25 (OH)₂Ds (VD₃R) exist in more than 30 tissues and cancer cell lines (Reichel, H. and Norman, A.W. (1989) Annu. Rev. Med. 40:71-78), including the normal eye (Johnson JA et al. Curr Eye Res. 1995 Feb; 14(2): 101-8).

Vitamin D₃ and its hormonally active forms are well-known regulators of calcium and phosphorus homeostasis. These compounds are known to stimulate, at least one of, intestinal absorption of calcium and phosphate, mobilization of bone mineral, and retention of calcium in the kidneys. Furthermore, the discovery of the presence of specific vitamin D receptors in more than 30 tissues has led to the identification of vitamin D₃ as a pluripotent regulator outside its classical role in calcium/bone homeostasis. A paracrine role for 1 -alp ha,25 (OH)₂ D3 has been suggested by the combined presence of enzymes capable of oxidizing vitamin D3 into its active forms, e.g., 25-OHD-l -alp ha- hydroxylase, and specific receptors in several tissues such as bone, keratinocytes, placenta, and immune cells. Moreover, vitamin D3 hormone and active metabolites have been found to be capable of regulating cell proliferation and differentiation of both normal and malignant cells (Reichel, H. et al. (1989) Ann. Rev. Med. 40: 71-78).

Given the activities of vitamin D3 and its metabolites, much attention has focused on the development of synthetic analogues of these compounds. A large number of these analogues involve structural modifications in the A ring, B ring, C/D rings, and, primarily, the side chain (Bouillon, R. et al. (1995) Endocrine Reviews 16(2):201-204). Although a vast majority of the vitamin D3 analogues developed to date involve structural modifications in the side chain, a few studies have reported the biological profile of A-ring diastereomers (Norman, A.W. et al. (1993) J. Biol. Chem. 268 (27): 20022-20030). Furthermore, biological esterification of steroids has been studied (Hochberg, R.B., (1998) Endocr. Rev. 19(3): 331-348), and esters of vitamin D₃ are known (WO 97/11053).

Moreover, despite much effort in developing synthetic analogues, clinical applications of vitamin D and its structural analogues have been limited by the undesired side effects elicited by these compounds after administration to a subject for known indications/applications of vitamin

D compounds.

The activated form of vitamin D, vitamin D3, and some of its analogues have been described as potent regulators of cell growth and differentiation. It has previously been found that vitamin D3 as well as an analogue (analogue V), inhibited BPH cell proliferation and counteracted the mitogenic activity of potent growth factors for BPH cells, such as keratinocyte growth factor (KGF) and insulin-like growth factor (IGFl). Moreover, the analogue induced bcl-2 protein expression, intracellular calcium mobilization, and apoptosis in both unstimulated and KGF-stimulated BPH cells. As described in the Examples herein, the inventors have found that vitamin D compounds, such as Compound A, can lower IL-8 levels in vitro and can lower seminal IL-8 levels in human patients.

Thus, in one aspect, the invention provides the use of a vitamin D compound in the treatment of male sub- fertility. Also provided is a method for the treatment of sub-fertility in a male subject by administering an effective amount of a vitamin D compound. Further provided is the use of a vitamin D compound in the manufacture of a medicament for the treatment of male sub- fertility. Further provided is a vitamin D compound for use in the treatment of male sub- fertility. Also provided is a kit containing a vitamin D compound together with instructions directing administration of said compound to a subject in need of treatment for male sub-fertility thereby to treat male sub-fertility in said subject.

In one embodiment, the male subject has a vitamin D deficiency. In another embodiment, the male subject does not have a vitamin D deficiency.

Suitably the treatment by vitamin D compounds has no impact on calcium homeostasis in the subject. In one aspect, the invention provides a method of treatment of male sub-fertility using a vitamin D compound.

In another aspect, the invention provides a method for treatment of male sub-fertility in a subject, comprising administering to a subject in need thereof an effective amount of a vitamin D compound, such that male sub- fertility is treated in the subject. In one embodiment, the invention provides a method as described above, further comprising identifying a subject in need of treatment of male sub- fertility. In another embodiment, the invention provides a method as described above, further comprising the step of obtaining the vitamin D compound. In one embodiment of the methods described herein, the subject is a mammal. In a further embodiment, the subject is a human. In another embodiment, the invention provides a method as described herein wherein the vitamin D compound is formulated in a pharmaceutical composition together with a pharmaceutically acceptable diluent or carrier. In another aspect, the invention provides a use of a vitamin D compound in the manufacture of a medicament for the treatment of male sub- fertility.

In another aspect, the invention provides a pharmaceutical formulation comprising a vitamin D compound and a pharmaceutically acceptable carrier for use in the treatment of male sub- fertility.

In yet another aspect, the invention provides a pharmaceutical formulation comprising a vitamin D compound and a pharmaceutically acceptable carrier packaged with instructions for use in the treatment of male sub- fertility.

In another aspect, the invention provides a vitamin D compound for use in the treatment of male sub- fertility.

The invention provides for a kit containing a vitamin D compound together with instructions directing administration of said compound to a subject in need of the treatment of male sub- fertility thereby to treat male sub- fertility in said subject.

In one embodiment, the invention provides for the use, method, formulation, compound or kit, wherein the vitamin D compound is administered separately, sequentially or simultaneously in separate or combined pharmaceutical formulations with a second medicament for the treatment of male sub- fertility.. In another embodiment, the invention provides for the use, method, formulation, compound or kit, wherein said vitamin D compound is calcitriol, Compounds A-G as defined below. Most preferably the vitamin D compound is Compound A.

Brief Description of the Drawings

Figure 1 shows level of IL-8 in stimulated BPH cells in response to vitamin D compound treatment

Figure 2 shows correlation of seminal plasma IL-8 level with sperm motility in prostatic disease patients

Figure 3 shows correlation of seminal plasma IL-8 level with sperm motility in males of infertile couples

Figure 4 shows correlation of seminal plasma IL-8 level with semen parameters in males of infertile couples Figure 5 shows change in level of inflammatory markers (and in the case of TIMP-I an inhibitor of an inflammatory marker) in seminal fluid of subjects treated with placebo or Compound A.

Detailed Description of the Invention Before further description of the present invention, and in order that the invention may be more readily understood, certain terms are first defined and collected here for convenience.

By "male sub- fertility" is meant a deficient or sub-optimal fertility in males as demonstrated, for example, by poor semen quality. By "poor semen quality" is meant a lower than average read-out in a measurement of one or more relevant criteria including: ejaculate volume, pH, sperm count, motility, morphology and viability, and concentration of energy sources such as fructose, and particularly sperm count, motility, morphology and/and viability, and especially sperm motility. By "treatment" when used herein in respect of the treatment of male sub-fertility is meant treatment leading to improvement in male fertility (eg as indicated by an increase in sperm motility).

By "improvement in male fertility" or "improvement in fertility" (in the context of male fertility) is meant an improvement in actual fertility (likelihood of conception) or an improvement in parameters related to or predictive of fertility such as semen quality.

Specifically, improvement in semen quality means improvement in one or more of the following parameters: ejaculate volume, pH, sperm density, motility, morphology and viability, and concentration of energy sources such as fructose, and most particularly sperm density, motility, morphology and/and viability. By "vitamin D deficiency" is meant a condition which can result from: inadequate intake coupled with inadequate sunlight exposure, disorders that limit its absorption, conditions that impair conversion of vitamin D into active metabolites, such as liver or kidney disorders, or, rarely, by a number of hereditary disorders. Deficiency results in altered calcium homeostasis leading to impaired bone mineralization, bone softening diseases, rickets in children and osteomalacia in adults, and may contribute to osteoporosis.

The male sub-fertility that may be treated according to the present invention may, in particular, be associated with elevated IL-8 in seminal plasma. It may also be associated with elevated levels of other inflammatory markers such as MCP-I, IP-IO, MIP-Ia, MIP-Ib, MMP-2, MMP-9 and PTX3. Sub-fertile subjects that may be treated may, for example, suffer from BPH. Other sub-fertile subjects that may be treated may, for example, suffer from CP eg CP category III (pelvic pain the absence of demonstrable bacterial infection) (also known as chronic pelvic pain syndrome (CPPS)), specifically divided into category IIIA (inflammatory) or IIIB (noninflammatory) based on the presence of leukocytes in expressed prostatic secretion or seminal plasma respectively . Other sub-fertile subjects that may be treated may, for example, not present with anti-sperm antibodies. Presence of anti-sperm antibodies is typically determined from blood serum (see eg Bubanovic et al (2004) infra).

"Elevated IL-8 levels" mean a level of IL-8 in seminal plasma which is greater (eg at least 25% greater, for example at least 50% greater perhaps at least 100% greater) than that typically found in a population of individual males not presenting with sub- fertility. A typical normal level of IL-8 in seminal plasma is 3.75% ng/ml. Reference to elevated levels of other inflammatory markers may be interpreted similarly.

"Prostatic disease" includes BPH and chronic prostatitis. Those skilled in the art will recognise that the vitamin D compounds may be used in human or veterinary medicine. Thus, in accordance with the invention, the terms "subject" and "patient" are used interchangeably, and are intended to include mammals, for example, humans. It is preferred that the vitamin D compound be used in the treatment of male sub-fertility in human patients.

The term "administration" or "administering" includes all routes of introducing the vitamin D compound(s) to a subject to perform their intended function. Examples of routes of administration which can be used include injection (subcutaneous, intravenous, parenterally, intraperitoneally), or administration by oral, inhalation, rectal or transdermal routes or via urethral instillation. The pharmaceutical preparations are, of course, given by forms suitable for each administration route. For example, these preparations are administered in tablets or capsule form, by injection, infusion, inhalation, lotion, ointment, suppository, etc. Oral administration is preferred. The injection can be bolus or can be continuous infusion. Depending on the route of administration, the vitamin D compound can be coated with or disposed in a selected material to protect it from natural conditions which may detrimentally affect its ability to perform its intended function. The vitamin D compound can and preferably will be administered alone, or alternatively may be administered in conjunction with either another agent useful in the treatment of male sub-fertility (for example antibiotics, anti- inflammatory compounds eg corticosteroids such as dexamethasone, anti-oxidants), or with a pharmaceutically-acceptable carrier, or both. The vitamin D compound can be administered prior to the administration of the other agent, simultaneously with the agent, or after the administration of the agent. Furthermore, the vitamin D compound can also be administered in a pro-form which is converted into its active metabolite, or more active metabolite in vivo.

The term "effective amount" includes an amount effective, at dosages and for periods of time necessary, to achieve the desired result, i.e. sufficient to treatment of male sub- fertility. An effective amount of vitamin D compound may vary according to factors such as the causative background (eg underlying disease state or condition involved), age and weight of the subject, and the ability of the vitamin D compound to elicit a desired response in the subject. Dosage regimens may be adjusted to provide the optimum prophylactic response. An effective amount is also one in which any toxic or detrimental effects {e.g., side effects) of the vitamin D compound are outweighed by the prophylactically beneficial effects.

An effective amount of vitamin D compound {i.e., an effective dosage) may range from about 0.001 to 30 ug/kg body weight, preferably about 0.01 to 25 ug/kg body weight, more preferably about 0.1 to 20 ug/kg body weight, and even more preferably about 1 to 10 ug/kg, 2 to 9 ug/kg, 3 to 8 ug/kg, 4 to 7 ug/kg, or 5 to 6 ug/kg body weight per day. The skilled artisan will appreciate that certain factors may influence the dosage required to effectively treat male sub- fertility in a subject, including but not limited to the severity of the condition, previous treatments, the general health and/or age of the subject, and other diseases present. In addition, the dose administered will also depend on the particular vitamin D compound used, the effective amount of each compounds can be determined by titration methods known in the art. The treatment of male sub-fertility in a subject with an effective amount of a vitamin D compound will typically involve a series of administrations. In one example, a subject is administered a vitamin D compound in the range of between about 0.1 to 20 ug/kg body weight, one time per day for one or two weeks or more. As a specific example a compound such as Compound A may be administered at an oral dose of 150ug per day eg for a period of 12 weeks or more. An "on-off ' or intermittent administration regime can also be considered. It will be appreciated that the effective dosage of a vitamin D compound used for the treatment of male sub-fertility may increase or decrease over the course of a particular period of administration. The term "alkyl" refers to the radical of saturated aliphatic groups, including straight- chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. The term alkyl further includes alkyl groups, which can optionally further include (for example, in one embodiment alkyl groups do not include) oxygen, nitrogen, sulfur or phosphorus atoms replacing one or more carbons of the hydrocarbon backbone, e.g., oxygen, nitrogen, sulfur or phosphorus atoms. In preferred embodiments, a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C1-C30 for straight chain, C3-C30 for branched chain), preferably 26 or fewer, and more preferably 20 or fewer, especially 6 or fewer. Likewise, preferred cycloalkyls have from 3- 10 carbon atoms in their ring structure, and more preferably have 3, 4, 5, 6 or 7 carbons in the ring structure.

Moreover, the term alkyl as used throughout the specification and claims is intended to include both "unsubstituted alkyls" and "substituted alkyls," the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. It will be understood by those skilled in the art that the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate. Cycloalkyls can be further substituted, e.g., with the substituents described above. An "alkylaryl" moiety is an alkyl substituted with an aryl (e.g., phenylmethyl (benzyl)).

Unsubstituted alkyl (including cycloalkyl) groups or groups substituted by halogen, especially fluorine, are generally preferred over other substituted groups. The term "alkyl" also includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively.

Unless the number of carbons is otherwise specified, "lower alkyl" as used herein means an alkyl group, as defined above, but having from one to ten carbons, more preferably from one to six, and most preferably from one to four carbon atoms in its backbone structure, which may be straight or branched-chain. Examples of lower alkyl groups include methyl, ethyl, propyl (n- propyl and i-propyl), butyl (tert-butyl, n-butyl and sec-butyl), pentyl, hexyl, heptyl, octyl and so forth. In preferred embodiment, the term "lower alkyl" includes a straight chain alkyl having 4 or fewer carbon atoms in its backbone, e.g., C1-C4 alkyl. Thus specific examples of alkyl include C 1-6 alkyl or Ci-4alkyl (such as methyl or ethyl).

Specific examples of hydroxy alkyl include Ci-βhydroxyalkyl or Ci-₄hydroalkyl (such as hy droxymethy 1) .

The terms "alkoxyalkyl," "polyaminoalkyl" and "thioalkoxyalkyl" refer to alkyl groups, as described above, which further include oxygen, nitrogen or sulfur atoms replacing one or more carbons of the hydrocarbon backbone, e.g., oxygen, nitrogen or sulfur atoms.

The term "aryl" as used herein, refers to the radical of aryl groups, including 5- and 6- membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, pyrrole, furan, thiophene, imidazole, benzoxazole, benzothiazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like. Aryl groups also include polycyclic fused aromatic groups such as naphthyl, quinolyl, indolyl, and the like.

Those aryl groups having heteroatoms in the ring structure may also be referred to as "aryl heterocycles," "heteroaryls" or "heteroaromatics." The aromatic ring can be substituted at one or more ring positions with such substituents as described above, as for example, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, amino carbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Aryl groups can also be fused or bridged with alicyclic or heterocyclic rings which are not aromatic so as to form a polycycle (e.g., tetralin).

The terms "alkenyl" and "alkynyl" refer to unsaturated aliphatic groups analogueous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond, respectively. For example, the invention contemplates cyano and propargyl groups. The term "chiral" refers to molecules which have the property of non-superimposability of the mirror image partner, while the term "achiral" refers to molecules which are superimposable on their mirror image partner.

The term "diastereomers" refers to stereoisomers with two or more centers of dissymmetry and whose molecules are not mirror images of one another.

The term "enantiomers" refers to two stereoisomers of a compound which are non- superimposable mirror images of one another. An equimolar mixture of two enantiomers is called a "racemic mixture" or a "racemate."

As used herein, the term "halogen" designates -F, -Cl, -Br or -I; the term "sulfhydryl" or "thiol" means -SH; the term "hydroxyl" means -OH.

The term "haloalkyl" is intended to include alkyl groups as defined above that are mono- , di- or polysubstituted by halogen, e.g., Ci-βhaloalkyl or Ci-₄haloalkyl such as fluoromethyl and trifluoromethyl.

The term "heteroatom" as used herein means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, sulfur and phosphorus.

The terms "polycyclyl" or "poly cyclic radical" refer to the radical of two or more cyclic rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls) in which two or more carbons are common to two adjoining rings, e.g., the rings are "fused rings". Rings that are joined through non-adjacent atoms are termed "bridged" rings. Each of the rings of the polycycle can be substituted with such substituents as described above, as for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, amino carbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkyl, alkylaryl, or an aromatic or heteroaromatic moiety.

The term "isomers" or "stereoisomers" refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space. The terms "isolated" or "substantially purified" are used interchangeably herein and refer to vitamin D₃ compounds in a non-naturally occurring state. The compounds can be substantially free of cellular material or culture medium when naturally produced, or chemical precursors or other chemicals when chemically synthesized. In one embodiment of the invention an isolated vitamin D compound is at least 75% pure, especially at least 85% pure, in particular at least 95% pure and preferably at least 99% pure on a w/w basis, said purity being by reference to compounds with which the vitamin D compound is naturally associated or else chemically associated in the course of chemical synthesis. In certain preferred embodiments, the terms "isolated" or "substantially purified" also refer to preparations of a chiral compound which substantially lack one of the enantiomers; i.e., enantiomerically enriched or non-racemic preparations of a molecule.

Similarly, the terms "isolated epimers" or "isolated diastereomers" refer to preparations of chiral compounds which are substantially free of other stereochemical forms. For instance, isolated or substantially purified vitamin D3 compounds include synthetic or natural preparations of a vitamin D₃ enriched for the stereoisomers having a substituent attached to the chiral carbon at position 3 of the A-ring in an alpha-configuration, and thus substantially lacking other isomers having a beta-configuration. Unless otherwise specified, such terms refer to vitamin D₃ compositions in which the ratio of alpha to beta forms is greater than 1 : 1 by weight. For instance, an isolated preparation of an a epimer means a preparation having greater than 50% by weight of the alpha-epimer relative to the beta stereoisomer, more preferably at least 75% by weight, and even more preferably at least 85% by weight. Of course the enrichment can be much greater than 85%, providing "substantially epimer-enriched" preparations, i.e., preparations of a compound which have greater than 90% of the alpha-epimer relative to the beta stereoisomer, and even more preferably greater than 95%. The term "substantially free of the beta stereoisomer" will be understood to have similar purity ranges.

As used herein, the term "vitamin D compound" includes any compound being an analogue of vitamin D that is capable of treating male sub- fertility. Generally, compounds which are ligands for the Vitamin D receptor (VDR ligands) and which are capable of treating male sub-fertility are considered to be within the scope of the invention. Vitamin D compounds are preferably agonists of the vitamin D receptor. Thus, vitamin D compounds are intended to include secosteroids. Examples of specific vitamin D compounds suitable for use in the methods of the present invention are further described herein. A vitamin D compound includes vitamin D₂ compounds, vitamin D3 compounds, isomers thereof, or derivatives/analogues thereof. Preferred vitamin D compounds are vitamin D3 compounds which are ligands of (more preferably are agonists of) the vitamin D receptor. Preferably the vitamin D compound (e.g., the vitamin D₃ compound) is a more potent agonist of the vitamin D receptor than the native ligand (i.e., the vitamin D, e.g., vitamin D3). Vitamin Di compounds, vitamin D₂ compounds and vitamin D3 compounds include, respectively, vitamin D₁, D₂, D3 and analogues thereof. In certain embodiments, the vitamin D compound may be a steroid, such as a secosteroid, e.g., calciol, calcidiol or calcitriol. Non- limiting examples of certain preferred vitamin D compounds in accordance with the invention include those described in U.S. Patent No. 6,492,353 and published international applications WO 2005/030222. As used herein, the term "obtaining" includes purchasing, synthesizing, isolating or otherwise acquiring one or more of the the vitamin D compounds used in practicing the invention. The term "secosteroid" is art-recognized and includes compounds in which one of the cyclopentanoperhydro-phenanthrene rings of the steroid ring structure is broken. For example, l-alpha,25 (OH)₂Ds and analogues thereof are hormonally active secosteroids. In the case of vitamin D₃, the 9-10 carbon-carbon bond of the B-ring is broken, generating a seco-B-steroid. The official IUPAC name for vitamin D3 is 9,10-secocholesta-5,7,10(19)-trien-3B-ol. For convenience, a 6-s-trans conformer of l-alpha,25 (OH)₂Ds is illustrated herein having all carbon atoms numbered using standard steroid notation.

In the formulas presented herein, the various substituents on ring A are illustrated as joined to the steroid nucleus by one of these notations: a dotted line ( — ) indicating a substituent which is in the beta-orientation (i.e. , above the plane of the ring), a wedged solid line (^•*) indicating a substituent which is in the alpha-orientation (i.e. , below the plane of the molecule), or a wavy line ( ^^^^ ) indicating that a substituent may be either above or below the plane of the ring. In regard to ring A, it should be understood that the stereochemical convention in the vitamin D field is opposite from the general chemical field, wherein a dotted line indicates a substituent on Ring A which is in an alpha-orientation (i.e. , below the plane of the molecule), and a wedged solid line indicates a substituent on ring A which is in the beta-orientation (i.e. , above the plane of the ring).

Furthermore the indication of stereochemistry across a carbon-carbon double bond is also opposite from the general chemical field in that "Z" refers to what is often referred to as a "cis" (same side) conformation whereas "E" refers to what is often referred to as a "trans" (opposite side) conformation. Regardless, both configurations, cis/trans and/or Z/E are contemplated for the compounds for use in the present invention.

As shown, the A ring of the hormone l-alpha,25(OH)₂D3 contains two asymmetric centers at carbons 1 and 3, each one containing a hydroxyl group in well-characterized configurations, namely the 1 -alpha- and 3-beta- hydroxyl groups. In other words, carbons 1 and 3 of the A ring are said to be "chiral carbons" or "carbon centers."

With respect to the nomenclature of a chiral center, terms "d" and "1" configuration are as defined by the IUPAC Recommendations. As to the use of the terms, diastereomer, racemate, epimer and enantiomer will be used in their normal context to describe the stereochemistry of preparations.

Also, throughout the patent literature, the A ring of a vitamin D compound is often depicted in generic formulae as any one of the following structures:

wherein Xi and X₂ are defined as H or =CH₂; or

wherein Xi and X₂ are defined as H₂ or CH₂.

Although there does not appear to be any set convention, it is clear that one of ordinary skill in the art understands either formula (A) or (B) to represent an A ring in which, for example, Xi is =CH₂ and X₂ is defined as H₂ , as follows:

For purposes of the instant invention, formula (B) will be used in all generic structures.

In one embodiment of the invention, the vitamin D compound is a compound of formula

(I):

(I) wherein:

X is hydroxy 1 or fluoro; Y is H₂ or CH₂;

Zi and Z₂ are H or a substituent represented by formula (II), provided Zi and Z₂ are different (preferably Zi and Z₂ do not both represent formula (H)):

wherein:

Z3 represents the above-described formula (I);

A is a single bond or a double bond;

R₁, R₂, and Z₄, are each, independently, hydrogen, alkyl, or a saturated or unsaturated carbon chain represented by formula (III), provided that at least one of Ri, R₂, and Z₄ is the saturated or unsaturated carbon chain represented by formula (III) and provided that all of Ri, R₂, and Z₄ are not saturated or unsaturated carbon chain represented by formula (III):

wherein:

Z₅ represents the above-described formula (II);

A₂ is a single bond, a double bond, or a triple bond; and

A₃ is a single bond or a double bond; and

R₃, and R₄, are each, independently, hydrogen, alkyl, haloalkyl, hydroxyalkyl; and R₅ is H₂ or oxygen. R₅ may also represent hydrogen or may be absent.

Thus, in the above structure of formula (III) (and in corresponding structures below), when A₂ represents a triple bond R5 is absent. When A₂ represents a double bond R5 represents hydrogen. When A₂ represents a single bond R5 represents a carbonyl group or two hydrogen atoms. In another embodiment of the invention, the vitamin D compound is a compound of formula (IV):

wherein: Xi and X₂ are H₂ or CH₂, wherein Xi and X₂ are not CH₂ at the same time;

A is a single or double bond; A₂ is a single, double or triple bond; A3 is a single or double bond;

Ri and R₂ are hydrogen, Ci -C₄ alkyl or 4-hydroxy-4-methylpentyl, wherein Ri and R₂ are not both hydrogen;

R₅ is H₂ or oxygen, R₅ may also represent hydrogen or may be absent; R₃ is C₁-C₄ alkyl, hydroxyalkyl or haloalkyl, eg., fluoroalkyl, e.g., fluoromethyl and trifluoromethyl; and

R₄ is C₁-C₄ alkyl, hydroxyalkyl or haloalkyl, eg., fluoroalkyl, e.g., fluoromethyl and trifluoromethyl .

In yet another embodiment of the invention, the vitamin D compound is a compound of formula (V):

wherein:

Xi and X₂ are H₂ or CH₂, wherein Xi and X₂ are not CH₂ at the same time;

A is a single or double bond;

A₂ is a single, double or triple bond; A3 is a single or double bond;

Ri and R₂ are hydrogen, Ci -C₄ alkyl, wherein Ri and R₂ are not both hydrogen;

R₅ is H₂ or oxygen, R₅ may also represent hydrogen or may be absent;

R₃ is C₁-C₄ alkyl, hydroxyalkyl or haloalkyl, e.g., fluoroalkyl, e.g., fluoromethyl and trifluoromethyl; and

R₄ is C₁-C₄ alkyl, hydroxyalkyl haloalkyl, e.g., or fluoroalkyl, e.g., fluoromethyl and trifluoromethyl.

An example of the above structure of formula (V) is l,25-dihydroxy-16-ene-23-yne cholecalciferol. In yet another embodiment, the vitamin D compound is a "geminal" compound of formula (VI):

wherein: Xi is H₂ or CH₂; A₂ is a single, a double or a triple bond;

R₃ is C₁-C₄ alkyl, hydroxyalkyl, or haloalkyl, e.g., fluoroalkyl, e.g., fluoromethyl and trifluoromethyl;

R₄ is C₁-C₄ alkyl, hydroxyalkyl or haloalkyl, e.g., fluoroalkyl, e.g., fluoromethyl and trifluoromethyl; and the configuration at C₂o is R or S.

Compounds of this type may be referred to as "geminal" or "gemini" vitamin D3 compounds due to the presence of two alkyl chains at C20.

An example geminal compound of formula (VI) is l,25-dihydroxy-21-(3-hydroxy-3- methylbutyl)-19-nor-cholecalciferol (elsewherein herein referred to as "Compound B"):

The synthesis of l,25-dihydroxy-21-(3-hydroxy-3-methylbutyl)-19-nor-cholecalciferol is described in WO 98/49138 and US 6,030,962, the disclosures of which are incorporated herein by reference. The synthesis is described below in Example 2.

In another embodiment, the vitamin D compound is a compound of formula (VII):

wherein:

A is a single or double bond;

Ri and R₂ are each, independently, hydrogen, alkyl (for example methyl);

R3, and R₄, are each, independently, alkyl, and

X is hydroxy 1 or fluoro.

In a further embodiment, the vitamin D compound is a compound having formula (VIII):

wherein:

Ri and R₂, are each, independently, hydrogen, or alkyl, e.g., methyl;

R₃ is alkyl, e.g., methyl,

R₄ is alkyl, e.g., methyl; and

X is hydroxy 1 or fluoro.

In specific embodiments of the invention, the vitamin D compound is selected from the group consisting of:

In other specific embodiments of the invention, the vitamin D compound is selected from the group consisting of:

In further specific embodiments of the invention, the vitamin D compound is selected from the group of geminal compounds consisting of:

In yet another aspect, the invention provides Gemini vitamin D₃ compounds of formula

(IX):

wherein:

Ai is a single or double bond;

A₂ is a single, a double or a triple bond;

R₁, R₂, R3 and R₄ are each independently Ci -C₄ alkyl, Ci -C₄ deuteroalkyl, hydroxyalkyl, or haloalkyl;

R5, Re and R₇ are each independently hydroxyl, OC(O)Ci-C₄ alkyl, OC(O)hydroxyalkyl, or OC(O)haloalkyl; the configuration at C20 is R or S;

Xi is H₂ or CH₂; Z is hydrogen when at least one of Ri and R₂ is Ci-C₄ deuteroalkyl and at least one OfR₃ and R₄ is haloalkyl or when at least one of Ri and R₂ is haloalkyl and at least one OfR₃ and R₄ is Ci-C₄ deuteroalkyl; or Z is -OH, =0, -SH, or -NH₂; and pharmaceutically acceptable esters, salts, and prodrugs thereof.

Various embodiments of this aspect of the invention include individual compounds of formula I wherein: Ai is a single bond; A₂ is a single bond; A₂ is a triple bond; R₁, R₂, R₃, and R₄ are each independently methyl or ethyl; R₁, R₂, R₃, and R₄ are each independently Ci-C₄ deuteroalkyl or haloalkyl; R5 is hydroxyl; R₆ and R₇ are hydroxyl; R₆ and R₇ are each OC(O)C₁- C₄ alkyl; Xi is H₂; Xi is CH₂; Z is hydrogen; or Z is =0.

In certain embodiments, R5, R₆ and R₇ are hydroxyl. In other embodiments, R₆ and R₇ are each acetyloxy. In yet other embodiments, Z is hydrogen when at least one of Ri and R₂ is Ci -C₄ deuteroalkyl and at least one OfR₃ and R₄ is haloalkyl or when at least one of Ri and R₂ is haloalkyl and at least one of R₃ and R₄ is Ci-C₄ deuteroalkyl; Z is

-OH, =0, -SH, or -NH₂ when Xi is CH₂; Z is -OH, =0, -SH, or -NH₂ when Xi is H₂ and the configuration at C₂o is S; or Z is =0, -SH, or -NH₂ when Xi is H₂ and the configuration at C₂o is R. In one embodiment, Z is -OH.

Still other embodiments of this aspect of invention include those wherein Xi is CH₂; A₂ is a single bond; R₁, R₂, R₃, and R₄ are each independently methyl or ethyl; and Z is -OH. In one embodiment, Xi is CH₂; A₂ is a single bond; R₁, R₂, R₃, and R₄ are each independently methyl or ethyl; and Z is =0. In one embodiment, Xi is H₂; A₂ is a single bond; R₁, R₂, R₃, and R₄ are each independently methyl or ethyl; the configuration at C₂o is S; and Z is -OH. In another embodiment, Xi is H₂; A₂ is a single bond; R₁, R₂, R₃, and R₄ are each independently methyl or ethyl; and Z is =0. In these embodiments, R₁, R₂, R₃, and R₄ are advantageously each methyl.

In certain embodiments, the haloalkyl is fluoroalkyl. Advantageously, fluoroalkyl is fluoromethyl or trifluoromethyl.

Additional embodiments of this aspect of the invention include compounds Xi is H₂; A₂ is a triple bond; Ri and R₂ are each Ci-C₄ deuteroalkyl; R₃ and R₄ are each haloalkyl; and Z is hydrogen. In other embodiments, Xi is CH₂; A₂ is a triple bond; Ri and R₂ are each Ci-C₄ deuteroalkyl; R₃ and R₄ are each haloalkyl; and Z is hydrogen.

In these embodiments, Ri and R₂ are advantageously each deuteromethyl and R₃ and R₄ are advantageously each trifluoromethyl.

Specific compounds of the invention include: 1, 25-Dihydroxy-21-(2R,3-dihydroxy-3- methyl-butyl)-20R-cho lecalcifero 1:

1 , 25-Dihydroxy-21 -(2R,3-dihydroxy-3-methyl-butyl)-20S-cholecalciferol:

1 , 25-Dihydroxy-20S-21 -(3-hydroxy-3-methyl-butyl)-24-keto- 19-nor-cholecalciferol:

and

1 ,25-Dihydroxy-21 (3-hydroxy-3-trifluoromethyl-4-trifluoro-butynyl)-26,27-hexadeutero-20S- cholecalciferol :

In still further specific embodiments of the invention, the vitamin D compound is a geminal compound of formula

wherein:

Xi is H₂ or CH₂;

A₂ is a single, a double or a triple bond;

R₁, R₂, R₃ and R₄ are each independently C₁-C₄ alkyl, hydroxyalkyl, or haloalkyl, e.g., fluoroalkyl, e.g., fluoromethyl and trifluoromethyl; Z is -OH, Z may also be =0, -NH₂ or -SH; and the configuration at C₂o is R or S, and pharmaceutically acceptable esters, salts, and prodrugs thereof. In a further embodiment, Xi is CH₂. In another embodiment, A₂ is a single bond. In another, R₁, R₂, R₃, and R₄ are each independently methyl or ethyl. In a further embodiment, Z is -OH. In another, Xi is CH₂; A₂ is a single bond; R₁, R₂, R3, and R₄ are each independently methyl or ethyl; and Z is -OH. In an even further embodiment, R₁, R₂, R₃, and R₄ are each methyl.

In a further embodiment of the invention, the vitamin D compound is a geminal compound of the formula:

33 50

The chemical names of compounds 33 and 50 mentioned above are l,25-dihydroxy-21- (2R,3-dihydroxy-3-methyl-butyl)-20R-cholecalciferol and 1 ,25-dihydroxy-21 -(2R,3-dihydroxy- 3-methyl-butyl)-20S-cholecalciferol respectively.

Additional embodiments of geminal compounds include the following vitamin D compounds for use in accordance with the invention:

(1 ,25-Dihydroxy-21 -(2R,3-dihydroxy-3-methyl-butyl)-20S- 19-nor-cholecalciferol),

(1 ,25-Dihydroxy-20S-21 -(3-hydroxy-3-methyl-butyl)-24-keto- 19-nor-cholecalciferol),

(l,25-Dihydroxy-20S-21-(3-hydroxy-3-methyl-butyl)-24-keto-cholecalciferol),

(l,25-Dihydroxy-21(3-hydroxy-3-trifluoromethyl-4-trifluoro-butynyl)-26,27- hexadeutero- 19-nor-20S-cholecalciferol) and

(l,25-Dihydroxy-21(3-hydroxy-3-trifluoromethyl-4-trifluoro-butynyl)-26,27- hexadeutero-20S-cholecalciferol).

In further embodiments of the invention, the vitamin D compound is a compound of formula (XI):

wherein:

Xi and Xi are each independently H₂ or =CH₂, provided Xi and Xi are not both =CH₂; Ri and R₂ are each independently, hydroxyl, OC(O)Ci-C₄ alkyl, OC(O)hydroxyalkyl, OC(O)fluroralkyl;

R₃ and R₄ are each independently hydrogen, Ci -C₄ alkyl, hydroxyalkyl or haloalkyl, or R3 and R₄ taken together with C₂o form C3-C6 cylcoalkyl; and

R₅ and Re are each independently C₁-C₄ alkyl or haloalkyl; and pharmaceutically acceptable esters, salts, and prodrugs thereof. Suitably R₃ and R₄ are each independently hydrogen, Ci-C₄ alkyl, or R₃ and R₄ taken together with C₂o form C3-C6 cylcoalkyl.

In one example set of compounds R5 and Re are each independently Ci-C₄ alkyl. In another example set of compounds R5 and Re are each independently haloalkyl e.g., Ci-C₄ fiuoroalkyl. When R3 and R₄ are taken together with C20 to form C3-C6 cycloalkyl, an example is cyclopropyl.

In one embodiment, Xi and Xi are each H₂. In another embodiment, R₃ is hydrogen and R₄ is Ci-C₄ alkyl. In a preferred embodiment R₄ is methyl.

In another embodiment, R₅ and Re are each independently methyl, ethyl, fluoromethyl or trifluoromethyl. In a preferred embodiment, R₅ and Re are each methyl.

In yet another embodiment, Ri and Ri are each independently hydroxyl or OC(O)Ci-C₄ alkyl.

In a preferred embodiment, Ri and Ri are each OC(O)Ci-C₄ alkyl. In another preferred embodiment, Ri and Ri are each acetyloxy. An example of such a compound is 1 ,3-0-diacetyl- 1 ,25-dihydroxy- 16-ene-24-keto- 19- nor-cholecalciferol ("Compound C"), having the following structure:

In another embodiment of the invention the vitamin D compound for use in accordance with the invention is 2-methylene-19-nor-20(S)-l-alpha,25-hydroxyvitamin D₃:

The synthesis of this and related compounds is described in WO02/05823 and US5,536,713 which are herein incorporated in their entirety by reference.

In another embodiment of the invention, the vitamin D compound is a compound of the formula (XII):

wherein:

Ai is single or double bond;

A₂ is a single, double or triple bond; Xi and X₂ are each independently H or =CH₂, provided Xi and X₂ are not both =CH₂;

Ri and R₂ are each independently H, OC(O)Ci-C₄ alkyl (for example OAc), OC(O)hydroxyalkyl, OC(O)halo alkyl; such as OC(O)Ci-C₄ alkyl (for example OAc), OC(O)hydroxyalkyl; R3, R₄ and R5 are each independently hydrogen, C1-C4 alkyl, hydroxyalkyl, or haloalkyl, or R₃ and R₄ taken together with C₂o form C₃-C₆ cycloalkyl; and

R₆ and R₇ are each independently Ci_₄alkyl or haloalkyl; and

R₈ is H, -COCi-C₄alkyl (e.g. Ac), -COhydroxyalkyl or -COhaloalkyl; and pharmaceutically acceptable esters, salts, and prodrugs thereof. When R₃ and R₄ are taken together with C₂o to form C₃-C₆ cycloalkyl an example is cyclopropyl.

Suitably R₆ and R₇ are each independently haloalkyl. R₈ may suitably represent H or Ac.

In one embodiment, Ai is a single bond and A₂ is a single bond, E or Z double bond, or a triple bond, for example Ai is a single bond and A₂ is a single bond. In another embodiment, Ai is a double bond and A₂ is a single bond, E or Z double bond, or a triple bond. One of ordinary skill in the art will readily appreciate that when A₂ is a triple bond, R5 is absent

In one embodiment, Xi and X₂ are each H. In another embodiment, Xi is CH₂ and X₂ is H₂. In another embodiment, R₃ is hydrogen and R₄ is Ci-C₄ alkyl. In a preferred embodiment R₄ is methyl. In another embodiment R₃ and R₄ taken together with C₂o form C₃-C₆ cycloalkyl eg cyclopropyl.

In another example set of compounds Ri and R₂ are OH or OC(O)Ci-C₄ alkyl, for example Ri and R₂ both represent OAc.

In one set of example compounds R₆ and R₇ are each independently Ci_₄alkyl. In another set of example compounds R₆ and R₇ are each independently haloalkyl. In another embodiment, R₆ and R₇ are each independently methyl, ethyl or fluoroalkyl, for example they are both methyl. In a preferred embodiment, R₆ and R₈ are each trifluoro alkyl, e.g., trifluoromethyl.

Suitably R5 represents hydrogen.

Suitably R₈ represents hydrogen. In another embodiment, Ri and R₂ are OH or OC(O)Ci-C₄ alkyl, Xi is =CH₂ and X₂ is H,

Ai is single bond, A₂ is a single bond, R₃ and R₄ taken together with C₂o form C₃-C₆ cycloalkyl, R₅ is hydrogen, R₆ and R₇ are each independently Ci_₄alkyl, and R₈ is H. In yet another embodiment, the invention provides for the use, method, formulation, compound or kit, wherein Ri and R₂ are OH or OAc, R₃ and R₄ taken together with C₂o form cyclopropyl, and R₆ and R₇ are each methyl.

Thus, in certain embodiments, vitamin D compounds for use in accordance with the invention are represented by formula (XII):

wherein:

Ai is single or double bond;

A₂ is a single, double or triple bond;

Xi and X₂ are each independently H or =CH₂, provided Xi and X₂ are not both =CH₂;

Ri and R₂ are each independently OC(O)Ci-C₄ alkyl, OC(O)hydroxyalkyl, or OC(O)haloalkyl;

R3, R₄ and R5 are each independently hydrogen, Ci -C₄ alkyl, hydroxyalkyl, or haloalkyl, with the understanding that R₅ is absent when A₂ is a triple bond, or R₃ and R₄ taken together with C₂o form C3-C6 cycloalkyl;

R^ and R₇ are each independently alkyl or haloalkyl; and

R₈ is H, C(O)Ci-C₄ alkyl, C(O)hydroxyalkyl, or C(O)haloalkyl; and pharmaceutically acceptable esters, salts, and prodrugs thereof.

In preferred embodiments, when Ai is single bond, R3 is hydrogen, and R₄ is methyl, then A2 is a double or triple bond.

An example compound of the above-described formula (XII) which is one of the preferred compounds in the context of the present invention is l,3-di-O-acetyl-l,25-dihydroxy- 16,23Z-diene-26,27-hexafluoro- 19-nor-cholecalciferol:

In another preferred embodiment the compound is one of formula (XIII), wherein Ri and R₂ are each OAc; Ai is a double bond; A₂ is a triple bond; and R₈ is either H or Ac:

In certain embodiments of the above-represented formula (XII), vitamin D compounds for use in accordance with the invention are represented by the formula (XIV):

Other example compounds of the above-described formula (XIV) include:

1 ,3-di-O-acetyl- 1 ,25-dihydroxy-23-yne-cholecalciferol;

1 ,3-di-O-acetyl- 1 ,25-dihydroxy- 16-ene-23-yne-cholecalciferol; 1 ,3-di-O-acetyl- 1 ,25-dihydroxy- 16,23E-diene-cholecalciferol;

1 ,3-di-O-acetyl- 1 ,25-dihydroxy- 16-ene-cholecalciferol;

1 ,3,25-Tri-O-acetyl- 1 ,25-dihydroxy- 16-ene-23-yne-26,27-hexafluoro-cholecalciferol:

1 ,3-di-O-acetyl- 1 ,25-dihydroxy- 16-ene-23-yne-26,27-hexafluoro-cholecalciferol;

1 ,3-Di-O-acetyl- 1 ,25-dihydroxy- 16,23E-diene-25R-26-trifluoro-cholecalciferol; 1 ,3-Di-O-acetyl- 1 ,25-Dihydroxy- 16-ene-23-yne-26,27-hexafluoro- 19-nor- cholecalciferol;

1 ,3,25-Tri-O-acetyl- 1 ,25-Dihydroxy- 16-ene-23-yne-26,27-hexafluoro- 19-nor- cholecalciferol;

1 ,3-di-O-acetyl- 1 ,25-dihydroxy- 16-ene- 19-nor-cholecalciferol; 1 ,3-Di-O-acetyl- 1 ,25-dihydroxy- 16-ene-23-yne- 19-nor-cholecalciferol;

1 ,3-Di-O-acetyl- 1 ,25-dihydroxy- 16-ene-23-yne-26,27-bishomo- 19-nor-cholecalciferol;

In certain other embodiments of the above-represented formula (XII), the vitamin D compounds for use in accordance with the invention are represented by the formula (XV):

In a preferred embodiment, Xi is =CH2 and X₂ is H₂. When Ai is a single bond, and A₂ is a triple bond, it is preferred that R₈ is H or C(O)CH3, and R₆ and R₇ are alkyl, preferably methyl. When Ai is a single bond, and A₂ is a single bond, it is preferred that R₈ is H or C(O)CH₃, and R₆ and R₇ are alkyl, preferably methyl. When Ai is a double bond, and A₂ is a single bond, it is preferable that R₈ is H or C(O)CH₃, and R₆ and R₇ are alkyl, preferably methyl.

In another preferred embodiment, Xi and X₂ are each H₂. When Ai is a single bond, and A₂ is a triple bond, it is preferred that R₈ is H or C(O)CH₃, and R₆ and R₇ are alkyl or haloalkyl. It is preferred that the alkyl group is methyl, and the haloalkyl group is trifluoroalkyl, preferably trifluoromethyl. When Ai is a single bond, and A₂ is a double bond, it is preferred that R₈ is H or C(O)CH₃, R₆ and R₇ are haloalkyl, preferably trifluoroalkyl, preferably trifluoromethyl. When Ai is a double bond, and A₂ is a single bond, it is preferred that R₈ is H or C(O)CH₃, R₆ and R₇ are alkyl, preferably methyl.

Other example compounds of the above-described formula (XV) include: 1 ,3-Di-O-acetyl- 1 ^S-dihydroxy^O-cyclopropyl^-yne- 19-nor-cholecalciferol:

1 ,3,25-tri-O-acetyl- 1 ^S-dihydroxy^O-cyclopropyl^-yne^β^y-hexafluoro- 19-nor- cholecalciferol;

1 ,3-di-O-acetyl- 1 ^S-dihydroxy^O-cyclopropyl^-yne^β^y-hexafluoro- 19-nor- cholecalciferol; l,3-di-O-acetyl-l,25-dihydroxy-20-cyclopropyl-23-yne-cholecalciferol;

1 ,3-di-O-acetyl- 1 ,25-dihydroxy-20-cyclopropyl-23Z-ene-26,27-hexafluoro- 19-nor- cholecalciferol;

1 ,3-di-O-acetyl- 1 ,25-dihydroxy-20-cyclopropyl-cholecalciferol; 1 ,3-di-O-acetyl- 1 ,25-dihydroxy- 16-ene-20-cyclopropyl- 19-nor-cholecalciferol; and 1 ,3-Di-O-acetyl- 1 ,25-dihydroxy- 16-ene-20-cyclopropyl-cholecalciferol.

A preferred compound of formula XV is l,3-di-O-acetyl-l,25-dihydroxy-20-cyclopropyl- 23E-ene-26,27-hexafluoro- 19-nor-cholecalciferol:

An example of a preferred compound is l^-Di-O-acetyl-l^S-dihydroxy^O-cyclopropyl- cholecalciferol (referred to as "Compound D") having the formula:

"Compound D"

Such compounds are described in WO2005/030222, the contents of which are herein incorporated by reference in their entirety. The invention also embraces use of esters and salts of Compound D. Esters include pharmaceutically acceptable labile esters that may be hydro lysed in the body to release Compound D. Salts of Compound D include adducts and complexes that may be formed with alkali and alkaline earth metal ions and metal ion salts such as sodium, potassium and calcium ions and salts thereof such as calcium chloride, calcium malonate and the like. However, although Compound D may be administered as a pharmaceutically acceptable salt or ester thereof, preferably Compound D is employed as is i.e., it is not employed as an ester or a salt thereof. Another compound is l,25-dihydroxy-20,21,28-cyclopropyl-cholecalciferol having the formula:

The compound is described in U.S. 6,492,353, the contents of which are herein incorporated by reference in their entirety.

The invention also embraces use of esters and salts of l,25-dihydroxy-20,21,28- cyclopropyl-cholecalciferol. Esters include pharmaceutically acceptable labile esters that may be hydro lysed in the body to release l,25-dihydroxy-20,21,28-cyclopropyl-cholecalciferol. Salts of l,25-dihydroxy-20,21,28-cyclopropyl-cholecalciferol include adducts and complexes that may be formed with alkali and alkaline earth metal ions and metal ion salts such as sodium, potassium and calcium ions and salts thereof such as calcium chloride, calcium malonate and the like. However, although l,25-dihydroxy-20,21,28-cyclopropyl-cholecalciferol may be administered as a pharmaceutically acceptable salt or ester thereof, preferably it is employed as is i.e., it is not employed as an ester or a salt thereof.

In a further embodiment, vitamin D compounds for use in the invention are compounds of the formula (XVI):

wherein:

X is H₂ or CH₂ ;

Ri is hydrogen, hydroxy or fluorine;

R₂ is hydrogen or methyl;

R₃ is hydrogen or methyl provided that when R₂ or R₃ is methyl, R₃ or R₂ must be hydrogen;

R₄ is methyl, ethyl or trifluoromethyl;

R₅ is methyl, ethyl or trifluoromethyl;

A is a single or double bond;

B is a single, E-double, Z-double or triple bond.

In preferred compounds, each of R₄ and R5 is methyl or ethyl, for example 1-alpha- fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol, herein after referred to as "Compound A", having the formula:

Such compounds and methods of synthesis are described in Radino v et al. J. Org. Chem. 2001, 66, 6141; Daniewski et al. US patent 6,255,501; Batcho et al. US patent 5,939,408, and EP808833, the contents of which are herein incorporated by reference in their entirety. An improved synthesis of 1 -alpha- fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi- cholecalciferol is described below in Example 1.

Other preferred vitamin D compounds for use in accordance with the invention include those having formula (XVII):

wherein:

B is single, double, or triple bond;

Xi and X₂ are each independently H₂ or CH₂, provided Xi and X₂ are not both CH₂; and

R₄ and R₅ are each independently alkyl or haloalkyl.

Examples of compounds of formula (XVII) include the following:

1 ,25-Dihydroxy- 16-ene-23-yne-20-cyclopyl-cholecalciferol:

,25-Dihydroxy- 1 β-ene^S-yne^O-cyclopropyl- 19-nor-cholecalciferol:

,25-Dihydroxy- 1 ό-ene^O-cyclopropyl^S-yne^ό^V-hexafluoro- 19-nor-cholecalciferol:

,25-Dihydroxy- 16-ene-20-cyclopropyl-23-yne-26,27-hexafluoro-cholecalciferol:

,25-Dihydroxy- 1 β^SE-diene-lO-cyclopropyl-lβ^V-hexafluoro- 19-nor-cholecalciferol:

,25-Dihydroxy- 16,23E-diene-20-cyclopropyl-26,27-hexafluoro-cholecalciferol:

,25-Dihydroxy- 16,23Z-diene-20-cyclopropyl-26,27-hexafluoro- 19-nor-cholecalciferol:

1 ,25-Dihydroxy- 16,23Z-diene-20-cyclopropyl-26,27-hexafluoro-cholecalciferol:

1 ,25-Dihydroxy- 16-ene-20-cyclopropyl- 19-nor-cholecalciferol:

l,25-Dihydroxy-16-ene-20-cyclopropyl-cholecalciferol ("Compound E"):

Another vitamin D compound of the invention is l,25-dihydroxy-21(3-hydroxy-3- trifluoromethyl-4-trifluoro-butynyl)-26,27-hexadeutero-19-nor-20S-cholecalciferol.

Still other preferred vitamin D compounds for use in accordance with the invention include those having formula (XVIII):

In a preferred embodiment, Ai is a double bond, and Xi is =CH2 and X₂ is H₂. When A₂ is a triple bond, it is preferred that Rs is H or C(O)CH3, and R₆ and R₇ are alkyl or haloalkyl. It is preferred that the alkyl group is methyl and the haloalkyl group is trifluoroalkyl, preferably trifluoromethyl. When A₂ is a double bond, it is preferred that Rs is H or C(O)CH3, and R₆ and R₇ are alkyl, preferably methyl. It is also preferred that R₆ and R₇ are independently alkyl and haloalkyl. When A₂ is a single bond, it is preferred that Rs is H or C(O)CH3, and R₆ and R₇ are alkyl, preferably methyl.

In a preferred embodiment, Ai is a double bond, and Xi and X₂ are each H₂. When A₂ is a triple bond, it is preferred that Rs is H or C(O)CH3, and R₆ and R₇ are alkyl or haloalkyl. It is preferred that the alkyl group is methyl or ethyl and the haloalkyl group is trifluoroalkyl, preferably trifluoromethyl. When A₂ is a double bond, it is preferred that Rs is H or C(O)CH3, and R₆ and R₇ are haloalkyl, preferably trifluoroalkyl, preferably trifluoromethyl. When A₂ is a single bond, it is preferred that Rs is H or C(0)CH3, and R₆ and R₇ are alkyl, preferably methyl. In another embodiment of the invention of formula (XVIII), Ri and R₂ are OC(O)CH₃,

Ai is a single bond, and A₂ is a single, double or triple bond, except that when R3 is H and R₄ is methyl, A₂ is a double or triple bond. In a preferred embodiment, R3 is H, R₄ is methyl, R5 is absent, Rs is H or C(O)CH3, and R₆ and R₇ are alkyl, preferably methyl. Preferred compounds of the present include the following: l,3-Di-O-acetyl-l,25- dihydroxy- 16,23Z-diene-26,27-hexafluoro- 19-nor-cholecalciferol, 1 ,3-Di-O-acetyl- 1 ,25- Dihydroxy- 16-ene-23-yne-26,27-hexafluoro- 19-nor-cholecalciferol, 1 ,3,25-Tri-O-acetyl- 1 ,25- Dihydroxy- 16-ene-23-yne-26,27-hexafluoro- 19-nor-cholecalciferol, 1 ,3-Di-O-acetyl- 1 ,25- dihydroxy- 16-ene-23-yne-cholecalciferol, 1 ,3-Di-O-acetyl- 1 ,25-dihydroxy- 16,23E-diene- cholecalciferol, l,3-Di-O-acetyl-l,25-dihydroxy-16-ene-cholecalciferol , 1,3,25-Tri-O-acetyl- 1 ,25-dihydroxy- 16-ene-23-yne-26,27-hexafluoro-cholecalciferol , 1 ,3-Di-O-acetyl- 1 ,25- dihydroxy- 16-ene-23-yne-26,27-hexafluoro-cholecalciferol , 1 ,3-Di-O-acetyl- 1 ,25-dihydroxy- 16,23E-diene-25R,26-trifluoro-cholecalciferol , 1 ,3-Di-O-acetyl- 1 ,25-dihydroxy- 16-ene- 19-nor- cholecalciferol , l,3-Di-O-Acetyl-l,25-dihydroxy-16-ene-23-yne-l 9-nor-cholecalciferol, 1,3-Di- O-acetyl- 1 ,25-dihydroxy- 16-ene-23-yne-26,27-bishomo- 19-nor-cholecalciferol and 1 ,3-Di-O- acetyl- 1 ,25 -dihydroxy-23 -yne-cho lecalcifero 1.

These compounds can be prepared, e.g., as described in PCT Publication WO2005030222.

Yet further preferred vitamin D compounds for use in accordance with the invention include those having formula

wherein: Ai is single or double bond;

A₂ is a single, double or triple bond,

Xi and X₂ are each independently H₂ or CH₂, provided Xi and X₂ are not both CH₂;

Ri and R₂ are each independently OC(O)Ci-C₄ alkyl, OC(O)hydroxyalkyl, or OC(O)haloalkyl; R3, R₄ and R5 are each independently hydrogen, Ci -C₄ alkyl, hydro xyalkyl, or haloalkyl, or R₃ and R₄ taken together with C₂o form C₃-C₆ cylcoalkyl;

R₆ and R₇ are each independently haloalkyl; and

R₈ is H, OC(O)Ci-C₄ alkyl, OC(O)hydroxyalkyl, or OC(O)haloalkyl; and pharmaceutically acceptable esters, salts, and prodrugs thereof. In preferred embodiments, R₆ and R₇ are each independently trihaloalkyl, especially trifluoromethyl.

These compounds can be prepared, e.g., as described in PCT Publication WO2005030222, the contents of which are incorporated herein by reference.

Gemini 20-alkyl, e.g., methyl, vitamin D3 compounds are contemplated by the instant invention. In one aspect, the formula (XX):

wherein:

Ai is a single or double bond; A₂ is a single, a double or a triple bond;

Ri, R₂, R₃ and R₄ are each independently alkyl, deuteroalkyl, hydroxyalkyl, or haloalkyl; R₅ is halogen, hydroxyl, OC(O)alkyl, OC(O)hydroxyalkyl, or OC(O)haloalkyl; R₆ is halogen, hydroxyl, OC(O)alkyl, OC(O)hydroxyalkyl, or OC(O)haloalkyl; Xi is H₂ or CH₂; Y is alkyl; and pharmaceutically acceptable esters, salts, and prodrugs thereof. In one aspect, the invention provides a vitamin D₃ compound having formula (XX-a):

wherein:

A₂ is a single, a double or a triple bond;

Ri, R₂, R₃ and R₄ are each independently alkyl, hydroxyalkyl, or haloalkyl; R₅ is halogen, hydroxyl, OC(O)alkyl, OC(O)hydroxyalkyl, or OC(O)haloalkyl; R₆ is hydroxyl, OC(O)alkyl, OC(O)hydroxyalkyl, or OC(O)haloalkyl; Xi is H₂ or CH₂; and pharmaceutically acceptable esters, salts, and prodrugs thereof. In certain aspects, the invention provides a compound having formula (XX-b):

wherein:

R5 is fluoro or hydroxyl; Xi is H₂ or CH₂; and pharmaceutically acceptable esters, salts, and prodrugs thereof. In other aspects, the invention provides a compound having formula (XX-c):

wherein:

A₂ is a single, a double or a triple bond; R5 is fluoro or hydroxyl; Xi is H₂ or CH₂; and pharmaceutically acceptable esters, salts, and prodrugs thereof. In another aspect, the invention provides a compound having formula (XX-d):

wherein:

A₂ is a single, a double or a triple bond;

R5 is fluoro or hydroxyl;

Xi is H₂ or CH₂; and pharmaceutically acceptable esters, salts, and prodrugs thereof. In yet another aspect, the invention provides a compound having formula (XX-e):

wherein:

A₂ is a single, a double or a triple bond;

R5 is fluoro or hydroxyl;

Xi is H₂ or CH₂; and pharmaceutically acceptable esters, salts, and prodrugs thereof.

In still another aspect, the invention provides a compound having formula (XX-f):

wherein:

A₂ is a single, a double or a triple bond;

R5 is fluoro or hydroxyl;

Xi is H₂ or CH₂; and pharmaceutically acceptable esters, salts, and prodrugs thereof.

Preferred compounds of the invention include the following compounds, which are further exemplified in Chart 1. The syntheses of compounds of formula (XX) are included at Examples 3-41 below.

Chart 1

In another aspect, the invention provides a vitamin D₃ compound of formula XXII:

wherein: A is single or double bond; B is a single, double, or triple bond; X is H₂ or CH₂; Y is hydroxyl, OC(O)Ci-C₄ alkyl, OC(O)hydroxyalkyl, OC(O)haloalkyl; or halogen; Z is hydroxyl, OC(O)Ci-C₄ alkyl, OC(O)hydroxyalkyl, or OC(O)haloalkyl; and pharmaceutically acceptable esters, salts, and prodrugs thereof.

Preferred compounds of the present invention are summarized in Table 1 and the syntheses of such compounds are detailed in Examples 42-50 below.

Table 1

The use of compounds having the structures given above is extended to pharmaceutically acceptable esters, salts, and prodrugs thereof.

A vitamin D compound of particular interest is Compound A. Other compounds of interest are calcitriol and Compounds B-G.

Other example compounds of use in the invention which are vitamin D receptor agonists include paricalcitol (ZEMPLAR™) (see US Patent 5,587,497), tacalcitol (BONALF A™) (see US Patent 4,022,891), doxercalciferol (HECTOROL™) (see Lam et al. (1974) Science 186, 1038), maxacalcitol (0XAR0L™) (see US Patent 4,891,364), calcipotriol (DAIV0NEX™) (see US Patent 4,866,048), and falecalcitriol (FULSTAN™).

Other compounds include ecalcidene, calcithiazol and tisocalcitate.

Other compounds include atocalcitol, lexacalcitol and seocalcitol.

Another compound of possible interest is secalciferol ("OSTEO D").

Other non- limiting examples of vitamin D compounds that may be of use in accordance with the invention include those described in published international applications: WO2006/036813, WO2005/082375, WO2005/030223, WO2005/030222, WO2005/027923, WO2004/098522, WO2004/098507, WO2002/094247, WO98/49138, WO 01/40177, WO0010548, WO0061776, WO0064869, WO0064870, WO0066548, WO0104089, WOOl 16099, WO0130751, WO0140177, WO0151464, WO0156982, WO0162723, WO0174765, WO0174766, WO0179166, WO0190061, WO0192221, WO0196293, WO02066424, WO0212182, WO0214268, WO03004036, WO03027065, WO03055854, WO03088977, WO04037781, WO04067504, WO8000339, WO8500819, WO8505622, WO8602078, WO8604333, WO8700834, WO8910351, WO9009991, WO9009992, WO9010620, WO9100271, WO9100855, WO9109841, W09112239, W09112240, W09115475, WO9203414, WO9309093, WO9319044, WO9401398, WO9407851, WO9407852, WO9408958, WO9410139, WO9414766, WO9502577, WO9503273, WO9512575, WO9527697, WO9616035, WO9616036, WO9622973, WO9711053, WO9720811, WO9737972, WO9746522, WO9818759, WO9824762, WO9828266, WO9841500, WO9841501, WO9849138, WO9851663, WO9851664, WO9851678, WO9903829, WO9912894, WO9915499, WO9918070, WO9943645, WO9952863, those described in U.S. Patent Nos.: US3856780, US3994878, US4021423, US4026882, US4028349, US4225525, US4613594, US4804502, US4898855, US 4929609, US5039671, US5087619, US5145846, US5247123, US5342833, US 5393900, US5428029, US5451574, US5612328, US 5747478, US5747479, US5804574, US5811414, US5856317, US5872113, US5888994, US5939408, US5962707, US5981780, US6017908, US6030962, US6040461, US6100294, US6121312 , US6329538, US6331642, US6392071, US6452028, US6479538, US6492353,

US6537981, US6544969, US6559138, US6667298, US6683219, US6696431, US6774251, and those described in published US Patent Applications: US2001007907, US2003083319, US2003125309, US2003130241, US2003171605, US2004167105, US2004214803 and US2005065124. It will be noted that the structures of some of the compounds of the invention include asymmetric carbon atoms. Accordingly, it is to be understood that the isomers arising from such asymmetry (e.g., all enantiomers and diastereomers) are included within the scope of this invention, unless indicated otherwise. Such isomers can be obtained in substantially pure form by classical separation techniques and/or by stereochemically controlled synthesis. Naturally occurring or synthetic isomers can be separated in several ways known in the art. Methods for separating a racemic mixture of two enantiomers include chromatography using a chiral stationary phase (see, e.g., "Chiral Liquid Chromatography," W.J. Lough, Ed. Chapman and Hall, New York (1989)). Enantiomers can also be separated by classical resolution techniques. For example, formation of diastereomeric salts and fractional crystallization can be used to separate enantiomers. For the separation of enantiomers of carboxylic acids, the diastereomeric salts can be formed by addition of enantiomerically pure chiral bases such as brucine, quinine, ephedrine, strychnine, and the like. Alternatively, diastereomeric esters can be formed with enantiomerically pure chiral alcohols such as menthol, followed by separation of the diastereomeric esters and hydrolysis to yield the free, enantiomerically enriched carboxylic acid. For separation of the optical isomers of amino compounds, addition of chiral carboxylic or sulfonic acids, such as camphorsulfonic acid, tartaric acid, mandelic acid, or lactic acid can result in formation of the diastereomeric salts. The invention also provides a pharmaceutical composition, comprising an effective amount of a vitamin D compound as described herein and a pharmaceutically acceptable carrier. In a further embodiment, the effective amount is effective to treatment of male sub-fertility as described previously.

In an embodiment, the vitamin D compound is administered to the subject using a pharmaceutically-acceptable formulation, e.g., a pharmaceutically-acceptable formulation that provides sustained delivery of the vitamin D compound to a subject for at least 12 hours, 24 hours, 36 hours, 48 hours, one week, two weeks, three weeks, or four weeks after the pharmaceutically-acceptable formulation is administered to the subject.

In certain embodiments, these pharmaceutical compositions are suitable for topical or oral administration to a subject. In other embodiments, as described in detail below, the pharmaceutical compositions of the present invention may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, boluses, powders, granules, pastes; (2) parenteral administration, for example, by subcutaneous, intramuscular or intravenous injection as, for example, a sterile solution or suspension, (3) topical application, for example, as a cream, ointment or spray applied to the skin; (4) intravaginally or intrarectally, for example, as a pessary, cream or foam; or (5) aerosol, for example, as an aqueous aerosol, liposomal preparation or solid particles containing the compound. The phrase "pharmaceutically acceptable" refers to those vitamin D compounds of the present invention, compositions containing such compounds, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. The phrase "pharmaceutically-acceptable carrier" includes pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject chemical from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically- acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations.

Wetting agents, emulsifϊers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions. Examples of pharmaceutically-acceptable antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfϊte, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

The compositions may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.

The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the subject intended to receive the dose and the particular mode of administration. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a prophylactic effect. Generally, out of one hundred per cent, this amount will range from about 0.1 per cent to about ninety-nine percent of active ingredient, preferably from about 5 per cent to about 70 per cent, most preferably from about 10 per cent to about 30 per cent.

Methods of preparing these compositions include the step of bringing into association a vitamin D compound(s) with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a vitamin D compound with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.

Compositions of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil- in- water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a vitamin D compound(s) as an active ingredient. A compound may also be administered as a bolus, electuary or paste. In solid dosage forms of the invention for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, acetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard- filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.

A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered active ingredient moistened with an inert liquid diluent.

The tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical- formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be sterilized by, for example, filtration through a bacteria- retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients. Liquid dosage forms for oral administration of the vitamin D compound(s) include pharmaceutically-acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifϊers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

In addition to inert diluents, the oral compositions can include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.

Suspensions, in addition to the active vitamin D compound(s) may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxy ethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

Pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more vitamin D compound(s) with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active agent.

Compositions of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate. Dosage forms for the topical or transdermal administration of a vitamin D compound(s) include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active vitamin D compound(s) may be mixed under sterile conditions with a pharmaceutically-acceptable carrier, and with any preservatives, buffers, or propellants which may be required. The ointments, pastes, creams and gels may contain, in addition to vitamin D compound(s) of the present invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.

Powders and sprays can contain, in addition to a vitamin D compound(s), excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane. The vitamin D compound(s) can be alternatively administered by aerosol. This is accomplished by preparing an aqueous aerosol, liposomal preparation or solid particles containing the compound. A nonaqueous (e.g., fluorocarbon propellant) suspension could be used. Sonic nebulizers are preferred because they minimize exposing the agent to shear, which can result in degradation of the compound.

Ordinarily, an aqueous aerosol is made by formulating an aqueous solution or suspension of the agent together with conventional pharmaceutically-acceptable carriers and stabilizers. The carriers and stabilizers vary with the requirements of the particular compound, but typically include nonionic surfactants (T weens, Pluronics, or polyethylene glycol), innocuous proteins like serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars or sugar alcohols. Aerosols generally are prepared from isotonic solutions.

Transdermal patches have the added advantage of providing controlled delivery of a vitamin D compound(s) to the body. Such dosage forms can be made by dissolving or dispersing the agent in the proper medium. Absorption enhancers can also be used to increase the flux of the active ingredient across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the active ingredient in a polymer matrix or gel. Pharmaceutical compositions of the invention suitable for parenteral administration comprise one or more vitamin D compound(s) in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.

Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin. In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form.

Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

Injectable depot forms are made by forming microencapsule matrices of vitamin D compound(s) in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly (anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.

An exemplary oral formulation of Compound A comprises:

The invention also provides kits for treatment of male sub- fertility. In one embodiment, the kit includes an effective amount of a vitamin D compound in unit dosage form, together with instructions for administering the vitamin D compound to a subject suffering from male sub- fertility.

In preferred embodiments, the kit comprises a sterile container which contains the vitamin D compound; such containers can be boxes, ampules, bottles, vials, tubes, bags, pouches, blister-packs, or other suitable container form known in the art. Such containers can be made of plastic, glass, laminated paper, metal foil, or other materials suitable for holding medicaments.

The instructions will generally include information about the use of the compound for treatment of male sub- fertility; in preferred embodiments, the instructions include at least one of the following: description of the compound; dosage schedule and administration for treatment of male sub-fertility precautions; warnings; indications; counter-indications; overdosage information; adverse reactions; animal pharmacology; clinical studies; and/or references. The instructions may be printed directly on the container (when present), or as a label applied to the container, or as a separate sheet, pamphlet, card, or folder supplied in or with the container.

When the vitamin D compound(s) are administered as pharmaceuticals, to humans and animals, they can be given per se or as a pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically-acceptable carrier.

Regardless of the route of administration selected, the vitamin D compound(s), which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically-acceptable dosage forms by conventional methods known to those of skill in the art.

Actual dosage levels and time course of administration of the active ingredients in the pharmaceutical compositions of the invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. An exemplary dose range is from 0.1 to 300 ug per day

A preferred dose of the vitamin D compound for the present invention is the maximum that a patient can tolerate and not develop hypercalcemia. Preferably, the vitamin D compound of the present invention is administered at a concentration of about 0.001 ug to about 100 ug per kilogram of body weight, about 0.001 - about 10 ug/kg or about 0.001 ug - about 100 ug/kg of body weight. Ranges intermediate to the above-recited values are also intended to be part of the invention.

The vitamin D compound may be administered separately, sequentially or simultaneously in separate or combined pharmaceutical formulations with a second medicament for the treatment of male sub-fertility (for example a second vitamin D compound of the present invention, or an antibiotic, or an anti- inflammatory compound, or antioxidant compounds). Such combination therapy may increase the efficacy of the overall treatment or may permit the second medicament to be used in a lower amount than without the vitamin D compound.

When vitamin D compounds of the invention are combined with an anti-oxidant, exemplary antioxidant compounds include vitamin C, vitamin E, lycopene, carnitine and glutathione.

Where male sub-fertility is associated with a particular underying disease or disorder, the vitamin D compound for use in the treatment of male sub-fertility may be administered with a further medicament for the treatment or prevention of the underlying disease or disorder. It may be advantageous to monitor seminal plasma IL-8 levels (i) before treatment in order to identify the individuals who may be expected to benefit from vitamin D compound treatment; and (ii) during and after treatment to determine response to treatment. Thus as a further aspect of the invention there is provided a method for improving fertility in a sub-fertile male subject, comprising (i) determining whether the subject has elevated seminal plasma IL-8 levels relative to male subjects of normal fertility and (ii) if so, administering to said sub-fertile subject an effective amount of a vitamin D compound, such that fertility is improved in said subject. There is also provided a kit comprising (i) means to determine the level of IL-8 in the seminal plasma of a sub-fertile male subject (ii) a vitamin D compound and (iii) instructions directing administration of said compound to said subject, provided said subject has elevated seminal plasma IL-8 levels relative to subjects of normal fertility, thereby to improve fertility in said sub-fertile subject.

Synthesis of Compounds of the Invention

The syntheses of compounds of the invention have been described in the art, for example, in WO2006/036813, WO2005/082375, WO2005/030223, WO2005/030222, WO2005/027923, WO2004/098522, WO2004/098507, WO2002/094247, WO98/49138, U.S. 6,492,353, U.S. 6,030,962 and U.S. 5,939,408, the contents of which are incorporated herein by reference in their entirety.

EXEMPLIFICATION OF THE INVENTION

The present invention will now be described with reference to the following non-limiting examples.

SYNTHETIC EXAMPLES

All operations involving vitamin D3 analogs were conducted in amber-colored glassware in a nitrogen atmosphere. Tetrahydrofuran was distilled from sodium-benzophenone ketyl just prior to its use and solutions of solutes were dried with sodium sulfate. Melting points were determined on a Thomas-Hoover capillary apparatus and are uncorrected. Optical rotations were measured at 25 °C. ¹H NMR spectra were recorded at 400 MHz in CDCI3 unless indicated otherwise. TLC was carried out on silica gel plates (Merck PF-254) with visualization under short-wavelength UV light or by spraying the plates with 10% phosphomolybdic acid in methanol followed by heating. Flash chromatography was carried out on 40-65 μm mesh silica gel. Preparative HPLC was performed on a 5^χ50 cm column and 15-30 μm mesh silica gel at a flow rate of 100 ml/min.

EXAMPLE 1

Synthesis ofl-alpha-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi- cholecalciferol

t-Butyl-dimethyl-(4-methylene-3-{2-[7a-methyl-l-(l,4,5-trimethyl-hex-2-enyl)- octahydro-inden-4-ylidene]-ethylidene}-cyclohexyloxy)-silane

To a stirred solution of 4-Methylene-3-{2-[7a-methyl-l-(l,4,5-trimethyl-hex-2-enyl)- octahydro-inden-4-ylidene]-ethylidene}-cyclohexanol (100.00 g, 0.25 mol) in DMF (250 mL), imidazole (40.80 g, 0.6 mol) and (t-butyldimethyl)silyl chloride (45.40 g, 0.3 mol) were added successively. The reaction mixture was stirred at room temperature for Ih, diluted with hexane (750 mL), washed with water (500 mL), IN HCl (500 mL), brine (500 mL) and dried over Na₂SO₄. The residue (155 g) after evaporation of the solvent was filtered through a plug of silica gel (500 g, 5% AcOEt in hexane) to give the title compound (115.98 g, 0.23 mol, 92%).

¹H-NMR: δ 0.04 and 0.08 (2s, 6H), 0.59 (s, 3H), 0.90 (d, 3H, J=6.6 Hz), 0.92 (d, 3H, J=6.6 Hz), 0.98 (s, 9H), 0.99 (d, 3H, J=7.0 Hz), 1.06 (d, 3H, J=6.8 Hz), 1.10-2.95 (m, 21H), 5.11 (br s, 2H), 5.22 (m, 2H), 6.49 (br s, 2H).

2-[5-(tert-Butyl-dimethyl-silanyloxy)-2-methylene-cyclohexylidene]-ethanol and 1- (2-Hydroxy-l-methyl-ethyl)-7a-methyl-octahydro-inden-4-ol

A stream of ozone was passed through a stirred solution of t-Butyl-dimethyl-(4- methylene-3-{2-[7a-methyl-l-(l,4,5-trimethyl-hex-2-enyl)-octahydro-inden-4-ylidene]- ethylidene}-cyclohexyloxy)-silane (23.4 g, 45.8 mmol), pyridine (5.0 mL) and Sudane Red 7B (15.0 mg) in dichloro methane (550 mL), at -55 to -6O⁰C until Sudane Red decolorized ( 55 min). Sodium borohydride (6.75 g, 180 mmol) was then added followed by ethanol (250 mL). The reaction was allowed to warm to room temperature and stirred at room temperature for Ih. Acetone (15 mL) was added and, after 30 min brine (300 mL) was added. The mixture was diluted with ethyl acetate (500 mL) and washed with water (600 mL). The aqueous phase was extracted with AcOEt (300 mL). The combined organic phases were dried over Na₂SO₄. The residue (26.5 g), after evaporation of the solvent, was filtered through a plug of silica gel (500 g, 15%, 30% and 50% AcOEt in hexane) to give: Fraction A (5.9 g, mixture containing the desired A-ring (ca 83% pure by NMR) ¹H NMR : δ 5.38 (IH, t, J=6.4Hz), 4.90 (IH, brs), 4.57 (IH, brs), 4.22 (IH, dd, J=7.3, 12.5 Hz), 4.13 (IH, dd, J=6.3, 12.5 Hz), 3.78 (IH, m), 2.40-1.30 (6H, m), 0.83 (9H, s), 0.01 (3H, s), 0.00 (3H, s); Fraction A was used for the synthesis of the A-ring precursor. Fraction B (14.6 g, mixture containing a CD-rings fragments on a different stage of oxidation). Fraction B was further ozonolyzed in order to obtain the Lythgoe diol. A stream of ozone was passed through a stirred solution of Fraction B (14.6 g) and Sudane Red 7B (3.0 mg) in ethano 1(225 mL) at -55 to -6O⁰C for 30min ( Sudane Red decolorized). Sodium borohydride (3.75 g, 100 mmol) was added and the reaction was allowed to warm to room temperature and stirred at room temperature for Ih. Acetone (5 mL) was added and, after 30 min brine (200 mL) was added. The mixture was diluted with dichloromethane (300 mL) and washed with water (250 mL). The aqueous phase was extracted with dichloromethane (200 mL). The combined organic phases were, evaporated to dryness (the last portion was evaporated with addition of toluene 100 mL). The residue (16.2 g) was dissolved in dichloromethane (100 mL), concentrated to a volume of ca 20 mL diluted with petroleum ether (30 mL) and set aside in the fridge for crystallization. The white powder was filtered of (4.05 g), the mother liquor was concentrated and filtered through silica gel (10Og, 5% MeOH in CH₂Cl₂) to give yellow oil (9.4 g), which was recrystallized (20 mL, dichloromethane; petroleum ether 1 :2) to give white powder (1.79 g). Thus the total yield of the Lythgoe diol was (5.84 g, 27.5 mmol, 60 % from D₂) ¹H NMR : δ 4.08 (IH, m), 3.64 (IH, dd, J=3.3, 10.6 Hz), 3.39 (IH, dd, J=6.6, 10.6 Hz), 2.04- 1.14 (15H, m), 1.03 (3H, d, J=6.6 Hz), 0.96 (3H, s).

l-(2-Hydroxy-l-methyl-ethyl)-7a-methyl-octahydro-inden-4-ol and l-(2-Hydroxy-l- methyl-ethyl)-7a-methyl-octahydro-inden-4-ol

t-Butyl-dimethyl-(4-methylene-3-{2-[7a-methyl-l-(l,4,5-trimethyl-hex-2-enyl)-octahydro-inden- 4-ylidene]-ethylidene}-cyclohexyloxy)-silane (98.8 g, 249 mmol) was dissolved in dichloromethane (900 mL) and ethanol (400 mL), pyridine (25.0 mL) and Sudane Red 7B (30.0 mg) were added and the mixture was cooled down to -65 to -7O⁰C. A stream of ozone was passed through for 3h. (until Sudane Red decolorized, reaction was also followed by TLC and decolorization of Sudane Red corresponds to consumption of Vitamin D₂). Sodium borohydride (24.Og, 0.64 mol) was added portion-wise and the reaction was allowed to warm to room temperature and stirred at room temperature for Ih. Acetone (75 mL) was added portion- wise (to keep temperature under 35⁰C) and the reaction mixture was stored overnight in the fridge. The mixture was washed with water (600 mL). The aqueous phase was extracted with dichloromethane (6x 300 mL). The combined organic phases were dried over Na₂SO₄. The residue (118 g) after evaporation of the solvent was passed through a plug of silica gel (0.5 kg, 30%, 50% AcOEt in hexane) to give: Fraction A (69.7 g, CD-rings fragments); Fraction B (4.8 g of a pure Lythgoe diol after crystallization from hexane:AcOEt 3:1); Fraction C (12.3 g of a pure compound starting material, after crystallization from AcOEt); Fraction D (11.5 g, mixture of the starting material and 4-Methylene-cyclo hexane- 1,3-diol).

Fraction A was further ozonolyzed in order to obtain the diol. A stream of ozone was passed through a stirred solution of Fraction A (69.7 g) in ethanol(500 mL), dichloromethane (600 mL) and Sudane Red 7B (3.0 mg) at -65 to -7O⁰C for 3h. ( Sudane Red decolorized). Sodium borohydride (22.5g, 0.6 mol) was added and the reaction was allowed to warm to room temperature and stirred at room temperature for Ih. Acetone (125 mL) was added portion- wise (to keep temperature under 35⁰C) and the reaction mixture was stored overnight in the fridge. The mixture was washed with water (600 mL). The aqueous phase was extracted with dichloromethane (2x 300 mL) and with AcOEt (300 mL). The combined organic phases were dried over Na₂SO₄ and evaporated to dryness. The residue (55.Og) was purified by crystallization (AcOEt :Hexane 1 :2) to give: Fraction E (15.7 g of a pure crystalline diol); Fraction F (35 g, of mixture containing Lythgoe diol). Fraction F (35 g) was passed through a plug of silica gel (0.5 kg, 30%, 50% AcOEt in hexane) to give after crystallization (AcOEt :Hexane 1 :2) Fraction G (18.9 g), thus the overall yield of diol was 39.4g 74.5% from the starting material).

¹H NMR : δ 5.38 (IH, t, J=6.4Hz), 4.90 (IH, brs), 4.57 (IH, brs), 4.22 (IH, dd, J=7.3, 12.5 Hz), 4.13 (IH, dd, J=6.3, 12.5 Hz), 3.78 (IH, m), 2.40-1.30 (6H, m), 0.83 (9H, s), 0.01 (3H, s), 0.00 (3H, s);

Fraction D (11.5 g) was passed through a plug of silica gel (0.3 kg, 50% AcOEt in hexane) to give (after crystallization (AcOEt): Fraction H (1.1 g of a pure crystalline l-(2-Hydroxy-l- methyl-ethyl)-7a-methyl-octahydro-inden-4-ol, 2.8%); Fraction I (10.2 g, mixture of the desired compound. Thus the overall yield of the isolated (S)-(Z)-3-(2-Hydroxy-ethylidene)-4- methylene-cyclohexanol is 13.4 g, 34.8%

1H NMR : δ 5.51 (IH, t, J=6.6Hz), 5.03 (IH, brs), 4.66 (IH, brs), 4.24 (2H, m), , 3.94

(IH, m), 2.55 (IH, dd, J=3.9, 13.2 Hz), 2.41 (IH, m), 2.25 (IH, dd, J=7.8, 12.9 Hz), 1.94 (IH, m), 1.65 (IH, m). (S)-(Z)-2-[5-(tert-butyldimethyl)silanyloxy)-2-methylene-cyclohexylidene]-ethanol

To a stirred solution (S)-(Z)-3-(2-Hydroxy-ethylidene)-4-methylene-cyclohexanol (4.04 g, 26.3 mmol) in dichloromethane (40 mL), imidazole (5.36 g, 78.7 mmol) and (tert-butyldimethyl)silyl chloride (9.50 g, 63.0 mmol) were added successively. The reaction mixture was stirred at room temperature for 100 min. after which water (25 mL) was added. After 15 min. the mixture was diluted with hexane (350 mL), washed with water (2x100 mL) and brine (50 mL) and dried over Na₂SO₄. The residue (10.7 g) after evaporation of the solvent was dissolved in tetrahydofurane (50 mL), Bu₄NF (26.5 mL, 1M/THF) was added at +5⁰C and the mixture was stirred at +5⁰C for 45 min. and additional 30 min. at room temperature. The mixture was diluted with water (100 mL) and ethyl acetate (250 mL). After separation organic layer was washed with water (100 mL) and brine (50 mL). Aqueous layers were extracted with ethyl acetate (5x50 mL). The combined organic layers were dried over Na₂SO₄. The residue after evaporation of the solvent was purified by FC (15Og, 10%, 50% and 100% AcOEt in hexane) to give the titled compound. (6.43 g, 85% pure by NMR , 78% of the title compound,)

¹H NMR : δ 5.38 (IH, t, J=6.4Hz), 4.90 (IH, brs), 4.57 (IH, brs), 4.22 (IH, dd, J=7.3, 12.5 Hz), 4.13 (IH, dd, J=6.3, 12.5 Hz), 3.78 (IH, m), 2.40-1.30 (6H, m), 0.83 (9H, s), 0.01 (3H, s), 0.00 (3H, s).

Synthesis of the A-ring precursor

(2R,3S,7S)- [7-(t-butyldimethyl)silanyloxy)-4-methylene-l-oxa- spiro [2.5] oct-2-yl] -methanol

To a stirred solution of a crude (S)-(Z)-2-[5-(tert-butyldimethyl)silanyloxy)-2-methylene- cyclohexylidene]-ethanol (5.9 g, ca 18.3 mmol, Fraction A from ozonolsysis) in dichloromethane (120 mL) at room temperature, AcONa (2.14 g, 26.1 mmol) was added followed by 72% mCPBA (4.32 g, 18.0 mmol). The reaction mixture was then stirred at 1O⁰C for l/2h then diluted with hexane (200 rnL) washed with 10% K₂CO₃ (3x150 mL), and dried over Na₂SO₄. The residue after evaporation of solvent (6.6 g) was filtered through a plug of silica gel (150 g, 10% AcOEt in hexane) to give the crude title compound (4.87 g, ca 15.4 mmol, 84%) ¹H-NMR: δ 0.063 and 0.068 (2s, 6H), 0.88 (s, 9H), 1.38-1.49 (m, IH), 1.54 (m, IH, OH), 1.62 (m, IH), 1.96 (m, 3H), 2.43 (m, IH), 3.095 (t, IH, J = 5.6 Hz), 3.60 (m, 2H), 3.86 (m, IH), 4.91 (m, IH).

Benzoic acid (2R,3S,7S)-7-(t-butyldimethyl)silanyloxy)-4-methylene-l-oxa- spiro[2.5]oct-2-yl methyl ester

To a stirred solution of (2R,3S,7S)- [7-(t-butyldimethyl)silanyloxy)-4-methylene-l-oxa- spiro[2.5]oct-2-yl]-methanol (4.87 g, ca 15.4 mmol) in pyridine (25 mL) at room temperature, benzoyl chloride (2.14 mL, 18.4 mmol) was added and the reaction mixture was stirred for Ih. Water (25 mL) was added and after stirring for 45 min at room temperature the mixture was diluted with hexane (80 mL), washed with saturated NaHCO₃ solution (50 mL), and dried over Na₂SO₄. The residue after evaporation of solvent (17.5 g) was purified by FC (150 g, 10% AcOEt in hexane) to give the title compound (5.44 g, 14.0 mmol, 91%) ¹H NMR: δ 8.04-7.80 (2H, m), 7.56-7.50 (IH, m), 7.44-7.37 (2H, m), 4.94 (IH, brs), 4.92 (IH, brs), 4.32 (IH, dd,

J=4.8, 11.9 Hz), 4.14 (IH, dd, J=6.2, 11.9 Hz), 3.83 (IH, m), 3.21 (IH, dd, J=4.8, 6.2 Hz), 2.42 (IH, m), 2.04-1.90 (3H, m), 1.64-1.34 (2H, m), 0.83 (9H, s), 0.02 (3H, s), 0.01 (3H, s).

Benzoic acid (2R,3S,5R,7S)-7-(t-butyldimethyl)silanyloxy)-5-hydroxy-4-methylene- l-oxa-spiro[2.5]oct-2-yl methyl ester

T a stirred solution of Benzoic acid (2R,3S,7S)-7-(t-butyldimethyl)silanyloxy)-4- methylene-l-oxa-spiro[2.5]oct-2-yl methyl ester (10.0 g , 25.7 mmol) ) in dioxane (550 mL) at 85⁰C was added selenium dioxide, (3.33 g, 30.0 mmol) followed by t-butyl hydrogen peroxide (9.0 mL, 45.0 mmol, 5-6 M in nonane) and the reaction mixture was stirred at 85⁰C for 16 h, after which selenium dioxide (1.11 g, 10.0 mmol) was added followed by t-butyl hydrogen peroxide (3.0 mL, 15.0 mmol, 5-6 M in nonane) and the reaction mixture was stirred at 85⁰C for additional 6 h. The solvent was removed under vacuum and the residue (15.3 g) was filtered through a plug of silica gel (300g, 20% AcOEt in hexane) to give: starting material (970 mg, 10% ) and a mixture of produce epimer a and epimer b (8.7g). This mixture was divided into 3 portion (2.9 g each) and purified twice by FC (200 g, 5% isopropanol in hexane, same column was used for all six chromatographs) to give: Epimer b (1.83 g, as a 10:1 mixture of 10b:10a ca 16% of 5α-hydroxy compound); Epimer a (6.0 g, 14.8 mmol, 58%) as white crystals. The structure of Epimer a was confirmed by X-ray crystallography.

¹H NMR: δ 8.02-7.90 (2H, m), 7.58-7.50 (IH, m), 7.46-7.38 (2H, m), 5.25 (IH, br s), 5.11 (IH, br s), 4.26 (IH, dd, J=5.5, 12.1 Hz), 4.15 (IH, dd, J=5.9, 12.1 Hz), 4.07 (IH, m), 3.87 (IH, m), 3.19 (IH, dd, J=5.5, 5.9 Hz), 2.34-1.10 (5H, m), 0.81 (9H, s), 0.01 (3H, s), 0.00 (3H, s).

Benzoic acid (2R,3S,5S,7R)-7-(t-butyldimethyl)silanyloxy)-5-fluoro-4- methylene-1- oxa-spiro [2.5] oct-2-ylm ethyl ester

O

To a stirred solution of a diethylamino sulfur trifluoride (DAST) (2.0 mL, 16.0 mmol) in trichloroethylene (20 mL) a solution of Benzoic acid (2R,3S,5R,7S)-7-(t- butyldimethyl)silanyloxy)-5-hydroxy-4-methylene-l-oxa-spiro[2.5]oct-2-yl methyl ester (2.78 g, 6.87 mmol) in trichloroethylene (126 mL was added at -75⁰C. After stirring for 20 min at -75⁰C methanol (5.5 mL) was added followed by saturated NaHCO₃ solution (6 mL) and the resulting mixture was diluted with hexane (150 mL) and washed with saturated NaHCO₃ solution (100 mL), dried over Na₂SO₄ and concentrated. The residue (4.5 g) was purified by FC (150 g, DCM :hexane: AcOEt 10:20:0.2) to give the title compound (2.09 g, 5.14 mmol, 75%) ¹H NMR: δ 8.02-7.99 (2H, m), 7.53-7.45 (IH, m), 7.40-7.33 (2H, m), 5.26 (2H, m), 5.11 (IH, dt, J=3.0, 48.0 Hz), 4.46 (IH, dd, J=3.3, 12.5 Hz), 4.21 (IH, m), 3.94 (IH, dd, J=7.7, 12.5 Hz), 3.29 (IH, dd, J=3.3, 7.7 Hz), 2.44-1.44 (4H, m), 0.80 (9H, s), 0.01 (3H, s), 0.00 (3H, s).

Benzoic acid 2- [5-(tert-butyl-dimethyl-silanyloxy)-3-fluoro-2-methylene- cyclohexylidene] -ethyl ester

A mixture of tris(3,5-dimethylpyrazoyl)hydridoborate rhenium trioxide (265 mg, 0.50 mmol), triphenylphosphine (158 mg, 0.6 mmol), Benzoic acid (2R,3S,5S,7R)-7-(t- butyldimethyl)silanyloxy)-5-fluoro-4- methylene- l-oxa-spiro[2.5]oct-2-ylmethyl ester (203 mg, 0.5 mmol) and toluene (8 mL) was sealed in an ampule under argon and heated at 100⁰C for 14h. (TLC, 10% AcOEt in hexane, mixture of substrate and product, ca 1 :1). Rhenium oxide did not completely solubilized. A solution of triphenylphosphine (158 mg, 0.6 mmol) in toluene (4 mL) was added and the heating continued for 6h. The reaction mixture was cooled to room temperature filtered through a plug of silica gel and then the residue after evaporation of the solvent was purified by FC (2Og, 5% AcOEt in hexane) to give : titled compound (120 mg, 0.31 mmol, 61% of the desire product ) and 70 mg of the starting material plus minor contaminations, ca 34 %.

(lZ,3S,5R)- 2-[5-(t-butyldimethyl)silanyloxy)-3-fluoro-2-methylene- cyclohexylidene] -ethanol

To a solution of Benzoic acid 2-[5-(tert-butyl-dimethyl-silanyloxy)-3-fluoro-2- methylene-cyclohexylidene]-ethyl ester (150 mg, 0.38 mmol) in methanol (3mL) was added sodium methoxide (0.5 mL, 15% in methanol). After stirring for Ih at room temperature water was added (6 mL) and the mixture was extracted with methylene chloride (3x 10 mL). The combined organic layers was dried over Na₂SO₄ and evaporated to dryness. The residue (0.2 g) was purified by FC (2Og, 15% AcOEt in hexane) to give the titled compound (80 mg, 0.28 mmol, 73% of the product).

(lR,3Z,5S)-t-butyl-[3-(2-chloro-ethylidene)-5-fluoro-4-methylene-cyclohexyloxy]- dimethylsilane

To a solution of (1Z,3S, 5R)- 2-[5-(t-butyldimethyl)silanyloxy)-3-fluoro-2-methylene- cyclohexylidene]-ethanol (8.07 g, 28.2 mmol) and triphosgene (4.18 g, 14.1 mmol) in hexane (150 rnL) at O⁰C was added over 30 min a solution of pyridine (4.5 rnL, 55.6 mmol) in hexane (20 mL) and the reaction mixture was stirred at this temperature for 30 min and at room temperature for another 30 min. The reaction mixture was washed with CuSO₄ aq (3 x 200 mL). The combined aqueous layers were back-extracted with hexane (2 x 100 mL). The organic layers were combined, dried (MgSO₄), and concentrated in vacuo to give the title compound (9.0 g, overweight). This material was used immediately in the next step without further purification. [CC]²⁵D + 73.0° (c 0.28, CHCl₃); IR (CHCl₃) 1643, 838 cm ^l; ¹H-NMR δ 0.08 (s, 6H), 0.88 (s, 9H), 1.84-2.03 (m, IH), 2.12 (br s, IH), 2.24 (m, IH), 2.48 (br d, J = 13 Hz, IH), 4.06-4.26 (m, 3H), 5.10 (br d, J = 48 Hz), 5.16 (s, 1 H), 5.35 (s, 1 H), 5.63 (br t, J = 6 Hz, 1 H).

(lS,3Z,5R)-l-fluoro-5-(t-butyldimethyl)silanyloxy)-2-methenyl-3- (diphenylphosphinoyl)ethylidene cyclohexane

Diphenylphosphine oxide (6.70 g, 33.1 mmol) was added portionwise, over 15 min to a suspension of NaH (1.33 g, 33.1 mmol, 60% dispersion in mineral oil) in DMF (50 mL) at 10 ⁰C. The resulting solution was stirred at room temperature for 30 min and cooled to - 60 ⁰C. The solution of crude (lR,3Z,5S)-t-butyl-[3-(2-chloro-ethylidene)-5-fluoro-4-methylene- cyclohexyloxy]-dimethylsilane (9.0 g) in DMF (20 mL)was then added dropwise. The reaction mixture was stirred at -6O⁰C for 2h and at room temperature for Ih, diluted with diethyl ether (600 mL) and washed with water (3x200 mL). The aqueous layers were extracted with diethyl ether (200 mL). The combined organic layers were dried (MgSO₄) and concentrated under reduced pressure to give white solid. The crude product was recrystallized from diisopropyl ether (25 mL). The resulting solid was collected by filtration, washed with cold diisopropyl ether (5 mL) and dried under high vacuum to give the title compound (7.93 g). The mother liquor was concentrated and the residue was subjected to chromatography on silca gel (50 g, 30%-50% AcOEt in hexane) to give title compound (2.22 g). Thus the total yield of the of (1S,3Z,5R)-1- fluoro-5-(t-butyldimethyl)silanyloxy)-2-methenyl-3-(diphenyl phosphinoyl)ethylidene cyclohexane was (10.1 g, 21.5 mmol, 76% overall from (1Z,3S,5R)- 2-[5-(t- butyldimethyl)silanyloxy)-3-fluoro-2-methylene-cyclohexylidene]-ethanol. [Cc]²⁵D + 50.2° (c 0.84, CHCl₃); IR (CHCl₃) 835, 692 cm^"1; UVλ _max (ethanol) 223 (ε 22770), 258 (1950), 265 (1750), 272 nm (1280); MS, m/e 470 (M⁺), 455 (4), 450 (8), 413 (98), 338 (9), 75 (100); ¹H- NMR: δ 0.02 (s, 6 H), 0.84 (s, 9H), 1.76-1.93 (m, 1 H), 2.16 (m, 2 H), 2.42 (br d, 1 H), 3.28 (m, 2 H), 4.01 (m, 1 H), 5.02 (dm, J = 44 Hz, 1 H), 5.14 (s, 1 H), 5.30 (s, 1 H), 5.5 (m, 1 H), 7.5 (m, 6 H), 7.73 (m, 4 H). Analysis Calcd for C₂₇H₃₆O₂FPSi: C 68.91, H 7.71; F 4.04; Found: C 68.69, H 7.80, F 3.88.

Larger Scale Synthesis of the A-ring precursor

(2R,3S,7S)- [7-(t-butyldimethyl)silanyloxy)-4-methylene-l-oxa-

To a stirred solution of crude (S)-(Z)-2-[5-(tert-butyldimethyl)silanyloxy)-2-methylene- cyclohexylidene]-ethanol (13.5 g, ca 40 mmol) in dichloromethane (100 mL) at room temperature, was added AcONa (4.5 g, 54.8 mmol), followed by 77% mCPBA (8.96 g, 40.0 mmol) at +5⁰C. The reaction mixture was then stirred at +5⁰C for 1.5h, diluted with hexane (500 mL), washed with water (200 mL) and NaHCO₃ (2x 200 mL) and dried over Na₂SO₄. The residue after evaporation of solvent (12.36 g) was used for the next step without further purification. ¹H-NMR: δ 0.063 and 0.068 (2s, 6H), 0.88 (s, 9H), 1.38-1.49 (m, IH), 1.54 (m, IH, OH), 1.62 (m, IH), 1.96 (m, 3H), 2.43 (m, IH), 3.095 (t, IH, J = 5.6 Hz), 3.60 (m, 2H), 3.86 (m, IH), 4.91 (m, IH).

Benzoic acid (2R,3S,7S)-7-(t-butyldimethyl)silanyloxy)-4-methylene-l-oxa- spiro [2.5] oct-2-yl methyl ester

To a stirred solution of (2R,3S,7S)-[7-(tert-butyldimethyl)silanyloxy)-4-methylene-l-oxa- spiro[2.5]oct-2-yl]-methanol (12.36 g) in pyridine (50 rnL) at room temperature, was added benzoyl chloride (8.5 mL, 73 mmol) and the reaction mixture was stirred for 2h. Water (60 mL) was added and after stirring for 45 min at room temperature the mixture was diluted with hexane (250 mL), washed with NaHCO_3aq (2x250 mL), brine (250 mL) and dried over Na₂SO₄. The residue after evaporation of the solvent (15.28 g) was used for the next step without further purification. ¹H NMR: δ 8.04-7.80 (2H, m), 7.56-7.50 (IH, m), 7.44-7.37 (2H, m), 4.94 (IH, brs), 4.92 (IH, brs), 4.32 (IH, dd, J=4.8, 11.9 Hz), 4.14 (IH, dd, J=6.2, 11.9 Hz), 3.83 (IH, m), 3.21 (IH, dd, J=4.8, 6.2 Hz), 2.42 (IH, m), 2.04-1.90 (3H, m), 1.64-1.34 (2H, m), 0.83 (9H, s), 0.02 (3H, s), 0.01 (3H, s).

Benzoic acid (2R,3S,5R,7S)-7-(t-butyldimethyl)silanyloxy)-5-hydroxy-4-methylene- l-oxa-spiro[2.5]oct-2-yl methyl ester

To a stirred solution of benzoic acid (2R,3S,7S)-7-(tert-butyldimethyl)silanyloxy)-4-methylene- l-oxa-spiro[2.5]oct-2-yl methyl ester (15.28 g) ) in dioxane (450 mL) at 85⁰C was added selenium dioxide (4.26 g, 38.4 mmol), followed by tert-butyl hydrogen peroxide (7.7 mL, 38.4 mmol, 5-6 M in nonane) and the reaction mixture was stirred at 85⁰C for 13h, after which selenium dioxide (2.39 g, 21.5 mmol) was added, followed by tert-butyl hydrogen peroxide (4.3 mL, 21.5 mmol, 5-6 M in nonane) and the reaction mixture was stirred at 85⁰C for additional 24h. The mixture was filtered off through a plug of silica gel (0.5 kg, AcOEt). The solvent was removed under vacuum and the residue was dissolved in AcOEt (250 mL) and washed with water (3x 100 mL). The organic layer was dried over Na₂SO₄ and evaporated under vacuum. The residue (16 g) was purified by flash chromatography (0.5 kg, 10, 15 and 20% AcOEt in hexane) to give: Fraction A (1.1 g, of a starting material); Fraction B (0.78 g, of epimer b); Fraction C (3.01 g, 65:35 (epimer b:epimer a); Fraction D (6.22 g, 5:95 (epimer b:epimer a); Fraction D was crystallized two times (each time using the remaining oil) from hexane to give pale yellow solid Fraction E (6.0 g in total) and yellow-red oil Fraction F (0.2 g in total). Fractions C and F were purified by flash chromatography (300 g, 20% AcOEt in hexane) to give: Fraction G (0.8 g, of epimer b); Fraction H (2.4 g, 8:92 epimer b:epimer a). Fraction H was crystallized two times (each time using the remaining oil) from hexane to give pale yellow solid Fraction I (2.2 g in total) and yellow-red oil Fraction J (0.2 g in total). Fractions E and I were combined to give epimer a (8.2 g, 20.3 mmol, 50.7% total yield. [α]²² _D -10.6° (c 0.35, EtOH); ¹H NMR: δ 8.04 (2H, m), 7.58 (IH, m), 7.46 (2H, m), 5.32 (IH, br s), 5.18 (IH, br s), 4.33 (IH, dd, J=5.2, 11.9 Hz), 4.21 (IH, dd, J=6.0, 11.9 Hz), 4.14 (IH, ddd, J=2.6,4.9, 10.0 Hz), 3.94 (IH, m), 3.25 (IH, dd, J=5.5, 5.9 Hz), 2.38 (IH, m), 2.05 (IH, t, J=I 1.5 Hz), 1.64 (IH, ddd, J=1.9, 4.3, 12.2 Hz), 1.52 dt, J=I Ll, 11.7 Hz), 1.28 (IH, m), 0.87 (9H, s), 0.07 (3H, s), 0.06 (3H, s);

¹³C NMR : 166.31(0), 145.52(0), 133.29(1), 129.65(1), 129.54(0), 128.46(1), 107.44(2),68.51(l), 65.95(1), 62.75(2), 61.62(1), 61.09(0), 45.23(2), 44.33(2), 25.72(3), 18.06(0), -4.72(3); MS Hi?- ES: CaICd- FOr C₂₂H₃₂O₅Si: M+Na 427.1911 Found: 427.1909.

Benzoic acid (2R,3S,5S,7R)-7-(t-butyldimethyl)silanyloxy)-5-fluoro-4- methylene-1- oxa-spiro [2.5] oct-2-ylmethyl ester

O

To a stirred solution of diethylaminosulfur trifluoride (16.5 mL, 126.0 mmol) in trichloroethylene (140 mL) was added a solution of benzoic acid (2R,3S,5R,7S)-7-(tert- butyldimethyl)silanyloxy)-5-hydroxy-4-methylene-l-oxa-spiro[2.5]oct-2-yl methyl ester epimer a (18.7 g, 46.2 mmol) in trichloroethylene (100 mL at -75⁰C. After stirring for 20 min. at -75⁰C methanol (40 mL) was added, followed by NaHCO3_aq (50 mL) and the resulting mixture was diluted with hexane (700 mL) and washed with NaHCO3_aq (600 mL), dried over Na₂SO₄ and concentrated on rotary evaporator. The residue (25.6 g) was purified by flash chromatography (50Og, DCM:hexane:AcOEt 10:20:0.2) to give the titled compound (13.9 g, 34.2 mmol, 74%); [CC]²⁹D +38.9° (c 0.8, CHCl₃); ¹H NMR: δ 8.07 (2H, m), 7.57 (IH, m), 7.44 (2H, m), 5.33 (2H, m), 5.20 (IH, dt, J=2.9, 48Hz), 4.55 (IH, dd, J=3.2, 12.3 Hz), 4.29 (IH, m), 4.02 (IH, dd, J=7.9, 12.3 Hz), 3.37 (IH, dd, J=3.2, 7.7 Hz), 2.45 (IH, m), 2.05 (IH, t, J=I 1.9 Hz), 1.73 (IH, dm), 1.62 (IH, m), 0.88 (9H, s), 0.08 (3H, s), 0.06 (3H, s); ¹³C NMR : 166.25(0), 139.95(0, d, J=17Hz), 132.97(1), 129.75(0), 129.62(1), 128.24(1), 116.32(2, d, J=9Hz), 92.11 (1, d, J=162Hz), 65.23(1), 63.78(2), 62.29(1), 60.35(0), 44.38(2), 41.26(2, d, J=23Hz), 25.81(3), 18.13(0), -4.66(3); MS HR-ES: Calcd. For C₂₂H₃i0₄SiF: M+H 407.2049 Found: 407.2046.

(lE,3S,5R)- 2-[5-(tert-Butyldimethyl)silanyloxy)-3-fluoro-2-methylene-cyclohexylidene]- ethanol

Tungsten hexachloride (36.4 g, 91 mmol) was added at -75⁰C to THF (800 mL). The temperature was adjusted to -65⁰C and nBuLi (73 mL, 182.5 mmol, 2.5M solution in hexane) was added maintaining temperature below -2O⁰C. After the addition was completed the reaction mixture was allowed to come to room temperature and it was stirred for 30 min., cooled down to O⁰C, when a solution of benzoic acid (2R,3S,5S,7R)-7-(tert-butyldimethyl)silanyloxy)-5-fluoro-4- methylene-l-oxa-spiro[2.5]oct-2-yl methyl ester (18.5 g, 45.5 mmol) in THF (50 mL) was added. Thus formed mixture was allowed to come to room temperature (2h) and stirred for 16h. Methanol (400 mL) was added followed by sodium methoxide (250 mL, 15% in methanol), the resulting mixture was stirred for 30 min then diluted with AcOEt (1 L) and washed with water (1 L) and brine (500 mL). The residue (21.6 g) after evaporation of the dried (Na₂SO₄) solvent was used for the next step without further purification.

¹H-NMR (CDCl₃); δ 0.09 (s, 6H), 0.81 (s, 9H), 1.80-2.22 (m, 3H), 2.44 (m, IH), 4.10 (m, IH), 4.14 (d, 2H, J=6.9 Hz), 4.98 (br s, IH), 5.10 (d, IH, J = 50.0 Hz), 5.11 (s, IH), 5.79 (t, IH, J = 6.8 Hz).

(1Z,3S,5R)- 2-[5-(tert-Butyldimethyl)silanyloxy)-3-fluoro-2-methylene-cyclohexylidene]- ethanol

A solution of (1E,3S,5R)- 2-[5-(tert-butyldimethyl)silanyloxy)-3-fluoro-2-methylene- cyclohexylidene]-ethanol (21.6 g, crude containing ca 10% of the Z isomer) and 9-fluorenone (1.8 g, 10 mmol) in tert-Butyl-methyl ether (650 mL) was irradiated with 450W hanovia lamp with uranium core filter for 8 h. The residue after evaporation of solvent (23.95g) was purified by flash chromatography (75Og, 5%,20%, AcOEt in hexane) to give the title compound (10.4 g, 36.3 mmol, 80% from benzoic acid (2R,3S,5S,7R)-7-(tert-butyldimethyl)silanyloxy)-5-fluoro-4- methylene- l-oxa-spiro[2.5]oct-2-yl methyl ester). [α]³⁰ _D +40.1° (c 0.89, EtOH) ¹H-NMR : δ 5.65(1H, t, J=6.8Hz), 5.31(1H, dd, J=1.5, 1.7Hz), 5.10 (IH, ddd, J=3.2, 6.0, 49.9Hz), 4.95(1H, d, J=I.7Hz), 4.28(1H, dd, J=7.3, 12.6Hz), 4.19 (IH, ddd, J=I.7, 6.4, 12.7Hz), 4.15(1H, m), 2.48 (IH, dd, J=3.8, 13.0Hz), 2.27-2.13 (2H, m), 1.88 (IH, m), 0.87 (9H, s), 0.07 (6H,s). ¹³C-NMR: 142.54(0,d, J=17Hz), 137.12(0, d, J=2.3Hz), 128.54(1), 115.30(2, d, J=IOHz), 92.11 (1, d, J=168Hz), 66.82(1, d, J=4.5Hz), 59.45(2), 45.15(2), 41.44(2, d, J=21Hz), 25.76(3), 18.06(0), -4.75(3), -4.85(3).

(lR,3Z,5S)-t-butyl-[3-(2-chloro-ethylidene)-5-fluoro-4-methylene-cyclohexyloxy]- dimethylsilane

To a solution of (1Z,3S,5R)- 2-[5-(tert-Butyldimethyl)silanyloxy)-3-fluoro-2-methylene- cyclohexylidene]-ethanol (8.07 g, 28.2 mmol) and triphosgene (4.18 g, 14.1 mmol) in hexane (150 rnL) at O⁰C was added over 30 min a solution of pyridine (4.5 rnL, 55.6 mmol) in hexane (20 mL) and the reaction mixture was stirred at this temperature for 30 min and at room temperature for another 30 min. The reaction mixture was washed with CuSO₄ aq (3 x 200 mL). The combined aqueous layers were back-extracted with hexane (2 x 100 mL). The organic layers were combined, dried (MgSO₄), and concentrated in vacuo to give the title compound (9.0 g, overweight). This material was used immediately in the next step without further purification. [CC]²⁵D + 73.0° (c 0.28, CHCl₃); IR (CHCl₃) 1643, 838 cm ^l; ¹H-NMR δ 0.08 (s, 6H), 0.88 (s, 9H), 1.84-2.03 (m, IH), 2.12 (br s, IH), 2.24 (m, IH), 2.48 (br d, J = 13 Hz, IH), 4.06-4.26 (m, 3H), 5.10 (br d, J = 48 Hz), 5.16 (s, 1 H), 5.35 (s, 1 H), 5.63 (br t, J = 6 Hz, 1 H).

(lS,3Z,5R)-l-fluoro-5-(t-butyldimethyl)silanyloxy)-2-methenyl-3-

(diphenylphosphinoyl)ethylidene cyclohexane

Diphenylphosphine oxide (6.70 g, 33.1 mmol) was added portionwise, over 15 min to a suspension of NaH (1.33 g, 33.1 mmol, 60% dispersion in mineral oil) in DMF (50 mL) at 10 ⁰C. The resulting solution was stirred at room temperature for 30 min and cooled to - 60 ⁰C. The solution of crude (lR,3Z,5S)-t-butyl-[3-(2-chloro-ethylidene)-5-fluoro-4-methylene- cyclohexyloxy]-dimethylsilane (9.0 g) in DMF (20 mL)was then added dropwise. The reaction mixture was stirred at -6O⁰C for 2h and at room temperature for Ih, diluted with diethyl ether (600 mL) and washed with water (3x200 mL). The aqueous layers were extracted with diethyl ether (200 mL). The combined organic layers were dried (MgSO₄) and concentrated under reduced pressure to give white solid. The crude product was recrystallized from diisopropyl ether (25 mL). The resulting solid was collected by filtration, washed with cold diisopropyl ether (5 mL) and dried under high vacuum to give the title compound (7.93 g). The mother liquor was concentrated and the residue was subjected to chromatography on silca gel (50 g, 30%-50% AcOEt in hexane) to give title compound (2.22 g). Thus the total yield of the of the titled compound was (10.1 g, 21.5 mmol, 76% overall from (1Z,3S,5R)- 2-[5-(tert- Butyldimethyl)silanyloxy)-3-fluoro-2-methylene-cyclohexylidene]-ethanol. [Cc]²⁵D + 50.2° (c 0.84, CHCl₃); IR (CHCl₃) 835, 692 cm^"1; UVλ _max (ethanol) 223 (ε 22770), 258 (1950), 265 (1750), 272 nm (1280); MS, m/e 470 (M⁺), 455 (4), 450 (8), 413 (98), 338 (9), 75 (100); ¹H-

NMR: δ 0.02 (s, 6 H), 0.84 (s, 9H), 1.76-1.93 (m, 1 H), 2.16 (m, 2 H), 2.42 (br d, 1 H), 3.28 (m, 2 H), 4.01 (m, 1 H), 5.02 (dm, J = 44 Hz, 1 H), 5.14 (s, 1 H), 5.30 (s, 1 H), 5.5 (m, 1 H), 7.5 (m, 6 H), 7.73 (m, 4 H). Analysis Calcd for C₂₇H₃₆O₂FPSi: C 68.91, H 7.71; F 4.04; Found: C 68.69, H 7.80, F 3.88.

Synthesis of C,D-ring/side chain precursor

(S)-2-((lR,3aR,4S,7aR)-4-hydroxy-7a-methyl-octahydro-inden-l-yl)- propionaldehyde

A 250-mL flask was charged with 0.99 g (4.67 mmol) of Lythgoe diol, 75 mg (0.48 mmol) of TEMPO, 146 mg (0.53 mmol) of tetrabutylammonium chloride hydrate, and dichloromethane (50 mL). To this vigorously stirred solution was added a buffer solution (50 mL) prepared by dissolving sodium hydrogen carbonate (4.2 g) and potassium carbonate (0.69 g) in a volume of 100 mL of water. The mixture was stirred vigorously and 839 mg (6.28 mmol) ofN-chlorosuccinimide was added. TLC (1 :2, ethyl acetate - heptane) showed the gradual conversion of educt (Rf 0.32) to the titled aldehyde (Rf 0.61). After 18 h an additional quantity of 830 mg (6.28 mmol) of N-chlorosuccinimide was added and one hour later 20 mg of TEMPO was added and the mixture was stirred for 24 h. The organic layer was separated and the aqueous layer re-extracted with dichloromethane (3 x 50 rnL). The combined organic extracts were washed with brine, dried and concentrated in vacuo. The residue was purified by column chromatography (SiO₂, ethyl acetate / heptane = 1 :3) to furnish 876 mg of crude aldehyde (89%) ¹H NMR : δ 9.58 (IH, d, J=2.8 Hz), 4.12 (IH, m), 2.50-2.30 (IH, m), 2.10-1.10 (13H, m), 1.11 (3H, d, J=7.0 Hz), 0.99 (3H, s).

(lR,3aR,4S,7aR)-7a-methyl-l-((S)-l-methyl-2-oxo-ethyl)- octahydroinden-4-yl ester

Crude (S)-2-((lR,3aR,4S,7aR)-4-hydroxy-7a-methyl-octahydro-inden-l-yl)- propionaldehyde (255 mg, 1.21 mmol) was dissolved in pyridine (1 mL), the so In. cooled in an ice bath and DMAP (5 mg) and acetic anhydride (0.5 mL) were added. The mixture was stirred at room temperature for 24 h then diluted with water (10 mL), stirred for 10 min and equilibrated with ethyl acetate (30 mL). The organic layer was washed with a mixture of water (10 mL) and 1 N sulfuric acid (14 mL), then with water (10 mL) and saturated sodium hydrogen carbonate solution (10 mL), then dried and evaporated. The resulting residue (201 mg) was chromatographed on a silica gel column using 1 :4 ethyl acetate - hexane as mobile phase. The fractions containing the product were pooled and evaporated to give the title compound as a colorless syrup (169 mg, 0.67 mmol, 67%). ¹H NMR (300 MHz, CDCl₃): δ 9.56 (IH, d, J=2.0 Hz), 5.20 (IH, br s), 2.44-2.16 (IH, m), 2.03 (3H, s), 2.00-1.15 (12H, m), 1.11 (3H, d, J=7.0 Hz), 0.92 (3H, s).

Acetic acid (3aR,4S,7aR )-l-E-ethylidene-7a-methyl-octahydroinden-4-yl ester

To a solution of (lR,3aR,4S,7aR)-7a-methyl-l-((S)-l-methyl-2-oxo-ethyl)- octahydroinden-4-yl ester (480 mg, 1.90 mmol) in diethylether (5 mL) was added 10% Pd on Carbon (25 mg). The suspension was stirred at room temperature for 20 min., filtered through a path of Celite and the filtrate was concentrated in vacuo. To the residue was added benzalacetone (350 mg, 2.40 mmol, distilled) and 10% Pd on Carbon (50 mg). The suspension was degassed by evacuating the flask and refilling with nitrogen (2x). Then the flask was immersed in a 230 ⁰C heating bath for 40 min. After cooling at room temperature the suspension was diluted with ethyl acetate, filtered through a path of Celite and the filtrate was concentrated in vacuo. The residue was purified by column chromatography (SiO₂, ethyl acetate / heptane = 1 :9) affording 290 mg (68%) of a mixture of CD olefins. GC analysis: titled product (54%); Z isomer (4%); internal olefin (27%); terminal olefin (5%); other impurities (10%).

(2R,3aR,4S,7aR)-l-E-ethylidene-2-hydroxy-7a-methyl-octahydroinden-4-yl ester (a) and acetic acid (2S,3aR,4S,7aR)-l-E)-ethylidene-2-hydroxy-7a-methyl-octahydroinden-4- yl ester (b)

7% 35% 6%

50%

SeO₂, 'BuOOH, DCM 0 ⁰C - r t , 3 d + other isomers

ca 28%

30% traces

To a suspension of SeO₂ (460 mg, 4.15 mmol) in dichloro methane (30 mL) was added te/t.-buty Hydroperoxide (9.0 mL, 70 w/w-% solution in water, 65.7 mmol). The suspension was stirred at room temperature for 30 min., cooled at 0 ⁰C and a solution of CD-isomers (9.13 g, 41.1 mmol, contains ca 50% of 16) in dichloromethane (35 mL) was added dropwise within 30 min. The reaction mixture was allowed to reach room temperature overnight and stirring was continued at 30 ⁰C for 2 days. Conversion was checked by GC. The reaction was quenched by addition of water and the aqueous layer was extracted with dichloromethane (3x). The combined organic layers were washed with water (4x), washed with brine, dried (Na₂SO₄), filtered and the filtrate was concentrated in vacuo. The residue was purified by column chromatography (SiO₂, ethyl acetate / heptane = 1 :3) affording three main fractions: Fraction 1 : Ketone (2.08 g, 42% yield); contaminated with 2 impurities; purity -75%; Fraction 2: mixed fraction of alcohol epimer a + unwanted isomer (1.32 g); Fraction 3: Alcohol epimer a (2.10 g, 42% yield); contaminated with ca. 12% byproduct, but pure enough for further synthesis. Fraction 2 was purified again by column chromatography affording 1.01 g (20% yield) of alcohol epimer a contaminated with ca. 20% of an unwanted isomer, but pure enough for further synthesis. *Note: During the oxidation reaction the formation of both isomers epimer a and epimer b was observed by tic and GC. After prolonged reaction times the intensity of the lower spot on tic (mixture of epimer b and other isomers) decreased and the formation of ketone was observed. It is important that not only conversion of starting material to alcohol epimer a and epimer b is complete but also that epimer epimer b is completely oxidized to ketone. Epimer epimer b can not be separated from unwanted isomers. Retention times on GC: starting material ret. Time = 8.06 min; product ret. Time = 9.10 min; epimer b ret. Time = 9.30 or 9.34 min; ketone ret. Time = 9.60 min. epimer a: ¹H NMR : δ 0.94 (s, 3 H), 1.30 (m, 1 H), 1.40-1.46 (m, 1 H), 1.46-1.80 (m, 4 H), 1.77 (dd, J= 7.2, 1.2 Hz, 3 H), 1.80-1.94 (m, 4 H), 2.02 (s, 3 H), 4.80 (br. s, 1 H), 5.23 (m, 1 H), 5.47 (qd, J= 7.2, 1.2 Hz, 1 H). GC-MS: m/e 223 (M - 15), 178 (M - 60), 163 (M - 75). epimer b: ¹H NMR : δ 1.24 (s, 3 H), 1.38-1.60 (m, 5 H), 1.68-1.88 (m, 3 H), 1.72 (dd, J= 7.2, 1.2 Hz, 3 H), 1.99 (ddd, J= 11.0, 7.0, 3.7 Hz, 1 H), 2.03 (s, 3 H), 2.26 (m, 1 H), 4.36 (m, 1 H), 5.14 (m, 1 H), 5.30 (qd, J= 7.2, 1.2 Hz, 1 H). GC-MS: m/e 223 (M - 15), 178 (M - 60), 163 (M - 75).

Reduction of ketone to alcohol epimer b

A solution of ketone (2.08 g, contaminated with 2 impurities) in methanol (8 mL) was cooled at 0 ⁰C and sodium borohydride (0.57 g, 15.1 mmol) was added in portions. After stirring at 0 ⁰C for 1 h, tic showed complete conversion (no UV active compound visible on tic). The reaction mixture was quenched by addition of sat. aqueous NH₄Cl solution (30 mL). Water was added and the aqueous layer was extracted with ethyl acetate (3x). The combined organic layers were washed with brine, dried (Na₂SO₄), filtered and the filtrate was concentrated in vacuo. The residue was purified by column chromatography (SiO₂, ethyl acetate / heptane = 1 :3) affording alcohol epimer b (1.20 g, 24% over two steps) as a colorless oil.

Acetic acid (3aR,4S,7aR )-7a-methyl-l-(l-(R)-methyl-3-oxo-propyl)-3a,4,5,6,7,7a- hexahydro-3H-inden-4-yl ester

60% Both (2R,3aR,4S,7aR)- 1 -E-ethylidene^-hydroxy^a-methyl-octahydroinden^-yl ester (a) and acetic acid (2S,3aR,4S,7aR)-l-E)-ethylidene-2-hydroxy-7a-methyl-octahydroinden-4-yl ester (b) (4.3 g, 18.1 mmol, purity 90%) were converted to compound Acetic acid (3aR,4S,7aR )- 7a-methyl-l-(l-(R)-methyl-3-oxo-propyl)-3a,4, 5,6,7, 7a-hexahydro-3H-inden-4-yl ester in three batches. To a solution of epimer a (2.1 g, 8.82 mmol) in ethyl vinyl ether (20 mL) was added Hg(OAc)₂ (2.23 g, 7.00 mmol). The suspension was poured into a pyrex pressure tube, flushed with N₂ and closed tightly. The mixture was stirred at 120 ⁰C for 24 h, cooled at room temperature and filtered. The filtrate was concentrated in vacuo and the residue was combined with the crude product of the two other batches and purified twice* by column chromatography (SiO₂, ethyl acetate / heptane = 1 :4) affording the titled compound (2.58 g, 60%) as a slightly yellow oil. The product solidified upon storage in the freezer. A second purification by column chromatography was advantageous due to the byproducts present in the starting material.

To a solution of epimers a and b (173 mg, 0.73 mmol) in toluene (2 mL) was added a catalytic amount of [Ir(COD)Cl]₂ (5 mg), Na₂CO₃ (46 mg, 0.44 mmol) and vinyl acetate (0.13 mL, 1.45 mmol). After heating the suspension at 100 ⁰C for 2 h, tic indicates ca. 20% conversion to intermediate. (J. Am. Chem. Soc, 2002, 134, 1590-1591.) More vinyl acetate (0.15 mL) was added and stirring at 100 ⁰C was continued for 18 h. According tic a mixture of intermediate and the titled compound was formed but conversion of the starting material was still not complete. More vinyl acetate (2 mL) was added and stirring at 100 ⁰C was continued for 24 h. Tie shows complete conversion of the starting material to a mixture of intermediate and the titled compound. The suspension was concentrated in vacuo and the residue was purified by column chromatography (SiO₂, ethyl acetate / heptane = 1:9) affording 60 mg of intermediate (31%) and 45 mg of the titled compound (23%). ¹H NMR : δ 1.02 (s, 3 H), 1.14 (d, J= 7.1 Hz, 3 H), 1.36 (M, 1 H), 1.47-1.62 (m, 2 H), 1.72-1.90 (m, 4 H), 2.03 (s, 3 H), 2.02-2.14 (m, 2 H), 2.33 (ddd, J = 16.2, 7.3, 2.6 Hz, 1 H), 2.53 (ddd, J= 16.2, 5.8, 1.8 Hz, 1 H), 2.72 (m, 1 H), 5.19 (m, 1 H), 5.40 (m, 1 H), 9.68 (s, 1 H).

5(R)-( (3aR,4S,7aR )-4-acetoxy-7a-methyl-3a,4,5,6,7,7a-hexahydro-3H-inden-l-yl)- hex-2-E-enoic acid ethyl ester

THF

Acetic acid (3aR,4S,7aR )-7a-methyl-l-(l-(R)-methyl-3-oxo-propyl)-3a,4,5,6,7,7a- hexahydro-3H-inden-4-yl ester (2.24 g, 8.47 mmol) and triethyl phosphonoacetate (5.74 g, 25.6 mmol, 3 eq.) were dissolved under N₂ atmosphere in THF (40 mL, freshly distilled over Na/benzophenone). The mixture was cooled at -100 ⁰C and a solution of LiHMDS in hexanes (16.8 mL, 1 M solution, 2eq.) was added dropwise within 20 min. After stirring at -100 ⁰C <-> - 78 ⁰C for 70 min. the reaction was quenched by dropwise addition of water (10 mL) and subsequently addition of sat. NH₄Cl solution (10 mL). Water was added and it was extracted with tert. butyl methyl ether (3x). The combined organic layers were washed with water (2x), brine (Ix), dried (Na₂SO₄), filtered and the filtrate was concentrated in vacuo. The residue was purified by column chromatography (SiO₂, ethyl acetate / heptane = 1 :10) affording ester the titled compound (2.15 g, 76%) as a colorless oil; purity according NMR: >95% (no Z-isomer detected). ¹H NMR : δ 0.99 (s, 3 H), 1.06 (d, J= 7.2 Hz, 3 H), 1.27 (t, J= 7.1 Hz, 3 H), 1.36 (td, J= 13.3, 4.0 Hz, 1 H), 1.46-1.62 (m, 2 H), 1.72-1.90 (m, 4 H), 1.96-2.17 (m, 3 H), 2.03 (s, 3 H), 2.22-2.39 (m, 2 H), 4.17 (q, J= 7.2 Hz, 2 H), 5.20 (br. s, 1 H), 5.37 (br. s, 1 H), 5.78 (dm, J = 15.4 Hz, 1 H), 6.88 (dt, J= 15.4, 7.3 Hz, 1 H). HPLC: purity > 99% (218 nm). HPLC-MS: m/e 357 (M + 23), 275 (M - 59).

(SaR^S^aR J-l-CCS^J-S-ethyl-S-hydroxy-l-methyl-hept-S-enyO-Ta-methyl-

3a,4,5,6,7,7a-hexahydro-3H-inden-4-ol

CeCl₃ x 7 H₂O (29.1 g) was dried in vacuo (10^" mbar) in a three-necked flask at 160 ⁰C for 6 h affording anhydrous CeCl₃ (18.7 g, 76.0 mmol, 12 eq.). After cooling at room temperature the flask was purged with nitrogen. THF (200 mL, freshly distilled over Na/benzophenone) was added and the mixture was stirred at room temperature for 18 h. Subsequently the suspension was cooled at 0 ⁰C and a solution of EtMgBr in THF (75 mL, 1 M solution) was added dropwise within 20 min. After stirring the light brown suspension at 0 ⁰C for 2 h a solution of 5(R)-( (3aR,4S,7aR )-4-acetoxy-7a-methyl-3a,4,5,6,7,7a-hexahydro-3H-inden- l-yl)-hex-2-E-enoic acid ethyl ester (2.15 g, 6.42 mmol) in THF (30 mL, freshly distilled over Na/benzophenone) was added dropwise within 10 min. After stirring at 0 ⁰C for 30 min. tic showed complete conversion and the reaction was quenched by addition of water (60 mL). More water was added and the mixture was extracted with 50% ethyl acetate in heptane (3x). The combined organic layers were washed with sat. NaHCO₃ solution (2x), brine (Ix), dried (Na₂SO₄), filtered and the filtrate was concentrated in vacuo affording a slightly yellow oil. The crude product (2.4 g) was combined with a 2^nd batch (600 mg crude (3aR,4S,7aR )-l-((S,E)-5- ethyl-5-hydroxy-l-methyl-hept-3-enyl)-7a-methyl-3a,4, 5,6,7, 7a-hexahydro-3H-inden-4-ol obtained from 550 mg of starting material). Purification by column chromatography (SiO₂, ethyl acetate / heptane = 1 :3) afforded (3aR,4S,7aR )-l-((S,E)-5-ethyl-5-hydroxy-l-methyl-hept-3- enyl)-7a-methyl-3a,4,5,6,7,7a-hexahydro-3H-inden-4-ol (2.45 g, 99%) as a colorless oil. ¹H NMR : δ 0.84 (t, J= 7.3 Hz, 6 H), 1.04 (d, J= 7.2 Hz, 3 H), 1.05 (s, 3 H), 1.23-1.60 (m, 9 H), 1.67-2.02 (m, 6 H), 2.12-2.32 (m, 3 H), 4.17 (m, 1 H), 5.33 (m, 1 H), 5.35 (dm, J= 15.4 Hz, 1 H), 5.51 (ddd, J= 15.4, 7.4, 6.5 Hz, 1 H). HPLC: purity = 98% (212 nm). HPLC-MS: m/e 330 (M + 24), 289 (M - 17), 271 (M - 35).

(3aR,4S,7aR )-l-((S,E)-5-ethyl-5-hydroxy-l-methyl-hept-3-enyl)-7a-methyl- 3a,4,5,6,7,7a-hexahydro-3H-inden-4-one

A solution of (3aR,4S,7aR )-l-((S,E)-5-ethyl-5-hydroxy-l-methyl-hept-3-enyl)-7a- methyl-3a,4, 5,6,7, 7a-hexahydro-3H-inden-4-ol (465 mg, 1.52 mmol) in dichloromethane (30 rnL) was cooled in an ice-bath and treated portion- wise with pyridinium dichromate (1.28 g, 3.40 mmol, 2.2 eq.). The reaction mixture was stirred at 0 ⁰C for 6 h and at room temperature for 18 h. The reaction mixture was filtered through a path of Celite. The filtercake was washed with dichloromethane and the combined filtrates were concentrated in vacuo. The residue was purified by column chromatography (SiO₂, 25% ethyl acetate in heptane) affording the titled compound (320 mg, 69%) as a colorless oil. ¹H NMR : δ 0.82 (s, 3 H), 0.85 (br. t, J= 7.2 Hz, 6 H), 1.05 (d, J= 6.9 Hz, 3 H), 1.34 (br. s, 1 H), 1.52 (br. q, J= 6.9 Hz, 4 H), 1.65 (td, J= 12.1, 5.6 Hz, 1 H), 1.84-1.93 (m, 1 H), 1.93-2.16 (m, 4 H), 2.16-2.33 (m, 4 H), 2.42 (ddt, J= 15.4, 10.4, 1.6 Hz, 1 H), 2.82 (dd, J= 10.4, 6.0 Hz, 1 H), 5.30 (m, 1 H), 5.38 (dm, J= 15.6 Hz, 1 H), 5.54 (ddd, J= 15.6, 7.1, 6.0 Hz, 1 H).

Larger Scale Synthesis ofC,D-ring/side chain precursor

Acetic acid (IR, 3aR, 4S, 7aR)-l-((S)-l-hydroxypropan-2-yl)-7a-methyl-octahydro-lH-

A 1 1 round bottom flask equipped with stirring bar and Claisen adapter with rubber septum was charged with Lythgoee diol starting material (38.41 g, 180.9 mmol), dichloromethane (400 mL), pyridine (130 mL) and DMAP (5.0Og, 40.9 mmol). Acetic anhydride (150 mL) was added slowly and the mixture was stirred at room temperature for 14.5 h. Methanol (70 mL) was added drop wise (exothermic reaction) to the reaction mixture and the solution was stirred for 30 min. Water (1 L) was added and the aqueous layer was extracted with dichloromethane (2x250 mL). The extracts were washed with IN HCl (200 mL) and solution OfNaHCO₃ (200 mL), dried (Na₂SO₄) and evaporated to dryness with toluene (150 mL). The residue was dissolved in methanol (300 mL) and sodium carbonate (40.0 g) was added. The suspension was stirred for 24 h. Additional portion of sodium carbonate (10.0 g) was added and the reaction mixture was stirred for 18 h. Methanol was removed on a rotary evaporator. Water (500 mL) was added and the mixture was extracted with ethyl acetate (3x250 mL), dried (Na₂SO₄) and concentrated in vacuo. The residue was purified by FC (0.4 kg of silica gel, 20%, 30% hexane - ethyl acetate) to give the title compound Acetic acid (IR, 3aR, 4S, 7aR)-l -((S)-I -hydroxypropan-2-yl)-7a- methyl-octahydro-lH-inden-4-yl ester (45 g, 98%). ¹H NMR (DMSO-D6) 5.03(1H, br s),

4.26(1H, dd, J=5.9, 5.1 Hz), 3.42-3.36(1H, m), 3.10-3.02(1H, m), 1.99(3H, s), 1.96-1.91(1H, m), 1.77-1.58(3H, m), 1.50-1.08(9H, m), 0.93(3H, d, J=6.6 Hz), 0.85(3H, s).

Acetic acid (IR, 3aR, 4S, 7aR)-7a-methyl-l-((S)-oxopropan-2-yl)-octahydro-lH-inden-4-yl ester

To a cooled solution (-65⁰C ) of oxalyl chloride (17 mL, 195 mmol) in dichloromethane (150 mL) was added within 35 min. a solution of DMSO (27 mL, 380 mmol) in dichloromethane (200 mL), keeping the temperature below -65⁰C. After complete addition stirring at -65⁰C was continued for 15 min. Subsequently a solution of acetic acid (IR, 3aR, 4S, 7aR)-l -((S)-I- hydroxypropan-2-yl)-7a-methyl-octahydro-lH-inden-4-yl ester (41 g, 161 mmol) in dichloromethane (300 mL) was added dropwise within 80 min., keeping the temperature below - 65⁰C. During addition a solid precipitated. After complete addition stirring at -65⁰C was continued for 1 h. Subsequently a solution of triethylamine (110 mL) in dichloromethane (200 mL) was added dropwise within 30 min. After complete addition stirring at -65⁰C was continued for 45 min. The cooling bath was removed and the reaction mixture was allowed to warm to 5⁰C within 1 h. Dichloromethane (ca. 600 mL) was removed by distillation under reduced pressure and to the residue was added water (600 mL) and tert-Butyl-methyl ether (500 mL). The organic layer was separated and the aqueous layer was extracted with tert-Butyl-methyl ether (2x200 mL). The combined organic layers were dried (Na₂SO₄), filtered and concentrated in vacuo. The residue was purified by column chromatography (800 g of silica gel, 15% ethyl acetate in heptane) affording 38 g (94 %) of the title compound as a slightly yellow oil. ¹H NMR (CDCl₃): δ 9.56 (IH, d, J=2.0 Hz), 5.20 (IH, br s), 2.44-2.16 (IH, m), 2.03 (3H, s), 2.00-1.15 (12H, m), 1.11 (3H, d, J=7.0 Hz), 0.92 (3H, s).

Acetic acid (3aR,4S,7aR )-l-E-ethylidene-7a-methyl-octahydroinden-4-yl ester

27% 5%

54% 4%

Benzalacetone was purified by bulb to bulb distillation (130 ⁰C, 10 Λ-^"2 mbar) before use. To a solution of acetic acid (IR, 3aR, 4S, 7aR)-7a-methyl-l-((S)-oxopropan-2-yl)-octahydro-lH- inden-4-yl ester (38.3 g, 0.15 mol) in diethyl ether (240 mL) was added 10% palladium on charcoal (1.8 g). The suspension was stirred at room temperature for 45 min., filtered through a path of Celite and the filtrate was concentrated in vacuo. To the residue was added benzalacetone (28.3 g, 0.19 mol) and 10% palladium on charcoal (1.8 g). The suspension was degassed by evacuating the flask and refilling with nitrogen. Then the flask was partially immersed in a 230 ⁰C oil bath for 40 min. After cooling at room temperature the suspension was diluted with ethyl acetate, filtered through a path of Celite and the filtrate was concentrated in vacuo. The residue was purified by column chromatography (1800 g of SiO₂, 5-10% ethyl acetate in heptane) affording 21.6 g (65%) of a mixture of ^17E, Δ^17Z, Δ¹⁶ and Δ²⁰ indene olefins, which are present in 51%, 4%, 25%, and 1%, respectively (GC analysis). The mixture of isomers was used in the next step without further purification.

51% 25% 4% 1%

¹U NMR (CDCl₃, signals of the desired Δ^17E isomer): 5.21 (m, IH), 4.98-5.07 (m, IH), 2.15-2.35 (m, 2H), 2.05 (s, 3H), 1.53 (d, 3H, J=7 Hz),δ 0.96 (s, 3H). In a different experiment the desired product was isolated from the mixture of olefins (Δ^17E: Δ^17Z: Δ¹⁶: Δ²⁰= 65:4:27:4) by silver nitrate impregnated silica gel medium pressure chromatography in a 55% yield (U.S. Pat. 5,939,408).

(2R,3aR,4S,7aR)-l-E-ethylidene-2-hydroxy-7a-methyl-octahydroinden-4-yl ester (17a) and acetic acid (2S,3aR,4S,7aR)-l-E)-ethylidene-2-hydroxy-7a-methyl- octahydroinden-4-yl ester

7% 35% 6%

50%

30% traces

To a suspension Of SeO₂ (1.4 g; 12.6 mmol) in dichloromethane (55 mL) was added t.-butyl- hydroperoxide (17 mL, 70 w/w-% solution in water, 124 mmol). The suspension was stirred at room temperature for 30 min, cooled at 0 ⁰C and a solution of acetic acid (3aR, 4S, 7aS,E)-l- ethylidene-7a-methyl-octahydro-lH-inden-4-yl ester (18.8 g, 84.5 mmol, as part of a mixture of Δ^17E, Δ^17Z, Δ¹⁶and Δ²indene olefins; contains 51% of desired isomer Acetic acid (3aR,4S,7aR )-l- E-ethylidene-7a-methyl-octahydroinden-4-yl ester) in dichloromethane (70 mL) was added dropwise. The reaction mixture was stirred at 0 ⁰C for 1 h, at room temperature for 18 h and subsequently at 30 ⁰C for 3 days. To the reaction mixture was added water (350 mL) and ethyl acetate (400 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (Ix 400 mL, 1 x 350 mL, 1 x 150 mL). Water (600 ml) was added to the combined organic fractions and the layers were mixed thoroughly for 60 min by magnetic stirring. The organic layer was separated, dried (Na₂SO₄) and concentrated in vacuo. The residue was purified by column chromatography (1 kg SiO₂; eluting with 4 L 20% AcOEt in heptane, 4 L 25% AcOEt in heptane, 4 L 33% AcOEt in heptane) affording: Fraction A (4.2 g, mixture containing ca. 75% of a ketone fragment); Fraction B (7.2 g of alcohol Acetic acid (3aR,4S,7aR )-l-E-ethylidene-7a- methyl-octahydroinden-4-yl ester, purity ca. 90%). Fraction A was dissolved in methanol (100 mL) and cooled at 0 ⁰C. Sodium borohydride (1.1 g, 29 mmol) was added in portions. After stirring at 0 ⁰C for 40 min., tic showed complete conversion. The reaction mixture was quenched by addition of sat. aqueous NH₄Cl solution (30 mL) and was extracted with ethyl acetate (3x). The combined organic layers were washed with brine, dried (Na₂SO₄), filtered and the filtrate was concentrated in vacuo. The residue (4.5 g) was purified by column chromatography (SiO₂, ethyl acetate / heptane = 1 :3) to give: Fraction C (3.2 g, of alcohol acetic acid (2S,3aR,4S,7aR)- l-E)-ethylidene-2-hydroxy-7a-methyl-octahydroinden-4-yl ester (b)). Fraction B and C were combined affording 10.4 g of a mixture of alcohol (2R,3aR,4S,7aR)-l-E-ethylidene-2-hydroxy- 7a-methyl-octahydroinden-4-yl ester (a) and acetic acid (2S,3aR,4S,7aR)-l-E)-ethylidene-2- hydroxy-7a-methyl-octahydroinden-4-yl ester (b) (93% yield based on the amount of 51% of starting material in the mixture of CD olefins) as a colorless oil.

Alcohol a: ¹H NMR (CDCl₃): δ 5.47 (qd, J= 7.2, 1.2 Hz, 1 H), 4.80 (br. s, 1 H), 5.23 (m, 1 H), 1.80-1.94 (m, 4 H), 2.02 (s, 3 H), 1.77 (dd, J= 7.2, 1.2 Hz, 3 H), 1.46-1.80 (m, 4 H), 1.40-1.46 (m, 1 H), 1.30 (m, 1 H), 0.94 (s, 3 H); GC-MS: m/e 223 (M - 15), 178 (M - 60), 163 (M - 75); MS: m/e 223 (M - 15), 178 (M - 60), 163 (M - 75).

Alcohol b: ¹H NMR (CDCl₃): δ 5.30 (qd, J= 7.2, 1.2 Hz, 1 H), 5.14 (m, 1 H), 4.36 (m, 1 H), 2.26 (m, 1 H), 2.03 (s, 3 H), 1.99 (ddd, J= 11.0, 7.0, 3.7 Hz, 1 H), 1.72 (dd, J= 7.2, 1.2 Hz, 3 H), 1.68-1.88 (m, 3 H), 1.38-1.60 (m, 5 H), 1.24 (s, 3 H); GC-MS: m/e 223 (M - 15), 178 (M - 60), 163 (M - 75); MS: m/e 223 (M - 15), 178 (M - 60), 163 (M - 75).

Acetic acid (3aR,4S,7aR )-7a-methyl-l-(l-(R)-methyl-3-oxo-propyl)-3a,4,5,6,7,7a-

60%

A mixture of acetic acid (2R,3aR,4S,7aR,Z)-l-ethylidene-2-hydroxy-7a-methyl-octahydro-lH- inden-4-yl ester and acetic acid (2S,3aR,4S,7aS,Z)-l-ethylidene-2-hydroxy-7a-methyl- octahydro-lH-inden-4-yl ester (12.5 g, 47 mmol) was dissolved in ethyl vinyl ether (150 mL). Hg(OAc)₂ (14.1 g, 44 mmol) was added and the suspension was poured into a pyrex pressure tube, flushed with N₂ and closed tightly. The mixture was stirred at 130 ⁰C for 18 h, cooled at room temperature and concentrated in vacuo. The residue was purified by column chromatography (SiO₂, 7.5-30% ethyl acetate in heptane) to give: Fraction A (8.1 g (65%) of the titled compound); Fraction B (1.8 g, mixture containing ca 50% of the titled compound). Fraction B was purified by column chromatography (SiO₂, 7.5-30% ethyl acetate in heptane) to give: Fraction C (0.6 g of the titled compound). Fraction A and C were combined affording 8.7 g (70%) of the titled compound as a colorless oil. ¹H NMR (CDCl₃) : δ 9.68 (s, 1 H), 5.40 (m, 1 H), 5.19 (m, 1 H), 2.72 (m, 1 H), 2.53 (ddd, J= 16.2, 5.8, 1.8 Hz, 1 H), 2.33 (ddd, J= 16.2, 7.3, 2.6 Hz, 1 H), 2.03 (s, 3 H), 2.02-2.14 (m, 2 H), 1.72-1.90 (m, 4 H), 1.47-1.62 (m, 2 H), 1.36 (M, 1 H), 1.14 (d, J= 7.1 Hz, 3 H), 1.02 (s, 3 H).

5(R)-( (3aR,4S,7aR )-4-acetoxy-7a-methyl-3a,4,5,6,7,7a-hexahydro-3H-inden-l-yl)- hex-2-E-enoic acid ethyl ester

THF

Acetic acid (3aR,4S,7aS)-7a-methyl-l-((S)-4-oxobutan-2-yl)-3a,4,5,6,7,7a-hexahydro-3H-inden- 4-yl ester (16.2 g; 61 mmol) and triethyl phosphonoacetate (36 ml; 183 mmol, 3 eq.) were dissolved under N₂ atmosphere in THF (200 mL, freshly distilled over Na/benzophenone). The mixture was cooled to -90 ⁰C and a solution of LiHMDS in hexanes (122 mL, 1 M solution, 2 eq.) was added dropwise within 45 min. keeping the temperature below -90 ⁰C. After complete addition the reaction mixture was allowed to warm to -78 ⁰C and stirring was continued at this temperature for 70 min. The reaction was quenched by dropwise addition of a mixture of water (64 ml) and sat. NH₄Cl solution (32 mL). To the reaction mixture was added tert-butyl methyl ether (400 ml) and water (400 mL), the organic layer was separated and concentrated in vacuo affording fraction A. The aqueous layer was extracted with tert-butyl methyl ether (Ix 400 ml, Ix 200 ml). The organic layers were combined with fraction A, washed with water (2x 200 ml), washed with brine (Ix 150 ml), dried (Na₂SO₄), filtered and the filtrate was concentrated in vacuo. The residue was purified by column chromatography (SiO₂, ethyl acetate / heptane = 1 :10) affording the title compound (18 g, 88%) as a E/Z-mixture (E:Z = 10:1). ¹H NMR (CDCl₃): δ 6.88 (dt, J= 15.4, 7.3 Hz, 1 H), 5.78 (dm, J= 15.4 Hz, 1 H), 5.37 (br. s, 1 H), 5.20 (br. s, 1 H), 4.17 (q, J= 7.2 Hz, 2 H), 2.03 (s, 3 H), 2.22-2.39 (m, 2 H), 1.96-2.17 (m, 3 H), 1.72- 1.90 (m, 4 H), 1.46-1.62 (m, 2 H), 1.36 (td, J= 13.3, 4.0 Hz, 1 H), 1.27 (t, J= 7.1 Hz, 3 H), 1.06 (d, J= 7.2 Hz, 3 H), 0.99 (s, 3 H); MS: m/e 357 (M + 23), 275 (M - 59).

(3aR,4S,7aR )-l-((S,E)-5-ethyl-5-hydroxy-l-methyl-hept-3-enyl)-7a-methyl- 3a,4,5,6,7,7a-hexahydro-3H-inden-4-ol

A l L round bottom flask was charged with cerium(III)chloride heptahydrate (234 g, 0.63 mol) and water (ca. 70 g) was removed in vacuo (10^~2 mbar) via bulb to bulb distillation by heating slowly at 70 ⁰C (30 min), 95 ⁰C (3 h), 120 ⁰C (1 h) and 160 ⁰C (3 h), respectively. After cooling overnight and under vacuo at room temperature the off-white cerium(III)chloride monohydrate (162 g) was transferred into a 3 L three-necked flask equipped with a magnetic stirring bar. The last equivalent of water was removed by stirring and heating in vacuo (10^~2 mbar) at 90 ⁰C (1 h), 120 ⁰C (1 h), 160 ⁰C (1 h) and 210 ⁰C (4 h), respectively. Condensate water on top of the flask was removed by heating with a hot gun. When no more formation of condensate was observed, removal of water was complete. The flask was cooled at room temperature and flushed with nitrogen. THF (1.3 L) was added and the mixture was stirred at room temperature for 18 h. The milky suspension was cooled at 0 ⁰C and a solution of EtMgBr in THF (610 mL, 1 M solution) was added dropwise within 1 h. After stirring at 0 ⁰C for 2 h a solution of (S,E)-5-((3aR,4S,7aS)- 4-acetoxy-7a-methyl-3a,4,5,6,7,7a-hexahydro-3H-inden-l-yl)-hexenoic acid ethyl ester (16.2 g, 48.4 mmol, contaminated with ca. 10% of the corresponding Z-isomer) in THF (75 mL) was added dropwise within 1 h. After stirring at 0 ⁰C for 1 h tic showed complete conversion and the reaction was quenched by slow addition of water (150 mL, exothermic reaction), upon which a sticky solid precipitated. The solution (Fraction A) was decanted and the residual solid was mixed thoroughly with water (1 L) to give an aqueous suspension (Fraction B). Fraction A and B were combined and extracted four times with a mixture of ethyl acetate (500 mL) and heptane (500 mL). The combined organic layers were washed with sat. NaHCO₃ solution (2x), brine

(Ix), dried (Na₂SO₄), filtered and the filtrate was concentrated in vacuo. The residue (17 g) was purified by column chromatography (1 kg SiO₂, 20% ethyl acetate in heptane) affording the title compound (13.4 g, 98%) as a slightly yellow oil. Purity according HPLC: 93.1% (λ = 212 nm). The product was purified again by column chromatography (1 kg SiO₂, 20% ethyl acetate in heptane) to give: Fractions A 11.91 g, (86% yield) of the titled compound as a colorless oil; purity according HPLC: >96.5% (λ = 212 nm); Fraction B 1.40 g, (10% yield) of the titled compound as a colorless oil; purity according HPLC: 86.9% (λ = 212 nm); ¹H NMR (CDCl₃): δ 5.51 (ddd, J= 15.4, 7.4, 6.5 Hz, 1 H), 5.35 (dm, J= 15.4 Hz, 1 H), 5.33 (m, 1 H), 4.17 (m, 1 H), 2.12-2.32 (m, 3 H), 1.67-2.02 (m, 6 H), 1.23-1.60 (m, 9 H), 1.05 (s, 3 H), 1.04 (d, J= 7.2 Hz, 3 H), 0.84 (t, J= 7.3 Hz, 6 H); MS: m/e 329 (M + 23), 289 (M - 17), 271 (M - 35).

(SaR^S^aR J-l-CCS^J-S-ethyl-S-hydroxy-l-methyl-hept-S-enyO-Ta-methyl- 3a,4,5,6,7,7a-hexahydro-3H-inden-4-one

A solution of (3aR,4S,7aS)-l-((S,E)-6-ethyl-6-hydroxyoct-4-en-2-yl)-7a-methyl-3a,4,5,6,7,7a- hexahydro-3H-inden-4-ol (4.70 g, 15.3 mmol, purity according HPLC: 96.5% (λ = 212 nm) in dichloromethane (200 mL) was cooled in an ice-bath and treated portionwise with pyridinium dichromate (13.1 g, 34.9 mmol, 2.2 eq.). The reaction mixture was allowed to warm at room temperature overnight, filtered through a path of Celite and the filtercake was washed with dichloromethane. The combined filtrates were washed with a 2 M KHCO3 solution, washed with brine, dried (Na₂SO₄) and concentrated in vacuo, the residue was purified by column chromatography (SiO₂, 25% ethyl acetate in heptane) affording the title compound (4.0 g, 85%) as a colorless oil.

¹H NMR (CDCl₃): δ 5.54 (ddd, J= 15.6, 7.1, 6.0 Hz, 1 H), 5.38 (dm, J= 15.6 Hz, 1 H), 5.30 (m, 1 H), 2.82 (dd, J= 10.4, 6.0 Hz, 1 H), 2.42 (ddt, J= 15.4, 10.4, 1.6 Hz, 1 H), 2.16-2.33 (m, 4 H), 1.93-2.16 (m, 4 H), 1.84-1.93 (m, 1 H), 1.65 (td, J= 12.1, 5.6 Hz, 1 H), 1.52 (br. q, J = 6.9 Hz, 4 H), 1.34 (br. s, 1 H), 1.05 (d, J= 6.9 Hz, 3 H), 0.85 (br. t, J= 7.2 Hz, 6 H), 0.82 (s, 3 H).

Coupling and Synthesis

l-(5-Ethyl-l-methyl-5-trimethylsilanyloxy-hept-3-enyl)-7a-methyl-3,3a,5,6,7,7a- hexahydro-inden-4-one

To a solution of (3aR,4S,7aR )- 1-((S, E)-5-ethyl-5 -hydroxy- l-methyl-hept-3 -enyl)-7a- methyl-3a,4, 5,6,7, 7a-hexahydro-3H-inden-4-one (320 mg, 1.05 mmol) in dichloromethane (20 mL) was added l-(trimethylsilyl)imidazole (0.2 mL, 1.34 mmol). The reaction mixture was stirred at room temperature for 4 d. Reaction control (tic) showed complete conversion. The mixture was concentrated in vacuo and the residue was purified by column chromatography (SiO₂, 10% ethyl acetate in heptane) affording the titled compound (377 mg, 95%) as a colorless oil.

1 α-Fluoro-25-hydroxy- 16-23E-diene-26,27-bishomo-20-epi-cholecalciferol

To a stirred solution of 240 mg (0.51 mmole) of (lS,3Z,5R)-l-fluoro-5-(t- butyldimethyl)silanyloxy)-2-methenyl-3-(diphenylphosphinoyl)ethylidene cyclohexane in 5 ml of anhydrous tetrahydrofuran at -78 ⁰C was added 0.319 ml (0.51 mmole) of 1.6M n- butyllithium in hexane, dropwise under argon. After stirring for 5 min, to thus obtained red solution was added a solution of 103 mg (0.273 mmole) of l-(5-Ethyl-l-methyl-5- trimethylsilanyloxy-hept-3-enyl)-7a-methyl-3,3a,5,6,7,7a-hexahydro-inden-4-one in 4 ml of anhydrous tetrahydrofuran, dropwise over a 10 min period. The reaction mixture was stirred at - 78 ⁰C for 2 hrs, then placed in freezer (-20 ⁰C) for one hour, quenched by addition of 10 ml of a 1 : 1 mixture of 2N Rochelle salt and 2N potassium bicarbonate and warmed up to room temperature. After dilution with additional 25 ml of the same salts mixture, it was extracted with 3 x 90 ml of ethyl acetate. The combined organic layers were washed three times with water and brine, dried over sodium sulfate and evaporated to dryness. The residue was purified by FLASH chromatography on a 30 mm x 7" silica gel column with hexane-ethyl acetate (1 :4), to give 145 mg of disilylated title compound. To a solution of 145 mg of disilyl intermediate in 3 ml anhydrous tetrahydrofuran was added 1.7 ml (1.7 mmole) of IM tetrabutyl-ammonium fluoride in tetrahydrofuran under argon. The reaction mixture was stirred at room temperature for 18 hrs, and then quenched by addition of 10 ml water and stirring for 15 min. It was diluted with 20 ml of water and brine and extracted with 3 x 80 ml ethyl acetate. The organic layers were washed four times with water and brine, dried over sodium sulfate, and evaporated to dryness. The crude product was purified by FLASH chromatography on a 30 mm x 5" silica gel column with hexane-ethyl acetate (3:2), and by HPLC on a YMC 50 mm x 50 cm silica gel column with hexane-ethyl acetate (1 :1). It gave 90 mg (74%) of the title compound, crystallization from methyl acetate-hexane.

Larger Scale Coupling and Synthesis

l-(5-Ethyl-l-methyl-5-trimethylsilanyloxy-hept-3-enyl)-7a-methyl-3,3a,5,6,7,7a- hexahydro-inden-4-one

To a solution of of (3aR,7aS)-l-((S,E)-6-ethyl-6-hydroxyoct-4-en-2-yl)-7a-methyl-3,3a,5,6,7,7a- hexahydro-3H-inden-4-one (4.0 g, 13.1 mmol) in dichloromethane (200 niL) was added 1- (trimethylsilyl)imidazole (2.2 niL, 14.9 mmol). The reaction mixture was stirred at room temperature for 18 h. According tic conversion was not complete and additional 1- (trimethylsilyl)imidazole (4.3 mL, 29.1 mmol) was added and stirring was continued for 5 h. The mixture was concentrated in vacuo at 30 ⁰C and the residue was purified by column chromatography (200 g SiO₂, 10% ethyl acetate in heptane) affording the title compound (4.6 g, 93%) as a colorless oil. Purity according HPLC: 100% (λ = 265 nm); ¹H NMR (CDCl₃): δ 5.28- 5.52 (m, 3 H), 2.83 (dd, J= 10.4, 6.1 Hz, 1 H), 2.43 (ddm, J= 15.4, 10.4 Hz, 1 H), 2.18-2.32 (m, 4 H), 1.94-2.18 (m, 4 H), 1.85-1.93 (m, 1 H), 1.76 (td, J= 12.4, 5.6 Hz, 1 H), 1.53 (br. q, J= 7.3 Hz, 4 H), 1.16 (d, J= 6.9 Hz, 3 H), 0.83 (s, 3 H), 0.81 (br. t, J= 7.1 Hz, 6 H), 0.47 (s, 9 H); MS: m/e 376 (M), 361 (M - 15), 347 (M - 29).

A 25 ml flask was charged with (lS,3Z,5R)-l-Fluoro-5-(tert-Butyldimethyl)silanyloxy)-2- methenyl-3-(diphenylphosphinoyl)ethylidene cyclohexane (748 mg,1.59 mmol, 1.2 eq) and (3aR,7aS)-l-((S,E)-6-ethyl-6-(trimethylsilyloxy)oct-4-en-2-yl)-7a-methyl-3,3a,5,6,7,7a- hexahydro-3H-inden-4-one (499 mg, 1.32 mmol). The mixture was co-evaporated with toluene (3x 5 mL), dissolved in THF (10 mL, freshly distilled over Na/benzophenone) and cooled to -55 ⁰C. LiHMDS (1.65 mL, 1 M solution in THF, 1.2 eq.) was added dropwise within 5 min. The deep red solution was allowed to warm to -25 ⁰C within 1.5 h. TBAF (9 mL, 1 M solution in THF) was added (color turns to orange) and the mixture was allowed to warm to room temperature overnight. The reaction was quenched by pouring slowly into an ice-cold 1 M aqueous solution OfKHCO₃. Thus formed mixture was extracted with ethyl acetate (3x 25 mL). The combined organic layers were washed with water, brine (3x), dried (Na₂SO₄) and concentrated in vacuo at 30 ⁰C. The residue was purified by column chromatography (25% ethyl acetate in heptane), affording: Fraction A: 35 mg (7%) of epimerized CD-block e/?z-(3aR,7aS)-l- ((S,E)-6-ethyl-6-(trimethylsilyloxy)oct-4-en-2-yl)-7a-methyl-3,3a,5,6,7,7a-hexahydro-3H-inden- 4-one. Fraction B: traces of Vitamin D -related byproducts. Fraction C: 27 mg (5%) of the titled compound as a white solid; purity according HPLC: 96.8% (λ = 265 nm). Fraction D: 450 mg (75%) of the titled compound as a white solid; purity according HPLC: 93.7% (λ = 265 nm). Fraction E: 30 mg (5%) of the titled compound as a white solid; purity according HPLC: 92.9% (λ = 265 nm). Fraction D was dissolved in methyl formate (3-4 mL). Heptane (15 mL) was added and the flask was flushed with nitrogen gas until the solution became cloudy. The product started to crystallize and for complete crystallization the flask was stored at 4 ⁰C for 1 h. The solvent was decanted and the remaining solid was washed with cold heptane (3 x 5 mL). After flushing with nitrogen gas the solid was dried in vacuo affording: Fraction F: 331 mg (56% yield) of the titled compound as a white solid; purity according HPLC: 100% (λ = 265 nm); ¹H NMR (CD₃CN): δ 6.42 (br d, 1 H), 6.10 (br d, 1 H), 5.51 (ddd, 1 H), 5.39 (br d, 1 H), 5.36 (br s, 1 H), 5.35 (br d, 1 H), 5.13 (ddd, 1 H), 5.07 (br s, 1 H), 3.97-4.05 (m, 1 H), 2.92 (d, 1 H), 2.85 (dd, 1 H), 2.57 (dd, 1 H), 2.38 (dd, 1 H), 2.14-2.29 (m, 5 H), 1.96-2.04 (m, 2 H), 1.84-1.89 (m, 1 H), 1.73-1.82 (m, 3 H), 1.64-1.72 (m, 1 H), 1.53 (ddd, 1 H), 1.45 (br. q, 4 H), 1.04 (d, 3 H), 0.81 (t, 6 H), 0.69 (s, 3 H); ¹³C NMR (CD₃CN): 160.12, 143.37 (d, J= 17Hz), 142.83, 137.33, 133.21 (d, J=2Hz), 126.96, 124.84, 120.83, 117.33 (d, J=32Hz), 115.40 (d, J=IOHz), 93.74, 91.51, 74.83, 65.72 (d, J=5Hz), 58.19, 50.31, 45.14, 40.94 (d, J=21Hz), 39.78, 35.21, 33.34, 33.33, 32.46, 29.33, 28.63, 23.56, 20.33, 16.74, 1.41. ¹⁹F NMR (CD₃CN): δ -177.55; MS: m/e 482 (M + 39), 465 (M + 23), 425 (M - 17). UV λmax: 244 nm (ε 13747), 270 nm (ε 13756) (CH₃OH). [α]^D ₂₅ +101 (c 1.92, CH₃OH).

Alternate Coupling and Synthesis

1 α-Fluoro-25-hydroxy- 1 ό-lSE-diene-lό^T-bishomo-lO-epi-cholecalciferol

A solution of lS,3Z,5R)-l-Fluoro-5-(tert-Butyldimethyl)silanyloxy)-2-methenyl-3- (diphenylphosphinoyl)ethylidene cyclohexane (278 mg, 0.59 mmol, 3.6 eq.) in THF (10 mL, distilled over Na-benzophenone) was cooled at -75 ⁰C and n-BuLi (0.23 mL, 2.5 M solution in hexanes, 0.57 mmol) was added dropwise. The red solution was stirred for 20 min. during which the temperature was allowed to rise to -50 ⁰C. A solution of (3aR,7aS)-l-((S,E)-6-ethyl-6- hydroxyoct-4-en-2-yl)-7a-methyl-3,3a,5,6,7,7a-hexahydro-3H-inden-4-one (50 mg, 0.164 mmol) in THF (2 niL, distilled over Na-benzophenone) was added dropwise at -50 ⁰C within 5 min. Stirring was continued for 2 h during which the temperature was allowed to rise to -10 ⁰C. Tie showed ca. 20% conversion. To the yellow solution was added dropwise TBAF (1.8 mL, 1 M solution in THF, containing ca. 5% water) upon which the solution turned red-brown. The reaction mixture was allowed to reach room temperature overnight. The reaction mixture was quenched by addition of an ice-cold aqueous 1 M KHCO3 solution (3 g in 30 mL of water) and the mixture was extracted with ethyl acetate (2 x 40 mL). The combined organic layers were washed with water and brine, dried (Na₂SO₄), filtered and the filtrate was concentrated in vacuo at 30 ⁰C. The residue was purified by column chromatography (SiO₂, 25% ethyl acetate in heptane) affording the titled compound (13 mg, 18%) as a white foam.

EXAMPLE 2

Synthesis of21-(3-Hydwxy-3-methylbutyl)-l,25-dihydwxy-19-nor-cholecalcifewl

[lR-[lα(2E,4E,7E),3aβ,4α,7aα]]-5-[4-[[(l,l-dimethylethyl)dimethylsilyl]oxy] Octahydro- 7a-methyl-lH-inden-l-yl]-2,4,7-nonatrienedioic acid diethyl ester

To a stirred solution of 3.08 g (10.0 mmol) of [lR-(lα,3aβ,4α,7aα)]-(l,l- dimethylethyl)dimethyl[[o ctahydro-7a-methyl- 1 -( 1 -methylethenyl)- 1 H-inden-4-yl]oxy]silane and 3.92 g (40.0 mmol) of ethyl propiolate in 20 mL of dichloromethane was added 40 mL (40.0 mmol) of a 1.0 M solution of ethylaluminum dichloride in hexanes. The mixture was stirred under argon at room temperature for 24 hrs, treated with 981 mg (10 mmol) of ethyl propiolate and 7.5 mL (7.5 mmol) of a 1.0 M solution of ethylaluminum dichloride in hexanes and stirred for an additional 18 hrs. The resultant orange-red solution was added portion- wise to a mixture of 200 mL ethyl acetate and 100 mL of 50% brine, and, after the fizzing had subsided, the organic phase was collected and the aqueous phase was re-extracted with 3x100 mL of ethyl acetate. The combined organic extracts were washed with 2x100 mL of 50% brine, dried (Na₂ SO4), and evaporated to give 5.76 g of a reddish gum, which was subjected to flash chromatography on 120 g of silica gel (40-65 μm mesh, 3.5 cm diameter column) with 10% ethyl acetate in hexanes as eluent, collecting 20-mL fractions. Fractions 21-32 were combined and evaporated to give 2.18 g of crude product. Further purification was achieved by HPLC (15- 30 μm mesh silica gel, 50 cm x 50 mm column, flow rate of 70 mL/min) with 7.5% ethyl acetate in hexanes as eluent to give 1.62 g (32%) of the titled compound, R_T 25 minutes, as a pale yellow gum: [α]²⁵ _D +83.50° (EtOH, c=0.98); UV (MeOH) 284 (ε=28,173), 207 (ε =16,884) nm; IR (CHCl₃) 1708, 1651, 1628 cm^"1 ; ^l H NMR (CDCl₃) δ 0.006 (6H, s), 0.80, 3H, s), 0.88 (9H, s), 1.16 (IH, t, J=7.6Hz), 1.28 (6H, overlapping t, J=7Hz), 1.67-1.78, (6H, m), 2.16 (IH, t, J=9Hz), 3.00, (IH, dd, J=6, 16, Hz), 3.35 (IH, dd, J=16,4 Hz), 4.02(1H, s), 4.16 (4H, overlapping q, J=7 Hz), 5.75 (IH, d, J=16 Hz), 5.84 (IH, d, J=15 Hz), 6.17 (IH, d, J=I l Hz), 6.88 (IH, dt, J=16,6 Hz), 7.50 (IH, dd, J=I l, 15, Hz); MS (EI) m/z 504 (M⁺, 23). Anal. Calcd for C₂₉ H₄₈ O₅ Si: C, 69.00;H, 9.58; Si, 5.56. Found: C, 68.94; H, 9.69; Si, 5.67.

[lR-(lα,3aβ,4α,7aα)]-5-[4-[[(l,l-dimethylethyl)dimet hylsilyl]oxy]Octahydro-7a-methyl- lH-inden-l-yl]nonanedioic acid diethyl ester

A stirred solution of 1.009 g (2.0 mmol) of [IR-[Ia (2E,4E,7E),3aβ,4a,7aa]]-5-[4-[[(l,l- dimethyl ethyl)dimethylsilyl]oxy]octahydro-7a-methyl- 1 H-inden- 1 -yl]-2,4,7-nonatriene dioic acid diethyl ester in 50 mL of ethyl acetate was hydrogenated over 200 mg of 10% palladium on charcoal at room temperature and atmospheric pressure until hydrogen absorption ceased (140 mL of hydrogen was absorbed during 2.5 hrs). The mixture was filtered over a pad of Celite, which was washed with 4x50 mL of ethyl acetate, and the combined filtrate and washings were evaporated to give 1.07 g of a colorless oil. This was purified by flash chromatography on 60 g of silica gel (40-65 μm mesh, 3.5 cm diameter column) with 12% ethyl acetate in hexanes as eluent, collecting 20-mL fractions. Fractions 7-12 were combined and evaporated to give 964 mg (94%) of the titled compound as a colorless oil: [α]²⁵ _D +32.1° (CHCl₃, c=1.04); IR (CHCl₃) 1726 cm^"1 ; * H NMR (CDCl₃) δ 0.00 (3H, s), 0.01 (3H, s), 0. 87 (9H, s), 0.88 (3H, s), 1.27 (6H, t, J=7 Hz), 1.28-1.90 (21H, m), 2.25 (4H, br t), 3.98 (IH, s), 4.11 (4H, q, J=7 Hz); MS (FAB) m/z 511 (M⁺ +1, 100). Anal. Calcd for C₂₉ H₅₄ O₅ Si: C, 68.11; H, 10.66; Si, 5.50. Found: C, 68.21;H, 10.85; Si, 5.43.

[lR-(lα,3aβ,4α,7aα)]-6-[4-[[(l,l-dimethylethyl)dimet hylsilyl]oxy]Octahydro-7a-methyl- lH-inden-l-yl]-2,10-dimethyl-2,10-undecane diol

To a stirred solution of 868 mg (1.7 mmol) of [lR-(lα,3aβ,4α,7aα)]-5-[4-[[(l,l- dimethylethyl)dime thylsilyl]oxy]octahydro-7a-methyl-lH-inden-l-yl]nonanedioic acid diethyl ester in 12 rnL of anhydrous THF was added dropwise, with cooling (ice bath), 5.0 mL (15 mmol) of a 3.0 M solution of methylmagnesium bromide in ether. The mixture was stirred at room temperature for 45 minutes, cooled to 5 ⁰C, and quenched by the dropwise addition of 3.0 mL of saturated NH₄Cl. After the fizzing had subsided, 15 mL of ethyl acetate and 15 mL of saturated NH4CI were added, stirring was continued for 20 minutes, and the mixture was poured into 100 mL of ethyl acetate and 50 mL of saturated NH4CI. The organic phase was collected and the aqueous phase was re-extracted with 3x60 mL of ethyl acetate. The combined organic extracts were washed with 2x100 mL of 50% brine, dried (Na₂SO₄), and evaporated to give 814 mg of a colorless gum, which was purified by flash chromatography on 100 g of silica gel (40-65 μm mesh, 3.5 cm diameter column) with 50% ethyl acetate in hexanes as eluent taking 20-mL fractions. Fractions 19-20 were combined and evaporated to give, after high vacuum drying (17 hrs), 763 mg (93%) of the titled compound as a colorless foam: [α]²⁵ _D +35.8° (EtOH, c=1.02); IR (CHCl₃) 3608 cm^"1 ; * H NMR (CDCl₃) δ 0.00 (6H, s), 0.88 (9H, s), 0.90 (3H, s), 1.20 (12H, s), 1.23-1.90. (27H, m), 3.99 (IH, s); MS (EI) m/z 482 (3, M⁺). Anal. Calcd for C₂₉ H₅₈ O₃ Si: C, 72.14;H, 12.11; Si, 5.82. Found: C, 72.18; H, 11.99; Si, 5.69.

[lS-(lα,3aβ,4α,7aα)]Octahydro-l-[5-hydroxy-l-(4-hydr oxy-4-methylpentyl)-5- methylhexyl] -7a-methyl-4H-inden-4-ol

To a stirred solution of 700 mg (1.45 mmol) of [lR-(lα,3aβ,4α,7aα)]-6-[4-[[(l,l- dimethylethyl)dimethylsilyl]oxy]octahydro-7a-methyl- 1 H-inden- 1 -yl]-2, 10-dimethyl-2, 10- undecanediol in 5 mL of THF and 15 mL of CH₃CN contained in a Teflon bottle was added 3.0 mL of an approximately 30% aqueous solution of fluorosilicic acid (prepared according to A. S. Pilcher and P. DeShong, J. Org. Chem., 1993, 58, 5130) and the mixture was stirred under argon at room temperature for 1.0 h. Four 2.0-mL portions of the fluorosilicic acid solution were then added at hourly intervals, for a total of 11 mL of reagent and a reaction time of 5 hrs. The reaction mixture was poured cautiously into a mixture of 125 mL of ethyl acetate and 75 mL of saturated aqueous KHCO₃ solution. After the fizzing had subsided, the organic phase was collected and the aqueous phase was re-extracted with 3x75 mL of ethyl acetate. The organic extracts were washed with 125 mL of 50% brine, dried (Na₂SO₄), and evaporated to give 534 mg of a gum, which was purified by flash chromatography on 70 g of silica gel (40-65 μm mesh, 3.5 cm diameter column) with 70% ethyl acetate as eluent, taking 20-mL fractions. Fractions 17-30 were combined, filtered and evaporated, and the residue was kept under high vacuum for 4 hrs to give 458 mg (85%) of the titled compound as a colorless foam: [α]²⁵ _D +26.2° (CHCl₃, c=0.76); IR (CHCl₃) 3608 cm^"1 ; ^! H NMR (CDCl₃) δ 0.93 (3H, s), 1.21 (12H, s), 1.24-1.60 (24H, m), 1.79-1.95 (4H, m), 4.07 (lH,s); MS (FAB) m/z 369 (M⁺ +H).

[lS-(lα,3aβ,7aα)]Octahydro-l-[5-hydroxy-l-(4-hydroxy-4-met hylpentyl)-5-methylhexyl]-

7a-methyl-4H-inden-4-one

To a stirred solution of 400 mg (1.08 mmol) of [lS-(lα,3aβ,4α,7aα)]octahydro-l-[5-hydroxy-l- (4-hyd roxy-4-methylpentyl)-5-methylhexyl]-7a-methyl-4H-inden-4-ol in 8.0 mL of dichloromethane was added 1.30 g (3.45 mmol) of pyridinium dichromate and the mixture was stirred at room temperature for 4.75 hrs. It was diluted with 20 mL of diisopropyl ether, stirred for a further 15 minutes and filtered over a pad of Celite. The Celite was washed with 4x40 mL of diisopropyl ether and the combined filtrate and washings were evaporated to give 405 mg of a pale yellow gum, which was purified by flash chromatography on 70 g of silica gel (40-65 μm mesh, 3.5 cm diameter column) with 75% ethyl acetate in hexanes as eluent taking 20-mL fractions. Fractions 17-30 were combined and evaporated to give a colorless gum, which was kept under high vacuum for 4.5 hrs to give 372 mg (94%) of the titled compound as a colorless gum: [CC]²⁵D 0.45° (EtOH, c=0.92); IR (CHCl₃) 3608,1706 cm^"1 ; ^l H NMR (CDCl₃) δ 0.63 (3H, s), 1.22 (12H, s), 1.30-2.10 (22H, m), 2.20-2.28 (2H, m), 2.45 (IH, dd, J=7.6,l l Hz); MS m/z 348 (M⁺ -18).

[lS-(lα,3aβ,7aα)]Octahydro-7a-methyl-l-[5-methyl-l-[4-methyl-4-

[(trimethylsilyl)oxy] pentyl] -5- [(trimethylsilyl)oxy] hexyl] -4H-inden-4-one

To a stirred solution of 366.6 mg (1.0 mmol) of [lS-(lα,3aβ,7aα)]octahydro-l-[5-hydroxy-l-(4- hydroxy-4-me thylpentyl)-5-methylhexyl]-7a-methyl-4H-inden-4-one in 10.0 mL of dichloromethane was added 1.25 mL (8.5 mmol) of l-(trimethylsilyl) imidazole and the mixture was stirred under argon at room temperature for 4.25 hrs. It was diluted with 7.0 mL of water, stirred for a further 15 minutes, and poured into a mixture of 75 mL of ethyl acetate and 50 mL of 50% brine. The organic phase was collected and the aqueous phase was re-extracted with 3x50 mL of ethyl acetate. The combined organic extracts were washed with 3x75 mL of 50% brine, dried (Na₂SO₄), and evaporated to give a colorless oil, which was purified by flash chromatography on 65 g of silica gel (40-65 μm mesh, 3.5 cm diameter column) with 20% ethyl acetate in hexanes as eluent, taking 20-mL fractions. Fractions 5-7 were combined, concentrated to ca. 5 mL, filtered through a 0.45 μm filter (Millex-HV) and evaporated to give a colorless oil, which was kept under high vacuum for 18 hrs to give 469 mg (91%) of the titled compound: [CC]²⁵D -3.21° (CHCl₃, c=0.87); IR (CHCl₃); 1706 cm^"1 ; * H NMR (CDCl₃) δ 0.01 (18H, s), 0.63 (3H, s), 1.20 (6H, s), 1.21 (6H, s),1.26-1.49 (14H, m), 1.50-2.10 (8H, m), 2.21-2.31 (2H, m), 2.46 (IH, dd, J=12,l 1 Hz); MS (EI) m/z 495 (M⁺ -15). Anal. Calcd for C₂₉ H₅₈O₃ Si₂ : C, 68.17;H, 11.44; Si, 10.99. Found: C, 68.19; H, 11.41; Si, 11.07.

(lα,3β,5Z,7E)-21-(3-hydroxy-3-methylbutyl)-9,10-Secocholesta-5,7 ,10, (19)-triene-l,3,25- triol

(H₃C)₃Si

To a stirred, cold (-78 ⁰C.) solution of 571 mg (1.0 mmol) of the reagent [3R-(3α,5β,Z)]-[3,5- bis[[(l,l-dimethylethyl)dimethylsilyl]oxy]cyclohexylidene]ethyl] diphenylphosphine oxide in

6.0 mL of anhydrous THF was added 0.65 mL (1.04 mmol) of a 1.6 M solution of n-butyllithium in hexanes. The resultant deep red solution was stirred at -78 ⁰C. for 10 minutes, treated with 204.4 mg (0.40 mmol) of [lR-(lα,3aβ,7aα)]octahydro-7a-methyl-l-[5-methyl-l-[4-methyl-4- [(trimethylsilyl) oxy]pentyl]-5-[(trimethylsilyl)oxy]hexyl]-4H-inden-4-one in 2.5 mL of anhydrous THF, and stirred at -78 ⁰C. for 3 hrs. The mixture was allowed to warm to room temperature, stirred for 15 minutes and quenched with 15 mL of a 1:1 mixture of IN Rochelle salt solution and IN KHCO₃ solution. After 10 minutes, the mixture was poured into a mixture of 70 mL of ethyl acetate and 40 mL of 1 :1 mixture of IN Rochelle salt solution and IN KHCO₃ solution. The organic phase was separated and the aqueous phase was re-extracted with 3x70 mL of ethyl acetate. The combined organic extracts were washed with 100 mL of 10% brine, dried (Na₂SO₄), and evaporated to give 760 mg of a colorless gum, which was purified by flash chromatography on 60 grams of silica gel (40-65 μm mesh; 3.5 cm diameter column) with 5% ethyl acetate in hexanes as eluent, taking 15 mL fractions. Fractions 5-10 were combined and evaporated to give 304 mg of a colorless gum. The latter was dissolved in 4.0 mL of THF, treated with 5.0 rnL of a 1.0 M solution of tetra-n-butylammonium fluoride in THF, and the solution was stirred under argon at room temperature for 42 hours. It was diluted with 15 mL of water, stirred for 15 minutes, and poured into a mixture of 75 mL of ethyl acetate and 50 mL of 10% brine. The organic phase was separated and the aqueous phase was re-extracted with 3x70 mL of ethyl acetate. The combined organic extracts were washed with 5x100 mL of water, dried (Na₂SO₄) and evaporated to give 186 mg of a semi-solid, which was purified by flash chromatography on 50 g of silica gel (40-65 μm mesh; 3.5 cm diameter column) with 7.5% 2- propanol in ethyl acetate as eluent, taking 15-mL fractions. Fractions 11-29 were combined and evaporated. The residue was dissolved in 20 mL of anhydrous methyl formate and the solution was filtered through a 0.4 μm filter. Evaporation of the filtrate gave 154 mg of the title compound as a colorless solid: [α]²⁵ _D +50.93° (MeOH, c=0.32); ^! H NMR (CDCl₃) δ 0.54 (3H, s), 1.21 (12H, s), 1.2-2.0 (27H, m), 2.20 (2H, m) 2.48 (IH, d, J=12 Hz), 2.25 (2H, m), 2.82 (IH, s), 4.06 (IH, br s) 4.10 (IH, br s), 5.85 (IH, d, J=12 Hz), 6.3O(1H, d, J=12 Hz); MS (FAB) m/z 490.4 (M⁺, 30).

EXAMPLE 3 Synthesis of l^S-Dihydroxy-lO-ø-hydroxy^-methyl-pentytycholecalciferol

(IR, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-l-(5-methyl-l-methylene-

5-trimethylsilanyloxy-hexyl)-octahydro-indene

A 50 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 1.78 g (4.510 mmol) of 6-[(1R, 3aR, 4S, 7aR)-4-(tert-butyl-dimethyl- silanyloxy)-7a-methyl-octahydro-inden-l-yl]-2-methyl-hept-6-en-2-ol and 15 ml of dichloromethane. A 1.98 ml (13.53 mmol) of l-(trimethylsilyl)imidazole was added dropwise. The mixture was stirred at room temperature for 2h. A 15 ml of water was added and the mixture was stirred for 10 min. The resulting mixture was dissolved by the addition of 100 ml of water. The aqueous layer was extracted three times with 50 ml of dichloromethane. The combined organic layers were washed with 30 ml of brine dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (75 cm ) using hexane: ethyl acetate (10:1) as mobile phase. Fractions containing product were pooled and evaporated to give 2.037 g (96%) of product as colorless oil.

2-[(1S, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden-l-yl]- 2-(4-methyl-4-trimethylsilanyloxy-pentyl)-cyclopropanecarboxylic acid ethyl ester

A 100 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 1.275 g (2.731 mmol) of (IR, 3aR, 4S, 7aR)-4-(tert-butyl-dimethyl- silanyloxy)-7a-methyl- 1 -(5-methyl- 1 -methylene-5 -trimethylsilanyloxy-hexyl)-octahydro-indene, 25 mg OfRh₂(OAc)₄ and 10 ml of dichloromethane. A solution of 935 mg (8.202 mmol) of ethyl diazoacetate in 20 ml of dichloromethane was added dropwise (5 ml/h) at room temperature. The mixture was stirred for 30 min. The reaction mixture was concentrated in vacuo and the remaining residue was chromatographed on column (100 cm³) using dichloromethane as mobile phase to give 1.236 g (82%) of products as mixture of isomers.

2-[(1S, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden-l-yl]- 2-(4-hydroxy-4-methyl-pentyl)-cyclopropanecarboxylic acid ethyl ester

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 1.236 g (2.235 mmol) of 2-[(1S, 3aR, 4S, 7aR)-4-(tert-butyl-dimethyl- silanyloxy)-7a-methyl-octahydro-nden-l-yl]-2-(4-methyl-4-trimethylsilanyloxy-pentyl)- cyclopropanecarboxylic acid ethyl ester, 4 ml of IM tetrabutylammonium fluoride in tetrahydrofurane and 4 ml of tetrahydrofurane. The reaction mixture was stirred at room temperature for 2h. The mixture was dissolved by the addition of 100 ml of ethyl acetate and extracted five times with 50 ml of water:brine (2:1) and 50 ml of brine, dried over Na₂SO₄ and evaporated to give 1.081 g of product as colorless oil (product was used to the next reaction without purification).

5-{l-[(lS, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden-l- yl]-2-hydroxymethyl-cyclopropyl}-2-methyl-pentan-2-ol

A 50 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with crude (ca. 2.2 mmol) of 2-[(1S, 3aR, 4S, 7aR)-4-(tert-butyl-dimethyl- silanyloxy)-7a-methyl-octahydro-inden-l-yl]-2-(4-hydroxy-4-methyl-pentyl)- cyclopropanecarboxylic acid ethyl ester and 6 ml of tetrahydrofurane. A 6 ml of IM lithium aluminium hydride in tetrahydrofurane was added dropwise and the reaction mixture was stirred at room temperature for 1.5h. Then the flask was placed into an ice bath and 5 ml of water was added dropwise. The mixture was dissolved by the addition of 50 ml of saturated solution of ammonium chloride, 50 ml of water and 25 ml of IM H₂SO₄, extracted three times with 50 ml of ethyl acetate, dried over Na₂SO₄ and evaporated. The residue was purified over silica gel (350cm³) using hexane:ethyl acetate (2:1, 1 :1) to give 876 mg (90%) of products as a mixture of isomers.

2-[(1S, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden-l-yl]- 2-(4-hydroxy-4-methyl-pentyl)-cyclopropanecarbaldehyde

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 575 mg (2.667mmol) of pyridinium chlorochromate, 650 mg of celite and 12 ml of dichloromethane. The 562 mg (1.128mmol) of 5-{l-[(lS, 3aR, 4S, 7aR)-4-(tert- butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden- 1 -yl]-2-hydroxymethyl-cyclopropyl} -2- methyl-pentan-2-ol in 4 ml of dichloromethane was added dropwise and mixture was stirred in room temperature for 2h. The reaction mixture was filtrated through column with silica gel (50 cm³) and celite (3 cm) using dichloromethane, dichloromethane: ethyl acetate (4:1, 3:1). The fractions containing product were pooled and evaporated to give 550 mg of product as yellow oil (product was used to the next reaction without purification).

3-[2-[(1S, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden-l- yl]-2-(4-hydroxy-4-methyl-pentyl)-cyclopropyl] -acrylic acid ethyl ester

A 50 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 15 ml of toluene and 4.5 ml of IM potassium te/t-butoxide in tetrahydrofurane was added. A 1.005 g (4.482 mmol) of triethyl phosphonoacetate in 0.5 ml of toluene was added dropwise at ca. 5⁰C. The mixture was stirred at room temperature for Ih. Then the mixture was cooled to -15⁰C and crude (ca. 1.281 mmol) of 2-[(1S, 3aR, 4S, 7aR)-4- (tert-butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden-l-yl]-2-(4-hydroxy-4-methyl- pentyl)-cyclopropanecarbaldehyde in 4 ml of toluene was added and stirring was continued at - 1O⁰C for 4h. The reaction mixture was quenched with 50 ml of saturated solution of ammonium chloride and diluted with 50 ml of ethyl acetate and the inorganic layer was extracted twice with 50 ml of ethyl acetate, washed with 25 ml of brine, dried and evaporated. The residue was purified over silica gel (150 cm³) using hexane: ethyl acetate (5:1, 3:1) as a mobile phase to give 518 mg (80% for two steps) of products as a mixture of isomers.

5-[(1R, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden-l-yl]-

9-hydroxy-5,9-dimethyl-decanoic acid ethyl ester

A 550 mg (1.085 mmol) of 3-[2-[(1S, 3aR, 4S, 7aR)-4-(tert-butyl-dimethyl-silanyloxy)- 7a-methyl-octahydro-inden- 1 -yl]-2-(4-hydroxy-4-methyl-pentyl)-cyclopropyl] -acrylic acid ethyl ester was hydrogenated over 200 mg of 10% Pd/C in 4 ml of ethanol at ambident temperature and atmospheric pressure of hydrogen. The reaction was monitoring by TLC (hexane:ethyl acetate-3:l). After 16h the catalyst was filtered off and solvent evaporated. The residue was purified over silica gel (100 cm³) using hexane:ethyl acetate (10:1, 8:1, 3:1) as a mobile phase to give 549 mg (99%) of product as a colorless oil (mixture of isomers). ESX

OH HO OH

MeMgBr »

Et₂O

T OSiMe₂t-Bu T OSiMe₂t-Bu

6-[(1R, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden-l-yl]- 2,6,10-trimethyl-undecane-2, 10-diol

A 50 ml round bottom flask equipped with stir bar, Claisen adapter with rubber septum was charged with 1.099 mg (2.151 mmol) of 5-[(1R, 3aR, 4S, 7aR)-4-(tert-butyl-dimethyl- silanyloxy)-7a-methyl-octahydro-inden-l-yl]-9-hydroxy-5,9-dimethyl-decanoic acid ethyl ester and 15 ml of diethyl ether. The solution was cooled in ace-water bath and 4.10 ml (12.792 mmol) of 3.12M solution of methylmagnesium bromide in diethyl ether was added dropwise. After completion of the addition the mixture was stirred at room temperature for 3.5h then cooled again in an ice bath. A 10 ml of saturated solution of ammonium chloride was added dropwise. The resulting precipitate was dissolved by the addition of 50 ml of water. The aqueous layer was re-extracted three times with 50 ml of ethyl acetate. The combined ether layers were dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (200 cm³) using hexane:ethyl acetate (3:1, 2:1, 1 :1) as mobile phase. The chromatography (200 cm ) was repeated for mixture fractions to give 1.017 g (95%) of product as colorless oil.

[α] „ = +36° c=0.36, CHCl₃ 1H NMR (CDCl₃): 3.98(1H, br s), 2.00-1.95(1H, m), 1.84-1.73(1H, m), 1.66-1.63(1H, m), 1.60-

1.47(4H, m), 1.43-1.30(1 IH, m), 1.29-1.14(8H, m), 1.20(12H, s), 1.04(3H, s), 0.90(3H, s),

0.88(9H, s), 0.00(3H, s), -0.01(3H, s)

¹³C NMR (CDCl₃): 71.07, 71.05, 69.67, 57.05, 53.05, 45.03, 44.98, 43.82, 41.63, 39.87, 39.37,

39.31, 34.44, 29.45, 29.39, 29.36, 29.33, 25.89, 23.09, 22.87, 21.99, 18.47, 18.11, 17.97, 17.86, 16.78, -4.69, -5.04

MS HRES Calculated for: C₃₀H₆₀O₃Si [M+Na]⁺ 519.4204

Observed: [M+Na]⁺ 519.4203

HO OH HO OH

Bu₄NF

THF

7O⁰C

OSiMe₂t-Bu OH 6-[(1R, 3aR, 4S, 7aR)-4-Hydroxy-7a-methyl-octahydro-inden-l-yl]-2,6,10-trimethyl- undecane-2,10-diol

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 884mg (1.779mmol) of 6-[(1R, 3aR, 4S, 7aR)-4-(tert-butyl-dimethyl- silanyloxy)-7a-methyl-octahydro-inden-l-yl]-2,6,10-trimethyl-undecane-2,10-diol and 10 ml of IM tetrabutylammonium fluoride in tetrahydrofurane. The reaction mixture was stirred at 70 ⁰C for 48h. (The new portion 5 ml of IM tetrabutylammonium fluoride in tetrahydrofurane was added after 24h). The mixture was dissolved by the addition of 150 ml of ethyl acetate and extracted six times with 50 ml of wateπbrine (1 : 1) and 50 ml of brine, dried over Na₂Sθ422 and evaporated. The oil residue was chromatographed on column (175 cm³) using hexane: ethyl acetate (2:1, 1 :1) as mobile phase to give 590 mg (87%) of product as colorless oil.

[α] ³ _D ² = +11.4° c=0.35, CHCl₃

¹H NMR (CDCl₃): 4.07(1H, br s), 2.02(1H, br d, J=12.6 Hz), 1.84-1.76(2H, m), 1.64-1.16(24H, m), 1.21(12H, s), 1.06(3H, s), 0.91(3H, s)

(IR, 3aR, 4S, 7aR)-l-[5-Hydroxy-l-(4-hydroxy-4-methyl-pentyl)-l,5-dimethyl-hexyl]-7a- methyl-octahydro-inden-4-one

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 1.745 g (4.638 mmol) of pyridinium dichromate, 2.00 g of celite and 15 ml of dichloromethane. A 590 mg (1.542 mmol) of 6-[(1R, 3aR, 4S, 7aR)-4-hydroxy-7a- methyl-octahydro-inden- 1 -yl]-2,6, 10-trimethyl-undecane-2, 10-diol in 4 ml of dichloromethane was added dropwise and mixture was stirred in room temperature for 5h. The reaction mixture was filtrated through column with silica gel (50 cm³) and celite (3 cm) using dichloromethane, dichloromethane: ethyl acetate (2:1, 1 :1) as a mobile phase. The fractions containing product were pooled and evaporated to give 577 mg (98%) of ketone.

HO OH Me₃SiO' OSiMe₃

TMS-imidazole CH₇Cl₇ (IR, 3aR, 4S, 7aR)-l-[l,5-Dimethyl-l-(4-methyl-4-trimethylsilanyloxy-pentyl)-5- trimethylsilanyloxy-hexyl]-7a-methyl-octahydro-inden-4-one

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 577 mg (1.516 mmol) of (IR, 3aR, 4S, 7aR)-l-[5-hydroxy-l-(4- hydroxy-4-methyl-pentyl)-l,5-dimethyl-hexyl]-7a-methyl-octahydro-inden-4-one and 10 ml of dichloromethane. A 1.80 ml (12.269mmol) of l-(trimethylsilyl) imidazole was added dropwise. The mixture was stirred at room temperature for 2h 30 min. The resulting mixture was dissolved by the addition of 100 ml of water. The aqueous layer was extracted four times with 50 ml of ethyl acetate. The combined organic layers were washed with 50 ml of brine, dried over Na₂SO₄ and evaporated.

The residue was purified over silica gel (50 cm³) using hexane: ethyl acetate (10:1) as a mobil phase to give a 739 mg (93%) of product as colorless oil.

¹H NMR (CDCl₃): 2.42(1H, dd, J=9.9, 7.3 Hz), 2.30-2.13(3H, m), 2.04-1.50(9H, m), 1.42- 1.14(1 IH, m), 1.21(6H, s), 1.20(6H, s), 0.90(3H, s), 0.73(3H, s), 0.11(9H, s), 0.10(9H, s)

l,25-Dihydroxy-20-(4-hydroxy-4-methyl-pentyl)cholecalciferol

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 700 mg (1.201 mmol) of (lS,5R)-l,5-bis-((tert- butyldimethyl)silanyloxy)-3-[2-(diphenylfosphinoyl)-eth-(Z)-ylidene]-2-methylene-cyclo hexane and 5 ml of tetrahydrofurane. The reaction mixture was cooled to -70 ⁰C and 0.75 ml (1.200 mmol) of 1.6M n-butyllithium was added dropwise. The resulting deep red solution was stirred at -78 ⁰C for 25 min and 300 mg (0.571 mmol) of (IR, 3aR, 4S, 7aR)-l-[l,5-dimethyl-l-(4- methyl-4-trimethylsilanyloxy-pentyl)-5-trimethylsilanyloxy-hexyl]-7a-methyl-octahydro-inden- 4-one was added dropwise in 1 ml of tetrahydrofurane. The reaction mixture was stirred for 5h and then the bath was removed and the mixture was poured into 50 ml of ethyl acetate and 100 ml of brine. The water fraction was extracted four times with 50 ml of ethyl acetate, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm³, protected from light) using hexane:ethyl acetate (20:1) as mobile phase. Fractions containing product were pooled and evaporated to give colorless oil (ca. 430 mg) which was treated with 5 ml of IM tetrabutylammonium fluoride in tetrahydrofurane. The reaction mixture was stirred at room temperature for 24h. The mixture was dissolved by the addition of 150 ml ethyl acetate and extracted six times with 50 ml of water:brine (1 : 1) and 50 ml of brine, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm³, protected from light) using ethyl acetate as mobile phase. Fractions containing product were pooled and evaporated to give colorless oil. Oil was crystallized from methyl acetate to give 183 mg (62%) of product .

[α] ²ζ = +12.3° c=0.40, EtOH

UV λmax (EtOH): 213 nm (ε 14606), 264 nm (ε 17481)

¹H NMR (CDCl₃): 6.18(1H, d, J=I Ll Hz), 5.97(1H, d, J=I 1.3 Hz), 5.23(1H, d, J=I.3 Hz), 4.86(1H, d, J=4.7 Hz), 4.75(1H, d, J=1.7 Hz), 4.54(1H, d, J=3.8 Hz), 4.2O-4.16(1H, m), 4.05(1H, s), 4.04(1H, s), 4.01-3.96(lH, m), 2.77(1H, br d, J=I 1.7 Hz), 2.35(1H, br d, J=I 1.5 Hz), 2.17(1H, dd, J=13.5, 5.2 Hz), 2.01-1.94(2H, m), 1.83-1.78(1H, m), 1.68-1.52(6H, m), 1.48- 1.05(16H, m), 1.06(12H, s), 0.86(3H, s), 0.60(3H, s)

¹³C NMR (CDCl₃): 149.41, 139.87, 135.74, 122.37, 117.81, 109.72, 68.72, 68.69, 68.34, 65.07, 56.64, 56.05, 46.17, 44.85, 44.79, 43.11, 40.53, 40.12, 39.56, 38.89, 29.48, 29.45, 29.18, 28.34, 23.15, 22.98, 21.89, 21.59, 18.07, 17.56, 14.70

MS HRES Calculated for: C₃₃H₅₆O₄ [M+Na]⁺ 539.4071

Observed: [M+Na]⁺ 539.4066

EXAMPLE 4

Synthesis of 1,2 S-Dihydroxy-lO-ø-hydroxy^-methyl-pentyty-l^nor-cholecalciferol

l,25-Dihydroxy-20-(4-hydroxy-4-methyl-pentyl)-19-nor-cholecalciferol

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 1.023 g (1.792 mmol) of (lR,3R)-l,3-bis-((tert- butyldimethyl)silanyloxy)-5-[2-(diphenylfosphinoyl)ethylidene]-cyclohexane and 5 ml of tetrahydrofurane. The reaction mixture was cooled to -70 ⁰C and 1.12 ml (1.792 mmol) of 1.6M n-butyllithium BuLi was added dropwise. The resulting deep red solution was stirred at -78° C for 25 min and 350 mg (0.667 mmol) of (IR, 3aR, 4S, 7aR)-l-[l,5-dimethyl-l-(4-methyl-4- trimethylsilanyloxy-pentyl)-5-trimethylsilanyloxy-hexyl]-7a-methyl-octahydro-inden-4-one in 1 ml of tetrahydrofurane. The reaction mixture was stirred for 5h and then the dry ice was removed from bath and the solution was allowed to warm up to -40 ⁰C in Ih. The mixture was poured into 50 ml of ethyl acetate and 100 ml of brine. The water fraction was extracted four times with 50 ml of ethyl acetate, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm³, protected from light) using hexane: ethyl acetate (30:1 and 10:1) as mobile phase. Fractions containing product were pooled and evaporated to give colorless oil (ca. 500 mg) which was treated with 6 ml of IM tetrabutylammonium fluoride in tetrahydrofurane. The reaction mixture was stirred at room temperature for 2Oh. The new portion 3 ml of IM tetrabutylammonium fluoride in tetrahydrofurane was added and the mixture was stirred for 22h. The mixture was dissolved by the addition of 150 ml of ethyl acetate and extracted six times with 50 ml of water:brine (1 : 1) and 50 ml of brine, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm , protected from light) using ethyl acetate as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. Oil was dissolved in methyl acetate and evaporated (2 times) to give 285 mg (85%) of product as a white solid.

[α] ² _D ³ = +38.2° c=0.38, CHCl₃

UV λmax (EtOH): 243 nm (ε 33019), 251 nm (ε 38843), 261 nm (ε 26515)

¹H NMR (CDCl₃): 6.29(1H, d, J=I Ll Hz), 5.83(1H, d, J=I Ll Hz), 4.12-4.O9(1H, m), 4.06-

4.00(1H, m), 2.80-2.71(2H, m), 2.47(1H, dd, J=13.3, 3.1 Hz), 2.23-2.17(2H, m), 2.05-1.91(3H, m), 1.78(1H, ddd, J=13.1, 8.3, 3.1 Hz), 1.67-1.16(24H, m), 1.21(12H, s), 0.89(3H, s), 0.63(3H, s) ¹³C NMR (CDCl₃): 142.76, 131.16, 123.67, 115.63, 71.04, 67.38, 67.15, 57.18, 56.69, 46.73, 44.97, 44.92, 44.66, 42.20, 41.15, 39.70, 39.54, 39.37, 37.22, 29.44, 29.39, 29.36, 28.90, 23.48, 23.14, 22.41, 21.97, 18.44, 17.95, 15.12 MS HRES Calculated for: C₃₂H₅₆O₄ [M+Na]⁺ 527.4071 Observed: [M+Na]⁺ 527.4073

EXAMPLE 5 Synthesis oj ^'la-Fluoro-25-hydroxy-20-(4-hydroxy-4-methyl-pentyl)-cholecalciferol

lα-Fluoro-25-hydroxy-20-(4-hydroxy-4-methyl-pentyl)-cholecalciferol A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 680 mg (1.445 mmol) of (lS,5R)-l-((tøt-butyldimethyl) silanyloxy)- 3-[2-(diphenylfosphinoyl)-eth-(Z)-ylidene]-5-fluoro-2-methylene-cyclohexane and 5 ml of tetrahydrofurane. The reaction mixture was cooled to -70° C and 0.9 ml (1.44 mmol) of 1.6M n- butyllithium was added dropwise. The resulting deep red solution was stirred at -78° C for 25 min and 300 mg (0.571 mmol) of (IR, 3aR, 4S, 7aR)-l-[l,5-dimethyl-l-(4-methyl-4- trimethylsilanyloxy-pentyl)-5-trimethylsilanyl oxy-hexyl]-7a-methyl-octahydro-inden-4-one was added dropwise in 1 ml of tetrahydrofurane. The reaction mixture was stirred for 4h and then the dry ice was removed from bath and the solution was allowed to warm up to -40° C in Ih. The mixture was poured into 50 ml of ethyl acetate and 100 ml of brine. The water fraction was extracted three times with 50 ml of ethyl acetate, dried over Na₂SO₄ and evaporated.

The oil residue was chromatographed on column (50 cm³, protected from light) using hexane: ethyl acetate (30:1 and 10:1) as mobile phase. Fractions containing product were pooled and evaporated to give colorless oil (ca. 399 mg) which was treated with 5 ml of IM tetrabutylammonium fluoride in tetrahydrofurane. The reaction mixture was stirred at room temperature for 2Oh. The mixture was dissolved by the addition of 150 ml of ethyl acetate and extracted six times with 50 ml of water:brine (1 : 1) and 50 ml of brine, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm³, protected from light) using ethyl acetate: hexane (2:1 and 3:1) as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. The product was dissolved in methyl acetate and evaporated (2 times) to give 243 mg (82%) of product as white foam.

[α] ² _D ⁸ = +9.3° c=0.40, CHCl₃

UV λmax (EtOH): 208 nm (ε 16024), 242 nm (ε 14965), 270 nm (ε 15024) 1H NMR (CDCl₃): 6.39(1H, d, J=I Ll Hz), 6.01(1H, d, J=11.3 Hz), 5.38(1H, s), 5.13(1H, ddd,

J=49.9, 6.8, 3.7 Hz), 5.09(1H, s), 4.25-4.18(1H, m), 2.82-2.77QH, m), 2.61(1H, dd, J=13.3, 3.7

Hz), 2.3O(1H, dd, J=13.3, 7.6 Hz), 2.22-2.13(1H, m), 2.07-1.94(3H, m), 1.76-1.15(24H, m),

1.21(12H, s), 0.89(3H, s), 0.63(3H, s)

¹³C NMR (CDCl₃): 143.30, 143.06(d, J=16.7 Hz), 131.40, 125.47, 117.37, 114.71(d, J=9.9 Hz), 91.53(d, J=172.6 Hz), 71.05, 71.05, 66.53, 66.47, 57.17, 56.74, 46.89, 44.96, 44.90, 41.17,

40.87, 40.67, 39.67, 39.51, 39.36, 29.41, 29.35, 29.07, 23.56, 23.11, 22.37, 21.90, 18.43, 17.94,

15.05

EXAMPLE 6 Synthesis of (20S)-l,25-Dihydroxy-20-(5,5,5-trifluoro-4-hydroxy-4-trifluoromethyl- pent-2-ynyl)cholecalcifewl

(IR, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-l-[3-(tert-butyl-dimethyl-silanyloxy)- l-methylene-propyl]-7a-methyl-octahydro-indene A 250 ml round bottom flask equipped with stir bar, Claisen adapter with rubber septum and nitrogen sweep was charged with 17.53 g (51.77 mmol) of 3-[(1R, 3aR, 4S, 7aR)-4-(tert- butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden-l-yl]-but-3-en-l-ol and 75 ml of dichloromethane. A 7.05 g (103.54 mmol) imidazole was added followed by 9.36 g (62.124 mmol) of t-butyldimethylsilyl chloride. The mixture was stirred for 2.5h. The mixture was then diluted with 100 ml of water and extracted four times with 50 ml of dichloromethane. The combined organic layers were dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (400 cm³) using hexane, hexane:ethyl acetate (50:1, 25:1) as mobile phase and collecting ca. 40 ml fractions to give 22.32 g (95%) of product as a colorless oil.

¹U NMR (CDCl₃): 4.87(1H, s), 4.8O(1H, s), 4.02(1H, br s), 3.67(2H, t, J=7.3 Hz), 2.34-2.14(2H, m), 2.06-2.00(1H, m), 1.85-1.27(9H, m), 1.20-1.08(2H, m), 0.89(18H, s), 0.79(3H, s), 0.05(6H, s), 0.02(3H, s), 0.01(3H, s).

2-[2-(tert-Butyl-dimethyl-silanyloxy)-ethyl]-2-[(lS, 3aR, 4S, 7aR)-4-(tert-butyl-dimethyl- silanyloxy)-7a-methyl-octahydro-inden-l-yl]-cyclopropanecarboxylic acid ethyl ester

A 250 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 10.00 g (22.08 mmol) of (IR, 3aR, 4S, 7aR)-4-(tert-butyl-dimethyl- silanyloxy)- 1 -[3-(tert-butyl-dimethyl-silanyloxy)- 1 -methylene-propyl]-7a-methyl-octahydro- indene, 200 mg Of Rh₂(OAc)₄ and 40 ml of dichloromethane. A solution of 5.304 g (46.486 mmol) of ethyl diazoacetate in 30 ml of dichloromethane was added dropwise (12 ml/h) at room temperature. The reaction mixture was concentrated in vacuo and the remaining residue was filtrated on column (200 cm³) using hexane:ethyl acetate (1 :1) as mobile phase. The solvent was evaporated and the oil residue was chromatographed on column (250 cm³) using hexane: ethyl acetate (25:1, 10:1 and 5:1) as mobile phase to give 8.44 g (71%) of products as a mixture of isomers.

{2-[2-(tert-Butyl-dimethyl-silanyloxy)-ethyl]-2-[(lS, 3aR, 4S, 7aR)-4-(tert-butyl-dimethyl- silanyloxy^a-methyl-octahydro-inden-l-yll-cyclopropylj-methanol

A 50 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 4.140 g (7.682 mmol) of 2-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]- 2-[(1S, 3aR, 4S, 7aR)-4-(tert-butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden-l-yl]- cyclopropanecarboxylic acid ethyl ester and 20 ml of dichloromethane. The reaction mixture was cooled to -70° C and 10.0 ml (15.0mmol) of 1.5M DIBAL-H in toluene was added dropwise during 45 min. The reaction was stirred at -70° C for Ih and then 5 ml of saturated solution of ammonium chloride was added dropwise.

The mixture was dissolved by the addition of 100 ml of water and 50 ml of IN HCl, extracted three times with 50 ml of ethyl acetate, dried over Na₂SO₄ and evaporated.

The oil residue was chromatographed on column (200 cm ) using hexane: ethyl acetate (10:1, 3:1) as mobile phase. The fractions containing product were pooled and evaporated to give 3.610 g, (94%) of products (mixture of isomers) as colorless oil.

2-[2-(tert-Butyl-dimethyl-silanyloxy)-ethyl]-2-[(lS, 3aR, 4S, 7aR)-4-(tert-butyl-dimethyl- silanyloxy)-7a-methyl-octahydro-inden-l-yl]-cyclopropanecarbaldehyde

A 250 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 6.074 g (28.178 mmol) of pyridinium chlorochromate, 7.00 g of celite and 100 ml of dichloromethane. A 6.970 g (14.027 mmol) of {2-[2-(tert-butyl-dimethyl- silanyloxy)-ethyl]-2-[(lS, 3aR, 4S, 7aR)-4-(tert-butyl-dimethyl-silanyloxy)-7a-methyl- octahydro-inden-l-yl]-cyclopropyl} -methanol in 10 ml of dichloromethane was added dropwise and mixture was stirred in room temperature for Ih. The reaction mixture was filtrated through column with silica gel (200 cm³) and celite (2 cm) and using dichloromethane as a mobile phase. The fractions containing product were pooled and evaporated to give oil (ca. 5.71 g). Product was used to the next reaction without purification.

3-{2-[2-(tert-Butyl-dimethyl-silanyloxy)-ethyl]-2-[(lS, 3aR, 4S, 7aR)-4-(tert-butyl-dimethyl- silanyloxy)-7a-methyl-octahydro-inden-l-yl]-cyclopropyl}-acrylic acid ethyl ester

A 250 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 80 ml of toluene and 35.0 ml (35.0 mmol) of IM potassium tert- butoxide in tetrahydrofurane was added. A 7.850 g (35.015 mmol) of triethyl phosphonoacetate in 5 ml of toluene was added dropwise at ca. 5 ⁰C. The mixture was stirred at room temperature for Ih. Then the mixture was cooled to -15 ⁰C and crude (ca. 11.54 mmol) 2-[2-(tert-butyl- dimethyl-silanyloxy)-ethyl]-2-[(lS, 3aR, 4S, 7aR)-4-(tert-butyl-dimethyl-silanyloxy)-7a-methyl- octahydro-inden-l-yl]-cyclopropanecarbaldehyde in 5 ml of toluene was added and stirring was continued at -10° C for 3h. The reaction mixture was quenched with 10 ml of aqueous saturated solution of ammonium chloride, diluted with 100 ml of saturated solution of ammonium chloride and extracted four times with 50 ml of toluene and then 50 ml of ethyl acetate. The organic layer was washed with 50 ml of brine, dried and evaporated. The residue was purified over silica gel (200 cm³) using hexane:ethyl acetate (20:1) as a mobile phase to give 5.750 g (88%) of products (mixture of isomers).

7-(tert-Butyl-dimethyl-silanyloxy)-5-[(lR, 3aR, 4S, 7aR)-4-(tert-butyl-dimethyl-silanyloxy)- 7a-methyl-octahydro-inden-l-yl]-5-methyl-heptanoic acid ethyl ester A 5.750 g (10.177 mmol) of 3-{2-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-2-[(lS, 3aR,

4S, 7aR)-4-(tert-butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden- 1 -yl]-cyclopropyl} - acrylic acid ethyl ester was hydrogenated over 1.60 g of 10% Pd/C in 40 ml of ethanol at room temperature and atmospheric pressure of hydrogen. The reaction was monitoring by TLC (hexane: ethyl acetate-50:l). After 18h the catalyst was filtered off and solvent evaporated. The residue was purified over silica gel (300cm³) using hexane: ethyl acetate (100:1, 50:1, 20:1) as a mobile phase to give 5.150 g (89%) of products (mixture of isomers).

8-(tert-Butyl-dimethyl-silanyloxy)-6-[(lR, 3aR, 4S, 7aR)-4-(tert-butyl-dimethyl-silanyloxy)-

7a-methyl-octahydro-inden-l-yl]-2,6-dimethyl-octan-2-ol

A 250 ml round bottom flask equipped with stir bar, Claisen adapter with rubber septum was charged with 5.11O g (8.980 mmol) of 7-(tert-butyl-dimethyl-silanyloxy)-5-[(lR, 3aR, 4S, 7aR)-4-(tert-butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden-l-yl]-5-methyl-heptanoic acid ethyl ester ester and 80 ml of diethyl ether. The solution was cooled in ace- water bath and 17.4 ml (54.3 mmol) of 3.12M solution of methyl magnesium bromide in diethyl ether was added dropwise. After completion of the addition the mixture was stirred at room temperature for 2.5h then cooled again in an ice bath. A 10 ml of saturated solution of ammonium chloride was added dropwise. The resulting precipitate was dissolved by the addition of 50 ml of saturated solution of ammonium chloride. The aqueous layer was extracted three times with 100 ml of ethyl acetate. The combined organic layers were dried (Na₂SO₄) and evaporated. The product was used to the next reaction without farther purification.

3-[(1R, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden-l-yl]-

3,7-dimethyl-octane- 1 ,7-diol

A 50 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with crude (ca. 8.98mmol) 8-(tert-butyl-dimethyl-silanyloxy)-6-[4-(tert- butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden-l-yl]-2,6-dimethyl-octan-2-ol, 10 ml of tetrahydrofurane and 15.0 ml (15.0 mmol) of IM tetrabutylammonium fluoride in tetrahydrofurane. The reaction mixture was stirred at room temperature for 2.5h. The mixture was dissolved by the addition of 150 ml of ethyl acetate and extracted six times with 50 ml of wateπbrine (1 :1) and 50 ml of brine, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed four times on columns (400cm ) using hexane: ethyl acetate (1 :1) as a mobile phase to give: 1^st - 1.456g (low polar epimer); 2^nd - 0.852g, (mixture of epimers)' 3^rd - 1.132^ (more polar epimer)' All products 3.44Og (88% two steps).

Low polar epimer: (3S)-3-[(lR, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a- methyl-octahydro-inden-l-yl]-3,7-dimethyl-octane-l,7-diol

[α] ³D¹ = +26.1° c=0.44, CHCl₃ 1H NMR (CDCl₃): 3.9O(1H, br s), 3.67(2H, br t, J=8.1 Hz),2.06-1.99(lH, m), 1.87-1.50(4H, m),

1.73(2H, t, J=7.9 Hz), 1.40-1.06(14H, m), 1.22(6H, s), 1.06(3H, s), 0.95(3H, s), 1.95-O.82(1H, m), 0.88(9H, s), 0.00(3H, s), -0.01(3H, s)

¹³C NMR (CDCl₃): 71.03, 69.58, 59.79, 57.32, 52.99, 44.78, 43.81, 41.64, 41.58, 40.26, 38.68,

34.37, 29.48, 29.36, 25.86, 23.49, 22.78, 21.72, 18.18, 18.09, 17.78, 16.78, -4.70, -5.07 MS HRES Calculated for: C₂₆H₅₂O₃Si [M+Na]⁺ 463.3578

Observed: [M+Na]⁺ 463.3580

More polar epimer: (3R)-3-[(lR, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a- methyl-octahydro-inden-l-yl]-3,7-dimethyl-octane-l,7-diol

[α] „ = +22.7° c=0.44, CHCl₃

¹H NMR (CDCl₃): 3.99-3.97QH, m), 3.65-3.61(2H, m), 1.97(1H, br d, J=12.3 Hz), 1.84- 1.72(1H, m), 1.66-1.50(6H, m), 1.45-1.15(14H, m), 1.21(6H, s), 1.05(3H, s), 0.95(3H, s), 0.87(9H, s), -0.01(3H, s), -0.02(3H, s)

¹³C NMR (CDCl₃): 71.05, 69.57, 59.47, 57.46, 53.02, 44.87, 43.90, 41.83, 41.61, 39.99, 38.93, 34.37, 29.43, 29.42, 25.87, 23.42, 22.84, 22.12, 18.57, 18.09, 17.81, 16.79, -4.69, -5.06 MS HRES Calculated for: C₂₆H₅₂O₃Si [M+Na]⁺ 463.3578 Observed: [M+Na]⁺ 463.3575

(3S)-3-[(lR, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden- l-yl]-7-hydroxy-3,7-dimethyl-octanal

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 1.572 g (7.292 mmol) of pyridinium chlorochromate, 1.60 g of celite and 25 ml of dichloromethane. A 1.607 g (3.646 mmol) of (3S)-3-[(lR, 3aR, 4S, 7aR)-4-(tert- butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden-l-yl]-3,7-dimethyl-octane-l,7-diol in 6 ml of dichloromethane was added dropwise and mixture was stirred at room temperature for Ih 45 min and additional portion 300 mg (1.392 mmol) of pyridinium chlorochromate was added. The reaction was stirred for next Ih 15 min. The reaction mixture was filtrated through column with silica gel (50 cm³) and celite (1 cm) using dichloromethane, dichloromethane: ethyl acetate (4:1). The fractions containing product were pooled and evaporated to give 1.58 g of product as yellow oil. The product was used to the next reaction without further purification.

(6S)-6-[(lR, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden- l-yl]-2,6-dimethyl-non-8-yn-2-ol

A 50 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 1.58 g (3.601 mmol) of (3S)-3-[(lR, 3aR, 4S, 7aR)-4-(tert-butyl- dimethyl-silanyloxy)-7a-methyl-octahydro-inden-l-yl]-7-hydroxy-3,7-dimethyl-octanal and 30 ml of methanol. A 1.416 g (7.37 mmol) of l-diazo-2-oxo-propyl)-phosphonic acid dimethyl ester in 3 ml of methanol was added and the resulting mixture was cooled in an ice bath. A 1.416 g (10.245 mmol) of potassium carbonate was added and the reaction mixture was stirred in the ice bath for 30 min and then at room temperature for 3h. A 100 ml of water was added and the mixture was extracted three times with 80 ml of ethyl acetate, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (250 cm ) using hexane: ethyl acetate (7:1) as mobile phase. Fractions containing product were pooled and evaporated to give 1.31O g (83%, 2 steps) of product as colorless oil.

[α] ³ _D° = +15.7° c=0.61, CHCl₃ ¹H NMR (CDCl₃): 3.98(1H, br s), 2.28(2H, d, J=2.1 Hz), 1.95-1.91(2H, m), 1.78(1H, dt, J=13.4, 3.8 Hz), 1.68-1.62(lH, m), 1.58-1.48(6H, m), 1.44-1.17(15H, m), 1.22(6H, s), 1.04(3H, s), 1.00(3H, s), 0.93-0.83(1H, m), 0.88(9H, s), -0.00(3H, s), -0.01(3H, s)

¹³C NMR (CDCl₃): 83.09, 71.03, 69.84, 69.64, 56.68, 52.95, 44.80, 43.71, 41.31, 40.21, 39.28, 34.33, 29.44, 29.29, 28.80, 25.85, 22.74, 22.69, 22.18, 18.14, 18.05, 17.73, 16.68, -4.77, -5.13 MS HRES Calculated for: C₂₇H₅₀O₂Si [M+Na]⁺ 457.3472

Observed: [M+Na]⁺ 457.3473

(IR, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-l-[(lS)-l,5-dimethyl-l-prop-2-ynyl-5- trimethylsilanyloxy-hexyl]-7a-methyl-octahydro-indene

A 50 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 1.300 g (2.990 mmol) of (6S)-6-[(lR, 3aR, 4S, 7aR)-4-(tert-butyl- dimethyl-silanyloxy)-7a-methyl-octahydro-inden-l-yl]-2,6-dimethyl-non-8-yn-2-ol and 25 ml of dichloromethane. A 2.00 ml (13.63 mmol) of l-(trimethylsilyl) imidasole was added dropwise. The mixture was stirred at room temperature for Ih.

A 100 ml of water was added and the mixture was extracted three times with 80 ml of hexane, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (75 cm ) using hexane:ethyl acetate (25:1) as mobile phase. Fractions containing product were pooled and evaporated to give 1.409 g (93%) of product as colorless oil.

¹H NMR (CDCl₃): 3.98(1H, br s), 2.27(2H, d, J=2.9 Hz), 1.97-1.91(2H, m), 1.82-1.75(1H, m), 1.69-1.62(lH, m), 1.59-1.50(2H, m), 1.42-1.20(12H, m), 1.20(6H, s), 1.05(3H, s), 1.00(3H, s), 0.93-0.85(1H, m), 0.88(9H, s), 0.10(9H, s), 0.00(3H, s), -0.01(3H, s)

(6S)-6-[(lR, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl- octahydro-inden- 1-yl] - 1 , 1 ,l-trifluoro-6, 10-dimethyl-2-trifluoromethyl- 10- trimethylsilanyloxy-undec-3-yn-2-ol A two neck 50 ml round bottom flask equipped with stir bar, Claisen adapter with rubber septum and funnel (with cooling bath) was charged with 1.390 g (2.742 mmol) of (IR, 3aR, 4S, 7aR)-4-(tert-butyl-dimethyl-silanyloxy)- 1 -[(15)- 1 ,5-dimethyl- 1 -prop-2-ynyl-5- trimethylsilanyloxy-hexyl]-7a-methyl-octahydro-indene and 30 ml of tetrahydrofurane. The funnel was connected to container with hexafluoroacetone and cooled (acetone, dry ice). The reaction mixture was cooled to -7O⁰C and 5.00 ml (8.00 mmol) of 1.6M n-butyllithium in tetrahydrofurane was added dropwise. After 30 min hexafluoroacetone was added (the contener's valve was opened three times). The reaction was stirred at -7O⁰C for 2h then 5.0 ml of saturated solution of ammonium chloride was added. The mixture was dissolved by the addition of 100 ml of saturated solution of ammonium chloride and extracted three times with 80 ml of ethyl acetate, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed twice to remove a large amount of polymer compounds. The first column (100 cm³) using hexane:ethyl acetate (10:1) as mobile phase. The second column (100 cm ) using hexane:ethyl acetate (25:1, 15:1) as mobile phase. Fractions containing product were pooled and evaporated to give 1.959 g of colorless oil. Product was used to the next reaction without farther purification.

(6S)-l,l,l-Trifluoro-6-[(lR, 3aR, 4S, 7aR)-4-hydroxy-7a-methyl-octahydro-inden-l-yl]- 6,10-dimethyH-trifluoromethyl-undec-S-yne-l,! 0-diol

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with crude (ca. 2.74 mmol) (6S)-6-[(lR, 3aR, 4S, 7aR)-4-(tert-butyl- dimethyl-silanyloxy)-7a-methyl-octahydro-inden- 1 -yl]- 1 ,1,1 -trifluoro-6, 10-dimethyl-2- trifluoromethyl-10-trimethylsilanyloxy-undec-3-yn-2-ol and 12.0 ml (12.0 mmol) of IM tetrabutylammonium fluoride in tetrahydrofurane and reaction was stirred at 7O⁰C. After 18h new portion 5.0 ml of IM tetrabutylammonium fluoride in tetrahydrofurane was added. The reaction mixture was stirred at 7O⁰C for next 80h.

The mixture was dissolved by the addition of 150 ml of ethyl acetate and extracted six times with 50 ml of wateπbrine (1 : 1) and 50 ml of brine and dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (200 cm ) using hexane: ethyl acetate (3:1, 2:1) as mobile phase. The fractions containing product were pooled and evaporated. The residue was crystallized from hexane-ethyl acetate to give 917 mg (69%, two steps) of product as a white crystal.

m.p. 146-147⁰C

[α] ³ _D° = -3.5° c=0.43, CHCl₃ ¹U NMR (CDCl₃): 4.08(1H, br s), 2.45(1H, AB, J=17 Hz), 2.36(1H, AB, J=17 Hz), 1.98- 1.92(1H, m), 1.85-1.74(2H, m), 1.67-1.18(18H, m), 1.25(6H, s), 1.07(3H, s), 1.02(3H, s) MS HRES Calculated for: C₂₄H₃₆F₆O₃ [M+Na]⁺ 509.2461

Observed: [M+Na]⁺ 509.2459

(IR, 3aR, 4S, 7aR)-7a-Methyl-l-[(lS)-6,6,6-trifluoro-5-hydroxy-l-(4-hydroxy-4-methyl- pentyl)-l-methyl-5-trifluoromethyl-hex-3-ynyl]-octahydro-inden-4-one A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 300 mg (0.617 mmol) of (6S)-l,l,l-trifluoro-6-[(lR, 3aR, 4S, 7aR)-4- hydroxy-7a-methyl-octahydro-inden- 1 -yl]-6, 10-dimethyl-2-trifluoromethyl-undec-3-yne-2, 10- diol and 10 ml of dichloromethane. A 696 mg (1.851 mmol) of pyridinium dichromate and 710 mg of celite were added and mixture was stirred in room temperature for 3h. The reaction mixture was filtrated through column with silica gel (50 cm³) and celite (2 cm) and using dichloromethane : ethyl acetate (4:1) as a mobile phase. The fractions containing product were pooled and evaporated to give yellow oil. The product was used to the next reaction without farther purification.

(20S)-l,25-Dihydroxy-20-(5,5,5-trifluoro-4-hydroxy-4-trifluoromethyl-pent-2- ynyl)cholecalciferol

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 1.798 g (3.084 mmol) of (lS,5R)-l,5-bis-((tert- butyldimethyl)silanyloxy)-3-[2-(diphenylfosphinoyl)-eth-(Z)-ylidene]-2-methylene-cyclohexane and 12 ml of tetrahydrofurane. The reaction mixture was cooled to -78⁰C and 1.9 ml (3.04 mmol) of 1.6M n-butyllithium in tetrahydrofurane was added dropwise. The resulting deep red solution was stirred at -78⁰C for 20 min and crude (ca 0.617mmol) (IR, 3aR, 4S, 7aR)-7a-methyl-l- [(I S)-6,6,6-trifluoro-5-hydroxy- 1 -(4-hydroxy-4-methyl-pentyl)- 1 -methyl-5-trifluoromethyl-hex- 3-ynyl]-octahydro-inden-4-one was added dropwise in 1.5 ml of tetrahydrofurane. The reaction mixture was stirred for 5h and then the bath was removed and the mixture was poured into 50 ml of ethyl acetate and 100 ml of brine. The water fraction was extracted three times with 50 ml of ethyl acetate, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (75 cm³, protected from light) using hexane:ethyl acetate (5:1) as mobile phase. Fractions containing product were pooled and evaporated to give colorless oil (293 mg) which was treated with 5 ml of IM tetrabutylammonium fluoride in tetrahydrofurane. The reaction mixture was stirred at room temperature for 4Oh. The mixture was dissolved by the addition of 150 ml of ethyl acetate and extracted six times with 50 ml of water:brine (1 : 1) and 50 ml of brine, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm³, protected from light) using ethyl acetate as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. Oil was dissolved in methyl acetate and evaporated (4 times) to give 190 mg (50% three steps) of product as white foam.

[α] ³ _D° = -4.6° c=0.35, CHCl₃

UV λmax (EtOH): 205.50 nm (ε 16586), 266.00 nm (ε 14319) 1H NMR (CDCl₃): 6.36(1H, d, J=I 1.3 Hz), 6.23(1H, br s), 6.00(1H, d, J=I Ll Hz), 5.32(1H, s), 4.98(1H, s), 4.43(1H, dd, J=7.7, 4.3 Hz), 4.25-4.20(1H, m), 2.82-2.79(1H, m),

2.59(1H, dd, J=13.1, 3.1 Hz), 2.44(1H, AB, J=17.2Hz), 2.37(1H, AB, J=17.2 Hz), 2.3O(1H, dd, J=13.2, 6.2 Hz, ), 2.06-1.87(4H, m), 1.72-1.36(1 IH, m), 1.26-1.21(1H, m), 1.24(6H, s), 0.99(3H, s), 0.64(3H, s)

¹³C NMR (CDCl₃): 147.48, 142.29, 133.16, 124.72, 121.32(q, J=287.1 Hz), 117.59, 11.68, 90.08, 72.62, 71.39, 70.73, 66.89, 57.28, 56.52, 46.65, 45.18, 43.20, 42.81, 41.04, 40.89, 40.03, 29.79, 29.35, 28.95, 23.45, 22.86, 22.60, 21.84, 17.77, 14.93

MS HRES Calculated for: C₃₃H₄₆F₆O₄ [M+Na]⁺ 643.3192

Observed: [M+Na]⁺ 643.3192

EXAMPLE 7

Synthesis of(20S)-l,25-Dihydroxy-20-(5,5,5-trifluoro-4-hydroxy-4-trifluoromethyl-pent-2- ynyl)-19-nor-cholecalciferol

(IR, 3aR, 4S, 7aR)-7a-Methyl-l-[(lS)-6,6,6-trifluoro-l-methyl-l-(4-methyl-4- trimethylsilanyloxy-pentyl)-5-trifluoromethyl-5-trimethylsilanyloxy-hex-3-ynyl]- octahydro-inden-4-one

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 585 mg (1.207 mmol) of (IR, 3aR, 4S, 7aR)-7a-methyl-l-[(lS)-6,6,6- trifluoro-5 -hydroxy- 1 -(4-hydroxy-4-methyl-pentyl)- 1 -methyl-5 -trifluoromethyl-hex-3 -ynyl] - octahydro-inden-4-one and 10 ml of dichloromethane. A 1.5 ml (10.2 mmol) of 1- (trimethylsilyl)imidazole was added dropwise. The mixture was stirred at room temperature for 3h. A 150 ml of ethyl acetate was added and the mixture was washed three times with 50 ml of water, dried over Na₂SO₄ and evaporated.

The oil residue was chromatographed on column (50 cm³) using hexane: ethyl acetate (10:1) as mobile phase. Fractions containing product were pooled and evaporated to give 660 mg (87%) of product as colorless oil.

¹H NMR (CDCl₃): 2.44-2.39(3H, m), 2.32-2.16(2H, m), 2.10-1.99(2H, m), 1.95-1.84(2H, m), 1.77-1.56(4H, m), 1.38-1.19(7H, m), 1.20(6H, s), 1.03(3H, s), 0.74(3H, s), 0.28(9H, s), 0.10(9H, s)

(20S)- 1 ,25-Dihydroxy-20-(5,5,5-trifluoro-4-hydroxy-4-trifluor omethyl-pent-2-ynyl)- 19-nor- cholecalciferol

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 618 mg (1,083 mmol) of (lR,3R)-l,3-bis-((tert-butyldimethyl) silanyloxy)-5-[2-(diphenylfosphinoyl)ethylidene]-cyclo hexane and 10 ml of tetrahydrofurane. The reaction mixture was cooled to -70 ⁰C and 0.67 ml (1.07 mmol) of 1.6M n-butyllithium BuLi was added dropwise. The resulting deep red solution was stirred at -70° C for 20 min and 335 mg (0.532 mmol) of (IR, 3aR, 4S, 7aR)-7a-methyl-l-[(lS)-6,6,6-trifiuoro-l-methyl-l-(4- methyl-4-trimethylsilanyloxy-pentyl)-5-trifluoromethyl-5-trimethylsilanyloxy-hex-3-ynyl]- octahydro-inden-4-one in 1.5 ml of tetrahydrofurane. The reaction mixture was stirred for 5h and then the dry ice was removed from bath and the solution was allowed to warm up to -40 ⁰C in Ih. The mixture was poured into 50 ml of ethyl acetate and 100 ml of brine. The water fraction was extracted four times with 50 ml of ethyl acetate, dried over Na₂SO₄ and evaporated.

The oil residue was chromatographed on column (50 cm³, protected from light) using hexane:ethyl acetate (10:1) as mobile phase. Fractions containing product were pooled and evaporated to give colorless oil (ca. 440 mg) which was treated with 10 ml of IM tetrabutylammonium fluoride in tetrahydrofurane. The reaction mixture was stirred at room temperature for 29h. The mixture was dissolved by the addition of 150 ml of ethyl acetate and extracted six times with 50 ml of water:brine (1 : 1) and 50 ml of brine, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm³, protected from light) using ethyl acetate as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. Oil was dissolved in methyl acetate and evaporated (2 times) to give 308 mg (95%) of product as white foam.

[α] ¹I = +38.8 c=0.42, EtOH

UV λmax (EtOH): 243 nm (ε 29530), 252 nm (ε 33645), 261 nm (ε 23156) 1H NMR (CDCl₃): 6.28(1H, d, J=I 1.3 Hz), 5.83(1H, d, J=I Ll Hz), 4.12-4.O9(1H, m), 4.05-4.01(1H, m), 2.80-2.72(2H, m), 2.46(1H, dd, J=13.4, 3.0 Hz), 2.42(1H, AB, J=16.8 Hz), 2.36(1H, AB, J=16.8 Hz), 2.22-2.16(2H, m), 2.04-1.86(6H, m), 1.80-1.38(17H, m), 1.23(6H, s), 0.99(3H, s), 0.63(3H, s)

¹³C NMR (CDCl₃): 142.13, 131.41, 123.55, 121.36(q, J=286.9 Hz, 115.88, 72.40, 71.40, 67.40, 67.15, 27.19, 56.47, 46.50, 44.44, 43.40, 41.94, 40.91, 40.83, 39.97, 37.09, 29.65, 29.29, 29.26, 28.79, 23.35, 22.79, 22.60, 21.81, 17.79, 15.00

MS HRES Calculated for: C₃₂H₄₆F₆O₄ [M+Na]⁺ 631.3192 Observed: [M+Na]⁺ 631.3191

EXAMPLE 8

Synthesis of(20S)-la-Fluow-25-hydwxy-20-(5,5,5-trifluow-4-hydwxy-4- trifluoromethyl-pent-2-ynyl)-cholecalciferol

(20S)-lα-Fluoro-25-hydroxy-20-(5,5,5-trifluoro-4-hydroxy-4-trifluoromethyl-pent-2-ynyl)- cholecalciferol

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 495 mg (1.052 mmol) of (lS,5R)-l-((tøt-butyldimethyl) silanyloxy)- 3-[2-(diphenylfosphinoyl)-eth-(Z)-ylidene]-5-fluoro-2-methylene-cyclohexane and 10 ml of tetrahydrofurane. The reaction mixture was cooled to -70° C and 0.65 ml (1.04 mmol) of 1.6M n- butyllithium was added dropwise. The resulting deep red solution was stirred at -70° C for 20 min and 300 mg (0.477 mmol) of (IR, 3aR, 4S, 7aR)-7a-methyl-l-[(lS)-6,6,6-trifluoro-l- methyl-l-(4-methyl-4-trimethylsilanyloxy-pentyl)-5-trifluoromethyl-5-trimethylsilanyloxy-hex- 3-ynyl]-octahydro-inden-4-one was added dropwise in 1.5 ml of tetrahydrofurane. The reaction mixture was stirred for 4h and then the dry ice was removed from bath and the solution was allowed to warm up to -40° C in Ih. The mixture was poured into 50 ml of ethyl acetate and 100 ml of brine. The water fraction was extracted three times with 50 ml of ethyl acetate, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm³, protected from light) using hexane: ethyl acetate (10:1) as mobile phase. Fractions containing product were pooled and evaporated to give colorless oil (ca. 429 mg) which was treated with 10 ml of IM tetrabutylammonium fluoride in tetrahydrofurane. The reaction mixture was stirred at room temperature for 18h. The mixture was dissolved by the addition of 150 ml of ethyl acetate and extracted six times with 50 ml of water:brine (1 : 1) and 50 ml of brine, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm³, protected from light) using ethyl acetate: hexane (1 :1) as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. The product was dissolved in methyl acetate and evaporated (2 times) to give 274 mg 92%) of product as white foam.

[α] ³ _D° = +27.0 c=0.50, EtOH

UV λmax (EtOH): 212 nm (ε 34256), 243 nm (ε 15866), 271 nm (ε 16512) 1H NMR (CDCl₃): 6.38(1H, d, J=I 1.3 Hz), 6.01(1H, d, J=I 1.3 Hz), 5.38(1H, s), 5.13(1H, ddd, J=49.9, 6.6, 3.6 Hz), 5.09(1H, s), 4.23-4.19(1H, m), 2.8O(1H, dd, J=12.0, 3.5 Hz), 2.61(1H, dd, J=13.3, 3.7 Hz), 2.43(1H, AB, J=16.9 Hz), 2.36(1H, AB, J=16.9 Hz), 2.3O(1H, dd, J=13.4, 7.9 Hz), 2.24-2.15(1H, m), 2.04-1.92(3H, m), 1.73-1.35(17H, m), 1.26-1.21(1H, m), 1.24(6H, s), 0.99(3H, s), 0.64(3H, s)

¹³C NMR (CDCl₃): 142.97(d, J=16.8 Hz), 142.69, 131.68(d, J=2.2 Hz), 125.37, 121.34(q, J=286.9 Hz), 117.63, 114.99(d, J=10.0 Hz), 91.61(d, J=172.4 Hz), 90.07, 72.62, 71.38, 66.56(d, J=6.0 Hz), 57.26, 56.53, 46.68, 44.91, 43.31, 40.97, 40.89, 40.68(d, J=20.6 Hz), 40.01, 29.67, 29.28, 28.98, 23.43, 22.81, 22.60, 21.78, 17.79, 14.96

MS HRES Calculated for: C₃₃H₄₅F₇O₃ [M+Na]⁺ 645.3149

Observed: [M+Na]⁺ 645.3148 EXAMPLE 9

Synthesis of(20S)-l,25-Dihydwxy-20-(5,5,5-trifluow-4-hydwxy-4-trifluowmethyl- pent-(2Z)-enyl)cholecalciferol

(3Z,6S)-l,l,l-Trifluoro-6-[(lR, 3aR, 4S, 7aR)-4-hydroxy-7a-methyl-octahydro-inden-l-yl]- 6,10-dimethyH-trifluoromethyl-undec-S-ene-l,! O-diol

A 25 ml round bottom flask was charged with 250 mg (0.514 mmol) of (6S)-1, 1,1- trifluoro-6-[(lR, 3aR, 4S, 7aR)-4-hydroxy-7a-methyl-octahydro-inden-l-yl]-6,10-dimethyl-2- trifluoromethyl-undec-3-yne-2,l O-diol, 70 mg of 5% Pd/CaCO₃, 6.0 ml of hexane, 2.4 ml of ethyl acetate and 0.23 ml of solution of quinoline in ethanol (prepared from 3.1 ml of ethanol and 168μl of quinoline). The substrate was hydrogenated at ambient temperature and atmospheric pressure of hydrogen. The reaction was monitoring by TLC (hexane:ethyl acetate - 2:1). After 7h the catalyst was filtered off and solvent evaporated. The residue was purified over silica gel (125 cm³) using hexane:ethyl acetate (2:1) as a mobile phase. Fractions containing product were pooled and evaporated to give 243 mg (97%) of product as colorless oil.

¹H NMR (CDCl₃): 6.14-6.O5(1H, m), 5.49(1H, d, J=12.5 Hz), 4.08(1H, br s), 2.83(1H, dd, J=15.9, 9.7 Hz), 2.48-2.38(1H, m), 1.85-1.75(2H, m), 1.65-1.20(17H, m), 1.22(3H, s), 1.20(3H, s), 1.08(3H, s), 1.03-0.96(lH, m), 1.00(3H, s)

¹³C NMR (CDCl₃): 140.22, 117.44, 71.79, 69.66, 56.74, 52.58, 44.11, 43.45, 41.19, 40.24, 39.64, 36.88, 33.44, 30.09, 28.88, 22.55, 22.21, 21.70, 17.63, 17.58, 16.54

(IR, 3aR, 4S, 7aR)-7a-Methyl-l-[(lS,3Z)-6,6,6-trifluoro-5-hydroxy-l-(4-hydroxy-4-methyl- pentyl)-l-methyl-5-trifluoromethyl-hex-3-enyl]-octahydro-inden-4-one

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 290 mg (0.594 mmol) of (3Z,6S)-l,l,l-trifiuoro-6-[(lR, 3aR, 4S, 7aR)-4-hydroxy-7a-methyl-octahydro-inden- 1 -yl]-6, 10-dimethyl-2-trifluoromethyl-undec-3-ene- 2,10-diol and 10 ml of dichloromethane. A 700 mg (1.861 mmol) pyridinium dichromate and 750 mg of celite was added and mixture was stirred in room temperature for 3h. The reaction mixture was filtrated through column with silica gel (75 cm³) and celite (2 cm) and using dichloromethane : ethyl acetate (4:1) as a mobile phase. The fractions containing product were pooled and evaporated to give yellow oil. The product was used to the next reaction without farther purification.

(20S)-l,25-Dihydroxy-20-(5,5,5-trifluoro-4-hydroxy-4-trifluoromethyl-pent-(2Z)- enyl)cholecalciferol

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 1.800 g (3.088 mmol) of (lS,5R)-l,5-bis-((tert-butyldimethyl) silanyloxy)-3-[2-(diphenylfosphinoyl)-eth-(Z)-ylidene]-2-methylene-cyclohexane and 10.0 ml of tetrahydrofurane. The reaction mixture was cooled to -78⁰C and 1.9 ml (3.04 mmol) of 1.6M n- butyllithium in tetrahydrofurane was added dropwise. The resulting deep red solution was stirred at -78⁰C for 20 min and 278 mg (0.571 mmol) of (IR, 3aR, 4S, 7aR)-7a-methyl-l-[(lS,3Z)- 6,6,6-trifluoro-5-hydroxy- 1 -(4-hydroxy-4-methyl-pentyl)- 1 -methyl-S-trifluoromethyl-hex-S- enyl]-octahydro-inden-4-one was added dropwise in 1.5 ml of tetrahydrofurane. The reaction mixture was stirred for 5h (last 0.5h at -2O⁰C) and then the bath was removed and the mixture was poured into 50 ml of ethyl acetate and 100 ml of brine. The water fraction was extracted three times with 50 ml of ethyl acetate, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (75 cm³, protected from light) using hexane: ethyl acetate (4:1) as mobile phase. Fractions containing product were pooled and evaporated to give colorless oil (309 mg) which was treated with 5 ml of IM tetrabutylammonium fluoride in tetrahydrofurane. The reaction mixture was stirred at room temperature for 22h.

The mixture was dissolved by the addition of 150 ml of ethyl acetate and extracted six times with 50 ml of wateπbrine (1 : 1) and 50 ml of brine, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm³, protected from light) using ethyl acetate as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. Oil was dissolved in methyl acetate and evaporated (4 times) to give 192 mg (54%, two steps) of product as white foam.

UV λmax (EtOH): 204.08 nm (ε 27522), 266.03 nm (ε 20144) 1H NMR (CDCl₃): 6.37(1H, d, J=I Ll Hz), 6.1O(1H, ddd, J=12.5, 9.0, 6.0 Hz), 6.00(1H, d, J=I 1.3 Hz), 5.47(1H, d, J=12.2 Hz), 5.32(1H, s), 5.07(1H, br, s), 4.99(1H, s), 4.43(1H, dd, J=7.8, 4.2 Hz), 4.25-4.20(1H, m), 2.85-2.79(2H, m), 2.59(1H, dd, J=13.4, 3.0 Hz), 2.46(1H, dd, J=16.4, 4.9 Hz), 2.31(1H, dd, J=13.4, 6.4 Hz), 2.04-1.97(3H, m), 1.9O(1H, ddd, J=12.0, 8.2, 3.2 Hz), 1.76-1.20(17H, m), 1.21(3H, s), 1.20(3H, s), 1.06-1.00(1H, m), 0,96(3H, s), 0.64(3H, s) 1³C NMR (CDCl₃): 147.51, 142.74, 140.17, 132.92, 124.88, 122.95(q, J=286.9 Hz),

122.80(q, J=285.5 Hz), 117.52, 117.39, 111.65, 71.94, 70.73, 66.88, 56.86, 56.65, 46.79, 45.20, 43.95, 42.83, 41.06, 40.09, 39.75, 37.22, 30.35, 29.05, 28.82, 23.58, 22.50, 22.19, 21.93, 17.53, 15.04

MS HRES Calculated for: C₃₃H₄₈F₆O₄ [M+Na]⁺ 645.3349 Observed: [M+Na]⁺ 645.3350

EXAMPLE 10 Synthesis of (20S)-l,25-Dihydroxy-20-[(2Z)-5,5,5-trifluoro-4-hydroxy-4-trifluoromethyl-pent-

2-enyl]-19-nor-cholecalciferol

(IR, 3aR, 4S, 7aR)-7a-Methyl-l-[(lS,3Z)-6,6,6-trifluoro-l-methyl-l-(4-methyl-4- trimethylsilanyloxy-pentylJ-S-trifluoromethyl-S-trimethylsilanyloxy-hex-S-enylJ-octahydro- inden-4-one

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 590 mg (1.213 mmol) of (IR, 3aR, 4S, 7aR)-7a-methyl-l-[(lS,3Z)- 6,6,6-trifluoro-5-hydroxy- 1 -(4-hydroxy-4-methyl-pentyl)- 1 -methyl-S-trifluoromethyl-hex-S- enyl]-octahydro-inden-4-one and 15 ml of dichloromethane. A 1.4 ml (9.5 mmol) of 1- (trimethylsilyl)imidazole was added dropwise. The mixture was stirred at room temperature for 4h. A 150 ml of ethyl acetate was added and the mixture was washed three times with 50 ml of water, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm ) using hexane: ethyl acetate (10:1) as mobile phase. Fractions containing product were pooled and evaporated to give 726 mg (95%) of product as colorless oil.

¹H NMR (CDCl₃): 6.07-5.99(1H, m), 5.41(1H, d, J=I 1.4 Hz), 2.52(2H, dd, J=6.2, 2.6 Hz), 2.44-2.38(1H, m), 2.31-1.54(1 IH, m), 1.36-1.14(6H, m), 1.19(6H, s), 0.97(3H, s), 0.74(3H, s), 0.25(9H, s), 0.09(9H, s)

(20S)-l,25-Dihydroxy-20-[(2Z)-5,5,5-trifluoro-4-hydroxy-4-trifluoromethyl-pent-2-enyl]-

19-nor-cholecalciferol

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 841 mg (1,473 mmol) of (lR,3R)-l,3-bis-((tert-butyldimethyl) silanyloxy)-5-[2-(diphenylfosphinoyl)ethylidene]-cyclo hexane and 10 ml of tetrahydrofurane. The reaction mixture was cooled to -70 ⁰C and 0.88 ml (1.41 mmol) of 1.6M n-butyllithium BuLi was added dropwise. The resulting deep red solution was stirred at -70° C for 20 min and 369 mg (0.585 mmol) of (IR, 3aR, 4S, 7aR)-7a-methyl-l-[(lS,3Z)-6,6,6-trifiuoro-l-methyl-l-(4- methyl-4-trimethylsilanyloxy-pentyl)-5-trifluoromethyl-5-trimethylsilanyloxy-hex-3-enyl]- octahydro-inden-4-one in 1.5 ml of tetrahydrofurane. The reaction mixture was stirred for 5h and then the dry ice was removed from bath and the solution was allowed to warm up to -40 ⁰C in Ih. The mixture was poured into 50 ml of ethyl acetate and 100 ml of brine. The water fraction was extracted three times with 50 ml of ethyl acetate, dried over Na₂SO₄ and evaporated.

The oil residue was chromatographed on column (50 cm³, protected from light) using hexane:ethyl acetate (10:1) as mobile phase. Fractions containing product were pooled and evaporated to give colorless oil (ca. 560 mg) which was treated with 8 ml of IM tetrabutylammonium fluoride in tetrahydrofurane. The reaction mixture was stirred at room temperature for 8h. The new portion 7 ml of IM tetrabutylammonium fluoride in tetrahydrofurane was added and the mixture was stirred for 4Oh. The mixture was dissolved by the addition of 150 ml of ethyl acetate and extracted six times with 50 ml of wateπbrine (1 :1) and 50 ml of brine, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm³, protected from light) using ethyl acetate as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. Oil was dissolved in methyl acetate and evaporated (2 times) to give 327 mg (92%) of product as white foam.

[α] ² _D ⁸ = +32° c=0.43, EtOH UV λmax (EtOH): 243.67 nm (ε 36197), 252.00 nm (ε 41649), 261.83 nm (ε 28455)

¹H NMR (CDCl₃): 6.31(1H, d, J=I 1.2 Hz), 6.11(1H, ddd, J=12.4, 9.3, 5.7 Hz), 5.84(1H, d, J=10.7 Hz), 5.48(1H, d, J=I 1.7 Hz), 4.12(1H, br s), 4.05(1H, br s), 2.86-2.72(3H, m), 2.50- 2.46(2H, m), 2.24-2.18(2H, m), 2.08-1.94(3H, m), 1.88-1.22Q8H, m), 1.22(6H, s), 1.06- 0.91(2H, m), 0.97(3H, s), 0.65(3H, s) MS HRES Calculated for: C₃₂H₄₈F₆O₄ [M+Na]⁺ 633.3349

Observed: [M+Na]⁺ 633.3348

EXAMPLE 11

Synthesis of(20S)-la-Fluow-25-hydwxy-20-f(2Z)-5,5,5-trifluow-4-hydwxy-4- trifluoromethyl-pent-2-enylJ-cholecalcifewl

(20S)-lα-Fluoro-25-hydroxy-20-[(2Z)-5,5,5-trifluoro-4-hydroxy-4-trifluoromethyl-pent-2- enyl] -cholecalciferol A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 712 mg (1.513 mmol) of (lS,5R)-l-((tøt-butyldimethyl) silanyloxy)- 3-[2-(diphenylfosphinoyl)-eth-(Z)-ylidene]-5-fluoro-2-methylene-cyclohexane and 10 ml of tetrahydrofurane. The reaction mixture was cooled to -70° C and 0.90 ml (1.44 mmol) of 1.6M n- butyllithium was added dropwise. The resulting deep red solution was stirred at -70° C for 20 min and 320 mg (0.507 mmol) of (IR, 3aR, 4S, 7aR)-7a-methyl-l-[(lS,3Z)-6,6,6-trifluoro-l- methyl-l-(4-methyl-4-trimethylsilanyloxy-pentyl)-5-trifluoromethyl-5-trimethylsilanyloxy-hex- 3-enyl]-octahydro-inden-4-one was added dropwise in 1.5 ml of tetrahydrofurane. The reaction mixture was stirred for 4h and then the dry ice was removed from bath and the solution was allowed to warm up to -40° C in Ih. The mixture was poured into 50 ml of ethyl acetate and 100 ml of brine. The water fraction was extracted three times with 50 ml of ethyl acetate, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm³, protected from light) using hexane: ethyl acetate (10:1) as mobile phase. Fractions containing product were pooled and evaporated to give colorless oil which was treated with 10 ml of IM tetrabutylammonium fluoride in tetrahydrofurane. The reaction mixture was stirred at room temperature for 6h 30 min.

The mixture was dissolved by the addition of 150 ml of ethyl acetate and extracted six times with 50 ml of wateπbrine (1 : 1) and 50 ml of brine, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm³, protected from light) using ethyl acetate :hexane (1 :1 and 2:1) as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. The product was dissolved in methyl acetate and evaporated (2 times) to give 300 mg 95%) of product as white foam.

[α] ² _D ⁸ = +20.2° c=0.55, EtOH

UV λmax (EtOH): 207.67 nm (ε 20792), 242.33 nm (ε 17972), 270.00 nm (ε 18053) 1H NMR (CDCl₃): 6.4O(1H, d, J=I Ll Hz), 6.11(1H, ddd, J=12.4, 9.5, 6.0 Hz), 6.02(1H, d, J=I Ll Hz), 5.49(1H, d, J=12.1 Hz), 5.39(1H, s), 5.14(1H, ddd, J=49.5, 7.2, 4.2 Hz), 5.1O(1H, s), 4.23(1H, br s), 2.87-2.80(2H, m), 2.62(1H, br d, J=12.1 Hz), 2.48-2.43(1H, m), 2.31(1H, dd, J=12.9, 7.5 Hz), 2.22-2.14(1H, m), 2.06-1.97(3H, m), 1.70-1.12(16H, m), 1.22(3H, s), 1.21(3H, m), 1.05-0.91(2H, m), 0.97(3H, s), 0.65(3H, s)

MS HRES Calculated for: C₃₃H₄₇F₇O₃ [M+Na]⁺ 647.3305

Observed: [M+Na]⁺ 647.3304

EXAMPLE 12

Synthesis of (20S)-l,25-Dihydroxy-20-[(2E)-5,5,5-trifluoro-4-hydroxy-4- trifluoromethyl-pent^-enylj-cholecalciferol

(3E,6S)-l,l,l-Trifluoro-6-[(lR, 3aR, 4S, 7aR)-4-hydroxy-7a-methyl-octahydro-inden-l-yl]- 6,10-dimethyH-trifluoromethyl-undec-S-ene-l,! 0-diol A 25 ml round bottom flask equipped with stir bar and condenser with nitrogen sweep was charged with 4.0 ml (4.0 mmol) of IM lithium aluminum hydride in tetrahydrofurane. The mixture was cooled to O⁰C and 216 mg (4.00 mmol) of sodium methoxide was added slowly followed by 300 mg (0.617 mmol) of (6S)-l,l,l-trifluoro-6-([(lR, 3aR, 4S, 7aR)-4-hydroxy-7a- methyl-octahydro-inden-l-yl]-6,10-dimethyl-2-trifluoromethyl-undec-3-yne-2,10-diol in 4.0 ml of tetrahydrofurane. The reaction mixture was stirred at 8O⁰C for 5h and then was cooled to O⁰C. A 1.0 ml of water, 1.0 ml of 2N NaOH and 20.0 ml of diethyl ether were added. The mixture was stirred at room temp for 30 min, 2.2 g OfMgSO₄ was added and mixture was stirred for next 15 min. The suspension was filtrated and solvent evaporated. The oil residue was chromatographed on columns (100 cm³ and 30 cm³) using dichloromethane: ethyl acetate (4:1) as mobile phase. Fractions containing product were pooled and evaporated to give 279 mg (93%) of product as colorless oil.

¹H NMR (CDCl₃): 6.32(1H, dt, J=15.7, 7.8 Hz), 5.59(1H, 15.7 Hz), 4.09(1H, br s), 2.29(2H, d, J=7.6 Hz), 2.01(1H, br d, J=3.3 Hz), 1.86-1-75(2H, m), 1.63-1.04(18H, m), 1.21(6H, s), 1.09(3H, s), 0.98(3H, s) 1³C NMR (CDCl₃): 137.07, 119.81, 71.52, 69.54, 69.57, 57.20, 52.53, 44.16, 43.50,

42.29, 41.43, 40.10, 40.04, 33.39, 29.33, 29.29, 23.01, 22.17, 21.69, 17.86, 17.51, 16.58

(IR, 3aR, 4S, 7aR)-7a-Methyl-l-[(lS,3E)-6,6,6-trifluoro-5-hydroxy-l-(4-hydroxy-4-methyl- pentyl)-l-methyl-5-trifluoromethyl-hex-3-enyl]-octahydro-inden-4-one

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 274 mg (0.561 mmol) of (6S,3E)-l,l,l-trifiuoro-6-[(lR, 3aR, 4S, 7aR)-4-hydroxy-7a-methyl-octahydro-inden- 1 -yl]-6, 10-dimethyl-2-trifluoromethyl-undec-3-ene- 2,10-diol and 10 ml of dichloromethane. A 704 mg (1.871 mmol) of pyridinium dichromate and 740 mg of celite was added and mixture was stirred in room temperature for 2h. The reaction mixture was filtrated through column with silica gel (100 cm ) using dichloromethane : ethyl acetate (4:1) as a mobile phase. The fractions containing product were pooled and evaporated to give 253 mg of yellow oil. The product was used to the next reaction without farther purification.

(20S)-l,25-Dihydroxy-20-[(2E)-5,5,5-trifluoro-4-hydroxy-4-trifluoromethyl-pent-2-enyl]- cholecalciferol A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 1.765 g (3.028 mmol) of (lS,5R)-l,5-bis-((tert-butyldimethyl) silanyloxy)-3-[2-(diphenylfosphinoyl)-eth-(Z)-ylidene]-2-methylene-cyclohexane and 10.0 ml of tetrahydrofurane. The reaction mixture was cooled to -78⁰C and 1.8 ml (2.88 mmol) of 1.6M n- butyllithium in tetrahydrofurane was added dropwise. The resulting deep red solution was stirred at -78⁰C for 20 min and 253 mg (0.520 mmol) of (IR, 3aR, 4S, 7aR)-7a-methyl-l-[(lS,3E)- 6,6,6-trifluoro-5-hydroxy- 1 -(4-hydroxy-4-methyl-pentyl)- 1 -methyl-S-trifluoromethyl-hex-S- enyl]-octahydro-inden-4-one was added dropwise in 1.5 ml of tetrahydrofurane. The reaction mixture was stirred for 5h (last 0.5h at -2O⁰C) and then the bath was removed and the mixture was poured into 50 ml of ethyl acetate and 100 ml of brine. The water fraction was extracted three times with 50 ml of ethyl acetate, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (60 cm³, protected from light) using hexane: ethyl acetate (4:1) as mobile phase. Fractions containing product were pooled and evaporated to give colorless oil (304 mg) which was treated with 5 ml of IM tetrabutylammonium fluoride in tetrahydrofurane. The reaction mixture was stirred at room temperature for 2 Ih.

The mixture was dissolved by the addition of 150 ml of ethyl acetate and extracted six times with 50 ml of wateπbrine (1 :1) and 50 ml of brine, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm³, protected from light) using ethyl acetate as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. Oil was dissolved in methyl acetate and evaporated (4 times) to give 176 mg (54%, two steps) of product as white foam.

[α] ²ζ = -4.5° c=0.33, CHCl₃

UV λmax (EtOH): 204.50 nm (ε 17846), 266.17 nm (ε 16508) 1H NMR (CDCl₃): 6.36(1H, d, J=I 1.3 Hz), 6.32(1H, dt, J=15.1, 7.5 Hz), 6.00(1H, d,

J=I Ll Hz), 5.59(1H, d, J=15.8 Hz, 5.33(1H, s), 4.99(1H, s), 4.53(1H, br s), 4.43(1H, dd, J=7.7, 4.3 Hz), 4.25-4.00(1H, m), 2.81(1H, dd, J=12.1, 3.8 Hz), 2.59(1H, dd, J=13.3, 2.9 Hz), 2.34- 2.29(3H, m), 2.05-1.96(3H, m), 1.93-1.87(1H, m), 1.71-1.21(17H, m), 1.21(6H, s), 1.12- 1.05(1H, m), 0.95(3H, s), 0.66(3H, s) 1³C NMR (CDCl₃): 147.48, 142.53, 136.92, 133.05, 124.83, 122.39(q, J=284.7 Hz),

119.76, 117.58, 117.49, 111, 71, 71.61, 70.73, 66.90, 57.39, 56.62, 46.79, 45.18, 43.99, 42.83, 42.48, 41.29, 40.13, 40.04, 29.62, 29.28, 28.98, 23.50, 23.06, 22.24, 21.90, 17.74, 15.11 MS HRES Calculated for: C₃₃H₄₈F₆O₄ [M+Na]⁺ 645.3349

Observed: [M+Na]⁺ 645.3346

EXAMPLE 13 Synthesis of (20S)-l,25-Dihydroxy-20-[(2E)-5,5,5-trifluoro-4-hydroxy-4- trifluoromethyl-pent-2-enyl]-19-nor-cholecalciferol

(IR, 3aR, 4S, 7aR)-7a-Methyl-l-[(lS,3E)-6,6,6-trifluoro-l-methyl-l-(4-methyl-4- trimethylsilanyloxy-pentylJ-S-trifluoromethyl-S-trimethylsilanyloxy-hex-S-enyll-octahydro- inden-4-one

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 577 mg (1.186 mmol) of (IR, 3aR, 4S, 7aR)-7a-methyl-l-[(lS,3E)- 6,6,6-trifluoro-5-hydroxy- 1 -(4-hydroxy-4-methyl-pentyl)- 1 -methyl-S-trifluoromethyl-hex-S- enyl]-octahydro-inden-4-one and 20 ml of dichloromethane. A 1.5 ml (10.2 mmol) of 1- (trimethylsilyl)imidazole was added dropwise. The mixture was stirred at room temperature for 5h 30min. A 150 ml of ethyl acetate was added and the mixture was washed three times with 50 ml of water, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (75 cm³) using hexane:ethyl acetate (10:1) as mobile phase. Fractions containing product were pooled and evaporated to give 710 mg (95%) of product as colorless oil.

¹H NMR (CDCl₃): 6.21(1H, dt, J=15.1, 7.2 Hz), 5.56(1H, d, J=15.4 Hz), 1.22-1.19(1H, m), 2.32-1.06(2H, m), 2.27(2H, d, J=7.0 Hz), 2.06-1.52(9H, m), 1.34-1.08(6H, m), 1.20(3H, s), 1.19(3H, s), 0.96(3H, s), 0.73(3H, s), 0.22(9H, s), 0.10(9H, s)

(20S)-l,25-Dihydroxy-20-[(2E)-5,5,5-trifluoro-4-hydroxy-4-trifluoromethyl-pent-2-enyl]-

19-nor-cholecalciferol

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 836 mg (1,464 mmol) of (lR,3R)-l,3-bis-((ter£-butyldimethyl) silanyloxy)-5-[2-(diphenylfosphinoyl)ethylidene]-cyclohexane and 10 ml of tetrahydrofurane. The reaction mixture was cooled to -70 ⁰C and 0.89 ml (1.42 mmol) of 1.6M n-butyllithium BuLi was added dropwise. The resulting deep red solution was stirred at -70° C for 20 min and 360 mg (0.571 mmol) of (IR, 3aR, 4S, 7aR)-7a-methyl-l-[(lS,3E)-6,6,6-trifiuoro-l-methyl-l-(4- methyl-4-trimethylsilanyloxy-pentyl)-5-trifluoromethyl-5-trimethylsilanyloxy-hex-3-enyl]- octahydro-inden-4-one in 1.5 ml of tetrahydrofurane. The reaction mixture was stirred for 5h and then the dry ice was removed from bath and the solution was allowed to warm up to -40 ⁰C in Ih. The mixture was poured into 50 ml of ethyl acetate and 100 ml of brine. The water fraction was extracted three times with 50 ml of ethyl acetate, dried over Na₂SO₄ and evaporated.

The oil residue was chromatographed on column (50 cm³, protected from light) using hexane:ethyl acetate (10:1) as mobile phase. Fractions containing product were pooled and evaporated to give colorless oil (ca. 440 mg) which was treated with 10 ml of IM tetrabutylammonium fluoride in tetrahydrofurane. The reaction mixture was stirred at room temperature for 26h. The new portion 2.5 ml of IM tetrabutylammonium fluoride in tetrahydrofurane was added and the mixture was stirred for next 6h.

The mixture was dissolved by the addition of 150 ml of ethyl acetate and extracted six times with 50 ml of wateπbrine (1 : 1) and 50 ml of brine, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm³, protected from light) using ethyl acetate as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. Oil was dissolved in methyl acetate and evaporated (2 times) to give 303 mg (87%) of product as white foam.

[α] ¹I = +41.8 c=0.44, EtOH

UV λmax (EtOH): 244 nm (ε 27480), 252 nm (ε 32212), 262 nm (ε 21694) 1H NMR (CDCl₃): 6.33(1H, dt, J=15.6, 7.8 Hz), 6.29(1H, d, J=9.0 Hz), 5.83(1H, d, J=I Ll Hz), 5.58(1H, d, J=15.6 Hz), 4.12-4.O9(1H, m), 4.05-4.02(1H, m), 2.79-2.71(2H, m), 2.46(1H, dd, J=13.2, 3.0 Hz), 2.29(2H, d, J=7.5 Hz), 2.20(2H, dd, J=13.3, 7.1 Hz), 2.04-1.75(7H, m), 1.68-1.46(9H, m), 1.41-1.21(6H, m), 1.21(6H, s), 1.12-1.O5(1H, m), 0.95(3H, s), 0.65(3H, s)

¹³C NMR (CDCl₃): 142.40, 136.79, 131.25, 123.64, 122.4(q, J=286.96 Hz), 119.83, 115.76, 71.59, 67.42, 67.18, 57.33, 56.56, 46.64, 44.52, 44.04, 42.40, 42.02, 41.24, 40.10, 40.01, 37.13, 29.54, 29.26, 28.83, 23.39, 23.07, 22.25, 21.87, 17.79, 15.17 MS HRES Calculated for: C₃₂H₄₈F₆O₄ [M+Na]⁺ 633.3349

Observed: [M+Na]⁺ 633.3349

EXAMPLE 14

Synthesis of (20S)-la-Fluoro-25-hydroxy-20-[(2E)-5, 5, 5-trifluoro-4-hydroxy-4- trifluoromethyl-pent-2-enyl]-cholecalciferol

(20S)-lα-Fluoro-25-hydroxy-20-[(2E)-5,5,5-trifluoro-4-hydroxy-4-trifluoromethyl-pent-2- enyl] -cholecalciferol A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 521 mg (1.107 mmol) of (lS,5R)-l-((tøt-butyldimethyl) silanyloxy)- 3-[2-(diphenylfosphinoyl)-eth-(Z)-ylidene]-5-fluoro-2-methylene-cyclohexane and 10 ml of tetrahydrofurane. The reaction mixture was cooled to -7O⁰ C and 0.69 ml (1.10 mmol) of 1.6M n- butyllithium was added dropwise. The resulting deep red solution was stirred at -70° C for 20 min and 324 mg (0.514 mmol) of (IR, 3aR, 4S, 7aR)-7a-methyl-l-[(lS,3E)-6,6,6-trifluoro-l- methyl-l-(4-methyl-4-trimethylsilanyloxy-pentyl)-5-trifluoromethyl-5-trimethylsilanyloxy-hex- 3-enyl]-octahydro-inden-4-one was added dropwise in 1.5 ml of tetrahydrofurane. The reaction mixture was stirred for 4h and then the dry ice was removed from bath and the solution was allowed to warm up to -40° C in Ih. The mixture was poured into 50 ml of ethyl acetate and 100 ml of brine. The water fraction was extracted three times with 50 ml of ethyl acetate, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm³, protected from light) using hexane: ethyl acetate (10:1) as mobile phase. Fractions containing product were pooled and evaporated to give colorless oil which was treated with 8 ml of IM tetrabutylammonium fluoride in tetrahydrofurane. The reaction mixture was stirred at room temperature for 9h.

The mixture was dissolved by the addition of 150 ml of ethyl acetate and extracted six times with 50 ml of wateπbrine (1 : 1) and 50 ml of brine, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm³, protected from light) using ethyl acetate:hexane (1 :1) as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. The product was dissolved in methyl acetate and evaporated (2 times) to give 305 mg 95%) of product as white foam.

[α] ¹I = +29.3 c=0.43, EtOH

UV λmax (EtOH): 210 nm (ε 13484), 243 nm (ε 13340), 271 nm (ε 13609) 1H NMR (CDCl₃): 6.39(1H, d, J=I 1.3 Hz), 6.32(1H, dt, J=15.6, 7.6 Hz), 6.01(1H, d,

J=I 1.3 Hz), 5.58(1H, d, J=15.8 Hz), 2.39(1H, s), 5.13(1H, ddd, J=49.9, 6.3, 3.8 Hz), 5.09(1H, s), 4.21(1H, br s), 2.81(1H, dd, J=I 1.8, 3.5 Hz), 2.61(1H, dd, J=13.2, 3.2 Hz), 2.32-2.28(3H, m), 2.23-2.15(lH, m), 2.04-1.93(3H, m), 1.70-1.48(9H, m), 1.41-1.21(8H, m), 1.21(6H, s), 1.12- 1.05(1H, m), 0.95(3H, s), 0.65(3H, s)

¹³C NMR (CDCl₃): 142.95(d, J=16.0 Hz), 136.84, 131.54, 125.42, 122.42(q, J=286.9 Hz), 119.78, 117.53, 114.96(d, J=10.0 Hz), 71.74, 66.56(d, J=6.0 Hz), 57.35, 56.61, 46.82, 44.91, 44.04, 42.40, 41.29, 40.69(d, J=20.6 Hz), 40.10, 39.98, 29.47, 29.20, 29.01, 23.47, 23.07, 22.22, 21.82, 17.79, 15.13

MS HRES Calculated for: C₃₃H₄₇F₇O₃ [M+Na]⁺ 647.3305

Observed: [M+Na]⁺ 647.3302

EXAMPLE 15

Synthesis of (20R)-l,25-Dihydroxy-20-(5,5,5-trifluoro-4-hydroxy-4-trifluoromethyl-pent-2- ynyl)-cholecalciferol

(3R)-3-[(lR, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden- l-yl]-7-hydroxy-3,7-dimethyl-octanal

A 50 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 1.558 g (7.228 mmol) of pyridinium chlorochromate, 1.60 g of celite and 20 ml of dichloromethane. A 1.440 g (3.267 mmol) of (3R)-3-[(lR, 3aR, 4S, 7aR)-4-(tert- butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden- 1 -yl]-3,7-dimethyl-octane- 1 ,7-diol in 10 ml of dichloromethane was added dropwise and mixture was stirred in room temperature for 2h 50min. The reaction mixture was filtrated through column with silica gel (75 cm ) and celite (2 cm) and using dichloromethane, dichloromethane: ethyl acetate (4:1) as a mobile phase. The fractions containing product were pooled and evaporated to give 1.298 g of yellow oil. The product was used to the next reaction without farther purification.

(6R)-6-[(lR, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden- l-yl]-2,6-dimethyl-non-8-yn-2-ol A 50 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 1.298 g (2.958 mmol) of (3R)-3-[(lR, 3aR, 4S, 7aR)-4-(tert-butyl- dimethyl-silanyloxy)-7a-methyl-octahydro-inden-l-yl]-7-hydroxy-3,7-dimethyl-octanal and 30 ml of methanol. A 1.137 g (5.916 mmol) of l-diazo-2-oxo-propyl)-phosphonic acid dimethyl ester in 3 ml of methanol was added and the resulting mixture was cooled in an ice bath to O⁰C. A 1.140 g (8.248 mmol) of potassium carbonate was added and the reaction mixture was stirred in the ice bath for 30 min and then at room temperature for 2h 50 min. A 100 ml of water was added and the mixture was extracted three times with 80 ml of ethyl acetate, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (200 cm³) using hexane: ethyl acetate

(7:1) as mobile phase. Fractions containing product were pooled and evaporated to give 1.151 g (81%) of product as colorless oil.

[α] ²ζ = +18.3° c=0.54, CHCl₃ 1H NMR (CDCl₃): 3.99(1H, br s), 2.16-2.07(2H, m), 2.00-1.97(1H, m), 1.92(1H, t, J=2.6

Hz), 1.84-1.74(1H, m), 1.67-1.64(1H, m), 1.58-1.22(16H, m), 1.22(6H, s), 1.04(3H, s), 0.99(3H, s), 0.88(9H, s), 0.00(3H, s), -0.01(3H, s)

MS HRES Calculated for: C₂₇H₅₀O₂Si [M+Na]⁺ 457.3472

Observed: [M+Na]⁺ 457.3473

(IR, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-l-[(lR)-l,5-dimethyl-l-prop- 2-ynyl-5-trimethylsilanyloxy-hexyl]-7a-methyl-octahydro-indene A 50 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 1.151 g (2.647 mmol) of (6R)-6-[(lR, 3aR, 4S, 7aR)-4-(tert-butyl- dimethyl-silanyloxy)-7a-methyl-octahydro-inden-l-yl]-2,6-dimethyl-non-8-yn-2-ol and 20 ml of dichloromethane. A 2.0 ml (13.63 mmol) of l-(trimethylsilyl)imidazole was added dropwise. The mixture was stirred at room temperature for Ih. A 100 ml of water was added and the mixture was extracted three times with 50 ml of ethyl acetate, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (75 cm³) using hexane: ethyl acetate (25:1) as mobile phase. Fractions containing product were pooled and evaporated to give 1.260 g (94%) of product as colorless oil.

[α] _D = +18.5° c=0.46, CHCl₃ ¹H NMR (CDCl₃): 3.98(1H, br s), 2.12-2.08(2H, m), 20.5-1.95(2H, m), 1.92-1.9O(1H, m), 1.83-1.21(16H, m), 1.21(6H, s), 1.04(3H, s), 0.98(3H, s), 0.88(9H, s), 0.11(9H, s), 0.00(3H, s), -0.01(3H, s)

¹³C NMR (CDCl₃): 83.00, 74.07, 69.70, 69.50, 56.63, 53.03, 45.66, 43.74, 41.35, 39.59, 5 39.45, 34.38, 29.99, 29.60, 25.85, 22.81, 22.43, 22.06, 18.56, 18.05, 17.76, 16.49, 2.65, -4.77, - 5.13

MS HRES Calculated for: C₃₀H₅₈O₂Si₂ [M+Na]⁺ 529.3867

Observed: [M+Na]⁺ 529.3868

(6R)-6-[(lR, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden- 1-yl] -1,1 , l-trifluoro-6, 10-dimethyl-2-trifluor omethyl- 10-trimethylsilanyloxy-undec-3-yn-2- ol 5 A two neck 50 ml round bottom flask equipped with stir bar, Claisen adapter with rubber septum and funnel (with cooling bath) was charged with 1.252 g (2.470 mmol) of (IR, 3aR, 4S, 7aR)-4-(tert-butyl-dimethyl-silanyloxy)- 1 -[(1 R)- 1 ,5-dimethyl- 1 -prop-2-ynyl-5- trimethylsilanyloxy-hexyl]-7a-methyl-octahydro-indene and 25 ml of tetrahydrofurane. The funnel was connected to container with hexafluoroacetone and cooled (acetone, dry ice). The0 reaction mixture was cooled to -7O⁰C and 2.4 ml (3.84 mmol) of 1.6M n-butyllithium in tetrahydrofurane was added dropwise. After 30 min hexafluoroacetone was added (the container's valve was opened three times). The reaction was stirred at -7O⁰C for 2h then 5.0 ml of saturated solution of ammonium chloride was added.

The mixture was dissolved by the addition of 100 ml of saturated solution of ammonium5 chloride and extracted three times with 80 ml of ethyl acetate, dried over Na₂SO₄ and evaporated. The residue was chromatographed twice on columns (75 cm³) using hexane: ethyl acetate (10:1) as mobile phase to give 1.711 g of mixture of product and polymer (from hexafluoroacetone) .

(6R)-l,l,l-Trifluoro-6-[(lR, 3aR, 4S, 7aR)-4-hydroxy-7a-methyl-octahydro-inden-l-yl]- 6,10-dimethyl-2-trifluoromethyl-undec-3-yne-2,l 0-diol A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with crude (ca 2.470 mmol) (6R)-6-[(lR, 3aR, 4S, 7aR)-4-(tert-butyl- dimethyl-silanyloxy)-7a-methyl-octahydro-inden- 1 -yl]- 1 ,1,1 -trifluoro-6, 10-dimethyl-2- trifluoromethyl-10-trimethylsilanyloxy-undec-3-yn-2-ol and 15.0 ml (15.0 mmol) of IM tetrabutylammonium fluoride in tetrahydrofurane. The reaction mixture was stirred at 7O⁰C for 96h. The mixture was dissolved by the addition of 150 ml of ethyl acetate and extracted six times with 50 ml of wateπbrine (1 :1) and 50 ml of brine, dried OVCr Na₂SO₄ and evaporated. The oil residue was chromatographed on columns, 200cm³ and 75 cm³ using hexane:ethyl acetate (2:1). The fractions containing product were pooled and evaporated to give 979 mg (81%) of product as colorless oil.

[α] ³ _D° = +1.04° c=0.48, CHCl₃

¹H NMR (CDCl₃): 4.08(1H, br s), 2.24(1H, AB, J=17.2 Hz), 2.17(1H, AB, J=17.2 Hz), 2.05-2.02(1H, m), 1.85-1.76(2H, m), 1.66-1.20(18H, m), 1.26(3H, s), 1.25(3H, s), 1.07(3H, s), 1.01(3H, s)

MS HRES Calculated for: C₂₄H₃₆F₆O₃ [M+Na]⁺ 509.2461

Observed: [M+Na]⁺ 509.2463

(IR, 3aR, 4S, 7aR)-7a-Methyl-l-[(lR)-6,6,6-trifluoro-5-hydroxy-l-(4-hydroxy-4-methyl- pentyl)-l-methyl-5-trifluoromethyl-hex-3-ynyl]-octahydro-inden-4-one

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 291 mg (0.598 mmol) of (6R)-l,l,l-trifluoro-6-[(lR, 3aR, 4S, 7aR)-4- hydroxy-7a-methyl-octahydro-inden- 1 -yl]-6, 10-dimethyl-2-trifluoromethyl-undec-3-yne-2, 10- diol and 10 ml of dichloromethane. A 700 mg (1.861 mmol) of pyridinium dichromate and 720 mg of celite was added and mixture was stirred in room temperature for 3h. The reaction mixture was filtrated through column with silica gel (75 cm³) using dichloromethane, dichloromethane: ethyl acetate (4:1, 3:1). The fractions containing product were pooled and evaporated to give 271 mg (94%) of product as yellow oil.

(20R)-l,25-Dihydroxy-20-(5,5,5-trifluoro-4-hydroxy-4-trifluoromethyl-pent-2-ynyl)- cholecalciferol A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 2.118 g (3.634 mmol) of (lS,5R)-l,5-bis-((tøt- butyldimethyl)silanyloxy)-3-[2-(diphenylfosphinoyl)-eth-(Z)-ylidene]-2-methylene-cyclohexane and 10 ml of tetrahydrofurane. The reaction mixture was cooled to -78⁰C and 2.2 ml (3.52 mmol) of 1.6M n-butyllithium in tetrahydrofurane was added dropwise. The resulting deep red solution was stirred at -78⁰C for 20 min and 271 mg, (0.559 mmol) of (IR, 3aR, 4S, 7aR)-7a-methyl-l- [(lR,3E)-6,6,6-trifluoro-5-hydroxy- 1 -(4-hydroxy-4-methyl-pentyl)- 1 -methyl-5-trifluoromethyl- hex-3-ynyl]-octahydro-inden-4-one was added dropwise in 1.5 ml of tetrahydrofurane. The reaction mixture was stirred at -78⁰C for 5h and then the bath was removed and the mixture was poured into 100 ml of saturated solution of ammonium chloride and extracted three times with 50 ml of ethyl acetate, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm³, protected from light) using hexane: ethyl acetate (4:1) as mobile phase. The fractions contains impurities was chromatographed on column (50 cm³, protected from light) using hexane:ethyl acetate (5:1) as mobile phase. Fractions containing product were pooled and evaporated to give colorless oil (250 mg) which was treated with 5 ml of IM tetrabutylammonium fluoride in tetrahydrofurane. The reaction mixture was stirred at room temperature for 18h. The mixture was dissolved by the addition of 150 ml of ethyl acetate and extracted six times with 50 ml of water:brine (1 : 1) and 50 ml of brine, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm³, protected from light) using ethyl acetate as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. Oil was dissolved in methyl acetate and evaporated (4 times) to give 194 mg (56%) of product as white foam.

[α] ³ _D° = +7.9° c=0.38, EtOH

UV λmax (EtOH): 212.33 nm (ε 14113), 265.00 nm (ε 15960) 1H NMR (D6-DMSO): 8.93(1H, s), 6.18(1H, d, J=I 1.3 Hz), 5.96(1H, d, J=I 1.3 Hz),

5.22(1H, s), 4.86(1H, d, J=4.83 Hz), 4.75(1H, s), 4.54(1H, d, J=3.63 Hz), 4.2O-4.15(1H, m), 4.06(1H, s), 3.98(1H, br s), 2.77(1H, d, J=13.7 Hz), 2.4O-2.33(1H, m), 2.27-2.14(3H, m), 2.00- 1.90(2H, m), 1.82-1.78(2H, m), 1.64-1.54(5H, m), 1.47-1.18(1OH, m), 1.05(3H, s), 1.05(3H, s), 0.95(3H, s), 0.59(3H, s)

¹³C NMR (D6-DMSO): 149.38, 139.51, 135.94, 122.32, 121.47(q, J=287.5 Hz), 117.99, 109.77, 89.53, 70.58, 68.72, 68.35, 65.06, 56.02, 55.91, 46.06, 44.85, 44.65, 43.11, 29.30, 29.03, 28.78, 28.32, 23.05, 22.40, 21.90, 21.52, 18.27, 14.29

MS HRES Calculated for: C₃₃H₄₆F₆O₄ [M+Na]⁺ 643.3192

Observed: [M+Na]⁺ 643.3190

EXAMPLE 16

Synthesis of (20R)-l,25-Dihydroxy-20-(5,5,5-trifluoro-4-hydroxy-4-trifluoromethyl-pent-2- ynyl)-19-nor-cholecalciferol

HO ^CF₃ Me₃SiO ^CF₃

OH ~T> SiMe₃

CF, TMS-imidazole CF₃

CH₇Cl₇

(IR, 3aR, 4S, 7aR)-7a-Methyl-l-[(lR)-6,6,6-trifluoro-l-methyl-l-(4-methyl-4- trimethylsilanyloxy-pentyl)-5-trifluoromethyl-5-trimethylsilanyloxy-hex-3-ynyl]- octahydro-inden-4-one

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 399 mg (0.823 mmol) of (IR, 3aR, 4S, 7aR)-7a-methyl-l-[(lR)-6,6,6- trifluoro-5 -hydroxy- 1 -(4-hydroxy-4-methyl-pentyl)- 1 -methyl-5 -trifluoromethyl-hex-3 -ynyl] - octahydro-inden-4-one and 8.0 ml of dichloromethane. A 0.9 ml (6.2 mmol) of 1- (trimethylsilyl)imidazole was added dropwise. The mixture was stirred at room temperature for 4h. A 150 ml of hexane was added and the mixture was washed three times with 50 ml of water, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm³) using hexane:ethyl acetate (5:1) as mobile phase. Fractions containing product were pooled and evaporated to give 492 mg (95%) of product as oil.

(20R)- 1 ,25-Dihydroxy-20-(5,5,5-trifluoro-4-hydroxy-4-trifluor omethyl-pent-2-ynyl)- 19-nor- cholecalciferol

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 490 mg (0.858 mmol) of (lR,3R)-l,3-bis-((tert-butyl dimethyl)silanyloxy)-5-[2-(diphenylfosphinoyl)ethylidene]-cyclohexane and 8 ml of tetrahydrofurane. The reaction mixture was cooled to -70 ⁰C and 0.53 ml (0.848 mmol) of 1.6M n-butyllithium BuLi was added dropwise. The resulting deep red solution was stirred at -70° C for 30 min and 249 mg (0.396 mmol) of (IR, 3aR, 4S, 7aR)-7a-methyl-l-[(lR)-6,6,6-trifiuoro-l- methyl-l-(4-methyl-4-trimethylsilanyloxy-pentyl)-5-trifluoromethyl-5-trimethylsilanyloxy-hex- 3-ynyl]-octahydro-inden-4-one in 1.5 ml of tetrahydrofurane. The reaction mixture was stirred for 4.5h and then the dry ice was removed from bath and the solution was allowed to warm up to -55 ⁰C in Ih. The mixture was poured into ethyl acetate (50ml) and saturated solution of ammonium chloride (50ml). The water fraction was extracted with ethyl acetate (3x50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50 cm³, protected from light) using hexane: ethyl acetate (10:1) as mobile phase. Fractions containing product were pooled and evaporated to give colorless oil (ca. 349 mg) which was treated with 10 ml of IM tetrabutylammonium fluoride in tetrahydrofurane. The reaction mixture was stirred at room temperature for 63h. The mixture was dissolved by the addition of 150 ml of ethyl acetate and extracted six times with 50 ml of water:brine (1 : 1) and 50 ml of brine, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm³, protected from light) using hexane: terra hydrofurane (1 :1) as mobile phase. Fractions containing product were pooled and evaporated to give product 207 mg (86%) as white solid.

[α] ³ _D° = +44.7 c=0.51, EtOH UV λmax (EtOH): 242 nm (ε 30834)

¹H NMR (DMSO-D6): 8.96(1H, s), 6.08(1H, d, J=10.9 Hz), 5.78(1H, d, J=I 1.3 Hz),

4.48(1H, d, J=4.3 Hz), 4.38(1H, d, J=4.1 Hz), 4.07(1H, s), 3.91-3.85(1H, m), 3.84-3.77(1H, m), 2.74(1H, d, J=13.6 Hz), 2.43(1H, dd, J=13.4, 3.4 Hz), 2.28-2.20(3H, m), 2.07-1.93(4H, m), 1.84- 1.79(1H, m), 1.69-1.21(16H, m), 1.06(3H, s), 1.06(3H, s), 0.97(3H, s), 0.60(3H, s) 1³C NMR (D6-DMSO): 139.09, 134.88, 121.60(q, J=286.0 Hz), 120.90, 116.56, 89.61,

70.64, 70.45(sep, J=33.3 Hz), 68.77, 65.57, 65.30, 56.00, 55.92, 45.93, 44.66, 44.59, 42.22, 36.95, 29.27, 29.02, 28.78, 28.14, 22.87, 22.38, 21.93, 21.40, 18.24, 14.35

MS HRES Calculated for: C₃₂H₄₆F₆O₄ [M+Na]⁺ 631.3192

Observed: [M+Na]⁺ 631.3195

EXAMPLE 17 Synthesis of (20R)-la-Fluoro-25-hydroxy-20-(5,5,5-trifluoro-4-hydroxy-4-trifluoromethyl- pent-2-ynyl)-cholecalciferol

(20R)- 1 α-Fluoro-25-hydroxy-20-(5,5,5-trifluoro-4-hydroxy-4-trifluor omethyl-pent-2-ynyl)- cholecalciferol

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 460 mg (0.977 mmol) of (lS,5R)-l-((tøt-butyldimethyl) silanyloxy)- 3-[2-(diphenylfosphinoyl)-eth-(Z)-ylidene]-5-fluoro-2-methylene-cyclohexane and 8 ml of tetrahydrofurane. The reaction mixture was cooled to -70° C and 0.61 ml (0.976 mmol) of 1.6M n-butyllithium was added dropwise. The resulting deep red solution was stirred at -70° C for 20 min and 240 mg (0.382 mmol) of (IR, 3aR, 4S, 7aR)-7a-methyl-l-[(lR)-6,6,6-trifiuoro-l- methyl-l-(4-methyl-4-trimethylsilanyloxy-pentyl)-5-trifluoromethyl-5-trimethylsilanyloxy-hex- 3-ynyl]-octahydro-inden-4-one was added dropwise in 1.5 ml of tetrahydrofurane. The reaction mixture was stirred for 4.5h and then the dry ice was removed from bath and the solution was allowed to warm up to -40° C in 1.5h. The mixture was poured into ethyl acetate (50ml) and saturated solution of ammonium chloride (50ml). The water fraction was extracted with ethyl acetate (3x50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50 cm³, protected from light) using hexane:ethyl acetate (10:1) as mobile phase. Fractions containing product were pooled and evaporated to give colorless oil (ca. 239 mg) which was treated with 8 ml of IM tetrabutylammonium fluoride in tetrahydrofurane. The reaction mixture was stirred at room temperature for 17h.

The mixture was dissolved by the addition of 150 ml of ethyl acetate and extracted six times with 50 ml of wateπbrine (1 :1) and 50 ml of brine, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm³, protected from light) using ethyl acetate :hexane (1 :2 and 1 :1) as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. The product was dissolved in methyl acetate and evaporated (2 times) to give 196 mg (82%) of product as white foam.

[α] ³ _D° = +24.4 c=0.45, EtOH

UV λmax (EtOH): 241 nm (ε 17260), 273 nm (ε 16624) ¹H NMR (DMSO-D6): 8.95(1H, s), 6.37(1H, d, J=I 1.5 Hz), 5.93(1H, d, J=I Ll Hz), 5.39(1H, s), 5.14(1H, br d, J=47.1 Hz), 4.99(1H, d, J=I.9 Hz), 4.86(1H, d, J=4.3 Hz), 4.07(1H, s), 3.94-3.87QH, m), 2.83-2.80(1H, m), 2.28-2.05(4H, m), 2.00-1.93(2H, m), 1.83-1.21(17H, m), 1.06(3H, s), 1.06(3H, s), 0.96(3H, s), 0.59(3H, s) 1³C NMR (D6-DMSO): 143.27(d, J=16.7 Hz), 141.62, 133.20, 124.14, 121.59(q,

J=286.0 Hz), 117.49, 115.34(d, J=9.8 Hz), 92.05(d, J=166.9 Hz), 89.60, 70.64, 70.44(sep, J=32.6 Hz), 68.77, 64.55(d, J=4.5 Hz), 55.99, 55.92, 46.15, 44.83, 44.65, 40.68(d, J=20.5 Hz), 40.05, 39.79, 39.41, 29.27, 29.02, 28.76, 28.30, 22.95, 22.33, 21.87, 21.39, 18.24, 14.28

MS HRES Calculated for: C₃₃H₄₅F₇O₃ [M+Na]⁺ 645.3149 Observed: [M+Na]⁺ 645.3155

EXAMPLE 18

Synthesis of (20)-l,25-Dihydroxy-20-[(2Z)-5,5,5-trifluoro-4-hydroxy-4-trifluoromethyl- pent-2-enyl]-cholecalciferol (8)

(3Z,6R)-l,l,l-Trifluoro-6-[(lR, 3aR, 4S, 7aR)-4-hydroxy-7a-methyl-octahydro-inden-l-yl]- 6,10-dimethyH-trifluoromethyl-undec-S-ene-l,! 0-diol

A 25 ml round bottom flask was charged with 340 mg (0.699 mmol) of (6R)- 1,1,1 - trifluoro-6-[(lR, 3aR, 4S, 7aR)-4-hydroxy-7a-methyl-octahydro-inden-l-yl]-6,10-dimethyl-2- trifluoromethyl-undec-3-yne-2,10-diol, 100 mg of 5% Pd/CaCO₃, 8.0 ml of hexane, 3.3 ml of ethyl acetate and 0.32 ml of solution of quinoline in ethanol (prepared from 3.1 ml of ethanol and 168μl of quinoline). The substrate was hydrogenated at ambient temperature and atmospheric pressure of hydrogen. The reaction was monitoring by TLC (hexane:ethyl acetate - 2:1). After 7h the catalyst was filtered off and solvent evaporated. The residue was purified over silica gel (50 cm³) using hexane:ethyl acetate (2:1). Fractions containing product were pooled and evaporated to give 320 mg (94%) of product as colorless oil.

¹H NMR (CDCl₃): 6.12-6.O3(1H, m), 5.46(1H, d, J=13.2 Hz), 4.08(1H, br s), 2.46- 2.40(2H, m), 2.06-1.95(1H, m), 1.86-1.76(2H, m), 1.66-1.20(18H, m), 1.21(6H, s), 1.09(3H, s), 0.99(3H, s)

(IR, 3aR, 4S, 7aR)-7a-Methyl-l-[(lR,3Z)-6,6,6-trifluoro-5-hydroxy-l-(4-hydroxy-4-methyl- pentyl)-l-methyl-5-trifluoromethyl-hex-3-enyl]-octahydro-inden-4-one A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 315 mg (0.645 mmol) of (lR,3Z)-l,l,l-trifluoro-6-[(lR, 3aR, 4S, 7aR)-4-hydroxy-7a-methyl-octahydro-inden- 1 -yl]-6, 10-dimethyl-2-trifluoromethyl-undec-3-ene- 2,10-diol and 12.0 ml of dichloromethane. A 780 mg (1.861 mmol) of pyridinium dichromate was added and mixture was stirred in room temperature for 3h. The reaction mixture was filtrated through column with silica gel (100 cm³) using dichloromethane, dichloromethane: ethyl acetate (4:1, 3:1). The fractions containing product were pooled and evaporated to give 305 mg (97%) of product as yellow oil.

[α] ³ _D° = -25.9° c=0.37, CHCl₃ 1H NMR (CDCl₃): 6.07(1H, dt, J=12.4, 7.3 Hz), 5.49(1H, d, J=I 1.9 Hz), 4.33(1H, br s),

2.52(1H, dd, J=16.2, 7.7 Hz), 2.45-2.38(2H, m), 2.31-2.10(3H, m), 2.06-1.98(1H, m), 1.96- 1.81(1H, m), 1.79-1.35(12H, m), 1.23(6H, s), 0.99(3H, s), 0.75(3H, s)

MS HRES Calculated for: C₂₄H₃₆F₆O₃ [M+Na]⁺ 509.2461

Observed: [M+Na]⁺ 509.2463

(IR, 3aR, 4S, 7aR)-7a-Methyl-l-[(lR,3Z)-6,6,6-trifluoro-l-methyl-l-(4-methyl-4- trimethylsilanyloxy-pentylJ-S-trifluoromethyl-S-trimethylsilanyloxy-hex-S-enylJ-octahydro- inden-4-one

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 295 mg (0.606 mmol) of (IR, 3aR, 4S, 7aR)-7a-methyl-l-[(lR,3Z)- 6,6,6-trifluoro-5-hydroxy- 1 -(4-hydroxy-4-methyl-pentyl)- 1 -methyl-S-trifluoromethyl-hex-S- enyl]-octahydro-inden-4-one and 8.0 ml of dichloromethane. A 0.7 ml (4.8 mmol) of 1-

(trimethylsilyl)imidazole was added dropwise. The mixture was stirred at room temperature for 3h. A 100 ml of water was added and the mixture was extracted three times with 50 ml of ethyl acetate, dried over Na₂SO₄ and evaporated.

The oil residue was chromatographed on column (50 cm³) using hexane: ethyl acetate (10:1) as mobile phase. Fractions containing product were pooled and evaporated to give 362 mg (95%) of product as colorless oil.

¹H NMR (CDCl₃): 6.02-5.94(1H, m), 5.42(1H, d, J=I LO Hz), 2.50-2.40(2H, m), 2.35- 2.14(4H, m), 2.06-1.55(7H, m), 1.43-1.14(7H, m), 1.21(6H, s), 0.96(3H, s), 0.74(3H, s), 0.24(9H, s), 0.10(9H, s)

(20)- 1 ,25-Dihydroxy-20- [(2Z)-5,5,5-trifluoro-4-hydroxy-4-trifluor omethyl-pent-2-enyl] - cholecalciferol A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 757 mg (1.299 mmol) of (lS,5R)-l,5-bis-((tøt-butyl dimethyl)silanyloxy)-3 - [2-(diphenylfo sphinoyl)-eth-(Z)-ylidene] -2-methylene-cy clohexane and 10 ml of tetrahydrofurane. The reaction mixture was cooled to -78⁰C and 0.8 ml (1.28 mmol) of 1.6M n-butyllithium in tetrahydrofurane was added dropwise. The resulting deep red solution was stirred at -78⁰C for 20 min and 360 mg (0.571 mmol) of (IR, 3aR, 4S, 7aR)-7a-methyl-l- [(lR,3Z)-6,6,6-trifluoro- 1 -methyl- 1 -(4-methyl-4-trimethylsilanyloxy-pentyl)-5-trifluoromethyl- 5-trimethylsilanyloxy-hex-3-enyl]-octahydro-inden-4-one was added dropwise in 1.5 ml of tetrahydrofurane. The reaction mixture was stirred for 4h 30 min (last 0.5h at -3O⁰C) and then the bath was removed and the mixture was poured into 50 ml of ethyl acetate and 100 ml of brine. The water fraction was extracted three times with 50 ml of ethyl acetate, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm³, protected from light) using hexane:ethyl acetate (15:1) as mobile phase. Fractions containing product and some mono deprotected compound were pooled and evaporated to give colorless oil (430mg) which was treated with 10 ml of IM tetrabutylammonium fluoride in tetrahydrofurane. The reaction mixture was stirred at room temperature for 6h 40 min. The mixture was dissolved by the addition of 150 ml of ethyl acetate and extracted six times with 50 ml of water:brine (1 : 1) and 50 ml of brine, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm , protected from light) using ethyl acetate as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. Oil was dissolved in methyl acetate and evaporated (4 times) to give 278 mg (78%, two steps) of product as white foam.

[α] „ = +6.50^=0.51, EtOH

UV λmax (EtOH): 212.67 nm (ε 15573), 265.17 nm (ε 17296)

¹H NMR (D6-DMSO): 7.97(1H, s), 6.18(1H, d, J=I 1.3 Hz), 6.09(1H, dt, J=12.1, 6.3 Hz), 5.96(1H, d, J=I 1.3 Hz), 5.42(1H, d, J=12.1 Hz), 5.22(1H, s), 4.86(1H, d, J=4.8 Hz), 4.75(1H, s), 4.54(1H, d, J=3.6 Hz), 4.2O-4.36(1H, m), 4.04(1H, s), 4.00-3.96(1H, m), 2.77(1H, br d, J=I Ll Hz), 2.49-2.39(2H, m), 2.3591H, d, J=I 1.9 Hz), 2.16(1H, dd, J=13.4, 5.3 Hz), 2.00- 1.86(2H, m), 1.83-1.77(1H, m), 1.70-1.15(16H, m), 1.04(3H, s), 1.04(3H, s), 0.90(3H, s), 0.60(3H, s)

¹³C NMR (D6-DMSO): 149.40, 139.75, 139.21, 135.81, 122.94(q, J=287.7 Hz), 122.36, 117.87, 117.15, 109.75, 68.72, 68.34, 65.08, 56.56, 55.98, 46.15, 44.85, 44.69, 43.11, 40.35, 38.85, 36.04, 29.43, 29.12, 28.34, 23.13, 22.79, 21.83, 21.50, 17.96, 14.55

MS HRES Calculated for: C₃₃H₄₈F₆O₄ [M+Na]⁺ 645.3349

Observed: [M+Na]⁺ 645.3337

EXAMPLE 19

Synthesis of (20)-l,25-Dihydroxy-20-[(2Z)-5,5,5-trifluoro-4-hydroxy-4-trifluoromethyl-pent-2- enyl]-19-nor-cholecalciferol

(20)- 1 ,25-Dihydroxy-20- [(2Z)-5,5,5-trifluoro-4-hydroxy-4-trifluor omethyl-pent-2-enyl] - 19- nor-cholecalciferol

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 804 mg (1,408 mmol) of (lR,3R)-l,3-bis-((tøt-butyl dimethyl)silanyloxy)-5-[2-(diphenylfosphinoyl)ethylidene]-cyclohexane and 8 ml of tetrahydrofurane. The reaction mixture was cooled to -70 ⁰C and 0.88 ml (1.41 mmol) of 1.6M n- butyllithium BuLi was added dropwise. The resulting deep red solution was stirred at -70° C for 25 min and 441 mg (0.699 mmol) of (IR, 3aR, 4S, 7aR)-7a-methyl-l-[(lR,3Z)-6,6,6-trifiuoro-l- methyl- l-(4-methyl-4-trimethylsilanyloxy-pentyl)-5-trifluoromethyl-5-trimethylsilanyloxy-hex- 3-enyl]-octahydro-inden-4-one in 1.5 ml of tetrahydrofurane. The reaction mixture was stirred for 6h at -7O⁰C. The mixture was poured into ethyl acetate (50ml) and saturated solution of ammonium chloride (50ml). The water fraction was extracted with ethyl acetate (3x50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50 cm , protected from light) using hexane: ethyl acetate (25:1) as mobile phase. Fractions containing product were pooled and evaporated to give oil (ca. 615 mg) which was treated with 15 ml of IM tetrabutylammonium fluoride in tetrahydrofurane. The reaction mixture was stirred at room temperature for 18h. The new portion 5 ml of IM tetrabutylammonium fluoride in tetrahydrofurane was added and the mixture was stirred for next 48h. The mixture was dissolved by the addition of 150 ml of ethyl acetate and extracted six times with 50 ml of water:brine (1 :1) and 50 ml of brine, dried over Na₂SO₄ and evaporated.

The oil residue was chromatographed on column (50 cm³, protected from light) using ethyl acetate: hexane (1 :2, 1 :1 and 3:1) and ethyl acetate as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. Oil was dissolved in methyl acetate and evaporated (2 times) to give 395 mg (92%) of product as white foam.

[α] ²I = +42.6° c=0.50, EtOH

UV λmax (EtOH): 244 nm (ε 35888), 252 nm (ε 41722), 262 nm (ε 28261) 1H NMR (DMSO-D6): 7.99(1H, s), 6.14-6.O8(1H, m), 6.08(1H, d, J=12.4 Hz), 5.78(1H, d, J=I 1.3 Hz), 5.44(1H, d, J=12.4 Hz), 4.48(1H, d, J=4.1 Hz), 4.38(1H, d, J=4.1 Hz), 4.05(1H, s), 3.89-3.84(1H, m), 3.83-3.77QH, m), 2.73(1H, d, J=13.2 Hz), 2.49-2.41(2H, m), 2.26(1H, d, J=10.4 Hz), 2.07-1.96(4H, m), 1.72-1.20(18H, m), 1.05(3H, s), 1.05(3H, s), 0.91(3H, s), 0.61(3H, s) 1³C NMR (D6-DMSO): 139.41, 139.34, 134.75, 123.07(q, J=288.2 Hz), 120.95, 117.26,

116.46, 76.83(sep, J=28.1 Hz), 68.77, 65.59, 65.31, 56.56, 55.98, 46.01, 44.71, 44.61, 42.22, 40.35, 39.01, 38.78, 36.96, 36.07, 29.44, 29.11, 22.97, 22.78, 21.88, 21.38, 17.94, 14.64

MS HRES Calculated for: C₃₂H₄₈F₆O₄ [M+Na]⁺ 633.3349

Observed: [M+Na]⁺ 633.3357

EXAMPLE 20

Synthesis of (20)-la-Fluoro-25-hydroxy-20-[(2Z)-5, 5, 5-trifluoro-4-hydroxy-4-trifluoromethyl- pent-2-enylJ-cholecalcifewl

(20)- 1 α-Fluoro-25-hydroxy-20- [(2Z)-5,5,5-trifluoro-4-hydroxy-4-trifluor omethyl-pent-2- enyl] -cholecalciferol A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 673 mg (1.430 mmol) of (lS,5R)-l-((tert-butyl dimethyl)silanyloxy)- 3-[2-(diphenylfosphinoyl)-eth-(Z)-ylidene]-5-fluoro-2-methylene-cyclohexane and 8 ml of tetrahydrofurane. The reaction mixture was cooled to -70° C and 0.89 ml (1.42 mmol) of 1.6M n- butyllithium was added dropwise. The resulting deep red solution was stirred at -70° C for 20 min and 320 mg (0.507 mmol) of (IR, 3aR, 4S, 7aR)-7a-methyl-l-[(lR,3Z)-6,6,6-trifiuoro-l- methyl- 1 -(4-methyl-4-trimethyl silanyloxy-pentyl)-5-trifluoromethyl-5-trimethylsilanyloxy-hex- 3-enyl]-octahydro-inden-4-one was added dropwise in 1.5 ml of tetrahydrofurane. The reaction mixture was stirred for 4h and then the dry ice was removed from bath and the solution was allowed to warm up to -40° C in 2h. The mixture was poured into ethyl acetate (50ml) and saturated solution of ammonium chloride (50ml). The water fraction was extracted with ethyl acetate (3x50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50 cm , protected from light) using hexane:ethyl acetate (25:1) as mobile phase. Fractions containing product were pooled and evaporated to give oil (568 mg) which was treated with 10 ml of IM tetrabutylammonium fluoride in tetrahydrofurane. The reaction mixture was stirred at room temperature for 17h.

The mixture was dissolved by the addition of 150 ml of ethyl acetate and extracted six times with 50 ml of wateπbrine (1 : 1) and 50 ml of brine, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on two columns: 50 cm (protected from light) using ethyl acetate:hexane (1 :1) as mobile phase and 50 cm³ (protected from light) using hexane:ethyl acetate (2:1 and 1 :1) Fractions containing product were pooled and evaporated to give product as colorless oil. The product was dissolved in methyl acetate and evaporated (2 times) to give 365 mg 81%) of product as white foam.

[α] ² _D" = +22.2° c=0.49, EtOH UV λmax (EtOH): 210 nm (ε 15393), 243 nm (ε 15181), 270 nm (ε 15115)

¹H NMR (DMSO-D6): 7.99(1H, s), 6.36(1H, d, J=I 1.3 Hz), 6.1O(1H, dt, J=12.2, 6.3 Hz), 5.93(1H, d, J=I 1.3 Hz), 5.43(1H, d, J=12.2 Hz), 5.39(1H, s), 5.14(1H, br d, J=47.5 Hz), 4.99(1H, d, J=I.7 Hz), 4.85(1H, d, J=4.3 Hz), 4.05(1H, s), 3.94-3.88(1H, m), 2.81(1H, d, J=13.2 Hz), 2.47-2.41(2H, m), 2.16-2.05(2H, m), 2.01-1.96(2H, m), 1.83-1.18(17H, m), 1.05(3H, s), 1.05(3H, s), 0.90(3H, s), 0.60(3H, s)

¹³C NMR (DMSO-DO): 143.30(d, J=16.7 Hz), 141.89, 139.35, 133.08, 124.18, 123.05(q, J=288.2 Hz), 117.37, 117.24, 115.26(d, J=9.1 Hz), 92.02(d, J=167.6 Hz), 76.84(sep, J=28.1 Hz), 68.76, 64.53, 56.55, 55.95, 46.25, 44.82, 44.70, 40.68(d, J=20.5 Hz), 40.29, 38.95, 38.77, 36.06, 29.41, 29.12, 28.32, 23.03, 22.71, 21.81, 21.37, 17.93, 14.55

MS HRES Calculated for: C₃₃H₄₇F₇O₃ [M+Na]⁺ 647.3305

Observed: [M+Na]⁺ 647.3297

EXAMPLE 21

Synthesis of (20R)-l,25-Dihydroxy-20-[(2E)-5,5,5-trifluoro-4-hydroxy-4- trifluoromethyl-pent-2-enyl]-cholecalciferol

(3E,6R)-l,l,l-Trifluoro-6-[(lR, 3aR, 4S, 7aR)-4-hydroxy-7a-methyl-octahydro-inden-l-yl]- 6,10-dimethyH-trifluoromethyl-undec-S-ene-l,! 0-diol

A 25 ml round bottom flask equipped with stir bar and condenser with nitrogen sweep was charged with 4.5 ml (4.5 mmol) of IM lithium aluminum hydride in tetrahydrofurane and the mixture was cooled to O⁰C. A 243 mg (4.50 mmol) of sodium methoxide was added slowly followed by substrate 337 mg (0.693 mmol) of (3E,6R)-l,l,l-trifluoro-6-[(lR, 3aR, 4S, 7aR)-4- hydroxy-7a-methyl-octahydro-inden- 1 -yl]-6, 10-dimethyl-2-trifluoromethyl-undec-3-yne-2, 10- diol in 5 ml of tetrahydrofurane. The reaction mixture was stirred at 8O⁰C for 6h 30 min and then was cooled to O⁰C. A 1 ml of water, 1 ml of 2N NaOH and 20 ml of diethyl ether were added. The mixture was stirred at room temp for 30 min and 2.2 g Of MgSO₄ was added and mixture was stirred for next 15 min. The suspension was filtrated and solvent evaporated. The oil residue was chromatographed on column (100 cm³) using dichloro methane: ethyl acetate (4:1) as mobile phase. Fractions containing product were pooled and evaporated to give 330 mg (97%) of product as colorless oil.

¹H NMR (CDCl₃): 6.28(1H, dt, J=15.7, 7.3 Hz), 5.59(1H, d, J=15.4 Hz), 6.12(1H, br s), 2.12(2H, d, J=7.7 Hz), 2.06-1.98(1H, m), 1.85-1.74(2H, m), 1.68-1.16(18H, m), 1.22(6H, s), 1.08(3H, s), 0.98(3H, s)

(IR, 3aR, 4S, 7aR)-7a-Methyl-l-[(lR,3E)-6,6,6-trifluoro-5-hydroxy-l-(4-hydroxy-4-methyl- pentyl)-l-methyl-5-trifluoromethyl-hex-3-enyl]-octahydro-inden-4-one

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 330 mg (0.675 mmol) of (3E,6Z)-l,l,l-trifluoro-6-[(lR, 3aR, 4S, 7aR)-4-hydroxy-7a-methyl-octahydro-inden- 1 -yl]-6, 10-dimethyl-2-trifluoromethyl-undec-3-ene- 2,10-diol and 10 ml of dichloromethane. A 920 mg (2.445 mmol) of pyridinium dichromate was added and mixture was stirred in room temperature for 7h.

The reaction mixture was filtrated through column with silica gel (60 cm ) using dichloromethane : ethyl acetate (4:1) as mobile phase. The fractions containing product were pooled and evaporated to give 302 mg (92%) of product as colorless oil.

[α] ³ _D° = -17.7° c=0.46, CHCl₃

¹H NMR (CDCl₃): 6.3O(1H, dt, J=15.6, 7.7 Hz), 5.6O(1H, d, J=15.6 Hz), 2.4O(1H, dd, J=I Ll, 7.3 Hz), 2.30-2.14(6H, m), 2.06-1.98(1H, m), 1.96-1.81(1H, m), 1.78-1.30(13H, m), 1.24(3H, s), 1.23(3H, s), 0.98(3H, s), 0.74(3H, s)

¹³C NMR (CDCl₃): 212.12, 136.27, 120.28, 71.45, 62.27, 57.44, 50.69, 44.28, 42.02, 40.76, 40.17, 39.69, 39.65, 29.34, 29.23, 23.98, 22.66, 22.24, 18.67, 18.19, 15.47

MS HRES Calculated for: C₂₄H₃₆F₆O₃ [M+Na]⁺ 509.2461

Observed: [M+Na]⁺ 509.2463

(IR, 3aR, 4S, 7aR)-7a-Methyl-l-[(lR,3E)-6,6,6-trifluoro-l-methyl-l-(4-methyl-4- trimethylsilanyloxy-pentylJ-S-trifluoromethyl-S-trimethylsilanyloxy-hex-S-enyll-octahydro- inden-4-one

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 292 mg (0.600 mmol) of (IR, 3aR, 4S, 7aR)-7a-methyl-l-[(lR,3E)- 6,6,6-trifluoro-5-hydroxy- 1 -(4-hydroxy-4-methyl-pentyl)- 1 -methyl-S-trifluoromethyl-hex-S- enyl]-octahydro-inden-4-one and 8 ml of dichloromethane. A 0.7 ml (4.8 mmol) of 1- (trimethylsilyl)imidazole was added dropwise. The mixture was stirred at room temperature for 2h. A 100 ml of water was added and the mixture was extracted three times with 50 ml of ethyl acetate, dried over Na₂SO₄ and evaporated.

The oil residue was chromatographed on column (60 cm³) using hexane: ethyl acetate (10:1, 4:1) as mobile phase. Fractions containing product were pooled and evaporated to give 360 mg (95%) of product as colorless oil.

(20R)- 1 ,25-Dihydroxy-20- [(2E)-5,5,5-trifluoro-4-hydroxy-4-trifluor omethyl-pent-2-enyl] - cholecalciferol

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 760 mg (1.304 mmol) of (lS,5R)-l,5-bis-((te/t-butyl dimethyl)silanyloxy)-3 - [2-(diphenylfo sphinoyl)-eth-(Z)-ylidene] -2-methylene-cy clohexane and 10 ml of tetrahydrofurane. The reaction mixture was cooled to -78⁰C and 0.8 ml (1.28 mmol) of 1.6M n-butyllithium in tetrahydrofurane was added dropwise. The resulting deep red solution was stirred at -78⁰C for 20 min and 358 mg (0.567 mmol) of (IR, 3aR, 4S, 7aR)-7a-methyl-l- [(lR,3E)-6,6,6-trifluoro- 1 -methyl- 1 -(4-methyl-4-trimethylsilanyloxy-pentyl)-5-trifluoromethyl- 5-trimethylsilanyloxy-hex-3-enyl]-octahydro-inden-4-one was added dropwise in 1.5 ml of tetrahydrofurane. The reaction mixture was stirred for 4h (last 0.5h at -2O⁰C) and then the bath was removed and the mixture was poured into 50 ml of ethyl acetate and 100 ml of brine. The water fraction was extracted three times with 50 ml of ethyl acetate, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm³, protected from light) using hexane:ethyl acetate (10:1) as mobile phase. Fractions containing product and some mono deprotected compound were pooled and evaporated to give colorless oil (440 mg) which was treated with 10 ml of IM tetrabutylammonium fluoride in tetrahydrofurane. The reaction mixture was stirred at room temperature for 2 Ih.

The mixture was dissolved by the addition of 150 ml of ethyl acetate and extracted six times with 50 ml of wateπbrine (1 : 1) and 50 ml of brine, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm³, protected from light) using ethyl acetate as mobile phase. Fractions containing product were pooled and evaporated to give 30 5mg (86%, two steps) of product as colorless solid. [U] ³ _D ¹ = +13.4° c=0.44, EtOH

UV λmax (EtOH): 212.76 nm (ε 15453), 265.03(ε 17341)

¹H NMR (D6-DMSO): 8.04(1H, s), 6.28(1H, dt, J=15.5, 7.6 Hz), 6.18(1H, d, J=I Ll Hz), 5.97(1H, d, J=I Ll Hz), 5.61(1H, d, J=15.5 Hz), 5.22(1H, s), 4.75(1H, s), 4.19-4.16(1H, m), 3.98(1H, br s), 2.77(1H, d, 13.9 Hz), 2.35(1H, d, J=I 1.7 Hz), 2.16(1H, dd, J=13.6, 5.3 Hz), 2.07(2H, d, J=7.3 Hz), 1.99-1.90(2H, m), 1.81-1.78(1H, m), 1.64-1.55(6H, m), 1.48-1.17(12H, m), 1.05(6H, s), 0.90(3H, s), O.84(1H, s), 0.61(3H, s)

¹³C NMR (D6-DMSO): 149.34, 139.65, 136.40, 135.82, 122.60(q, J=287.7 Hz), 122.32, 119.80, 117.90, 109.76, 68.68, 68.36, 65.04, 56.35, 56.00, 46.18, 44.85, 44.64, 43.09, 41.05, 40.42, 29.34, 29.12, 28.31, 23.08, 22.47, 21.79, 21.58, 17.91, 14.57

MS HRES Calculated for: C₃₃H₄₈F₆O₄ [M+Na]⁺ 645.3349

Observed: [M+Na]⁺ 645.3355

EXAMPLE 22

Synthesis of (20R)-l,25-Dihydroxy-20-[(2E)-5,5,5-trifluoro-4-hydroxy-4- trifluoromethyl-pent-2-enyl]-19-nor-cholecalciferol

(20R)-l,25-Dihydroxy-20-[(2E)-5,5,5-trifluoro-4-hydroxy-4-trifluoromethyl-pent-2-enyl]-

19-nor-cholecalciferol

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 493 mg (0.864 mmol) of (lR,3R)-l,3-bis-((tert-butyl dimethyl)silanyloxy)-5-[2-(diphenylfosphinoyl)ethylidene]-cyclohexane and 8 ml of tetrahydrofurane. The reaction mixture was cooled to -70 ⁰C and 0.54 ml (0.86 mmol) of 1.6M n- butyllithium BuLi was added dropwise. The resulting deep red solution was stirred at -70° C for 25 min and 240 mg (0.380 mmol) of (IR, 3aR, 4S, 7aR)-7a-methyl-l-[(lR,3E)-6,6,6-trifiuoro-l- methyl- 1 -(4-methyl-4-trimethylsilanyloxy-pentyl)-5-trifluoromethyl-5-trimethylsilanyloxy-hex- 3-enyl]-octahydro-inden-4-one in 1.5 ml of tetrahydrofurane. The reaction mixture was stirred for 7h and then the dry ice was removed from bath and the solution was allowed to warm up to - 40 ⁰C in Ih. The mixture was poured into ethyl acetate (50ml) and saturated solution of ammonium chloride (50ml). The water fraction was extracted with ethyl acetate (3x50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (60 cm³, protected from light) using hexane: ethyl acetate (10:1) as mobile phase. Fractions containing product were pooled and evaporated to give colorless oil (ca. 380 mg) which was treated with 10 ml of IM tetrabutylammonium fluoride in tetrahydrofurane. The reaction mixture was stirred at room temperature for 5Oh. The mixture was dissolved by the addition of 150 ml of ethyl acetate and extracted six times with 50 ml of water, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (60 cm³, protected from light) using hexane :tetrahydrofurane (1 :1, 1 :2 and 1 :2 +10% methanol) as mobile phase. Fractions containing product were pooled and evaporated to give product 181 mg (78%)as colorless solid.

[α] ³ _D° = +52.8 c=0.50, EtOH UV λmax (EtOH): 241 nm (ε 26823)

¹H NMR (DMSO-D6): 8.05(1H, s), 6.29(1H, dt, J=15.3, 7.7 Hz), 6.07(1H, d, J=I 1.1 Hz), 5.78(1H, d, J=I Ll Hz), 5.63(1H, d, J=15.3 Hz), 4.48(1H, s), 4.38(1H, s), 4.06(1H, s), 3.87(1H, s), 3.8O(1H, s), 2.74(1H, d, J=14.5 Hz), 2.43(1H, dd, J=13.0, 3.4 Hz), 2.28-2.25(1H, m), 2.10-1.91(6H, m), 1.62-1.27(17H, m), 1.06(3H, s), 1.06(3H, s), 0.91(3H, s), 0.61(3H, s)

¹³C NMR (D6-DMSO): 139.25, 136.60, 134.79, 122.73(q, J=286.8 Hz), 120.93, 119.96, 116.50, 75.55(sep, J=28.8 Hz), 68.74, 65.57, 65.29, 56.38, 56.00, 46.05, 44.67, 44.60, 42.22, 41.07, 40.43, 36.95, 29.35, 29.12, 28.14, 22.92, 22.47, 21.83, 21.47, 17.90, 14.66

MS HRES Calculated for: C₃₂H₄₈F₆O₄ [M+Na]⁺ 633.3349

Observed: [M+Na]⁺ 633.3350

EXAMPLE 23

Synthesis of (20R)-la-Fluow-25-hydwxy-20-f(2E)-5, 5, 5-trifluow-4-hydwxy-4- trifluoromethyl-pent-2-enyl]-cholecalciferol

(20R)- 1 α-Fluoro-25-hydroxy-20- [(2E)-5,5,5-trifluoro-4-hydroxy-4-trifluor omethyl-pent-2- enyl] -cholecalciferol A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 439 mg (0.933 mmol) of (lS,5R)-l-((tøt-butyl dimethyl)silanyloxy)- 3-[2-(diphenylfosphinoyl)-eth-(Z)-ylidene]-5-fluoro-2-methylene-cyclohexane and 8 ml of tetrahydrofurane. The reaction mixture was cooled to -70° C and 0.58 ml (0.93 mmol) of 1.6M n- butyllithium was added dropwise. The resulting deep red solution was stirred at -70° C for 25 min and 238 mg (0.377 mmol) of (IR, 3aR, 4S, 7aR)-7a-methyl-l-[(lR,3E)-6,6,6-trifiuoro-l- methyl- 1 -(4-methyl-4-trimethyl silanyloxy-pentyl)-5-trifluoromethyl-5-trimethylsilanyloxy-hex- 3-enyl]-octahydro-inden-4-one was added dropwise in 1.5 ml of tetrahydrofurane. The reaction mixture was stirred for 6h and then the dry ice was removed from bath and the solution was allowed to warm up to -40° C in Ih. The mixture was poured into ethyl acetate (50ml) and saturated solution of ammonium chloride (50ml). The water fraction was extracted with ethyl acetate (3x50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50 cm , protected from light) using hexane:ethyl acetate (10:1) as mobile phase. Fractions containing product were pooled and evaporated to give colorless oil which was treated with 8 ml of IM tetrabutylammonium fluoride in tetrahydrofurane. The reaction mixture was stirred at room temperature for 15h.

The mixture was dissolved by the addition of 150 ml of ethyl acetate and extracted six times with 50 ml of water, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm³, protected from light) using ethyl acetate :hexane (1:2 and 1 :1) as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. The product was dissolved in methyl acetate and evaporated (2 times) to give 195 mg (83%) of product as white foam.

[α] ²I = +29.3 c=0.43, EtOH UV λmax (EtOH): 243 nm (ε 11639), 273 nm (ε 10871)

¹H NMR (DMSO-D6): 8.05(1H, s), 6.37(1H, d, J=I 1.3 Hz), 6.28(1H, dt, J=15.3, 7.6 Hz), 5.93(1H, d, J=I 1.3 Hz), 5.62(1H, d, J=15.6 Hz), 5.39(1H, s), 5.14(1H, br d, J=47.7 Hz), 4.99(1H, d, J=I.5 Hz), 4.87(1H, br s), 4.06(1H, br s), 3.93-3.88(1H, m), 2.81(1H, d, J=I 1.9 Hz), 2.16-2.06(4H, m), 1.99-1.91(2H, m), 1.82-1.26(17H, m), 1.06(3H, s), 1.06(3H, s), 0.90(3H, s), 0.60(3H, s)

¹³C NMR (D6-DMSO): 143.26(d, J=17.5 Hz), 141.80, 136.57, 133.12, 124.17, 122.73(q, J=285.2 Hz), 119.96, 117.42, 115.37(d, J=9.9 Hz), 92.06(d, J=166.9 Hz), 75.54(sep, J=28.8 Hz), 68.74, 64.55(d, J=4.5 Hz), 56.38, 55.99, 46.28, 44.84, 44.67, 41.07, 40.69(d, J=20.5 Hz), 40.39, 29.34, 29.14, 28.31, 22.99, 22.42, 21.76, 21.47, 17.90, 14.58 MS HRES Calculated for: C₃₃H₄₇F₇O₃ [M+Na]⁺ 647.3305

Observed: [M+Na]⁺ 647.3313

EXAMPLE 24 Synthesis of l,25-Dihydroxy-20S-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl- pentyl)-23-yne-26,27-hexafluorocholecalciferol

8-(tert-Butyl-dimethyl-silanyloxy)-6-[(lR, 3aR, 4S, 7aR)-4-(tert-butyl-dimethyl-silanyloxy)-

7a-methyl-octahydro-inden- 1-yl] -1,1 , l-trideutero-ό-methyH-trideuteromethyl-octan-l-ol

A 250ml round bottom flask equipped with stir bar, Claisen adapter with rubber septum was charged with 7-(tert-butyl-dimethyl-silanyloxy)-5-[(lR, 3aR, 4S, 7aR)-4-(tert-butyl- dimethyl-silanyloxy)-7a-methyl-octahydro-inden-l-yl]-5-methyl-heptanoic acid ethyl ester (18.770 g, 32.987 mmol) and ether (150 ml). The solution was cooled in ace-water bath and a 1.0M solution of methyl-d₃-magnesium iodide in diethyl ether (100.0 ml, lOO.Ommol) was added dropwise. After completion of the addition the mixture was stirred at room temperature for 3h then cooled again in an ice bath. A saturated solution of ammonium chloride (10ml) was added dropwise. The resulting precipitate was dissolved by the addition of saturated solution of ammonium chloride (100ml). The aqueous layer was extracted with diethyl ether (3xl00ml). The combined organic layers were dried (Na₂SO₄) and evaporated. The oil residue was used to next reaction.

(3S)-3-[(lR, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden- l-yl]-8,8,8-trideutero-3-methyl-7-trideuteromethyl-octane-l,7-diol and (3R)-3-[(lR, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden- l-yl]-8,8,8-trideutero-3-methyl-7-trideuteromethyl-octane-l,7-diol

A 250ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 8-(tert-butyl-dimethyl-silanyloxy)-6-[(lR, 3aR, 4S, 7aR)-4-(tert-butyl- dimethyl-silanyloxy)-7a-methyl-octahydro-inden- 1 -yl]- 1 ,1,1 -trideutero-6-methyl-2- trideuteromethyl-octan-2-ol (ca. 32.9mmol), tetrahydrofuran (60ml) and tetrabutylammonium fluoride (45.0ml, lM/tetrahydrofuran). The reaction mixture was stirred at room temperature for 2.5h. The mixture was dissolved by the addition of ethyl acetate (150ml) and washed six times with water:brine (1 :1, 100ml) and brine (50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed 10 times on columns (VersaPak Cartridge, 80x150 mm and 40x150 mm, hexane/ethyl acetate - 1 :1) to give products (12.72g, 87%):

5

(3S)-3-[(lR, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden- l-yl]-8,8,8-trideutero-3-methyl-7-trideuteromethyl-octane-l,7-diol (6.69 g, low polar epimer)

[(X]³ _J,¹= +16.0 (c=0.60, EtOH)

¹H NMR (CDCl₃): 3.99(1H, br s), 3.69-3.63(2H, m), 2.02(1H, br d, J=12.2 Hz), 1.82-1.48(7H, m), 1.40-1.09(14H, m), 1.06(3H, s), 0.95(3H, s), 0.88(9H, s), 0.00(3H, s), -0.01(3H, s) MS HRES Calculated for: C₂₆H₄₆D₆O₃Si [M+Na]⁺ 469.3954 0 Observed: [M+Na]⁺ 469.3956

(3R)-3-[(lR, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden- l-yl]-8,8,8-trideutero-3-methyl-7-trideuteromethyl-octane-l,7-diol (6.03 g, more polar epimer)

[(X]³ _J,¹= +20.0 (c=0.54, EtOH)

¹H NMR (CDCl₃): 3.99-3.97QH, m), 3.66-3.62(2H, m), 1.98(1H, br d, J=12.8 Hz), 1.84- 1.73(1H, m), 1.67-1.51(6H, m), 1.42-1.16(14H, m), 1.05(3H, s), 0.95(3H, s), 0.88(9H, s), 35 0.00(3H, s), -0.01(3H, s)

MS HRES Calculated for: C₂₆H₄₆D₆O₃Si [M+Na]⁺ 469.3954

Observed: [M+Na]⁺ 469.3957

(3S)-3-[(lR, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden- l-yl]-8,8,8-trideutero-7-hydroxy-3-methyl-7-trideuteromethyl-octanal

A 250 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with pyridinium chlorochromate (2.90 g, 13.45 mmol), celite (4.0 g) and dichloromethane (60 ml). The (3S)-3-[(lR, 3aR, 4S, 7aR)-4-(tert-butyl-dimethyl-silanyloxy)-7a- methyl-octahydro-inden- 1 -yl]-8,8,8-trideutero-3-methyl-7-trideuteromethyl-octane- 1 ,7-diol (4.00 g, 8.95 mmol) in dichloromethane (5 ml) was added dropwise and mixture was stirred in room temperature for 2h 40min.

The reaction mixture was filtrated through column with silica gel (200cm ) and celite (2cm) using dichloromethane, dichloromethane: ethyl acetate 4:1. The fractions containing product were pooled and evaporated to give oil (3.61 g, 91%). Product was used to the next reaction without purification.

(6S)-6-[(lR, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden- 1-yl] -1,1 , l-trideutero-6-methyl-2-trideuteromethyl-non-8-yn-2-ol

A 100ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with (3S)-3-[(lR, 3aR, 4S, 7aR)-4-(tert-butyl-dimethyl-silanyloxy)-7a- methyl-octahydro-inden- 1 -yl] -8 , 8 , 8-trideutero-7-hydroxy-3 -methyl-7-trideuteromethyl-octanal (3.61 g, 8.116 mmol) and methanol (65ml). l-diazo-2-oxo-propyl)-phosphonic acid dimethyl ester (3.00 g, 15.62 mmol) in methanol (3 ml) was added and the resulting mixture was cooled in an ice bath. Potassium carbonate (3.00 g, 21.74 mmol) was added and the reaction mixture was stirred in the ice bath for 30min and then at room temperature for 4h. Water (100ml) was added and the mixture was extracted with ethyl acetate (4x80ml), dried (Na₂SO₄) and evaporated.

The oil residue was chromatographed on column (300cm³) using hexane: ethyl acetate - 9:1 and 8: las mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil (3.131 g, 87.5%). [α]² _D ⁶= +17.6 (c=0.83, EtOH)

¹H NMR (CDCl₃): 3.98(1H, br d, J=2.13 Hz), 2.28(1H, AB, J=17.3 Hz), 2.26(1H, AB, J=17.3 Hz), 1.96-1.91(2H, m), 1.84-1.73(1H, m), 1.67-1.48(5H, m), 1.43-1.24(12H, m), 1.04(3H, s), 1.00(3H, s), 0.88(9H, s), 0.00(3H, s), -0.01(3H, s) 1³C NMR (CDCl₃): 83.06, 76.41(sep, J=29.6 Hz), 69.84, 69.55, 56.54, 52.87, 44.66,

43.68, 41.27, 40.16, 39.28, 34.32, 28.76, 25.87, 22.76, 22.69, 22.17, 18.10, 17.76, 16.78, -4.69, 5.05

MS HRES Calculated for: C₂₇H₄₄D₆O₂Si [M+Na]⁺ 463.3849

Observed: [M+Na]⁺ 463.3848

(IR, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-l-[(lS)-6,6,6-trideutero-l- methyl-l-(prop-2-ynyl)-5-trideuteromethyl-5-trimethylsilanyloxy-hexyl]-octahydro-indene A 100ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with (6S)-6-[(lR, 3aR, 4S, 7aR)-4-(tert-butyl-dimethyl-silanyloxy)-7a- methyl-octahydro-inden- 1 -yl]- 1 ,1,1 -trideutero-6-methyl-2-trideuteromethyl-non-8-yn-2-ol (3.100 g, 7.033 mmol) and dichloromethane (30 ml). l-(trimethylsilyl)imidazole (3.0 ml, 20.45 mmol) was added dropwise. The mixture was stirred at room temperature for Ih 45min. Water (100ml) was added and the mixture was extracted with ethyl acetate (3x100ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (125cm³) using hexane:ethyl acetate - 10:1 as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil (3.36g, 93%).

[α]² _D ⁶= +15.4 (c=0.52, CHCl₃)

¹H NMR (CDCl₃): 3.99(1H, br s), 2.27(2H, br s), 2.00-1.93(2H, m), 1.84-1.73(1H, m), 1.65(1H, d, J=14.3 Hz), 1.59-1.49(3H, m), 1.42-1.20(12H, m), 1.05(3H, s), 1.00(3H, s), 0.88(9H, s), 0.10(9H, s), 0.00(3H, s), -0.01(3H, s)

¹³C NMR (CDCl₃): 83.18, 76.66(sep, J=28.8 Hz), 69.74, 69.58, 56.62, 52.91, 45.38, 43.67, 41.27, 40.07, 39.28, 34.34, 28.77, 25.88, 22.76, 22.16, 18.13, 18.11, 17.77, 16.76, 2.74, - 4.69, -5.05

MS HRES Calculated for: C₃₀H₅₂D₆O₂Si₂ [M+Na]⁺ 535.4244

Observed: [M+Na]⁺ 535.4246

(6S)-6-[(lR, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden- 1-yl] -6-methyl- 11,11,11-trideutero- 10-trideuteromethyl- 1 , 1 , l-trifluoro-2-trifluoromethyl- 10-trimethylsilanyloxy-undec-S-yn-l-ol

A two neck 100ml round bottom flask equipped with stir bar, Claisen adapter with rubber septum and funnel (with cooling bath) was charged with (IR, 3aR, 4S, 7aR)-4-(tert-butyl- dimethyl-silanyloxy)-7a-methyl- 1 -[( 1 S)-6,6,6-trideutero- 1 -methyl- 1 -(prop-2-ynyl)-5- trideuteromethyl-5-trimethylsilanyloxy-hexyl]-octahydro-indene (3.330 g, 6.491 mmol) and tetrahydrofuran (40 ml). The funnel was connected to container with hexafluoroacetone and cooled (acetone, dry ice). The reaction mixture was cooled to -7O⁰C and n-butyllithium (6.10 ml, 9.76mmol) was added dropwise. After 30min hexafluoroacetone was added (the container's valve was opened three times). The reaction was steered at -7O⁰C for 2h then saturated solution of ammonium chloride (5ml) was added. The mixture was dissolved by the addition of saturated solution of ammonium chloride (100ml) and extracted with ethyl acetate (3x60ml), dried (Na₂SO₄) and evaporated. The residue was chromatographed twice on columns (300cm³, hexane:ethyl acetate - 25:1 and 20:1) to give the mixture of product and polimer (from hexafluoroacetone) (4.33 g). Product was used to the next reaction without purification.

(6S)-6-[(lR, 3aR, 4S, 7aR)-4-hydroxy-7a-methyl-octahydro-inden-l-yl]-6-methyl-ll,ll,ll- trideutero- 10-trideuter omethyl- 1 , 1 , l-trifluoro-l-trifluoromethyl-undec-S-yne-l, 10-diol

A 25ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with (6S)-6-[(lR, 3aR, 4S, 7aR)-4-(tert-butyl-dimethyl-silanyloxy)-7a- methyl-octahydro-inden- 1 -yl] -6-methyl- 11,11,11 -trideutero- 10-trideuteromethyl- 1,1,1 -trifluoro- 2-trifluoromethyl-10-trimethylsilanyloxy-undec-3-yn-2-ol (ca 3.3mmol) and tetrabutylammonium fluoride (25ml, lM/tetrahydrofuran) and reaction was stirred at 7O⁰C for 113h. The mixture was dissolved by the addition of ethyl acetate (150ml) and extracted six times with water-brine (1 :1, 50ml) and dried (Na₂SO₄) and evaporated. Product was crystallized from hexane (1.996 g, 62%). [(X]³ _J,¹= -6.3 (c=0.46, EtOH)

¹H NMR (DMSO-D6): 8.92(1H, s), 4.21(1H, d, J=3.0 Hz), 4.04(1H, s), 3.87(1H, s), 2.37(2H, s), 1.89(1H, d, J=I 1.5 Hz), 1.76-1.48(6H, m), 1.33-1.H(I lH, m), 1.02(3H, s), 0.96(3H, m)

¹³C NMR (DMSO-D6): 121.47(q, J=286.8 Hz), 89.70, 70.71, 70.40(sep, J=31.9 Hz), 68.41, 66.86, 56.24, 52.37, 44.45, 42.96, 40.44, 39.38, 33.70, 28.14, 22.43, 22.01, 21.68, 17.73, 17.46, 16.32

MS HRES Calculated for: C₂₄H₃₀D₆F₆O₃ [M+Na]⁺ 515.2837 Observed: [M+Na]⁺ 515.2838

(IR, 3aR, 7aR)-7a-Methyl-l-[(lS)-6,6,6-trifluororo-5-hydroxy-l-methyl-l-(5,5,5- trideutero-4-hydroxy-4-trideuter omethyl-pentyl)-5-trifluoromethyl-hex-3-ynyl] -octahydro- inden-4-one

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with pyridinium dirochromate (1.51 g, 4.01 mmol) and dichloromethane (20 ml). The (6S)-6-[(lR, 3aR, 4S, 7aR)-4-hydroxy-7a-methyl-octahydro-inden-l-yl]-6-methyl- 11,11,11 -trideutero- 10-trideuteromethyl- 1,1,1 -trifluoro-2-trifluoromethyl-undec-3-yne-2, 10-diol (712 mg, 1.445 mmol) in dichloromethane (5 ml) was added dropwise and mixture was stirred in room temperature for 2h 45 min.

The reaction mixture was filtrated through column with silica gel (50 cm ) using dichloromethane, dichloromethane: ethyl acetate 4:1. The fractions containing product were pooled and evaporated to give oil. The product was used to the next reaction without purification.

(IR, 3aR, 7aR)-7a-Methyl-l-[(lS)-6,6,6-trifluoro-l-methyl-l-(5,5,5-trideutero-4- trideuteromethyl-4-trimethylsilanyloxy-pentyl)-5-trifluoromethyl-5-trimethylsilanyloxy- hex-3-ynyl]-octahydro-inden-4-one A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with (IR, 3aR, 7aR)-7a-methyl-l-[(lS)-6,6,6-trifluororo-5-hydroxy-l- methyl-l-(5,5,5-trideutero-4-hydroxy-4-trideuteromethyl-pentyl)-5-trifluoromethyl-hex-3-ynyl]- octahydro-inden-4-one (ca. 1.445 mmol) and dichloromethane (10 ml). 1- (trimethylsilyl)imidazole (2.00 ml, 13.63 mmol) was added dropwise. The mixture was stirred at room temperature for 2h. Ethyl acetate (150ml) was added and the mixture was washed with water (3x50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm ) using hexane:ethyl acetate - 5:1 as mobile phase. The product is unstable on the silica gel (the monoprotected compound was obtained (246 mg)). Fractions containing product were pooled and evaporated to give product as colorless oil (585 mg, 64%).

¹U NMR (CDCl₃): 2.44-2.37(3H, m), 2.32-2.16(2H, m), 2.11-1.99(2H, m), 1.95- 1.84(2H, m), 1.81-1.52(5H, m), 1.38-1.20(6H, m), 1.03(3H, s), 0.74(3H, s), 0.28(9H, s), 0.10(9H, s)

l,25-Dihydroxy-20S-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl-pentyl)-23-yne-

26,27-hexafluorocholecalciferol

A 25ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with (lS,5R)-l,5-bis-((tert-butyldimethyl)silanyloxy)-3-[2- (diphenylfosphinoyl)-eth-(Z)-ylidene]-2-methylene-cyclohexane (532 mg, 0.913 mmol) and tetrahydrofuran (8 ml). The reaction mixture was cooled to -78⁰C and n-butyllithium (0.57 ml, 0.912 mmol)) was added dropwise. The resulting deep red solution was stirred at -7O⁰C for 20 min and (IR, 3aR, 7aR)-7a-methyl-l-[(lS)-6,6,6-trifiuoro-l-methyl-l-(5,5,5-trideutero-4- trideuteromethyl-4-trimethylsilanyloxy-pentyl)-5-trifluoromethyl-5-trimethylsilanyloxy-hex-3- ynyl]-octahydro-inden-4-one (281 mg, 0.443 mmol) was added dropwise in tetrahydrofuran (1.5ml). The reaction mixture was stirred for 5h (in last hour the temperature was increased from -70 do -55⁰C). The bath was removed and the mixture was poured into ethyl acetate (50ml) and saturated solution of ammonium chloride (50ml). The water fraction was extracted with ethyl acetate (3x50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm , protected from light) using hexane:ethyl acetate - 10:1 as mobile phase. Fractions containing product were pooled and evaporated to give colorless oil. The oil residue was used to next reaction. A 25ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with substrate and tetrabutylammonium fluoride (15ml, lM/tetrahydrofuran). The mixture was stirred for next 25h. The mixture was dissolved by the addition of ethyl acetate (150ml) and washed 6 times with water (50 ml) and brine (50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm , protected from light) using ethyl acetate as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. There was an impurity (BU3N) in the product (¹H, ¹³C NMR). Material was chromatographed on column (70cm³, protected from light) using hexane:ethyl acetate 1 :1 and ethyl acetate as mobile phase. Oil was dissolved in methyl acetate and evaporated (4 times) to give product as white foam (191 mg, 69%).

[α]² _D ⁵= +3.6 (c=0.44, EtOH) UV λmax (EtOH): 213 nm (ε 15402), 264 nm (ε 17663)

¹H NMR (DMSO-DO): 8.95(1H, br s), 6.18(1H, d, J=I Ll Hz), 5.97(1H, d, J=I Ll Hz), 5.23(1H, d, J=Ll Hz), 4.88(1H, d, J=3.4 Hz), 4.75(1H, d, J=I.7 Hz), 4.56(1H, s), 4.19(1H, br s), 4.06(1H, br s), 3.99(1H, br s), 2.78(1H, d, J=12.2 Hz), 2.45-2.29(2H, m), 2.17(1H, dd, J=13.2, 5.4 Hz), 1.96-1.91(2H, m), 1.84-1.73(2H, m), 1.65-1.18(17H, m), 0.96(3H, s), 0.61(3H, s) 1³C NMR (DMSO-D6): 149.40, 139.51, 135.95, 122.33, 121.49(q, J=286.0 Hz), 118.02,

109.77, 89.59, 70.84, 70.43(sep, J=31.9 Hz), 68.42, 68.37, 65.09, 56.36, 55.94, 45.97, 44.87, 44.43, 43.12, 39.98, 39.85, 39.43, 28.35, 28.27, 23.11, 22.51, 22.02, 21.42, 17.77, 14.44

MS HRES Calculated for: C₃₃H₄₀D₆F₆O₄ [M+Na]⁺ 649.3569

Observed: [M+Na]⁺ 649.3572

EXAMPLE 25

Synthesis of l,25-Dihydroxy-20S-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl- pentyl)-23-yne-26,27-hexafluow-19-nor-cholecalcifewl

l,25-Dihydroxy-20S-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl-pentyl)-23-yne-

26,27-hexafluoro-19-nor-cholecalciferol

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with (lR,3R)-l,3-bis-((tert-butyldimethyl)silanyloxy)-5-[2- (diphenylfosphinoyl)ethylidene]-cyclohexane (562 mg, 0.984 mmol) and tetrahydrofuran (8ml). The reaction mixture was cooled to -7O⁰C and n-butyllithium (0.61 ml, 0.98 mmol)) was added dropwise. The resulting deep red solution was stirred at -7O⁰C for 20 min and (IR, 3aR, 7aR)-7a- methyl- 1 -[( 1 S)-6,6,6-trifluoro- 1 -methyl- 1 -(5 ,5 ,5-trideutero-4-trideuteromethyl-4- trimethylsilanyloxy-penty^-S-trifluoromethyl-S-trimethylsilanyloxy-hex-S-ynylJ-octahydro- inden-4-one (296 mg, 0.466 mmol) was added dropwise in tetrahydrofuran (1.5ml). The reaction mixture was stirred for 4h 40 min (in last hour the temperature was increased from -70 do - 55⁰C). The bath was removed and the mixture was poured into ethyl acetate (50ml) and saturated solution of ammonium chloride (50ml). The water fraction was extracted with ethyl acetate (3x50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm , protected from light) using hexane: ethyl acetate - 10:1 as mobile phase. Fractions containing product and some mono deprotected compound were pooled and evaporated to give colorless oil (380 mg). A 25ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with substrate and tetrabutylammonium fluoride (15ml, lM/tetrahydrofuran). The mixture was stirred for next 49h. The mixture was dissolved by the addition of ethyl acetate (150ml) and extracted 6 times with water (50 ml) and brine (50ml), dried (Na₂SO₄) and evaporated.

The oil residue was chromatographed on column (50cm³, protected from light) using ethyl acetate as mobile phase. Fractions containing product were pooled and evaporated to give colorless oil. There was an impurity (BU3N) in the product (¹H, ¹³C NMR). Material was chromatographed twice on columns (60cm³, protected from light) using hexane: ethyl acetate 2:1 and ethyl acetate as mobile phase. Oil was dissolved in methyl acetate and evaporated (4 times) to give product as white foam (251 mg, 87%).

[α]² _D ²= +33.5 (c=0.48, EtOH) UV λmax (EtOH): 243 nm (ε 29859), 252 nm (ε 34930), 262 nm (ε 23522)

¹H NMR (DMSO-D6): 8.94(1H, s), 6.07(1H, d, J=I LO Hz), 5.78(1H, d, J=I LO Hz), 4.48(1H, d, J=4.0 Hz), 4.38(1H, d, J=4.0 Hz), 4.04(1H, s), 3.92-3.76(2H, m), 2.77(1H, br d, J=I LO Hz), 2.49-2.25(2H, m), 2.05-1.95(4H, m), 1.76-1.20(19H, m), 0.97(3H, s), 0.60(3H, s)

¹³C NMR (DMSO-D6): 138.95, 134.73, 121.50(q, J=286.0 Hz), 120.80, 116.47, 89.59, 70.84, 70.44(sep, J=31.9 Hz), 68.43, 65.57, 65.45, 65.28, 56.37, 55.91, 45.82, 44.59, 44.45, 42.23, 40.01, 39.43, 36.98, 28.29, 28.19, 22.98, 22.54, 22.08, 21.33, 17.78, 14.55

MS HRES Calculated for: C₃₂H₄₀D₆F₆O₄ [M+Na]⁺ 637.3569

Observed: [M+Na]⁺ 637.3570 EXAMPLE 26 Synthesis ofla-Fluoro-25-hydroxy-20S-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl- pentyl)-23-yne-26,27-hexafluorocholecalciferol

lα-Fluoro-25-hydroxy-20S-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl-pentyl)-23- yne-26,27-hexafluorocholecalciferol A 25ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with (lS,5R)-l-((tert-butyldimethyl)silanyloxy)-3-[2-(diphenylfosphinoyl)- eth-(Z)-ylidene]-5-fluoro-2-methylene-cyclohexane (500 mg, 1.062mmol) and tetrahydrofuran (8ml). The reaction mixture was cooled to -7O⁰C and n-butyllithium (0.66 ml, 1.06 mmol)) was added dropwise. The resulting deep red solution was stirred at -7O⁰C for 20 min and (IR, 3aR, 7aR)-7a-methyl- 1 -[( 1 S)-6,6,6-trifluoro- 1 -methyl- 1 -(5 ,5 ,5-trideutero-4-trideuteromethyl-4- trimethylsilanyloxy-penty^-S-trifluoromethyl-S-trimethylsilanyloxy-hex-S-ynylJ-octahydro- inden-4-one (269 mg, 0.424 mmol) was added dropwise in tetrahydrofuran (1.5 ml). The reaction mixture was stirred for 5h (in last hour the temperature was increased from -70 do -55⁰C). The bath was removed and the mixture was poured into ethyl acetate (50ml) and saturated solution of ammonium chloride (100ml). The water fraction was extracted with ethyl acetate (3x5 OmI), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm , protected from light) using hexane: ethyl acetate - 10:1 as mobile phase. Fractions containing product were pooled and evaporated to give colorless oil. The oil residue was used to next reaction. A 25ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with substrate and tetrabutylammonium fluoride (15ml, lM/tetrahydrofuran). The mixture was stirred for 6h. The mixture was dissolved by the addition of ethyl acetate (150ml) and washed 6 times with water (50 ml) and brine (50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm³, protected from light) using hexane:ethyl acetate -1 :1 as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. There was an impurity (BU3N) in the product (¹H, ¹³C NMR). Material was chromatographed on column (60cm³, protected from light) using hexane: ethyl acetate 2:1 and 1:1 as mobile phase. Oil was dissolved in methyl acetate and evaporated (4 times) to give product as white foam (229 mg, 86%).

[α]² _D ⁵= +20.9 (c=0.45, EtOH)

UV λmax (EtOH): 211 nm (ε 15893), 243 nm (ε 16109), 270 nm (ε 16096) 1H NMR (DMSO-D6): 8.93(1H, s), 6.36(1H, d, J=I Ll Hz), 5.93(1H, d, J=I 1.3 Hz),

5.38(1H, s), 5.14(1H, ddd, J=49.6, 3.4, 2.0 Hz), 4.98(1H, d , J=I.5 Hz), 4.86(1H, d, J=4.3 Hz), 4.05(1H, s), 3,94-3.88(1H, m), 2.81(1H, d, J=13.2 Hz), 2.44-2.35(2H, m), 2.16-2.08(2H, m), 1.98-1.93(2H, m), 1.84-1.17(17H, m), 0.95(3H, s), 0.59(3H, s)

¹³C NMR (DMSO-Do): 143.15(d, J=16.7 Hz), 141.49, 133.06, 124.03, 121.49(q, J=286.0 Hz), 117.40, 115.18(d, J=9.9 Hz), 91.97(d, J=166.9 Hz), 89.61, 70.85, 70.44(sep, J=31.9 Hz), 68.43, 64.55(d, J=4.6 Hz), 56.37, 55.91, 46.06, 44.84, 44.44, 40.70(d, J=20.5 Hz), 39.97, 39.81, 39.43, 28.37, 28.26, 23.06, 22.52, 22.02, 21.32, 17.77, 14.48

MS HRES Calculated for: C₃₃H₃₉D₆F₇O₃ [M+Na]⁺ 651.3526

Observed: [M+Na]⁺ 651.3528

EXAMPLE 27

Synthesis of l,25-Dihydroxy-20S-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl-pentyl)-

23Z-ene-26,27-hexafluorocholecalciferol

(6S, 3Z)-6-[(lR, 3aR, 4S, 7aR)-4-hydroxy-7a-methyl-octahydro-inden-l-yl]-6-methyl- 11,11,11-trideutero- 10-trideuter omethyl- 1 , 1 , l-trifluoro-2-trifluoromethyl-undec-3-ene-

2,10-diol A 50ml round bottom flask was charged with (6S)-6-[(lR, 3aR, 4S, 7aR)-4-hydroxy-7a- methyl-octahydro-inden- 1 -yl]-6-methyl- 11,11,11 -trideutero- 10-trideuteromethyl- 1,1,1 -trifluoro- 2-trifluoromethyl-undec-3-yne-2,10-diol (722 mg, 1.466 mmol), Pd/CaCO₃ (180 mg, 5%), hexane (16.8 ml), ethyl acetate (6.8 ml) and solution of quinoline in ethanol (0.65 ml, prepared from ethanol (3.1ml) and quinoline (168μl)). The substrate was hydrogenated at ambient temperature and atmospheric pressure of hydrogen. The reaction was monitoring by TLC (dichloro methane: ethyl acetate 4:1, 3x). After 5h 10 min the catalyst was filtered off (celite) and solvent evaporated. The residue was purified over silica gel (50 cm³) using dichloromethane: ethyl acetate 4:1. Fractions containing product were pooled and evaporated to give product as colorless oil (720 mg, 99%). [(X]³ _J,¹= +3.3 (c=0.49, EtOH)

¹H NMR (CDCl₃): 6.14-6.O5(1H, m), 5.48(1H, d, J=12.8 Hz), 4.08(1H, s), 2.83(1H, dd, J=15.6, 9.0 Hz), 2.48-2.40(1H, m), 2.00(1H, d, J=I 1.4 Hz), 1.85-1.73(2H, m), 1.64-1.24(18H, m), 1.08(3H, s), 0.99(3H, s)

¹³C NMR (CDCl₃): 140.29, 117.60, 71.72, 69.91, 56.94, 52.76, 44.28, 43.62, 41.36, 40.39, 39.79, 36.97, 33.53, 22.78, 22.40, 21.88, 17.81, 13.73

MS HRES Calculated for: C₂₄H₃₂D₆F₆O₃ [M+Na]⁺ 517.2994

Observed: [M+Na]⁺ 517.2997

(IR, 3aR, 7aR)-7a-Methyl-l-[(lS, 3Z)-6,6,6-trifluororo-5-hydroxy-l-methyl-l-(5,5,5- trideutero-4-hydroxy-4-trideuteromethyl-pentyl)-5-trifluoromethyl-hex-3-enyl]-octahydro- inden-4-one

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with pyridinium dichromate (1.50 g, 3.99 mmol) and dichloromethane (15 ml). The (6S, 3Z)-6-[(lR, 3aR, 4S, 7aR)-4-hydroxy-7a-methyl-octahydro-inden-l-yl]-6-methyl- 11,11,11 -trideutero- 10-trideuteromethyl- 1,1,1 -trifluoro-2-trifluoromethyl-undec-3-ene-2, 10-diol (710 mg, 1.436 mmol) in dichloromethane (5 ml) was added dropwise and mixture was stirred in room temperature for 6h.

The reaction mixture was filtrated through column with silica gel (50 cm ) using dichloromethane, dichloromethane: ethyl acetate 4:1, 3:1. The fractions containing product were pooled and evaporated to give oil (694 mg, 98%)

¹H NMR (CDCl₃): 6.1O(1H, m), 5.52(1H, d, J=12.4 Hz), 5.07(1H, br s), 2.92(1H, dd, J=16.1, 9.9 Hz), 2.48-2.38(2H, m), 2.91-1.25(18H, m), 0.99(3H, s), 0.74(3H, s)

(IR, 3aR, 7aR)-7a-Methyl-l-[(lS, 3Z)6,6,6-trifluoro-l-methyl-l-(5,5,5-trideutero-4- trideuteromethyl-4-trimethylsilanyloxy-pentyl)-5-trifluoromethyl-5-trimethylsilanyloxy- hex-3-enyl]-octahydro-inden-4-one

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with (IR, 3aR, 7aR)-7a-methyl-l-[(lS, 3Z)-6,6,6-trifluororo-5-hydroxy-l- methyl-l-(5,5,5-trideutero-4-hydroxy-4-trideuteromethyl-pentyl)-5-trifluoromethyl-hex-3-enyl]- octahydro-inden-4-one (690 mg, 1.401 mmol) and dichloromethane (8 ml). 1- (Trimethylsilyl)imidazole (1.8 ml, 12.3 mmol) was added dropwise. The mixture was stirred at room temperature for 1.5h. Ethyl acetate (150ml) was added and the mixture was washed three times with water (50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm³) using hexane:ethyl acetate - 10:1 as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil (854 mg, 96%).

l,25-Dihydroxy-20S-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl-pentyl)-23Z-ene-

26,27-hexafluorocholecalciferol

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with(lS,5R)-l,5-bis-((tert-butyldimethyl)silanyloxy)-3-[2-

(diphenylfosphinoyl)-eth-(Z)-ylidene]-2-methylene-cyclohexane (539 mg, 0.925 mmol) and tetrahydrofuran (8ml). The reaction mixture was cooled to -78⁰C and n-butyllithium (0.58 ml, 0.93 mmol) was added dropwise. The resulting deep red solution was stirred at -78⁰C for 20 min and (IR, 3aR, 7aR)-7a-methyl-l-[(lS, 3Z)6,6,6-trifluoro-l-methyl-l-(5,5,5-trideutero-4- trideuteromethyl-4-trimethylsilanyloxy-pentyl)-5-trifluoromethyl-5-trimethylsilanyloxy-hex-3- enyl]-octahydro-inden-4-one (270 mg, 0.424 mmol) was added dropwise in tetrahydrofuran (1.5ml). The reaction mixture was stirred for 4h 30 min and then the bath was removed and the mixture was poured into ethyl acetate (50ml) and saturated solution of ammonium chloride (60ml). The water fraction was extracted three times with ethyl acetate (50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm³, protected from light) using hexane:ethyl acetate - 10:1 as mobile phase. Fractions containing product and some mono deprotected compound were pooled and evaporated to give colorless oil (350 mg). A 25ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with oil and tetrabutylammonium fluoride (15ml, IM/ tetrahydrofuran). The mixture was stirred for next 24h. The mixture was dissolved by the addition of ethyl acetate (150ml) and extracted 6 times with water and brine (30ml+20ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm , protected from light) using ethyl acetate as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. Oil was dissolved in methyl acetate and evaporated (4 times) to give product as white foam (232 mg, 87%).

[α]² _D ⁷= -5.4 (c=0.46, EtOH)

UV λmax (EtOH): 213 nm (ε 15177), 266 nm (ε 18553)

¹H NMR (DMSO-D6): 8.02(1H, s), 6.19(1H, d, J=I 1.3 Hz), 6.11(1H, dt, J=12.1, 6.3 Hz), 5.98(1H, d, J=I Ll Hz), 5.42(1H, d, J=12.4 Hz), 5.23(1H, s), 4.87(1H, d, J=4.7 Hz), 4.76(1H, s), 4.55(1H, d, J=3.4 Hz), 4.2O-4.17(1H, m), 4.03(1H, s), 3.98(1H, br s), 2.82-2.75(2H, m), 2.45(1H, dd, J=16.6, 4.9 Hz), 2.36(1H, d, J=I 1.9 Hz), 2.17(1H, dd, J=13.04, 5.3 Hz), 2.04- 1.95(2H, m), 1.84-1.79(1H, m), 1.73-1.54(6H, m), 1.48-1.31(4H, m), 1.22-1.17(6H, m), 0.86(3H, s), 0.61(3H, s)

¹³C NMR (DMSO-D6): 149.41, 139.79, 139.46, 135.80, 122.95(q, J=186.7 Hz), 122.37, 117.85, 117.01, 109.75, 76.76(sep, J=28.9 Hz), 68.41, 68.37, 65.10, 56.45, 56.02, 51.21, 46.09, 44.87, 44.55, 43.12, 40.31, 39.37, 38.74, 35.68, 28.37, 23.21, 22.88, 21.81, 21.55, 17.60, 14.58 MS HRES Calculated for: C₃₃H₄₂D₆F₆O₄ [M+Na]⁺ 651.3725

Observed: [M+Na]⁺ 651.3728

EXAMPLE 28

Synthesis ofl,25-Dihydroxy-20S-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl-pentyl)- 23Z-ene-26,27-hexafluow-19-nor-cholecalcifewl

l,25-Dihydroxy-20S-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl-pentyl)-23Z-ene-

26,27-hexafluoro-19-nor-cholecalciferol

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with (lR,3R)-l,3-bis-((tert-butyldimethyl)silanyloxy)-5-[2- (diphenylfosphinoyl)ethylidene]-cyclohexane (541 mg, 0.948 mmol) and tetrahydrofuran (8ml). The reaction mixture was cooled to -78⁰C and n-butyllithium (0.59 ml, 0.94 mmol) was added dropwise. The resulting deep red solution was stirred at -78⁰C for 20 min and (IR, 3aR, 7aR)-7a- methyl- 1 -[(1 S, 3Z)6,6,6-trifluoro- 1 -methyl- 1 -(5,5,5-trideutero-4-trideuteromethyl-4- trimethylsilanyloxy-penty^-S-trifluoromethyl-S-trimethylsilanyloxy-hex-S-enylJ-octahydro- inden-4-one (286 mg, 0.449 mmol) was added dropwise in tetrahydrofuran (1.5ml). The reaction mixture was stirred for 4h 10 min and then the bath was removed and the mixture was poured into ethyl acetate (50ml) and saturated solution of ammonium chloride (60ml). The water fraction was extracted three times with ethyl acetate (50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm³, protected from light) using hexane:ethyl acetate - 10:1 as mobile phase. Fractions containing product and some mono deprotected compound were pooled and evaporated to give colorless oil (390 mg).

A 25ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with oil and tetrabutylammonium fluoride (15ml, IM/ tetrahydrofuran). The mixture was stirred for next 30h. The mixture was dissolved by the addition of ethyl acetate (150ml) and extracted 6 times with water and brine (30ml+20ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (60cm , protected from light) using ethyl acetate as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. Oil was dissolved in methyl acetate and evaporated (4 times) to give product as white foam (264 mg, 95%).

[α]² _D ⁶= +32.0 (C=OAl, EtOH)

UV λmax (EtOH): 244 nm (ε 31469), 252 nm (ε 36060), 262 nm (ε 24658) 1H NMR (DMSO-D6): 8.02(1H, s), 6.14-6.O8(1H, m), 6.08(1H, d, J=I 1.9 Hz), 5.78(1H, d, J=I Ll Hz), 5.43(1H, d, J=12.2 Hz), 4.49(1H, d, J=4.1 Hz), 4.39(1H, d, J=4.1 Hz), 4.04(1H, s), 3.88-3.78(2H, m), 2.82-2.72(2H, m), 2.48-2.42(2H, m), 2.31-2.25(1H, m), 2.07-1.90(4H, m), 1.73-1.18(17H, m), 0.87(3H, s), 0.61(3H, s)

¹³C NMR (DMSO-D6): 139.45, 139.19, 134.57, 122.94(q, J=286.8 Hz), 120.84, 117.02, 116.29, 76.75(sep, J=28.8 Hz), 68.41, 65.55, 65.27, 56.43, 55.98, 45.94, 44.60, 44.55, 42.23, 40.32, 39.38, 38.74, 36.97, 35.69, 28.21, 23.07, 22.89, 21.85, 21.44, 17.59, 14.69 MS HRES Calculated for: C₃₂H₄₂D₆F₆O₄ [M+Na]⁺ 639.3725

Observed: [M+Na]⁺ 639.3724

EXAMPLE 29 Synthesis ofla-Fluow-25-hydwxy-20S-20-(4-hydwxy-5,5,5-trideutew-4- tndeuteromethyl-pentyiyHZ-ene-ieyU-hexafluorocholecalciferol

lα-Fluoro-25-hydroxy-20S-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl-pentyl)-23Z- ene-26,27-hexafluorocholecalciferol

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with (lS,5R)-l-((tert-butyldimethyl)silanyloxy)-3-[2-(diphenylfosphinoyl)- eth-(Z)-ylidene]-5-fluoro-2-methylene-cyclohexane (462 mg, 0.982 mmol) and tetrahydrofuran (8ml). The reaction mixture was cooled to -78⁰C and n-butyllithium (0.61 ml, 0.98 mmol)) was added dropwise. The resulting deep red solution was stirred at -78⁰C for 20 min and (IR, 3aR, 7aR)-7a-methyl- 1 -[(1 S, 3Z)6,6,6-trifluoro- 1 -methyl- 1 -(5 ,5 ,5-trideutero-4-trideuteromethyl-4- trimethylsilanyloxy-penty^-S-trifluoromethyl-S-trimethylsilanyloxy-hex-S-enylJ-octahydro- inden-4-one (267 mg, 0.419 mmol) was added dropwise in tetrahydrofuran (1.5ml). The reaction mixture was stirred for 5h and then the bath was removed and the mixture was poured into ethyl acetate (50ml) and saturated solution of ammonium chloride (60ml). The water fraction was extracted with ethyl acetate (3x50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm³, protected from light) using hexane: ethyl acetate - 10:1 as mobile phase. Fractions containing product and some mono deprotected compound were pooled and evaporated to give colorless oil.

A 25ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with substrate and tetrabutylammonium fluoride (15ml, lM/tetrahydrofuran). The mixture was stirred for next 5h. The mixture was dissolved by the addition of ethyl acetate (150ml) and extracted 6 times with water and brine (30ml+20ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm , protected from light) using hexane:ethyl acetate (1 :1) as mobile phase.

Product contained some impurities and was rechromatographed on column (VersaPak, 40x75 mm) using hexane:ethyl acetate (1 :1) s mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. Oil was dissolved in methyl acetate and evaporated (4 times) to give product as white foam (244 mg, 92%). [α]² _D ⁶= +11.8 (c=0.51, EtOH)

UV λmax (EtOH): 244 nm (ε 15004), 270 nm (ε 15084)

¹H NMR (DMSO-DO): 8.02(1H, s), 6.36(1H, d, J=I 1.3 Hz), 6.14-6.O7(1H, m), 5.39(1H, d, J=I 1.3 Hz), 5.42(1H, d, J=I 1.9 Hz), 5.39(1H, s), 5.14(1H, br d, J=49.7 Hz), 4.99(1H, d, J=I.7

Hz), 4.86(1H, d, J=4.3 Hz), 4.03(1H, s), 3.93-3.88(1H, m), 2.82-2.74(2H, m), 2.48-2.43(2H, m),

2.17-1.97(4H, m), 1.84-1.55(6H, m), 1.46-1.32(4H, m), 1.29-1.16(7H, m), 0.86(3H, s), 0.60(3H, s)

¹³C NMR (DMSO-Do): 143.18(d, J=16.7 Hz), 141.74, 139.43, 132.93, 124.08, 122.95(q, J=286.7 Hz), 117.22, 117.01, 115.08(d, J=9.1 Hz), 91.93(d, J=166.9 Hz), 76.76(sep, J=28.0 Hz), 68.41, 64.56, 56.43, 55.96, 46.18, 44.82, 44.54, 40.69(d, J=20.5 Hz), 40.27, 38.73, 35.68, 28.38, 23.15, 22.85, 21.80, 21.45, 17.59, 14.61

MS HRES Calculated for: C₃₃H₄IU₆F₇O₃ [M+Na]⁺ 653.3682

Observed: [M+Na]⁺ 653.3689

EXAMPLE 30

Synthesis ofl,25-Dihydroxy-20S-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl-pentyl)- 23E-ene-26,27-hexafluorocholecalciferol

(6S, 3E)-6-[(lR, 3aR, 4S, 7aR)-4-hydroxy-7a-methyl-octahydro-inden-l-yl]-6-methyl- 11,11,11-trideutero- 10-trideuteromethyl- 1 , 1 , l-trifluoro-2-trifluoromethyl-undec-3-ene- 2,10-diol

A 25 ml round bottom flask equipped with stir bar and condenser with nitrogen sweep was charged with lithium aluminum hydride (12.0 ml, 12.0 mmol, lM/tetrahydrofuran) and the mixture was cooled to O⁰C. Sodium methoxide (648 mg, 12.0 mmol) was added slowly followed by (6S)-6-[(lR, 3aR, 4S, 7aR)-4-hydroxy-7a-methyl-octahydro-inden-l-yl]-6-methyl-l 1,11,11- trideutero- 10-trideuteromethyl- 1,1,1 -trifluoro-2-trifluoromethyl-undec-3-yne-2, 10-diol (740 mg, 1.502 mmol) in tetrahydrofuran (8ml). The reaction mixture was stirred at 8O⁰C for 4h and then was cooled to O⁰C. Saturated solution of ammonium chloride (5 ml) was added slowly followed by saturated solution of ammonium chloride (60 ml) and 2N HCl (20 ml). The mixture was extracted with ethyl acetate (3x50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on columns (50 cm³) using hexane:ethyl acetate - 4:1 as mobile phase. Fractions containing product were pooled and evaporated to give colorless oil (727 mg, 98%).

[α]³ _D°= -0.64 (C=OAl, EtOH) 1H NMR (CDCl₃): 6.32(1H, dt, J=15.4, 7.9), 5.58(1H, d, J=15.8 Hz), 4.09(1H, br s),

2.29(2H, d, J=8.1 Hz), 2.04-1.97(1H, m), 1.84-1.76(2H, m), 1.63-1.18(18H, m), 1.09(3H, s), 0.98(3H, s)

¹³C NMR (CDCl₃): 137.23, 120.09, 71.53, 69.83, 57.36, 52.71, 44.27, 43.69, 42.44, 41.61, 40.22, 33.54, 23.20, 22.36, 21.88, 18.02, 17.70, 17.31, 16.77 MS HRES Calculated for: C₂₄H₃₂D₆F₆O₃ [M+Na]⁺ 517.2994

Observed: [M+Na]⁺ 517.2994

(IR, 3aR, 7aR)-7a-Methyl-l-[(lS, 3E)-6,6,6-trifluoro-5-hydroxy-l-methyl-l-(5,5,5- trideutero-4-hydroxy-4-trideuter omethyl-pentyl)-5-trifluoromethyl-hex-3-enyl] -octahydro- inden-4-one

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with pyridinium dichromate (1.50 g, 3.99 mmol) and dichloromethane (15 ml). The (6S, 3E)-6-[(lR, 3aR, 4S, 7aR)-4-hydroxy-7a-methyl-octahydro-inden-l-yl]-6-methyl- 11,11,11 -trideutero- 10-trideuteromethyl- 1,1,1 -trifluoro-2-trifluoromethyl-undec-3-ene-2, 10-diol (730 mg, 1.476 mmol) in dichloromethane (5 ml) was added dropwise and mixture was stirred in room temperature for 4.5h.

The reaction mixture was filtrated through column with silica gel (50 cm ) using dichloromethane, dichloromethane: ethyl acetate 4:1. The fractions containing product were pooled and evaporated to give oil (706 mg, 97%).

[α]³ _D°= -20.0 (c=0.46, EtOH)

¹H NMR (CDCl₃): 6.33(1H, dt, J=15.3, 7.7 Hz), 5.61(1H, d, J=15.6 Hz), 2.43(1H, dd, J=I 1.2, 7.1 Hz), 2.33-2.19(4H, m), 2.17-2.12(1H, m), 2.06-2.00(1H, m), 1.95-1.84((1H, m), 1.80-1.54(7H, m), 1.40-1.20(5H, m), 1.15-1.O9(1H, m), 0.98(3H, s), 0.75(3H, s)

¹³C NMR (CDCl₃): 211.74, 136.54, 119.96, 71.25, 62.22, 57.49, 50.59, 43.80, 42.54, 40.85, 39.97, 39.80, 24.04, 23.03, 22.10, 18.67, 17.72, 15.71

MS HRES Calculated for: C₂₄H₃₀D₆F₆O₃ [M+Na]⁺ 515.2837

Observed: [M+Na]⁺ 515.2837

(IR, 3aR, 7aR)-7a-Methyl-l-[(lS, 3E)-6,6,6-trifluoro-l-methyl-l-(5,5,5-trideutero-4- trideuteromethyl-4-trimethylsilanyloxy-pentyl)-5-trifluoromethyl-5-trimethylsilanyloxy- hex-3-enyl]-octahydro-inden-4-one

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with (IR, 3aR, 7aR)-7a-methyl-l-[(lS, 3E)-6,6,6-trifluoro-5-hydroxy-l- methyl-l-(5,5,5-trideutero-4-hydroxy-4-trideuteromethyl-pentyl)-5-trifluoromethyl-hex-3-enyl]- octahydro-inden-4-one (698 mg, 1.417 mmol) and dichloromethane (8 ml). 1- (trimethylsilyl)imidazole (1.8 ml, 12.3 mmol) was added dropwise. The mixture was stirred at room temperature for 2h. Ethyl acetate (150ml) was added and the mixture was washed with water (4x50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (60cm³) using hexane:ethyl acetate - 10:1 as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil (871 mg, 96%).

l,25-Dihydroxy-20S-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl-pentyl)-23E-ene-

26,27-hexafluorocholecalciferol

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with (lS,5R)-l,5-bis-((tert-butyldimethyl)silanyloxy)-3-[2- (diphenylfosphinoyl)-eth-(Z)-ylidene]-2-methylene-cyclohexane (531 mg, 0.911 mmol) and tetrahydrofuran (8ml). The reaction mixture was cooled to -78⁰C and n-butyllithium (0.57 ml, 0.91 mmol)) was added dropwise. The resulting deep red solution was stirred at -78⁰C for 20 min and (IR, 3aR, 7aR)-7a-methyl-l-[(lS, 3E)-6,6,6-trifluoro-l-methyl-l-(5,5,5-trideutero-4- trideuteromethyl-4-trimethylsilanyloxy-pentyl)-5-trifluoromethyl-5-trimethylsilanyloxy-hex-3- enyl]-octahydro-inden-4-one (260 mg, 0.408 mmol) was added dropwise in tetrahydrofuran (1.5ml). The reaction mixture was stirred for 5h 30 min and then the bath was removed and the mixture was poured into ethyl acetate (50ml) and saturated solution of ammonium chloride (60ml). The water fraction was extracted with ethyl acetate (3x50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm³, protected from light) using hexane:ethyl acetate - 10:1 as mobile phase. Fractions containing product and some mono deprotected compound were pooled and evaporated to give colorless oil. A 25ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with substrate and tetrahydrofuran (5 ml). Tetrabutylammonium fluoride (2.1Og, 6.66 mmol) was added. The mixture was stirred for next 6h and tetrabutylammonium fluoride (5 ml, lM/tetrahydrofuran) was added. The reaction was stirred for next 15h. The mixture was dissolved by the addition of ethyl acetate (150ml) and extracted 6 times with water and brine (30ml+20ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm³, protected from light) using ethyl acetate as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. Oil was dissolved in methyl acetate and evaporated (4 times) to give product as white foam (186 mg, 73%).

[α]³ _D°= +4.5 (c=0.44, EtOH)

UV λmax (EtOH): 213 nm (ε 13978), 265 nm (ε 16276)

¹H NMR (CDCl₃): 6.37(1H, d, J=I Ll Hz), 6.31(1H, dd, J=15.6, 7.9 Hz), 6.00(1H, d, J=I Ll Hz), 5.59(1H, d, J=15.6 Hz), 5.33(1H, s), 4.99(1H, s), 4.43(1H, br s), 4.23(1H, br s), 2.81(1H, dd, J=12.2, 3.4 Hz), 2.59(1H, br d, J=10.5 Hz), 2.34-2.29(3H, m), 2.06-1.98(3H, m), 1.93-1.87(1H, m), 1.76-1.18(18H, m), 1.12-1.O6(1H, m), 0.95(3H, s), 0.66(3H, s)

¹³C NMR (DMSO-D6): 149.41, 139.75, 136.73, 135.85, 122.63(q, J=285.2 Hz), 122.39, 119.72, 117.94, 109.79, 75.51(sep, J=29.6 Hz), 68.41, 65.11, 56.54, 56.02, 46.13, 44.87, 44.43, 43.11, 41.20, 40.48, 28.37, 23.14, 22.90, 21.72, 21.52, 17.56, 14.70

MS HRES Calculated for: C₃₃H₄₂D₆F₆O₄ [M+Na]⁺ 651.3725

Observed: [M+Na]⁺ 651.3727

EXAMPLE 31

Synthesis of l,25-Dihydroxy-20S-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl-pentyl)- 23E-ene-26,27-hexafluow-19-nor-cholecalcifewl

l,25-Dihydroxy-20S-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl-pentyl)-23E-ene-

26,27-hexafluoro-19-nor-cholecalciferol A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with (lR,3R)-l,3-bis-((tert-butyldimethyl)silanyloxy)-5-[2- (diphenylfosphinoyl)ethylidene]-cyclohexane (546 mg, 0.956 mmol) and tetrahydrofuran (8ml). The reaction mixture was cooled to -78⁰C and n-butyllithium (0.60 ml, 0.96 mmol)) was added dropwise. The resulting deep red solution was stirred at -78⁰C for 20 min and (IR, 3aR, 7aR)-7a- methyl- 1 -[(1 S, 3E)-6,6,6-trifluoro- 1 -methyl- 1 -(5,5,5-trideutero-4-trideuteromethyl-4- trimethylsilanyloxy-penty^-S-trifluoromethyl-S-trimethylsilanyloxy-hex-S-enylJ-octahydro- inden-4-one (295 mg, 0.463 mmol) was added dropwise in tetrahydrofuran (1.5ml). The reaction mixture was stirred for 5h 30 min and then the bath was removed and the mixture was poured into ethyl acetate (50ml) and saturated solution of ammonium chloride (60ml). The water fraction was extracted with ethyl acetate (3x50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm³, protected from light) using hexane: ethyl acetate - 10:1 as mobile phase. Fractions containing product and some mono deprotected compound were pooled and evaporated to give colorless oil. A 25ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with substrate and tetrabutylammonium fluoride (15ml, lM/tetrahydrofuran). The mixture was stirred for next 42h. The mixture was dissolved by the addition of ethyl acetate (150ml) and extracted 6 times with water and brine (30ml+20ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm³, protected from light) using ethyl acetate as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. Oil was dissolved in methyl acetate and evaporated (4 times) to give product as white foam (280 mg, 98%).

[α]³ _D°= +41.1 (c=0.46, EtOH)

UV λmax (EtOH): 244 nm (ε 32355), 252 nm (ε 37697), 262 nm (ε 25353) 1H NMR (DMSO-D6): 8.04(1H, s), 6.32(1H, dt, J=15.6, 7.7 Hz), 6.07(1H, d, J=I 1.1

Hz), 5.78(1H, d, J=I Ll Hz), 5.63(1H, d, J=15.3 Hz), 4.5O(1H, d, J=3.4 Hz), 4.39(1H, d, J=3.4 Hz), 4.04(1H, s), 3.88(1H, br s), 3.80(1H, br s), 2.74(1H, br d, J=13.9 Hz), 2.44(1H, dd, J=13.0, 3.0 Hz), 2.33-2.21(2H, m), 2.07-1.95(2H, m), 1.69-1.04(17H, m), 0.90(3H, s), 0.62(3H, s)

¹³C NMR (DMSO-Do): 139.13, 136.71, 134.63, 122.44(q, J=285.2 Hz), 120.83, 119.71, 116.38, 75.51(sep, J=28.9 Hz), 68.37, 65.57, 65.28, 56.52, 55.97, 45.96, 44.59, 44.44, 42.23, 41.18, 40.48, 39.62, 39.58, 37.00, 28.19, 22.99, 22.91, 21.76, 21.42, 17.55, 14.79

MS HRES Calculated for: C₃₂H₄₂D₆F₆O₄ [M+Na]⁺ 639.3725

Observed: [M+Na]⁺ 639.3724

EXAMPLE 32

Synthesis ofla-Fluoro-25-hydroxy-20S-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl- pentyl)-23E-ene-26,27-hexafluorocholecalciferol

lα-Fluoro-25-hydroxy-20S-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl-pentyl)-23E- ene-26,27-hexafluorocholecalciferol

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with (lS,5R)-l-((tert-butyldimethyl)silanyloxy)-3-[2-(diphenylfosphinoyl)- eth-(Z)-ylidene]-5-fluoro-2-methylene-cyclohexane (473 mg, 1.005 mmol) and tetrahydrofuran (8ml). The reaction mixture was cooled to -78⁰C and n-butyllithium (0.63 ml, 1.01 mmol)) was added dropwise. The resulting deep red solution was stirred at -78⁰C for 20 min and (IR, 3aR, 7aR)-7a-methyl- 1 -[( 1 S, 3E)-6,6,6-trifluoro- 1 -methyl- 1 -(5 ,5 ,5-trideutero-4-trideuteromethyl-4- trimethylsilanyloxy-penty^-S-trifluoromethyl-S-trimethylsilanyloxy-hex-S-enylJ-octahydro- inden-4-one (271 mg, 0.426 mmol) was added dropwise in tetrahydrofuran (1.5ml). The reaction mixture was stirred for 4.5h and then the bath was removed and the mixture was poured into ethyl acetate (50ml) and saturated solution of ammonium chloride (60ml). The water fraction was extracted with ethyl acetate (3x50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm³, protected from light) using hexane: ethyl acetate - 10:1 as mobile phase. Fractions containing product and some mono deprotected compound were pooled and evaporated to give colorless oil.

A 25ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with substrate and tetrabutylammonium fluoride (10ml, lM/tetrahydrofuran). The mixture was stirred for next 17h. The mixture was dissolved by the addition of ethyl acetate (150ml) and extracted 6 times with water and brine (30ml+20ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm³, protected from light) using hexane:ethyl acetate (1 :1) as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. Oil was dissolved in methyl acetate and evaporated (4 times) to give product as white foam (226 mg, 84%).

[α]²> +25.3 (c=0.45, EtOH)

UV λmax (EtOH): 243 nm (ε 14182), 269 nm (ε 14044)

¹H NMR (DMSO-D6): 8.03(1H, s), 6.36(1H, d, J=10.9 Hz), 6.33-6.27(1H, m), 5.93(1H, d, J=I Ll Hz), 5.63(1H, d, J=15.4 Hz), 5.38(1H, s), 5.14(1H, br d, J=49.7 Hz), 4.99(1H, s),

4.86(1H, d, J=4.3 Hz), 4.03(1H, s), 3.94-3.88(1H, m), 2.81(1H, br d, J=12.4 Hz), 2.34-2.20(2H, m), 2.16-2.06(2H, m), 2.00-1.95(1H, m), 1.84-1.02(18H, m), 0.89(3H, s), 0.61(3H, s)

¹³C NMR (DMSO-D6): 143.17(d, J=16.7 Hz), 141.68, 136.70, 132.97, 124.05, 122.62(q, J=286.7 Hz), 119.71, 117.29, 115.16, 91.95(d, J=166.9 Hz), 75.50(sep, J=28.8 Hz), 68.36, 64.56, 56.51, 55.95, 46.19, 44.83, 44.42, 41.15, 40.69(d, J=20.5 Hz), 40.41, 39.61, 28.36, 23.06, 22.88, 21.70, 21.40, 17.54, 14.71

MS HRES Calculated for: C₃₃H₄IU₆F₇O₃ [M+Na]⁺ 653.3682

Observed: [M+Na]⁺ 653.3686

EXAMPLE 33

Synthesis ofl,25-Dihydroxy-20R-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl-pentyl)-

23-yne-26,27-hexafluorocholecalcifewl

(3R)-3-[(lR, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden- l-yl]-8,8,8-trideutero-7-hydroxy-3-methyl-7-trideuteromethyl-octanal A 250 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with pyridinium chlorochromate (3.858 g, 17.898 mmol), celite (3.93 g) and dichloromethane (70 ml). The (3R)-3-[(lR, 3aR, 4S, 7aR)-4-(tert-butyl-dimethyl-silanyloxy)-7a- methyl-octahydro-inden- 1 -yl]-8,8,8-trideutero-3-methyl-7-trideuteromethyl-octane- 1 ,7-diol (5.0O g, 11.190 mmol) in dichloromethane (10 ml) was added dropwise and mixture was stirred in room temperature for 3h 45min. The reaction mixture was filtrated through column with silica gel (250cm ) and celite (lcm) and using dichloromethane, dichloromethane: ethyl acetate 4:1. The fractions containing product were pooled and evaporated to give oil (4.42 g, 89%).

(6R)-6-[(lR, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden- 1-yl] -1,1 , l-trideutero-6-methyl-2-trideuteromethyl-non-8-yn-2-ol

A 250ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with (3R)-3-[(lR, 3aR, 4S, 7aR)-4-(tert-butyl-dimethyl-silanyloxy)-7a- methyl-octahydro-inden- 1 -yl] -8 , 8 , 8-trideutero-7-hydroxy-3 -methyl-7-trideuteromethyl-octanal (4.42 g, 9.937 mmol) and methanol (65ml). l-diazo-2-oxo-propyl)-phosphonic acid dimethyl ester (3.75 g, 19.52 mmol) in methanol (3 ml) was added and the resulting mixture was cooled in an ice bath. Potassium carbonate (3.75 g, 27.13 mmol) was added and the reaction mixture was stirred in the ice bath for 30min and then at room temperature for 4h. Water (100ml) was added and the mixture was extracted with ethyl acetate (4x80ml), dried (Na₂SO₄) and evaporated. The residue was filtrated through silica gel (50 cm ) using hexane: ethyl acetate - 5:1 and evaporated.

The oil residue was chromatographed on column (VersaPak Cartridge 80x150 mm) using hexane :ethyl acetate - 5:1 and 4: las mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil (3.83 g, 87%).

¹H NMR (CDCl₃): 3.99(1H, br s), 2.12-1.92(4H, m), 1.83-1.75(1H, m), 1.68-1.22(17H, m), 1.04(3H, s), 0.99(3H, s), 0.88(9H, s), 0.00(3H, s), -0.01(3H, s)

¹³C NMR (CDCl₃): 82.90, 70.75, 69.67, 69.60, 60.33, 56.61, 52.99, 44.73, 43.71, 41.35, 39.55, 39.51, 34.34, 29.51, 25.83, 22.77, 22.39, 22.03, 18.49, 18.03, 17.73, 16.48, 14.19, -4.79, - 5.14

(IR, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-l-[(lR)-6,6,6-trideutero-l- methyl-l-(prop-2-ynyl)-5-trideuteromethyl-5-trimethylsilanyloxy-hexyl]-octahydro-indene

A 100ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with (6R)-6-[(lR, 3aR, 4S, 7aR)-4-(tert-butyl-dimethyl-silanyloxy)-7a- methyl-octahydro-inden- 1 -yl]- 1 ,1,1 -trideutero-6-methyl-2-trideuteromethyl-non-8-yn-2-ol (3.80 g, 8.62 mmol) and dichloromethane (30 ml). l-(trimethylsilyl)imidazole (3.7 ml, 25.22 mmol) was added dropwise. The mixture was stirred at room temperature for Ih 35min. Water (100ml) was added and the mixture was extracted with hexane (3x70ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (250 cm ) using hexane: ethyl acetate - 20:1 as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil (4.09 g, 93%).

(6R)-6-[(lR, 3aR, 4S, 7aR)-4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden- 1-yl] -6-methyl- 11,11,11-trideutero- 10-trideuteromethyl- 1 , 1 , l-trifluoro-2-trifluoromethyl-

10-trimethylsilanyloxy-undec-3-yn-2-ol

A two neck 100ml round bottom flask equipped with stir bar, Claisen adapter with rubber septum and funnel (with cooling bath) was charged with (IR, 3aR, 4S, 7aR)-4-(tert-butyl- dimethyl-silanyloxy)-7a-methyl- 1 -[(1 R)-6,6,6-trideutero- 1-methyl- 1 -(prop-2-ynyl)-5- trideuteromethyl-5-trimethylsilanyloxy-hexyl]-octahydro-indene (4.09 g, 7.97 mmol) and tetrahydrofuran (50 ml). The funnel was connected to container with hexafluoroacetone and cooled (acetone, dry ice). The reaction mixture was cooled to

-7O⁰C and n-butyllithium (7.5 ml, 12.00 mmol) was added dropwise. After 30min hexafluoroacetone was added (the container's valve was opened three times). The reaction was steered at -7O⁰C for 2h then saturated solution of ammonium chloride (5ml) was added. The mixture was dissolved by the addition of saturated solution of ammonium chloride (100ml) and extracted with ethyl acetate (3x80ml), dried (Na₂SO₄) and evaporated. The residue was chromatographed twice on columns (300cm³, hexane: ethyl acetate - 20:1) to give the mixture of product and polymer (from hexafluoroacetone) (5.56 g). Product was used to the next reaction without purification.

(6R)-6-[(lR, 3aR, 4S, 7aR)-4-hydroxy-7a-methyl-octahydro-inden-l-yl]-6-methyl-ll, 11,11- trideutero- 10-trideuter omethyl- 1 , 1 , l-trifluoro-l-trifluoromethyl-undec-S-yne-l, 10-diol A 100 ml round bottom flask equipped with stir bar and rubber septum was charged with (6R)-6-[(lR, 3aR, 4S, 7aR)-4-(tert-butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden-l-yl]- 6-methyl- 11,11,11 -trideutero- 10-trideuteromethyl- 1,1,1 -trifluoro-2-trifluoromethyl- 10- trimethylsilanyloxy-undec-3-yn-2-ol (5.56 g), acetonitrile (48ml) and tetrahydrofuran (12ml). A solution OfH₂SiF₆ (35%) was added in small portion: 5 ml, 2 ml (after Ih 20 min), 4 ml (after 50 min), 5 ml (after Ih 40 min), 5 ml (after Ih 30 min), 5 ml (after 16h). After next 5 h the resulting mixture was diluted with water (50ml) and poured into a mixture of ethyl acetate (50ml) and water (50ml). The organic phase was collected and the aqueous phase was re- extracted with ethyl acetate (2x5 OmI). The combined organic layers were dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (450 cm ) using dichloromethane: ethyl acetate (5:1) as mobile phase. The mixture fractions were purified on column (VersaPak Cartridge 40x150 mm) using hexane: ethyl acetate - 2:1 and 1:1 as mobile phase. Fractions containing product were pooled and evaporated to give product (3.303 g, 84% two steps).

[α]³ _D°= +1.4 (c=0.59, EtOH)

¹H NMR (CDCl₃): 4.09(1H, br s), 2.16(1H, AB, J=17.2 Hz), 2.23(1H, AB, J=17.2 Hz), 2.05-2.01(lH, m), 1.85-1.76(2H, m), 1.65-1.21(18H, m), 1.06(3H, s), 1.01(3H, s) 1³C NMR (CDCl₃): 121.35(q, J=286.0 Hz), 90.34, 72.39, 71.06(sep, J=32.6 Hz), 69.48,

56.99, 52.48, 43.51, 43.13, 40.91, 40.39, 39.97, 33.35, 30.05, 22.54, 22.14, 21.92, 18.09, 17.47, 16.10

MS HRES Calculated for: C₂₄H₃₀D₆F₆O₃ [M+Na]⁺ 515.2837

Observed: [M+Na]⁺ 515.2836

(IR, 3aR, 7aR)-7a-Methyl-l-[(lR)-6,6,6-trifluororo-5-hydroxy-l-methyl-l-(5,5,5- trideutero-4-hydroxy-4-trideuteromethyl-pentyl)-5-trifluoromethyl-hex-3-ynyl]-octahydro- inden-4-one

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with pyridinium dichromate (1.620 g, 4.306mmol) and dichloromethane (15 ml). The (6R)-6-[(lR, 3aR, 4S, 7aR)-4-hydroxy-7a-methyl-octahydro-inden-l-yl]-6-methyl- 11,11,11 -trideutero- 10-trideuteromethyl- 1,1,1 -trifluoro-2-trifluoromethyl-undec-3-yne-2, 10-diol (783 mg, 1.583 mmol) in dichloromethane (2 ml) and DMF (0.5 ml) was added dropwise and mixture was stirred in room temperature for 5 h. The reaction mixture was filtrated through column with silica gel (50 cm³) using dichloro methane, dichloro methane: ethyl acetate 4:1. The fractions containing product were pooled and evaporated to give product as yellow oil. The oil residue was used to next reaction.

(IR, 3aR, 7aR)-7a-Methyl-l-[(lR)-6,6,6-trifluoro-l-methyl-l-(5,5,5-trideutero-4- trideuteromethyl-4-trimethylsilanyloxy-pentyl)-5-trifluoromethyl-5-trimethylsilanyloxy- hex-3-ynyl]-octahydro-inden-4-one

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with (IR, 3aR, 7aR)-7a-methyl-l-[(lR)-6,6,6-trifluororo-5-hydroxy-l- methyl-l-(5,5,5-trideutero-4-hydroxy-4-trideuteromethyl-pentyl)-5-trifluoromethyl-hex-3-ynyl]- octahydro-inden-4-one (ca. 1.58 mmol) and dichloromethane (8 ml). l-(trimethylsilyl)imidazole (1.90 ml, 12.95 mmol) was added dropwise. The mixture was stirred at room temperature for 1.5h. Hexane (150ml) was added and the mixture was washed with water (3x50ml), dried (Na₂SO₄) and evaporated.

The oil residue was chromatographed on column (50cm³) using hexane:ethyl acetate - 5:1 as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil (918 mg, 95%).

[α]³ _D°= -20.8 (c=0.61, DMSO)

¹H NMR (CDCl₃): 2.41(1H, dd, J=I 1.3, 7.2 Hz), 2.31-2.12(4H, m), 2.05-1.24(15H, m), 1.00(3H, s), 0.73(3H, s), 0.27(9H, s), 0.10(9H, s)

MS HRES Calculated for: C₃₀H₄₄D₆F₆O₃Si₂ [M+Na]⁺ 657.3471

Observed: [M+Na]⁺ 657.3467

l,25-Dihydroxy-20R-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl-pentyl)-23-yne-

26,27-hexafluorocholecalciferol

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with (lS,5R)-l,5-bis-((tert-butyldimethyl)silanyloxy)-3-[2-

(diphenylfosphinoyl)-eth-(Z)-ylidene]-2-methylene-cyclohexane (500 mg, 0.858 mmol) and tetrahydrofuran (8ml). The reaction mixture was cooled to -7O⁰C and n-butyllithium (0.53 ml, 0.85 mmol)) was added dropwise. The resulting deep red solution was stirred at -7O⁰C for 20 min and (IR, 3aR, 7aR)-7a-Methyl-l-[(lR)-6,6,6-trifluoro-l-methyl-l-(5,5,5-trideutero-4- trideuteromethyl-4-trimethylsilanyloxy-pentyl)-5-trifluoromethyl-5-trimethylsilanyloxy-hex-3- ynyl]-octahydro-inden-4-one (314 mg, 0.495 mmol) was added dropwise in tetrahydrofuran (1.5ml). The reaction mixture was stirred for 8h (in last hour the temperature was increased from -70 do -5O⁰C). Saturated solution of ammonium chloride (ImI) was added and the bath was removed. The mixture was poured into ethyl acetate (50ml) and saturated solution of ammonium chloride (50ml). The water fraction was extracted with ethyl acetate (3x60ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm³, protected from light) using hexane:ethyl acetate - 10:1 as mobile phase. Fractions containing product and some mono deprotected compound were pooled and evaporated to give oil.

A 25ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with substrate and tetrabutylammonium fluoride (10ml, lM/tetrahydrofuran). The mixture was stirred for next 4 Ih. The mixture was dissolved by the addition of ethyl acetate (150ml) and extracted 6 times with water and brine (30ml+20ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (70cm , protected from light) using ethyl acetate as mobile phase. Fraction containing impurity was chromatographed on next column (70cm³, protected from light) using ethyl acetate as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. Oil was dissolved in methyl acetate and evaporated (4 times) to give product as white foam (198 mg, 64%).

[α]² _D ⁸= +11.0 (c=0.50, EtOH)

UV λmax (EtOH): 213 nm (ε 17873), 264 nm (ε 20804)

¹H NMR (DMSO-D6): 8.95(1H, s), 6.19(1H, d, J=I 1.3 Hz), 5.97(1H, d, J=I 1.3 Hz), 5.22(1H, s), 4.86(1H, d, J=4.9 Hz), 4.75(1H, d, J=I.9 Hz), 4.55(1H, d, J=3.8 Hz), 4.2O-4.18(1H, m), 4.04(1H, s), 4.01-3.98(1H, m), 2.78(1H, d, J=13.6 Hz), 2.35(1H, d, J=13.4 Hz), 2.28- 2.14(3H, m), 1.99-1.92(2H, m), 1.83-1.78(2H, m), 1.64-1.57(5H, m), 1.47-1.21(1OH, m), 0.96(3H, s), 0.60(3H, s) ¹³C NMR (DMSO-Do): 149.56, 139.66, 136.09, 122.45, 121.61(q, J=286.7 Hz), 118.13, 109.87, 89.59, 70.67, 70.46(sep, J=31.9 Hz), 68.48, 68.42, 65.13, 56.05, 55.96, 46.09, 44.88, 44.55, 43.13, 40.12, 38.88, 28.77, 28.31, 23.03, 22.37, 21.89, 21.51, 18.21, 14.25

MS HRES Calculated for: C₃₃H₄₀D₆F₆O₄ [M+Na]⁺ 649.3569 Observed: [M+Na]⁺ 649.3569

EXAMPLE 34 Synthesis of l,25-Dihydroxy-20R-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl-pentyl)-

23-yne-26,27-hexafluoro-19-nor-cholecalciferol

l,25-Dihydroxy-20R-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl-pentyl)-23-yne- 26,27-hexafluoro-19-nor-cholecalciferol

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with (lR,3R)-l,3-bis-((tert-butyldimethyl)silanyloxy)-5-[2- (diphenylfosphinoyl)ethylidene]-cyclohexane (568 mg, 0.995 mmol) and tetrahydrofuran (8ml). The reaction mixture was cooled to -7O⁰C and n-butyllithium (0.62 ml, 0.99 mmol) was added dropwise. The resulting deep red solution was stirred at -7O⁰C for 20 min and (IR, 3aR, 7aR)-7a- Methyl- 1 -[(1 R)-6,6,6-trifluoro- 1 -methyl- 1 -(5 ,5 ,5-trideutero-4-trideuteromethyl-4- trimethylsilanyloxy-penty^-S-trifluoromethyl-S-trimethylsilanyloxy-hex-S-ynylJ-octahydro- inden-4-one (306 mg, 0.482 mmol) was added dropwise in tetrahydrofuran (1.5ml). The reaction mixture was stirred for 6h and then saturated solution of ammonium chloride (ImI) was added and the bath was removed. The mixture was poured into ethyl acetate (50ml) and saturated solution of ammonium chloride (50ml). The water fraction was extracted with ethyl acetate (3x50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm³, protected from light) using hexane: ethyl acetate - 10:1 as mobile phase. Fractions containing product and some mono deprotected compound were pooled and evaporated to give oil. A 25ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with substrate and tetrabutylammonium fluoride (15ml, lM/tetrahydrofuran). The mixture was stirred for next 96h. The mixture was dissolved by the addition of ethyl acetate (150ml) and extracted 6 times with water and brine (30ml+20ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (60cm³, protected from light) using ethyl acetate as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. Oil was dissolved in methyl acetate and evaporated (4 times) to give product as white foam (223 mg, 75%).

[α]² _D ⁷= +45.5 (c=0.42, EtOH)

UV λmax (EtOH): 244 nm (ε 36685), 252 nm (ε 42933), 262 nm (ε 28904) 1H NMR (DMSO-D6): 8.95(1H, s), 6.07(1H, d, J=I Ll Hz), 5.78(1H, d, J=I Ll Hz),

4.48(1H, d, J=4.3 Hz), 4.38(1H, d, J=3.8 Hz), 4.04(1H, s), 3.90-3.76(2H, m), 2.74(1H, d, J=13.4 Hz), 2.43(1H, d, J=14.1 Hz), 2.28-2.19(3H, m), 2.07-1.93(3H, m), 1.81(1H, dd, J=9.6, 9.2 Hz), 1.68-1.22(17H, m), 0.96(3H, s), 0.59(3H, s)

¹³C NMR (DMSO-D6): 139.10, 134.88, 121.61(q, J=286.7 Hz), 120.92, 116.57, 89.60, 70.67, 68.49, 65.60, 65.32, 56.01, 55.94, 45.94, 44.60, 44.55, 42.23, 39.80, 36.96, 28.80, 28.15, 22.89, 22.39, 21.94, 21.42, 18.22, 14.37

MS HRES Calculated for: C₃₂H₄₀D₆F₆O₄ [M+Na]⁺ 637.3569

Observed: [M+Na]⁺ 637.3565

EXAMPLE 35

Synthesis ofla-Fluoro-25-hydroxy-20R-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl- pentyl)-23-yne-26,27-hexafluorocholecalciferol

lα-Fluoro-25-hydroxy-20R-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl-pentyl)-23- yne-26,27-hexafluorocholecalciferol

A 25ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with (lS,5R)-l-((tert-butyldimethyl)silanyloxy)-3-[2-(diphenylfosphinoyl)- eth-(Z)-ylidene]-5-fluoro-2-methylene-cyclohexane] (542 mg, 1.152mmol) and tetrahydrofuran (8ml). The reaction mixture was cooled to -7O⁰C and n-butyllithium (0.71 ml, 1.14 mmol) was added dropwise. The resulting deep red solution was stirred at -7O⁰C for 20 min and(lR, 3aR, 7aR)-7a-Methyl- 1 -[(1 R)-6,6,6-trifluoro- 1 -methyl- 1 -(5,5,5-trideutero-4-trideuteromethyl-4- trimethylsilanyloxy-penty^-S-trifluoromethyl-S-trimethylsilanyloxy-hex-S-ynylJ-octahydro- inden-4-one (292 mg, 0.460 mmol) was added dropwise in tetrahydrofuran (1.5 ml). ). The reaction mixture was stirred for 7h (in last hour the temperature was increased from -70 do - 5O⁰C). The bath was removed and the mixture was poured into ethyl acetate (50ml) and saturated solution of ammonium chloride (50ml). The water fraction was extracted with ethyl acetate (3x50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm³, protected from light) using hexane: ethyl acetate - 10:1 as mobile phase. Fractions containing product were pooled and evaporated to give oil. The oil residue was used to next reaction. A 25ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with substrate and tetrabutylammonium fluoride (8ml, lM/tetrahydrofuran). The mixture was stirred for next 48h. The mixture was dissolved by the addition of ethyl acetate (150ml) and extracted 6 times with water and brine (30ml+20ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm³, protected from light) using hexane: ethyl acetate - 1 :1 as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. Oil was dissolved in methyl acetate and evaporated (4 times) to give product as white foam (278 mg, 96%).

UV λmax (EtOH): 210 nm (ε 14823), 244 nm (ε 14731), 270 nm (ε 14798)

¹H NMR (DMSO-D6): 8.95(1H, s), 6.36(1H, d, J=I Ll Hz), 5.93(1H, d, J=I 1.3 Hz), 5.38(1H, s), 5.14(1H, br d, J=49.6 Hz), 4.98(1H, d, J=I.9 Hz), 4.86(1H, d, J=4.5 Hz), 4.04(1H, s), 3.94-3.87(1H, m), 2.82(1H, d, J=10.2 Hz), 2.27-2.05(4H, m), 2.00-1.93(2H, m), 1.83- 1.55(7H, m), 1.48-1.21(1OH, m), 0.95(3H, s), 0.58(3H, s) 1³C NMR (DMSO-D6): 143.31(d, J=16.7 Hz), 141.67, 133.23(d, J=I.5 Hz), 124.18,

121.64(q, J=286.0 Hz), 117.53, 115.37(d, J=9.2 Hz), 92.09(167.6 Hz), 89.59, 70.70, 70.48(sep, J=31.9 Hz), 68.51, 64.61, 64.57, 56.02, 55.96, 46.19, 44.86, 44.56, 40.71(d, J=19.7 Hz), 39.82, 28.80, 28.34, 22.98, 22.35, 21.90, 21.43, 18.24, 14.31

MS HRES Calculated for: C₃₃H₃₉D₆F₇O₃ [M+Na]⁺ 651.3526 Observed: [M+Na]⁺ 651.3530

EXAMPLE 36 Synthesis ofl,25-Dihydroxy-20R-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl-pentyl)-

23Z-ene-26,27-hexafluorocholecalciferol

(6R, 3Z)-6-[(lR, 3aR, 4S, 7aR)-4-hydroxy-7a-methyl-octahydro-inden-l-yl]-6-methyl- 11,11,11-trideutero- 10-trideuter omethyl- 1 , 1 , l-trifluoro-2-trifluoromethyl-undec-3-ene-

2,10-diol

A 50ml round bottom flask was charged with (6R)-6-[(lR, 3aR, 4S, 7aR)-4-hydroxy-7a- methyl-octahydro-inden- 1 -yl]-6-methyl- 11,11,11 -trideutero- 10-trideuteromethyl- 1,1,1 -trifluoro- 2-trifluoromethyl-undec-3-yne-2,10-diol (800 mg, 1.624 mmol), Pd/CaCO₃ (200 mg, 5%), hexane (18.6 ml), ethyl acetate (7.6 ml) and solution of quinoline in ethanol (0.72 ml, prepared from ethanol (3.1ml) and quinoline (168μl)). The substrate was hydrogenated at ambient temperature and atmospheric pressure of hydrogen. The reaction was monitoring by TLC (dichloromethane: ethyl acetate 4:1, 3x). After 5h 10 min the catalyst was filtered off (silica gel 50 cm , hexane: ethyl acetate 1 :1) and solvent evaporated. Product was crystallized from hexane:ethyl acetate (750 mg, 93%).

[α]³ _D°= -2.34 (c=0.47, EtOH)

¹H NMR (CDCl₃): 6.07(1H, dt, J=12.4, 7.2 Hz), 5.45(1H, d, J=12.4 Hz), 4.08(1H, d, J=2.1 Hz), 2.50-2.39(2H, m), 2.03(1H, d, J=I Ll Hz), 1.88-1.79(2H, m), 1.67-1.22(18H, m), 1.09(3H, s), 0.98(3H, s)

¹³C NMR (CDCl₃): 139.98, 122.83(q, J=286.7 Hz), 117.24, 71.45, 69.57, 56.67, 52.55, 44.08, 43.56, 41.21, 39.71, 39.13, 37.19, 33.39, 22.42, 22.15, 21.86, 17.92, 17.54, 16.47

MS HRES Calculated for: C₂₄H₃₂D₆F₆O₃ [M+Na]⁺ 517.2994

Observed: [M+Na]⁺ 517.2992

(IR, 3aR, 7aR)-7a-Methyl-l-[(lR, 3Z)-6,6,6-trifluororo-5-hydroxy-l-methyl-l-(5,5,5- trideutero-4-hydroxy-4-trideuteromethyl-pentyl)-5-trifluoromethyl-hex-3-enyl]-octahydro- inden-4-one A 50 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with pyridinium dichromate (1.520 g, 4.040 mmol) and dichloromethane (20 ml). The (6R, 3Z)-6-[(lR, 3aR, 4S, 7aR)-4-hydroxy-7a-methyl-octahydro-inden-l-yl]-6- methyl- 11,11,11 -trideutero- 10-trideuteromethyl- 1,1,1 -trifluoro-2-trifluoromethyl-undec-3-ene- 2,10-diol (730 mg, 1.476 mmol) in dichloromethane (5 ml) was added dropwise and mixture was stirred in room temperature for 4 h 20 min.

The reaction mixture was filtrated through column with silica gel (50 cm ) using dichloromethane, dichloromethane: ethyl acetate 4:1. The fractions containing product were pooled and evaporated. The product was used to the next reaction without purification.

(IR, 3aR, 7aR)-7a-Methyl-l-[(lR, 3Z)6,6,6-trifluoro-l-methyl-l-(5,5,5-trideutero-4- trideuteromethyl-4-trimethylsilanyloxy-pentyl)-5-trifluoromethyl-5-trimethylsilanyloxy- hex-3-enyl] -octahydro-inden-4-one

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with (IR, 3aR, 7aR)-7a-methyl-l-[(lR, 3Z)-6,6,6-trifluororo-5-hydroxy-l- methyl-l-(5,5,5-trideutero-4-hydroxy-4-trideuteromethyl-pentyl)-5-trifluoromethyl-hex-3-enyl]- octahydro-inden-4-one (ca. 1.47 mmol) and dichloromethane (8 ml). l-(trimethylsilyl)imidazole (1.80 ml, 12.27 mmol) was added dropwise. The mixture was stirred at room temperature for 3h. Water (50ml) was added and the mixture was extracted with ethyl acetate (3x50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (75cm³) using hexane:ethyl acetate - 5:1 as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil (766 mg, 81%)

¹H NMR (CDCl₃): 5.98(1H, dt, J=12.5, 6.2 Hz), 5.42(1H, d, J=I 1.4 Hz), 2.49-2.40(2H, m), 2.34-2.15(4H, m), 2.07-1.95(1H, m), 1.93-1.60(6H, m), 1.43-1.19(7H, m), 0.95(3H, s), 0.74(3H, s), 0.24(9H, s), 0.10(9H, s)

l,25-Dihydroxy-20R-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl-pentyl)-23Z-ene-

26,27-hexafluorocholecalciferol A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with (lS,5R)-l,5-bis-((tert-butyldimethyl)silanyloxy)-3-[2- (diphenylfosphinoyl)-eth-(Z)-ylidene]-2-methylene-cyclohexane (473 mg, 0.811 mmol) and tetrahydrofuran (8ml). The reaction mixture was cooled to -7O⁰C and n-butyllithium (0.50 ml, 0.80 mmol)) was added dropwise. The resulting deep red solution was stirred at -7O⁰C for 20 min and (IR, 3aR, 7aR)-7a-methyl-l-[(lR, 3Z)6,6,6-trifluoro-l-methyl-l-(5,5,5-trideutero-4- trideuteromethyl-4-trimethylsilanyloxy-pentyl)-5-trifluoromethyl-5-trimethylsilanyloxy-hex-3- enyl]-octahydro-inden-4-one (280 mg, 0.440 mmol) was added dropwise in tetrahydrofuran (1.5ml). The reaction mixture was stirred for 6h (in last hour the temperature was increased from -70 do -5O⁰C). Saturated solution of ammonium chloride (ImI) was added and the bath was removed. The mixture was poured into ethyl acetate (50ml) and saturated solution of ammonium chloride (100ml). The water fraction was extracted with ethyl acetate (3x70ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm³, protected from light) using hexane:ethyl acetate - 10:1 as mobile phase. Fractions containing product and some mono deprotected compound were pooled and evaporated to give colorless oil. A 25ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with substrate and tetrabutylammonium fluoride (15ml, lM/tetrahydrofuran). The mixture was stirred for next 29h. The mixture was dissolved by the addition of ethyl acetate (150ml) and extracted 6 times with water and brine (30ml+20ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm³, protected from light) using hexane:ethyl acetate - 1 :2 as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. Oil was dissolved in methyl acetate and evaporated (4 times) to give product as white foam (224 mg, 81%). [α]² _D ⁹= +7.5 (c=0.48, EtOH) UV λmax (EtOH): 213 nm (ε 15024), 265 nm (ε 17330) 1H NMR (DMSO-D6): 7.98(1H, s), 6.18(1H, d, J=I Ll Hz), 6.1O(1H, dt, J=12.8, 6.4

Hz), 5.97(1H, d, J=I 1.3 Hz), 5.43(1H, d, J=I 1.9 Hz), 5.23(1H, s), 4.86(1H, d, J=4.7 Hz), 4.75(1H, d, J=I.7 Hz), 4.54(1H, d, J=3.6 Hz), 4.21-4.16QH, m), 4.02(1H, s), 4.05-3.95(1H, m), 2.77(1H, d, J=I 1.7 Hz), 2.50-2.29(2H, m), 2.16(1H, dd, J=13.5, 5.2 Hz), 2.00-1.94(2H, m), 1.82- 1.78(1H, m), 1.71-1.25(17H, m), 0.90(3H, s), 0.61(3H, s)

¹³C NMR (DMSO-D6): 149.40, 139.76, 139.25, 135.81, 122.93(q, J=287.5 Hz), 122.35, 117.88, 117.11, 109.75, 76.78(sep, J=29.6 Hz), 68.41, 68.35, 65.07, 56.55, 55.98, 46.15, 44.86, 44.59, 43.11, 40.34, 38.76, 36.05, 28.98, 23.13, 22.80, 21.83, 29.50, 20.07, 17.93, 14.57

MS HRES Calculated for: C₃₃H₄₂D₆F₆O₄ [M+Na]⁺ 651.3725

Observed: [M+Na]⁺ 651.3726

EXAMPLE 37

Synthesis of l,25-Dihydroxy-20R-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl-pentyl)- 23Z-ene-26,27-hexafluow-19-nor-cholecalcifewl

l,25-Dihydroxy-20R-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl-pentyl)-23Z-ene-

26,27-hexafluoro-19-nor-cholecalciferol

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with (lR,3R)-l,3-bis-((tert-butyldimethyl)silanyloxy)-5-[2- (diphenylfosphinoyl)ethylidene]-cyclohexane (575 mg, 1.007 mmol) and tetrahydrofuran (8ml). The reaction mixture was cooled to -7O⁰C and n-butyllithium (0.61 ml, 0.98 mmol)) was added dropwise. The resulting deep red solution was stirred at -7O⁰C for 20 min and (IR, 3aR, 7aR)-7a- methyl- 1 -[(1 R, 3Z)6,6,6-trifluoro- 1 -methyl- 1 -(5 ,5 ,5-trideutero-4-trideuteromethyl-4- trimethylsilanyloxy-penty^-S-trifluoromethyl-S-trimethylsilanyloxy-hex-S-enylJ-octahydro- inden-4-one (303 mg, 0.476 mmol) was added dropwise in tetrahydrofuran (1.5ml). The reaction mixture was stirred for 5h and then saturated solution of ammonium chloride (ImI) was added and the bath was removed. The mixture was poured into ethyl acetate (50ml) and saturated solution of ammonium chloride (100ml). The water fraction was extracted with ethyl acetate (3x70ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm³, protected from light) using hexane: ethyl acetate - 10:1 as mobile phase. Fractions containing product and some mono deprotected compound were pooled and evaporated to give colorless oil. A 25ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with substrate and tetrabutylammonium fluoride (15ml, lM/tetrahydrofuran). The mixture was stirred for next 64h. The mixture was dissolved by the addition of ethyl acetate (150ml) and extracted 6 times with water and brine (30ml+20ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (60cm , protected from light) using ethyl acetate as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. Oil was dissolved in methyl acetate and evaporated (4 times) to give product as white foam (251 mg, 85%).

[α]² _D ⁹= +44.3 (c=0.42, EtOH)

UV λmax (EtOH): 244 nm (ε 36100), 252 nm (ε 42319), 262 nm (ε 28518)

¹H NMR (DMSO-D6): 7.99(1H, s), 6.14-6.O6(1H, m), 6.07(1H, d, J=12.4 Hz), 5.78(1H, d, J=I 1.3 Hz), 5.43(1H, d, J=12.2 Hz), 4.48(1H, d, J=4.0 Hz), 4.38(1H, d, J=4.1 Hz), 4.02(1H, s), 3.9O-3.84(1H, m), 3.84-3.76(1H, m), 2.73(1H, d, J=13.6 Hz), 2.54-2.41(2H, m), 2.26(1H, br d, J=10.4 Hz), 2.07-1.97(3H, m), 1.72-1.18(19H, m), 0.90(3H, s), 0.60(3H, s)

¹³C NMR (DMSO-D6): 139.25, 139.18, 134.60, 122.94(q, J=286.8 Hz), 120.82, 117.13, 116.33, 76.77(sep, J=28.0 Hz), 68.41, 65.54, 65.26, 56.53, 55.95, 46.00, 44.59, 42.22, 40.34, 38.78, 36.96, 36.07, 28.17, 22.99, 22.80, 21.89, 21.40, 17.94, 14.67

MS HRES Calculated for: C₃₂H₄₂D₆F₆O₄ [M+Na]⁺ 639.3725

Observed: [M+Na]⁺ 639.3717

EXAMPLE 38

Synthesis ofla-Fluoro-25-hydroxy-20R-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl- pentyl)-23Z-ene-26,27-hexafluorocholecalciferol

lα-Fluoro-25-hydroxy-20R-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl-pentyl)-

23Z-ene-26,27-hexafluorocholecalciferol

A 25ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with (lS,5R)-l-((tert-butyldimethyl)silanyloxy)-3-[2-(diphenylfosphinoyl)- eth-(Z)-ylidene]-5-fluoro-2-methylene-cyclohexane (520 mg, 1.105mmol) and tetrahydrofuran (8ml). The reaction mixture was cooled to -7O⁰C and n-butyllithium (0.69 ml, 1.10 mmol)) was added dropwise. The resulting deep red solution was stirred at -7O⁰C for 20 min and (IR, 3aR, 7aR)-7a-Methyl- 1 -[(1 R, 3Z)6,6,6-trifluoro- 1 -methyl- 1 -(5 ,5 ,5-trideutero-4-trideuteromethyl-4- trimethylsilanyloxy-penty^-S-trifluoromethyl-S-trimethylsilanyloxy-hex-S-enylJ-octahydro- inden-4-one (314 mg, 0.493 mmol) was added dropwise in tetrahydrofuran (1.5 ml). ). The reaction mixture was stirred for 5h 30 min (in last hour the temperature was increased from -70 do -5O⁰C). The bath was removed and the mixture was poured into ethyl acetate (50ml) and saturated solution of ammonium chloride (100ml). The water fraction was extracted with ethyl acetate (3x50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm , protected from light) using hexane:ethyl acetate - 10:1 as mobile phase. Fractions containing product were pooled and evaporated to give colorless oil. The oil residue was used to next reaction. A 25ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with substrate and tetrabutylammonium fluoride (10ml, lM/tetrahydrofuran). The mixture was stirred for next 22h. The mixture was dissolved by the addition of ethyl acetate (150ml) and extracted 6 times with water and brine (30ml+20ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm , protected from light) using hexane:ethyl acetate - 1 :1 as mobile phase. Fractions containing product and impurity were purified on column (50cm³, protected from light) using hexane: ethyl acetate - 2:1 and 1 :1 as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. Oil was dissolved in methyl acetate and evaporated (4 times) to give product as white foam (258 mg, 83%).

[α]² _D ⁸= +25.0 (c=0.44, EtOH)

UV λmax (EtOH): 210 nm (ε 15800), 245 nm (ε 15638), 269 nm (ε 15445) 1H NMR (DMSO-D6): 7.99(1H, s), 6.36(1H, d, J=I 1.3 Hz), 6.1O(1H, dt, J=I 1.9, 6.3 Hz), 5.92(1H, d, J=I 1.3 Hz), 5.43(1H, d, J=12.4 Hz), 5.39(1H, s), 5.14(1H, ddd, J=49.4, 5.5, 3.7 Hz), 4.98(1H, d, J=I.7 Hz), 4.85(1H, d, J=4.5 Hz), 4.02(1H, s), 3.93-3.87QH, m), 2.81(1H, d, J=12.8 Hz), 2.54-2.40(2H, m), 2.16-1.97(4H, m), 1.82-1.17(17H, m), 0.89(3H, s), 0.59(3H, s)

¹³C NMR (DMSO-DO): 143.13(d, J=16.7 Hz), 141.74, 139.20, 132.94, 124.06, 122.93(q, J=286.0 Hz), 117.26, 117.12, 115.18(d, J=9.1 Hz), 91.95(d, J=166.9 Hz), 76.78(sep, J=28.8 Hz), 68.41, 64.54, 65.50, 56.51, 55.92, 46.24, 44.81, 44.58, 40.68(d, J=20.5 Hz), 40.28, 38.97, 38.78, 36.07, 28.33, 23.06, 22.74, 21.83, 21.40, 17.93, 14.59

MS HRES Calculated for: C₃₃H₄IU₆F₇O₃ [M+Na]⁺ 653.3682

Observed: [M+Na]⁺ 653.3686

EXAMPLE 39

Synthesis of l,25-Dihydroxy-20R-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl- pentyl)-23E-ene-26,27-hexafluorocholecalciferol D₃C

.,CF₃

.*^H _/CF₃ ,*^H

CD₃ CD₃ OH

OH CF₃

CF₃

OH OH

(6R, 3E)-6-[(lR, 3aR, 4S, 7aR)-4-hydroxy-7a-methyl-octahydro-inden-l-yl]-6-methyl- 11,11,11-trideutero- 10-trideuter omethyl- 1 , 1 , l-trifluoro-2-trifluoromethyl-undec-3-ene-

2,10-diol

A 25 ml round bottom flask equipped with stir bar and condenser with nitrogen sweep was charged with lithium aluminum hydride (13.00 ml, 13.00 mmol, lM/tetrahydrofuran) and the mixture was cooled to O⁰C. Sodium methoxide (702 mg, 13.00 mmol) was added slowly followed by (6R)-6- [(I R, 3aR, 4S, 7aR)-4-hydroxy-7a-methyl-octahydro-inden-l-yl]-6-methyl- 11,11,11 -trideutero- 10-trideuteromethyl- 1,1,1 -trifluoro-2-trifluoromethyl-undec-3-yne-2, 10-diol (810 mg, 1.665 mmol) in tetrahydrofuran (8ml). The reaction mixture was stirred at 8O⁰C for 6.5h and then was cooled to O⁰C. Saturated solution of ammonium chloride (5 ml) was added slowly followed by saturated solution of ammonium chloride (60 ml) and 2N HCl (20 ml). The mixture was extracted with ethyl acetate (3x50ml), dried (Na₂SO₄) and evaporated.

The oil residue was chromatographed on columns (75 cm³) using hexane: ethyl acetate - 2:1 and 1 :1 as mobile phase. Fractions containing product were pooled and evaporated to give colorless oil (806 mg, 98%).

¹H NMR (CDCl₃): 6.28(1H, dt, J=15.4, 7.7 Hz), 5.59(1H, d, J=15.7 Hz), 4.08(1H, br s), 2.13-2.00(3H, m), 1.83-1.79(2H, m), 1.63-1.24(18H, m), 1.08(3H, s), 0.97(3H, s)

D₃C^ D₃C.

CF_{3 /}CF₃ HO'^' HO'

CD₃ OH CD₃ ^"~"OH

CF- CF₃

OH O

(IR, 3aR, 7aR)-7a-Methyl-l-[(lR, 3E)-6,6,6-trifluoro-5-hydroxy-l-methyl-l-(5,5,5- trideutero-4-hydroxy-4-trideuteromethyl-pentyl)-5-trifluoromethyl-hex-3-enyl]-octahydro- inden-4-one A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with pyridinium dichromate (1.600 g, 4.253 mmol) and dichloromethane (15 ml). The (6R, 3E)-6-[(lR, 3aR, 4S, 7aR)-4-hydroxy-7a-methyl-octahydro-inden-l-yl]-6- methyl- 11,11,11 -trideutero- 10-trideuteromethyl- 1,1,1 -trifluoro-l-trifluoromethyl-undec-S-ene- 2,10-diol (782 mg, 1.581 mmol) in dichloromethane (2 ml) was added dropwise and mixture was stirred in room temperature for 4 h 30 min.

The reaction mixture was filtrated through column with silica gel (25 cm³) using dichloromethane, dichloromethane: ethyl acetate 4:1. The fractions containing product were pooled and evaporated to give product as colorless oil (746 mg, 96%).

(IR, 3aR, 7aR)-7a-Methyl-l-[(lR, 3E)-6,6,6-trifluoro-l-methyl-l-(5,5,5-trideutero-4- trideuteromethyl-4-trimethylsilanyloxy-pentyl)-5-trifluoromethyl-5-trimethylsilanyloxy- hex-3-enyl]-octahydro-inden-4-one

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with (IR, 3aR, 7aR)-7a-methyl-l-[(lR, 3E)-6,6,6-trifluoro-5-hydroxy-l- methyl-l-(5,5,5-trideutero-4-hydroxy-4-trideuteromethyl-pentyl)-5-trifluoromethyl-hex-3-enyl]- octahydro-inden-4-one (746 mg, 1.515 mmol) and dichloromethane (10 ml). 1- (trimethylsilyl)imidazole (1.90 ml, 12.95 mmol) was added dropwise. The mixture was stirred at room temperature for 3h. Hexane (150ml) was added and the mixture was washed with water (3x50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm ) using hexane:ethyl acetate - 5:1 as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil (917 mg, 95%).

l,25-Dihydroxy-20R-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl-pentyl)-23E-ene-

26,27-hexafluorocholecalciferol A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with (lS,5R)-l,5-bis-((tert-butyldimethyl)silanyloxy)-3-[2- (diphenylfosphinoyl)-eth-(Z)-ylidene]-2-methylene-cyclohexane (460 mg, 0.789 mmol) and tetrahydrofuran (8ml). The reaction mixture was cooled to -7O⁰C and n-butyllithium (0.49 ml, 0.78 mmol)) was added dropwise. The resulting deep red solution was stirred at -7O⁰C for 20 min and (IR, 3aR, 7aR)-7a-Methyl-l-[(lR, 3E)-6,6,6-trifluoro-l-methyl-l-(5,5,5-trideutero-4- trideuteromethyl-4-trimethylsilanyloxy-pentyl)-5-trifluoromethyl-5-trimethylsilanyloxy-hex-3- enyl]-octahydro-inden-4-one (302 mg, 0.474 mmol) was added dropwise in tetrahydrofuran (1.5ml). The reaction mixture was stirred for 5.5h (in last hour the temperature was increased from -70 do -5O⁰C). Saturated solution of ammonium chloride (ImI) was added and the bath was removed. The mixture was poured into ethyl acetate (50ml) and saturated solution of ammonium chloride (50ml). The water fraction was extracted with ethyl acetate (3x50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm³, protected from light) using hexane:ethyl acetate - 10:1 as mobile phase. Fractions containing product and some mono deprotected compound were pooled and evaporated to give colorless oil.

A 25ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with substrate and tetrabutylammonium fluoride (15ml, lM/tetrahydrofuran). The mixture was stirred for next 18h. The mixture was dissolved by the addition of ethyl acetate (150ml) and washed 6 times with water (50 ml) and brine (50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm³, protected from light) using ethyl acetate as mobile phase (tetrahydrofuran was used to transfer material on kolumn). Fractions with product contained some impurity. Fractions containing product were pooled and evaporated to give a white solid. The solid phase was transferred to Buchner funnel (10-15 μm) with hexane and washed with hexane (20 ml) to remove impurity. Then product was removed from funnel with ethanol (25 ml) and solution was evaporated to give product as white solid (215 mg, 71%).

[α]² _D ⁷= +16.1 (c=0.44, EtOH)

UV λmax (EtOH): 214 nm (ε 1377), 265 nm (ε 1675) 1H NMR (DMSO-D6): 8.05(1H, s), 6.28(1H, dt, J=15.3, 7.7 Hz), 6.18(1H, d, J=I Ll

Hz), 5.97(1H, d, J=I 1.3 Hz), 5.62(1H, d, J=15.3 Hz), 5.22(1H, s), 4.87(1H, d, J=4.7 Hz), 4.75(1H, d, J=2.1 Hz), 4.55(1H, d, J=3.6 Hz), 4.21-4.16(1H, m), 4.04(1H, s), 4.05-3.95(1H, m), 2.79-2.76(1H, m), 2.35(1H, d, J=13.9 Hz), 2.16(1H, dd, J=13.3, 5.2 Hz), 2.07(2H, d, J=7.5 Hz), 2.00-1.90(2H, m), 1.82-1.78(1H, m), 1.65-1.55(6H, m), 1.43-1.24(1OH, m), 0.90(3H, s), 0.61(3H, s)

¹³C NMR (DMSO-D6): 149.37, 139.67, 136.44, 135.84, 122.60(q, J=286.8 Hz), 122.35, 119.82, 117.93, 109.79, 75.49(sep, J=28.8 Hz), 68.39, 65.06, 56.36, 56.01, 46.20, 44.87, 44.56, 43.11, 41.06, 40.43, 28.33, 23.09, 22.49, 21.80, 21.60, 17.90, 14.59 MS HRES Calculated for: C₃₃H₄₂D₆F₆O₄ [M+Na]⁺ 651.3725

Observed: [M+Na]⁺ 651.3729

EXAMPLE 40

Synthesis of l,25-Dihydroxy-20R-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl-pentyl)-

23E-ene-26,27-hexafluoro-19-nor-cholecalciferol

1 ,25-Dihydroxy-20R-20-(4-hydroxy-5,5,5-trideutero-4-trideuter omethyl-pentyl)-23E-ene-

26,27-hexafluoro-19-nor-cholecalciferol

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with (lR,3R)-l,3-bis-((tert-butyldimethyl)silanyloxy)-5-[2- (diphenylfosphinoyl)ethylidene]-cyclohexane (584 mg, 1.023 mmol) and tetrahydrofuran (8ml). The reaction mixture was cooled to -7O⁰C and n-butyllithium (0.63 ml, 1.01 mmol)) was added dropwise. The resulting deep red solution was stirred at -7O⁰C for 20 min and (IR, 3aR, 7aR)-7a- Methyl- 1 -[( 1 R, 3E)-6,6,6-trifluoro- 1 -methyl- 1 -(5 ,5 ,5-trideutero-4-trideuteromethyl-4- trimethylsilanyloxy-penty^-S-trifluoromethyl-S-trimethylsilanyloxy-hex-S-enylJ-octahydro- inden-4-one (308 mg, 0.484 mmol) was added dropwise in tetrahydrofuran (1.5ml). The reaction mixture was stirred for 6h and then saturated solution of ammonium chloride (ImI) was added and the bath was removed. The mixture was poured into ethyl acetate (50ml) and saturated solution of ammonium chloride (50ml). The water fraction was extracted with ethyl acetate (3x50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm³, protected from light) using hexane: ethyl acetate - 10:1 as mobile phase. Fractions containing product and some mono deprotected compound were pooled and evaporated to give colorless oil. A 25ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with substrate and tetrabutylammonium fluoride (15ml, lM/tetrahydrofuran). The mixture was stirred for next 96h. The mixture was dissolved by the addition of ethyl acetate (150ml) and washed 6 times with water (50 ml) and brine (50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm³, protected from light) using hexane tetrahydrofuran -1 :1, 1 :2 as mobile phase, (tetrahydrofuran contained some impurity). Fractions containing product were pooled and evaporated to give a white solid. The solid phase was transferred to Buchner funnel (10-15 μm) with hexane and washed with hexane (20 ml) to remove impurity. Then product was removed from funnel with ethanol (25 ml) and solution was evaporated to give product as white solid (274 mg, 92%).

[α]² _D ⁷= +48.2 (c=0.44, EtOH) UV λmax (EtOH): 244 nm (ε 35585), 252 nm (ε 41634), 262 nm (ε 28023)

¹H NMR (DMSO-D6): 8.05(1H, s), 6.29(1H, dt, J=15.6, 7.7 Hz), 6.07(1H, d, J=I 1.3 Hz), 5.78(1H, d, J=I 1.3 Hz), 5.62(1H, d, J=15.6 Hz), 4.48(1H, d, J=4.1 Hz), 4.38(1H, d, J=3.8 Hz), 4.04(1H, s), 3.9O-3.84(1H, m), 3.83-3.76(1H, m), 2.73(1H, d, J=13.2 Hz), 2.43(1H, dd, J=12.9, 3.3 Hz), 2.26(1H, d, J=10.4 Hz), 2.09-1.91(6H, m), 1.69-1.24(17H, m), 0.91(3H, s), 0.60(3H, s)

¹³C NMR (DMSO-Do): 139.10, 136.46, 134.64, 122.59(q, J=286.0 Hz), 120.80, 119.84, 116.38, 75.50(sep, J=28.8 Hz), 68.40, 65.54, 65.25, 56.36, 55.98, 46.04, 44.56, 42.22, 41.07, 40.43, 36.96, 28.16, 22.95, 22.50, 21.85, 21.50, 17.90, 14.70

MS HRES Calculated for: C₃₂H₄₂D₆F₆O₄ [M+Na]⁺ 639.3725 Observed: [M+Na]⁺ 639.3725

EXAMPLE 41

Synthesis ofla-Fluow-25-hydwxy-20R-20-(4-hydwxy-5,5,5-trideutew-4- tndeuteromethyl-pentyiyHE-ene-ieyU-hexafluorocholecalciferol

lα-Fluoro-25-hydroxy-20R-20-(4-hydroxy-5,5,5-trideutero-4-trideuteromethyl-pentyl)-

23E-ene-26,27-hexafluorocholecalciferol A 25ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with (lS,5R)-l-((tert-butyldimethyl)silanyloxy)-3-[2-(diphenylfosphinoyl)- eth-(Z)-ylidene]-5-fluoro-2-methylene-cyclo hexane (543 mg, 1.154mmol) and tetrahydrofuran (8ml). The reaction mixture was cooled to -7O⁰C and n-butyllithium (0.72 ml, 1.15 mmol)) was added dropwise. The resulting deep red solution was stirred at -7O⁰C for 20 min and (IR, 3aR, 7aR)-7a-Methyl-l-[(lR, 3E)-6,6,6-trifluoro-l -methyl- 1 -(5,5, 5-trideutero-4-trideuteromethyl-4- trimethylsilanyloxy-penty^-S-trifluoromethyl-S-trimethylsilanyloxy-hex-S-enylJ-octahydro- inden-4-one (279 mg, 0.438 mmol) was added dropwise in tetrahydrofuran (1.5 ml). ). The reaction mixture was stirred for 8h (in last hour the temperature was increased from -70 do - 5O⁰C). The bath was removed and the mixture was poured into ethyl acetate (50ml) and saturated solution of ammonium chloride (50ml). The water fraction was extracted with ethyl acetate (3x50ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm³, protected from light) using hexane:ethyl acetate - 10:1 as mobile phase. Fractions containing product were pooled and evaporated to give oil. The oil residue was used to next reaction. A 25ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with substrate and tetrabutylammonium fluoride (8ml, lM/tetrahydrofuran). The mixture was stirred for next 25h. The mixture was dissolved by the addition of ethyl acetate (150ml) and extracted 6 times with water and brine (30ml+20ml), dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (50cm³, protected from light) using hexane:ethyl acetate - 2:1, 1 :1 as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. Oil was dissolved in methyl acetate and evaporated (4 times) to give product as white foam (216 mg, 78%).

[α]²> +32.5 (c=0.48, EtOH)

UV λmax (EtOH): 211 nm (ε 16931), 243 nm (ε 17696), 269 nm (ε 17736) 1H NMR (DMSO-D6): 8.05(1H, s), 6.36(1H, d, J=I 1.3 Hz), 6.28(1H, dt, J=15.6, 7.6 Hz), 5.92(1H, d, J=I 1.3 Hz), 5.62(1H, d, J=15.3 Hz), 5.39(1H, s), 5.14(1H, br d, J=49.7 Hz), 4.99(1H, d, J=I.7 Hz), 4.86(1H, d, J=4.3 Hz), 4.04(1H, s), 3.94-3.86(1H, m), 2.81(1H, d, J=12.4 Hz), 2.15-2.06(4H, m), 1.99-1.91(3H, m), 1.82-1.55(6H, m), 1.46-1.20(1OH, m), 0.90(3H, s), 0.59(3H, s)

¹³C NMR (DMSO-D6): 143.29(d, J=17.4 Hz), 141.83, 136.58, 133.13(d, J=I.5 Hz), 124.20, 122.76(q, J=287.5 Hz), 119.99, 117.46, 115.39(d, J=9.9 Hz), 92.09(d, J=166.8 Hz), 75.57(sep, J=28.8 Hz), 68.48, 64.60, 64.56, 56.40, 56.02, 46.31, 44.86, 44.58, 41.11, 40.71(d, J=20.4 Hz), 40.43, 39.36, 28.34, 23.02, 22.44, 21.79, 21.50, 17.90, 14.60

MS HRES Calculated for: C₃₃H₄IU₆F₇O₃ [M+Na]⁺ 653.3682

Observed: [M+Na]⁺ 653.3684

EXAMPLE 42 Synthesis of l,25-Dihydroxy-20-cyclopropyl-26,27-hexadeutero-19-nor-cholecalciferol

(IR, 3aR, 4S, 7aR)-2-{l-[4-(tert-butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden-l- yl]-cyclopropyl} ethyl toluene-4-sulfonic acid ester

A 100 ml round bottom flask equipped with stir bar and nitrogen sweep was charged with 5.98g (16.958 mmol) of (IR, 3aR, 4S, 7aR)-2-{l-[4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl- octahydro-inden-l-yl]-cyclopropyl}-ethanol, 50 ml of dichloromethane, 6 ml of triethylamine and 230 mg (1.883 mmol) of 4-dimethylamino pyridine. A 4.83 g (25.334 mmol) of tosyl chloride was added in one portion. The mixture was stirred at room temperature for 2h. The suspension was poured into a mixture of 40 g of ice, 100 ml of saturated sodium hydrogen carbonate solution and 100 ml of hexane. The aqueous layer was re-extracted three times with 50 ml of dichloromethane. These combined extracts were washed with 100 ml of brine, dried over Na₂SO₄ and evaporated. The residue was purified on a short flash chromatography column using hexane : ethyl acetate (20:1) as mobile phase to give 9.0 g of crude product as colorless oil. Product was used to the next reaction without farther purification.

(IR, 3aR, 4S, 7aR)-2-(2-{l-[4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden- l-yl]-cyclopropyl}-ethyl)-malonic acid dimethyl ester

A 500 ml 3 -neck round bottom flask equipped with mechanical stirrer, additional funnel with nitrogen sweep and condenser was charged with 160 ml of toluene. A 5.20 g (130 mmol) of sodium hydride (60% dispersion in mineral oil) was added in one portion. To the stirred suspension was added dropwise a solution of 19.36 g (146.5 mmol) of dimethyl malonate in 50 ml of toluene. The gel was heated in 12O⁰C oil bath for 10 min and then a solution of 9.0 g (ca. 16.958 mmol) of crude (IR, 3aR, 4S, 7aR)-2-{l-[4-(tert-butyl-dimethyl-silanyloxy)-7a-methyl- octahydro-inden-l-yl]-cyclopropyl} ethyl toluene-4-sulfonic acid ester in 100 ml of toluene was added dropwise. The reaction was stirred at this temperature for 6h. The flask was placed into an ice bath and 100 ml of cold water was added to dissolve the voluminous precipitate. The mixture was equilibrated with 100 ml of hexane. The resulting aqueous phase was re-extracted three times with 50 ml of toluene. The combined extracts were washed with 100 ml of water and 50 ml of brine, then dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (500 cm³) using hexane : ethyl acetate (20:1; 15:1) as mobile phase and collecting ca. 50ml fractions. Fractions containing product were pooled and evaporated. The fractions which were mixtures were pooled, evaporated separately ande was re-chromatographed on column (300 cm³) using hexane : ethyl acetate (20:1) as mobile phase and collecting ca. 25 ml fractions. Fractions containing product were pooled and evaporated to give 6.148 g (78% for two steps) of product as colorless oil.

(IR, 3aR, 4S, 7aR)-4-{l-[4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden-l- yl]-cyclopropyl}-butyric acid methyl ester

A 100 ml round bottom flask equipped with stir bar and condenser with nitrogen sweep was charged with 6.11 g (13.091 mmol) of (IR, 3aR, 4S, 7aR)-2-(2-{l-[4-(tert-Butyl-dimethyl- silanyloxy)-7a-methyl-octahydro-inden-l-yl]-cyclopropyl}-ethyl)-malonic acid dimethyl ester, 25 ml of mixture of dimethylsulfoxide and water (100:1) and 1.11 g (26.185 mmol) of lithium chloride. The mixture was stirred and heated under nitrogen at 16O⁰C for 3h. Then the solution was allowed to cool and distributed between 100 ml of water and 200 ml of hexane The aqueous layer was extracted three times with 50 ml of hexane. The combined organic layers were washed five times with 50 ml of water and 50 ml of brine then dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (500 cm³) using hexane :ethyl acetate (50:1) as mobile phase and collecting ca. 50ml fractions. Fractions containing product were pooled and evaporated to give of colorless oil. The fractions which were mixtures were pooled, evaporated separately and re-chromatographed on column (160 cm ) using hexane : ethyl acetate (50:1). It gave 4.19 g (78%) of product.

¹H NMR (CDCl₃): 3.98(1H, br s), 3.66(3H, s), 2.29 - 2.23(2H, m), 2.10 - 1.75(5H, m), 1.68 - 1.22(1OH, m), 0.94(3H, s), 0.88(9H, s), 0.71 - O.65(1H, m), 0.61 - 0.50(1H, m), 0.21 - 0.14(2H, m), 0.00(3H, s), -0.02(3H, s), -0.05 - O.12(1H, m).

(IR, 3aR, 4S, 7aR)-5-{l-[4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-octahydro-inden-l- yl] -cyclopropyl}- 1 , 1 , l-trideutero-2-trideuter omethyl-pentan-2-ol

A 250 ml round bottom flask equipped with stir bar, Claisen adapter with rubber septum was charged with 3.012 g (7.370 mmol) of (IR, 3aR, 4S, 7aR)-4-{l-[4-(tert-Butyl-dimethyl- silanyloxy)-7a-methyl-octahydro-inden-l-yl]-cyclopropyl} -butyric acid methyl ester and 75 ml of anhydrous diethyl ether. The solution was cooled in ace-water bath and 20 ml (20 mmol) of IM methyl-ύfj-magnesiurn iodide in diethyl ether was added dropwise. After completion of the addition the mixture was stirred at room temperature for 1.5h then cooled again in an ice bath. A 25 ml of saturated solution of ammonium chloride was added dropwise. The resulting precipitate was dissolved by the addition of 100 ml of water. The aqueous layer was re-extracted three times with 50 ml of diethyl ether. The combined ether layers were dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (350 cm³) using hexane : ethyl acetate (9:1) as mobile phase and collecting ca. 50 ml fractions. Fractions containing product were pooled and evaporated to give of colorless oil. The fractions which were mixtures were pooled, evaporated separately and re-chromatographed on column (100 cm³) using hexane : ethyl acetate (9:1). It gave 2.95 g (96%) of product.

¹H NMR (CDCl₃): 3.99(1H, br s), 2.05 - 1.76(4H, m), 1.68 - 1.17(14H, m), 0.95(3H, s), 0.88(9H, s), 0.70 - 0.52(2H, m), 0.22 - 0.12(2H, m), 0.01(3H, s), -0.01(3H, s), -0.05 - -O.11(1H, m).

(IR, 3aR, 4S, 7aR)-l-[l-(4-Hydroxy-5,5,5-tridutero-4-trideuteromethyl-pentyl)- cyclopropyl]-7a-methyl-octahydro-inden-4-ol

A 50 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 2.940 g, (7.088 mmol) of (IR, 3aR, 4S, 7aR)-5-{l-[4-(tert-Butyl- dimethyl-silanyloxy)-7a-methyl-octahydro-inden- 1 -yl]-cyclopropyl} -1,1,1 -trideutero-2- trideuteromethyl-pentan-2-ol and 25 ml (25.0 mmol) of 1.0M tetrabutyl ammonium fluoride in tetrahydrofuran. The reaction mixture was stirred at 7O⁰C for 22h and the new portion 10 ml (10.0 mmol) of tetrabutylammonium fluoride was added. The reaction was stirred at 7O⁰C for next 26h. The mixture was dissolved by the addition of 150 ml of ethyl acetate and washed six times with 40 ml of water and 20 ml of brine, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (250cm ) using hexane : ethyl acetate (3:1) as mobile phase. Fractions containing product were pooled and evaporated to give 2.0O g (94%) of product.

(IR, 3aR, 7aR)-l-[l-(4-Hydroxy-5,5,5-trideutero-4-trideuteromethyl-pentyl)-cyclopropyl]-

7a-methyl-octahydro-inden-4-one

A 250 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 7.42 g (19.723 mmol) of pyridinium dichromate, 7.28 g of celite and 75 ml of dichloromethane. A 1.96 g (6.522 mmol) of (IR, 3aR, 4S, 7aR)-l-[l-(4-Hydroxy-5,5,5- tridutero-4-trideuteromethyl-pentyl)-cyclopropyl]-7a-methyl-octahydro-inden-4-ol in 5 ml of dichloromethane was added dropwise and mixture was stirred in room temperature for 6h. The reaction mixture was filtrated through column with 100 cm³ of silica gel using dichloromethane and dichloromethane : ethyl acetate (4:1, 3:1, 2:1) as mobile phases. The fractions containing product were pooled and evaporated to give 1.92 g (98%) of ketone.

¹H NMR (CDCl₃): 2.5O(1H, dd, J=I 1.4, 7.0 Hz), 2.29 - 2.12(4H, m), 2.05 - 1.86(3H, m), 1.75 - 1.17(9H, m), 1.08 - O.98(1H, m), 0.73 - 0.60(2H, m), 0.69(3H, s), 0.26 - 0.19(2H, m), 0.06 - - 0.01(lH, m).

(IR, 3aR, 7aR)-7a-Methyl-l-[l-(5,5,5-trideutero-4-trideuteromethyl-4-trimethylsilanyloxy- pentyl)-cyclopropyl]-octahydro-inden-4-one

TMS-imidasole CH_?C1_?

A 100 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 1.91 g (6.399 mmol) of (IR, 3aR, 7aR)-l-[l-(4-Hydroxy-5,5,5- trideutero-4-trideuteromethyl-pentyl)-cyclopropyl]-7a-methyl-octahydro-inden-4-one and 60 ml of dichloromethane. A 3.8 ml (25.90 mmol) of l-(trimethylsilyl)imidasole was added dropwise. The mixture was stirred at room temperature for Ih 45 min. A 25 ml of water was added and the mixture was stirred for 10 min. The resulting mixture was dissolved by the addition of 200 ml of water. The aqueous layer was extracted five times with 50 ml of ethyl acetate. The combined organic layers were washed with 50 ml of brine, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (200 cm³) using hexane : dichloromethane (2:1, 1 :1) and dichloromethane as mobile phases. Fractions containing product were pooled and evaporated to give 2.10 g (89%) of product as colorless oil.

1 α,25-Dihydroxy-20-cyclopropyl-26,27-hexadeutero- 19-nor-cholecalciferol

A 50 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 2.155 g (3.776 mmol) of (lR,3R)-l,3-bis-((tert- butyldimethyl)silanyloxy)-5-[2-(diphenylfosphinoyl)ethylidene]-cyclohexane and 15 ml of anhydrous tetrahydrofurane. The reaction mixture was cooled to -78⁰C and 2.3 ml (3.68 mmol) 1.6M n-butyllithium in hexane was added dropwise. The resulting deep red solution was stirred at -78⁰C for 20 min and 700 mg (1.888 mmol) of (IR, 3aR, 7aR)-7a-Methyl-l-[l-(5,5,5- trideutero-4-trideuteromethyl-4-trimethylsilanyloxy-pentyl)-cyclopropyl]-octahydro-inden-4-one was added dropwise in 2 ml of anhydrous tetrahydrofurane. The reaction mixture was stirred for 4h and then the bath was removed and the mixture was poured into 50 ml of ethyl acetate and 50 ml brine. The water fraction was extracted three times with 75 ml of ethyl acetate. All organic layers were combined, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (100 cm , protected from light) using hexane : ethyl acetate (20:1) as mobile phase. Fractions containing product were pooled and evaporated to give colorless oil which was treated with 20 ml 1.0M tetrabutylammonium fluoride in tetrahydrofurane. The reaction mixture was stirred at room temperature for 24h. The mixture was dissolved by the addition of 150 ml of ethyl acetate. The organic layer was washed five times with 50 ml of water and 50 ml of brine, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm³, protected from light) using ethyl acetate as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. Oil was dissolved in methyl acetate and evaporated (4 times) to give 525 mg (66%) of white foam. [(X]³V +47.8 c 0.46, CHCl₃

UV λmax (EtOH): 243nm (ε 32133), 251nm (ε 37757), 261nm (ε 25993) 1H NMR (CDCl₃): 6.3O(1H, d, J=I 1.3 Hz), 5.82(1H, d, J=I 1.3), 4.15 - 4.08(1H, m), 4.07- 4.00(1H, m), 2.82 - 2.78(1H, m), 2.73(1H, dd, J=13.1, 3.7 Hz), 2.48(1H, dd, J=13.3, 3.3 Hz), 2.24 - 1.24(21H, m), 1.19(1H, s), 1.00 - 0.91(1, m), 0.68 - 0.61(2H, m), 0.59(3H, s), 0.23 - 0.17(2H, m), 0.05 - -0.05(1H, m)

MS HRES Calculated for: C₂₇H₃₈D₆FO₃ [M+Na]⁺ 445.3559

Observed: [M+Na]⁺ 445.3561

EXAMPLE 43

Synthesis of Acetic acid lα-acetoxy-25-hydroxy-20-cyclopropyl-26,27-hexadeutero-19-nor- cholecalciferyl ester

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 245 mg (0.579 mmol) of lα,25-Dihydroxy-20-cyclopropyl-26,27- hexadeutero-19-nor-cholecalciferol and 6 ml of pyridine. The mixture was stirred at 0-5⁰C and 1 ml (10.6 mmol) of acetic anhydride was added dropwise. The reaction mixture was stirred at 0- 5⁰C for 17h and new portion 0.75 ml (7.9 mmol) of acetic anhydride was added dropwise. The reaction mixture was stirred for next 24h. The mixture was dissolved by the addition of 10 ml of water, stirred for 15 min and poured into 100 ml of ethyl acetate. The mixture was extracted five times with 50 ml of water and 50 ml of brine, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50cm³, protected from light) using hexane : ethyl acetate (2:1) as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. The product was dissolved in methyl acetate and evaporated (4 times) to give 259 mg (88%) of white foam. [(X]³⁰D= +8.2 c 0.45, CHCl₃

UV λmax (EtOH): 243nm (ε 34931), 251nm (ε 40870), 260nm (ε 27807) 1H NMR (CDCl₃): 6.25(1H, d, J=I Ll Hz), 5.72(1H, d, J=I 1.5 Hz), 5.12 - 5.06(2H, m), 2.80 - 2.76(1H, m), 2.60 - 2.44(3H, m), 2.27(1H, dd, J=13.5, 7.7 Hz), 2.14 - 1.87(6H, m), 2.03(3H, s), 2.00(3H, s), 1.70 - 1.25(1 IH, m), 1.18(1H, s), 1.00 - O.91(1H, m), 0.68 - 0.60(2H, m), 0.57(3H, s), 0.23 - 0.16(2H, m), 0.00 - -0.06(1H, m)

MS HRES Calculated for: C₃IH₄₂D₆FO₅ [M+Na]⁺ 529.3770

Observed: [M+Na]⁺ 529.3782

EXAMPLE 44

lα,25-Dihydroxy-20-cyclopropyl-26,27-hexadeutero-cholecalciferol

A 50 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 2.201 g (3.774 mmol) of (lS,5R)-l,5-bis-((tøt- butyldimethyl)silanyloxy)-3-[2-(diphenylfosphinoyl)-eth-(Z)-ylidene]-2-methylene-cyclo hexane and 15 ml of anhydrous tetrahydrofurane. The reaction mixture was cooled to -78⁰C and 2.3 ml (3.68 mmol) 1.6M n-butyllithium in hexane was added dropwise. The resulting deep red solution was stirred at -78⁰C for 20 min and 700 mg (1.888 mmol) of (IR, 3aR, 7aR)-7a-Methyl-l-[l- (5,5,5-trideutero-4-trideuteromethyl-4-trimethylsilanyloxy-pentyl)-cyclopropyl]-octahydro- inden-4-one was added dropwise in 2 ml of anhydrous tetrahydrofurane. The reaction mixture was stirred for 4h and then the bath was removed and the mixture was poured into 60 ml of ethyl acetate and 50 ml of brine. The water fraction was extracted four times with 75 ml of ethyl acetate, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (100 cm³, protected from light) using hexane : ethyl acetate (20:1) as mobile phase. Fractions containing product were pooled and evaporated to give colorless oil which was treated with 20 ml 1.0M tetrabutylammonium fluoride in tetrahydrofurane. The reaction mixture was stirred at room temperature for 24h. The mixture was dissolved by the addition of 150 ml of ethyl acetate and washed five times with 50 ml of water and 50 ml of brine, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (75 cm , protected from light) using ethyl acetate as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. Some fractions contain impurity were purified on column (50 cm , protected from light) using ethyl acetate : hexane (2:1) as mobile phase. The product was dissolved in methyl acetate and evaporated (4 times) to give 749 mg (91%) of white foam. [(X]³⁰D= +3.3 c 0.46, CHCl₃

UV λmax (EtOH): 213nm (ε 12528), 264nm (ε 14832) 1H NMR (CDCl₃): 6.37(1H, d, J=I 1.5 Hz), 5.99(1H, d, J=I Ll), 5.32(1H, s), 4.99(1H, s), 4.44 - 4.42(1H, m), 4.23(1H, br s), 2.84 - 2.8O(1H, m), 2.59(1H, dd, J=13.5, 3.5 Hz), 2.31(1H, dd, J=13.4, 6.4 Hz), 2.13 - 2.09(1H, m), 2.06 - 1.88(5H, m), 1.73 - 1.26(13H, m), 1.18(1H, br s), 0.99 - 0.90(1H, m), 0.68 - 0.61(2H, m), 0.59(3H, s), 0.21 - 0.16(2H, m), 0.00 - -0.06(1H, m) MS HRES Calculated for: C₂₈H₃₈D₆FO₃ [M+Na]⁺ 457.3559

Observed: [M+Na]⁺ 457.3563

EXAMPLE 45

Acetic acid lα-acetoxy-25-hydroxy-20-cyclopropyl-26,27-hexadeutero-cholecalciferyl ester

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 345 mg (0.794 mmol) of lα,25-Dihydroxy-20-cyclopropyl-26,27- hexadeutero-cholecalciferol and 7 ml of pyridine. The mixture was stirred at 0-5⁰C and 1.5 ml (15.9mmol) of acetic anhydride was added dropwise. The reaction mixture was stirred at 0-5⁰C for 17h and new portion 0.5 ml (5.3 mmol) of acetic anhydride was added. The next portion 1 ml (10.6 mmol) of acetic anhydride was added after next 25h. The reaction mixture was stirred for additional 16h. The mixture was dissolved by the addition of 15 ml of water, stirred for 15 min and poured into 120 ml of ethyl acetate. The mixture was extracted five times with 50 ml of water and 50 ml of brine, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (75cm³, protected from light) using hexane : ethyl acetate (2:1) as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. The product was dissolved in methyl acetate and evaporated (4 times) to give 364 mg (88%) of white foam. [(X]³⁰D= -20.2 c 0.46, CHCl₃

UV λmax (EtOH): 207nm (ε 14863), 250nm (ε 15225), 265nm (ε 15985) 1H NMR (CDCl₃): 6.34(1H, d, J=I 1.3 Hz), 5.89(1H, d, J=I 1.5 Hz), 5.47(1H, dd, J=6.2, 4.0 Hz), 5.3O(1H, s), 5.21 - 5.15(1H, m), 5.03(1H, d, J=I.7 Hz), 2.82 - 2.78(1H, m), 2.64(1H, dd, J=13.2, 4.3 Hz), 2.38 - 2.33(1H, m), 2.13 - 1.92(6H, m), 2.05(3H, s), 2.03(3H, s), 1.72 - 1.28(1 IH, m), 1.19(1H, s), 0.98 - 0.88(1H, m), 0.68 - 0.59(2H, m), 0.56(3H, s), 0.22 - 0.16(2H, m), 0.01 - - 0.06(1H, m)

MS HRES Calculated for: C₃₂H₄₂D₆FO₅ [M+Na]⁺ 541.3770

Observed: [M+Na]⁺ 541.3764

EXAMPLE 46 lα-Fluoro-25-hydroxy-20-cyclopropyl-26,27-hexadeutero-cholecalciferol

A 50 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 1.907 g (4.052 mmol) of (lS,5R)-l-((tert-butyldimethyl)silanyloxy)-3- [2-(diphenylfosphinoyl)-eth-(Z)-ylidene]-5-fluoro-2-methylene-cyclohexane and 15 ml of anhydrous tetrahydrofurane. The reaction mixture was cooled to -78⁰C and 2.5 ml (4.00 mmol) 1.6M n-butyllithium in hexane was added dropwise. The resulting deep red solution was stirred at -78⁰C for 20 min and 650 mg (1.754 mmol) of (IR, 3aR, 7aR)-7a-Methyl-l-[l-(5,5,5- trideutero-4-trideuteromethyl-4-trimethylsilanyloxy-pentyl)-cyclopropyl]-octahydro-inden-4-one was added dropwise in 2 ml of anhydrous tetrahydrofurane. The reaction mixture was stirred for 3.5h and then the bath was removed and the mixture was poured into 60 ml of ethyl acetate and 50 ml of brine. The water fraction was extracted four times with 60 ml of ethyl acetate dried (Na₂SO₄) and evaporated. The oil residue was chromatographed on column (75cm³, protected from light) using hexane :ethyl acetate - 20:1 as mobile phase. Fractions containing product were pooled and evaporated to give colorless oil which was treated with 20 ml 1.0M tetrabutylammonium fluoride in tetrahydrofurane. The reaction mixture was stirred at room temperature for 7.5h. The mixture was dissolved by the addition of 150 ml of ethyl acetate and washed five times with 50 ml of water and 50 ml of brine, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (75 cm³, protected from light) using hexane : ethyl acetate (1:1) as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. Some fractions contain impurity were purified on column (50 cm , protected from light) using hexane : ethyl acetate (2:1) as mobile phase. The product was dissolved in methyl acetate and evaporated (4 times) to give 629 mg (82%) of white foam. [(X]³⁰D= +22.1 c 0.43, CHCl₃ UV λmax (EtOH): 209nm (ε 14376), 243nm (ε 13949), 269nm (ε 14083) ¹U NMR (CDCl₃): 6.39(1H, d, J=I Ll Hz), 6.00(1H, d, J=I Ll Hz), 5.38(1H, s), 5.13(1H, ddd, J=49.5, 6.9, 3.7 Hz), 5.09(1H, s), 4.22(1H, br s), 2.84 - 2.8O(1H, m), 2.62(1H, dd, J=13.3, 3.7 Hz), 2.3O(1H, dd, J=13.3, 7.5 Hz), 2.23 - 1.92(6H, m), 1.74 - 1.26(12H, m), 1.18(1H, s), 0.98 - O.91(1H, m), 0.68 - 0.61(2H, m), 0.59(3H, s), 0.21 - 0.16(2H, m), 0.00 - -0.06(1H, m) MS HRES Calculated for: C₂₈H₃₇D₆FO₂ [M+Na]⁺ 459.3516

Observed: [M+Na]⁺ 459.3521

EXAMPLE 47 Acetic acid lα-fluoro-25-hydroxy-20-cyclopropyl-26,27-hexadeutero-cholecalciferyl ester

A 25 ml round bottom flask equipped with stir bar and Claisen adapter with rubber septum was charged with 300 mg (0.687 mmol) of lα-Fluoro-25-hydroxy-20-cyclopropyl-26,27- hexadeutero-cholecalciferol and 6 ml of pyridine. The mixture was stirred at 0-5⁰C and 1 ml (10.6 mmol) of acetic anhydride was added dropwise. The reaction mixture was stirred at 0-5⁰C for 16h and new portion 0.5 ml (5.3 mmol) of acetic anhydride was added. The reaction mixture was stirred for next 3h. The mixture was dissolved by the addition of 15 ml of water, stirred for 15 min and poured into 120 ml of ethyl acetate. The mixture was extracted five times with 50 ml of water and 50 ml of brine, dried over Na₂SO₄ and evaporated. The oil residue was chromatographed on column (50 cm³, protected from light) using hexane : ethyl acetate (3:1) as mobile phase. Fractions containing product were pooled and evaporated to give product as colorless oil. The product was dissolved in methyl acetate and evaporated (4 times) to give 292 mg (89%) of white foam. [(X]³⁰D= -15.9 c 0.46, CHCl₃

UV λmax (EtOH): 210nm (ε 11176), 245nm (ε 10496), 264nm (ε 10387) 1H NMR (CDCl₃): 6.36(1H, d, J=I 1.3 Hz), 6.00(1H, d, J=I 1.3 Hz), 5.4O(1H, s), 5.23 - 5.16(1H, m), 5.1O(1H, dm, J=49.7 Hz), 5.1O(1H, s), 2.82 - 2.79(1H, m), 2.64(1H, dd, J=13.7, 3.7 Hz), 2.41 - 2.36(1H, m), 2.23 - 1.93(6H, m), 2.04(3H, s), 1.73 - 1.26(12H, m), 0.99 - O.92(1H, m), 0.68 ■ 0.61(2H, m), 0.60(3H, s), 0.22 - 0.17(2H, m), 0.00 - -0.06(1H, m) MS HRES Calculated for: C₃₀H₃₉D₆FO₃ [M+Na]⁺ 501.3621

Observed: [M+Na]⁺ 501.3619

EXAMPLE 48

Synthesis of l,25-Dihydroxy-16-ene-20 cyclopropyl-26,27-hexadeutero-19-nor- cholecalciferol

(3aR, 4S,7aR)-l-E/Z -{l-[4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-3a,4,5,6,7,7a- hexahydro-3H-inden-l-yl])-cyclopropyl}-2-methoxy-vinyl

To a stirred suspension of pyridinium chlorochromate (10.3 g, 47.7 mmol) in dichloromethane

(10OmL) at room temperature was added dropwise a solution of (3aR, 4S,7aR)-{l-[4-(tert-Butyl- dimethyl-silanyloxy)-7a-methyl-3a,4,5,6,7,7a-hexahydro-3H-inden-l-yl]-cyclopropyl} -methanol (6.5 g, 19.31 mmol) in dichloromethene (10.0 mL). The reaction mixture was stirred for 1.0 h and filtered through Celite/ Silca gel column (2Og + 5Og), which was then washed with 10% AcOEt in hexane to give crude (3aR, 4S,7aR)-l-[4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl- 3a,4, 5,6,7, 7a-hexahydro-3H-inden-l-yl]-cyclopropanecarbaldehyde (5.6 g). To a stirred suspension of (methoxymethyl)triphenylphosphonium chloride (7.5 g, 21.88 mmol) in tetrahydrofurane (150 mL) at O⁰C was added dropwise sodium bis(trimethysilyl)amide (22 mL, 22 mmol, 1.0 M in THF). After 30 min. at 0° C the solution of (3aR, 4S,7aR)-l-[4-(tert-Butyl- dimethyl-silanyloxy)-7a-methyl-3a,4,5,6,7,7a-hexahydro-3H-inden-l-yl]- cyclopropanecarbaldehyde (5.6 g, 16.74 mmol) in tetrahydrofurane (20 mL) was added dropwise. The reaction mixture was stirred for Ih at O⁰C, then water (150 mL) was added and the reaction was extracted with hexane (2x150 mL) and dried over Na₂SO₄. The residue (12.5 g) after evaporationof the solvent was purified by FC (20Og, hexane, 5% AcOEt in hexane) to give the titled compound (5.41 g, 14.92 mmol, 77% )

(3aR, 4S,7aR)-l-{l-[4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-3a,4,5,6,7,7a-hexahydro-

3H-inden-l-yl])-cyclopropyl}-ethynyl

To a stirred solution of (3aR, 4S,7aR)-l-E/Z -{l-[4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl- 3a,4, 5,6,7, 7a-hexahydro-3H-inden-l-yl])-cyclopropyl}-2-methoxy- vinyl (5.41 g, 14.92 mmol) in dichloromethene (50 rnL) at room temperature was added acidic acid (25 mL ) and the reaction mixture was heated at reflux for 72 hours. NaHCO3_aq (35OmL) was added and the reaction mixture was extracted with dichloromethane (2x 200 mL), washed with brine (200 mL) and dried over Na₂SO₄) The residue after evaporation of the solvent (1.2 g) was purified by FC (15Og, hexane, 2% AcOEt in hexane) to give (3aR, 4S,7aR)-{l-[4-(tert-Butyl-dimethyl- silanyloxy)-7a-methyl-3a,4,5,6,7,7a-hexahydro-3H-inden- 1 -yl]-cyclopropyl} -acetaldehyde (3.65 g, 10.47 mmol). To a stirred solution of (3aR, 4S,7aR)-{l-[4-(tert-Butyl-dimethyl-silanyloxy)- 7a-methyl-3a,4,5,6,7,7a-hexahydro-3H-inden-l-yl]-cyclopropyl}-acetaldehyde (3.65 g, 10.47 mmol) in methanol (15 mL) at room temperature was added (l-diazo-2-oxo-propyl)-phosphonic acid dimethyl ester (3.0 g, 15.61 mmol ) in methanol (5 mL). The resulting mixture was cooled in an ice bath and potassium carbonate (3.07 g, 22.21 mmol, powdered) was added. The reaction mixture was stirred in the ice bath for 30 min and then at room temperature for 45 min. Water was added (100 mL) and the mixture was extracted with hexane (2x 150 mL). The combined extracts were washed with brine (10OmL) and dried over Na₂SO₄. The residue after evaporation of the solvent (3.9 g) was purified by FC (10Og, hexane, 2% AcOEt in hexane) to give the titled compound (2.6 g, 7.54 mmol, 72%) [CC]²⁸D= +29.8 c 0.8, CHCl₃

¹H NMR (CDCl₃): 5.45 (IH, br. s), 4.04 (IH, br. s), 2.40 (2H, m), 2.24 (IH, m), 1.96-1.38 (9H, m), 1.17 (3H, s), 0.88 (9H, s), 0.74-0.54 (4H, m), 0.01 (6H, s);

¹³C NMR (CDCl₃): 156.44(0), 125.39(1), 82.65(1), 69.39(0), 69.23(1), 55.92(1), 47.60(0), 36.42(2), 34.65(2), 30.76(2), 26.04(2), 20.34(3), 19.35(0), 18.30(2), 11.516(2), 10.97(2), - 4.55(3), -4.87(3);

MS HREI Calculated for C₂₂H₃₆OSi M+ 344.2535

Observed M+ 344.2539

(3aR, 4S,7aR)-7a-Methyl-l-[l-(5,5,5-trideutero-4-hydroxy-4-trideuteromethyl-pent-2- ynyl)-cyclopropyl]-3a,4,5,6,7,7a-hexahydro-3H-inden-4-ol

To a stirred solution of (3aR, 4S,7aR)-l-{l-[4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl- 3a,4, 5,6,7, 7a-hexahydro-3H-inden- 1 -yl])-cyclopropyl} -ethynyl

(1.6 g, 4.64 mmol) in tetrahydrofurane (22 rnL) at -78⁰C was added n-BuLi (4.35 mL, 6.96 mmol , 1.6M in hexane). After stirring at -78⁰C for 1 h., acetone-dβ (1.0 mL, 13.6 mmol, (D,99,96) was added and the stirring was continued for 2.5h. NH₄CUq was added (15 mL) and the mixture was stirred for 15min at room temperature then extracted with AcOEt (2x 50 mL). The combined extracts were washed with brine (5OmL) and dried over Na₂SO₄. The residue after evaporation of the solvent (2.4 g) was purified by FC (5Og, 10% AcOEt in hexane) to give (3aR, 4S,7aR)-5-{l-[4-(tert-Butyl-dimethyl-silanyloxy)-7a-methyl-3a,4,5,6,7,7a-hexahydro-3H-inden- l-yl]-cyclopropyl}-l,l,l-trideutero-2-trideuteromethyl-pent-3-yn-2-ol (1.81 g, 4.43 mmol) which was treated with tetrabutylammonium fluoride (12 mL, 12 mmol, 1.0M in THF) and stirred at 65-75⁰C for 48 h. The mixture was diluted with AcOEt (25 mL) and washed with water (5x 25 mL), brine (25 mL). The combined aqueous washes were extracted with AcOEt (25 mL) and the combined organic extracts were dried over Na₂SO₄). The residue after evaporation of the solvent (2.5 g) was purified by FC (10Og, 20% AcOEt in hexane) to give the titled compound (1.21 g, 4.11 mmol, 89 %)

[CC]³⁰D= +2.0 c 0.35, CHCl₃

¹H NMR (CDCl₃): 5.47 (IH, m), 4.15 (IH, m), 2.40 (2H, s), 2.28 (IH, ddd, J=13.4, 11.9, 1.5 Hz), 1.98-1.36 (1OH, m), 1.19 (3H, s), 0.70-0.52 (4H, m);

¹³C NMR (CDCl₃): 156.32(0), 125.22(1), 86.36(0), 80.33(0), 69.31(1), 69.14(0), 55.20(1), 47.01(0), 35.87(2), 33.70(2), 29.99(2), 27.34(2), 19.39(2), 19.29(0), 17.83(3), 11.05(2), 10.50(2);

MS HREI Calculated for Ci₉H₂₂O₂D₆ M+ 294.2466

Observed M+ 294.2474

(3aR, 4S,7aR)-7a-Methyl-l-[l-(5,5,5-trideutero-4-hydroxy-4-trideuteromethyl-pent-2Z- enyl)-cyclopropyl]-3a,4,5,6,7,7a-hexahydro-3H-inden-4-ol

The mixture of (3aR, 4S,7aR)-7a-Methyl-l-[l-(5,5,5-trideutero-4-hydroxy-4-trideuteromethyl- pent-2-ynyl)-cyclopropyl]-3a,4, 5,6,7, 7a-hexahydro-3H-inden-4-ol

(1.02 g, 3.46 mmol), ethyl acetate (14 mL), hexane (31 mL), absolute ethanol (1.25 mL), quinoline (66 μL) and Lindlar catalyst (222 mg, 5% Pd on CaCO₃ ) was hydrogenated at room temperature for 2 h. The reaction mixture was filtered through a celite pad and the pad was washed with AcOEt. The filtrates and the washes were combined and washed with IM HCl, NaHCO₃ and brine. After drying over Na₂SO₄ the solvent was evaporated and the residue (1.2 g) was purified by FC (75g, 20% AcOEt in hexane) to give the titled compound (890 mg, 3.0 mmol, 87 %)

[CC]²⁸D= +1.7 c 0.48, CHCl₃

¹H NMR (CDCl₃): 5.45 (IH, dt, J=I 1.9, 1.8 Hz), 5.42 (IH, m,), 5.36 (IH, dt, J=12.1, 6.3 Hz), 4.14 (IH, m), 2.43 (IH, m), 2.27 (IH, ddd, J=13.6, 12.2, 1.7 Hz), 2.00-1.24 (HH, m), 1.18 (3H, s), 0.70-0.36 (4H, m);

¹³C NMR (CDCl₃): 156.67(0), 136.58(1), 128.65(1), 125.21 (1), 71.48(0), 69.37(1), 55.28(1),

47.07(0), 35.89(2), 35.57 (2), 33.68(2), 30.04(2), 21.14(0), 19.37(3), 17.84(2), 11.85(2),

11.06(2); MS HRES Calculated for Ci₉H₂₄O₂D₆ M+H 296.2622

Observed M+H 296.2619

(3aR, 4S,7aR)-7a-Methyl-l-[l-(5,5,5-trideutero-4-hydroxy-4-trideuteromethyl-pentyl)- cyclopropyl]-3a,4,5,6,7,7a-hexahydro-3H-inden-4-ol

The mixture of (3aR, 4S,7aR)-7a-Methyl-l-[l-(5,5,5-trideutero-4-hydroxy-4-trideuteromethyl- pent-2Z-enyl)-cyclopropyl]-3a,4, 5,6,7, 7a-hexahydro-3H-inden-4-ol (860 mg, 2.9 mmol), l,4-bis(diphenyl-phosphino)butane 1,5 cyclooctadiene rhodium tetrafluoroborate (200 mg,0.28 mmol), dichloromethane (35 mL) and one drop of mercury was hydrogenated using Paar apparatus at room temperature and 50 p.s.i. pressure for 2h. The reaction mixture was filtered through Celite pad, which was then washed with ethyl acetate. The combine filtrates and washes were evaporated to dryness (950 mg) and purified three times by FC (100 g, 20% AcOEt in hexane) to give the titled compound (600 mg, 2.01 mmol, 69 %) [CC]³⁰D= -5.3 c 0.45, CHCl₃

¹H NMR (CDCl₃): 5.37 (IH, m,), 4.14 (IH, m), 2.32-1.20 (17H, m), 1.18 (3H, s), 0.64-0.26 (4H, m); 1³C NMR (CDCl₃): 156.84(0), 124.87(1), 70.79(0), 69.39(1), 55.42(1), 47.19(0), 43.75(2),

38.31(2), 35.86(2), 33.69(2), 29.97(2), 22.35(2), 21.14(0), 19.46(3), 17.88(2), 12.19(2), 11.28(2); MS HREI Calculated for Ci₉H₂₆O₂D₆ M+H 298.2779

Observed M+ H 298.2787

(3aR,7aR)-7a-Methyl-l-[l-(5,5,5-trideutero-4-trideuteromethyl-4-trimethylsilanyloxy- pentyl)-cyclopropyl]-3a,4,5,6,7,7a-hexahydro-3H-inden-4-one

To a stirred suspension of (3aR, 4S,7aR)-7a-Methyl-l-[l-(5,5,5-trideutero-4-hydroxy-4- trideuteromethyl-pentenyl)-cyclopropyl]-3a,4, 5,6,7, 7a-hexahydro-3H-inden-4-ol (450 mg, 1.51 mmol) and Celite (2.0 g) in dichloromethane (10 mL) at room temperature wad added pyridinium dichromate (1.13 g, 3.0 mmol). The resulting mixture was stirred for 3.5 h filtered through silica gel (10 g), and then silica gel pad was washed with 25% AcOEt in hexane. The combined filtrate and washes were evaporated, to give a crude (3aR,7aR)-7a-Methyl-l-[l- (5,5,5-trideutero-4-hydroxy-4-trideuteromethyl-pentenyl)-cyclopropyl]-3a,4,5,6,7,7a-hexahydro- 3H-inden-4-one (425 mg, 1.44 mmol, 95 %). To a stirred solution of (3aR,7aR)-7a-Methyl-l-[l- (5,5,5-trideutero-4-hydroxy-4-trideuteromethyl-pentenyl)-cyclopropyl]-3a,4,5,6,7,7a-hexahydro- 3H-inden-4-one (425 mg, 1.44 mmol) in dichloromethane (10 mL) at room temperature was added trimethylsilyl- imidazole (0.44 mL, 3.0 mmol). The resulting mixture was stirred for 1.0 h filtered through silica gel (15 g) and the silica gel pad was washed with 10% AcOEt in hexane. Combined filtered and washes were evaporated to give the titled compound (450 mg, 1.22 mmol,

85 %)

[CC]²⁹D= -14.2 c 0.43, CHCl₃ 1H NMR (CDCl₃): 5.33 (IH, dd, J=3.2, 1.5 Hz), 2.81 (IH, dd, J= 10.7, 6.4 Hz), 2.44 (IH, ddd, J=15.8, 10.7, 1.6 Hz), 2.30-1.12 (13H, m) overlapping 2.03 ( ddd, J= 15.9, 6.4, 3.2 Hz), 0.92 (3H, s), 0.66-0.28 (4H, m), 0.08 (9H, s);

¹³C NMR (CDCl₃): 210.74 (0), 155.41(0), 124.81(1), 73.71(0), 64.37(1), 53.92(0), 44.67(2), 40.46(2), 38.21(2), 34.80(2), 26.86(2), 24.06(2), 22.28(2), 21.28(0), 18.40(3), 12.59(2), 10.69(2), 2.62 (3);

MS HRES Calculated for C₂₂H₃₂O₂SiD₆ M+ 368.0318

Observed M+ 368.3029

1 α,25-Dihydroxy- 1 ό-ene-lO-cyclopropyHό^T-hexadeutero- 19-nor-cholecalciferol

To a stirred solution of a (li?,3i?)-l,3-bis-((tert-butyldimethyl)silanyloxy)-5-[2- (diphenylphosphinoyl)ethylidene]-cyclohexane (536 mg, 0.92 mmol) in tetrahydrofurane (7 mL) at -78⁰C was added n-BuLi (0.58 mL, 0.93 mmol). The resulting mixture was stirred for 15 min and solution of (3aR,7aR)-7a-Methyl-l-[l-(5,5,5-trideutero-4-trideuteromethyl-4- trimethylsilanyloxy-pentyl)-cyclopropyl]-3a,4,5,6,7,7a-hexahydro-3H-inden-4-one (170 mg, 0.46 mmol, in tetrahydrofurane (2mL) was added dropwise. The reaction mixture was stirred at -72⁰C for 3.5h diluted with hexane (35 mL) washed brine (30 mL) and dried over Na₂SO₄. The residue (725mg) after evaporation of the solvent was purified by FC (15g, 5% AcOEt in hexane) to give lα,3β-Di(tert-Butyl-dimethyl-silanyloxy)-25-trimethylsilanyloxy-16-ene-20- cyclopropyl-26,27-hexadeutero-l 9-nor-cholecalciferol (293 mg, 041 mmol). To the lα,3β-Di(tert-Butyl-dimethyl-silanyloxy)-25-trimethylsilanyloxy-16-ene-20-cyclopropyl- 26,27-hexadeutero-l 9-nor-cholecalciferol (293 mg, 0.41 mmol) tetrabutylammonium fluoride (4 mL, 4 mmol, IM solution in THF) was added, at room temperature. The mixture was stirred for 4Oh. diluted with AcOEt (25 mL) and washed with water (5x20 mL), brine (20 mL) and dried over Na₂SO₄. The residue (280 mg) after evaporation of the solvent was purified by FC (15g, 50% AcOEt in hexane and AcOEt) to give the titled compound (163 mg, 0.39 mmol, 84 %) [CC]²V +65.8 c 0.40, EtOH

UV λmax (EtOH): 243nm (ε32702251 nm (ε 39060), 261 nm (ε 26595); 1H NMR (CDCl₃): 6.30 (IH, d, J=I 1.3 Hz), 5.93 (IH, d, J=I 1.3 Hz), 5.36 (IH, m), 4.13 (IH, m), 4.05 (IH, m), 2.76 (2H, m), 2.52-1.10 (22H, m), 0.79 (3H, s ),0.66-0.24 (4H,m); 1³C NMR (CDCl₃): 157.05(0), 142.25(0), 131.15(0), 124.66(1), 123.70(1), 115.44(1), 70.82(0), 67.42(1), 67.22(1), 59.51(1), 50.17(0), 44.66(2), 43.79(2), 42.22(2), 38.18(2), 37.25(2), 35.64(2), 29.19(2), 28.56(2), 23.55(2), 22.31(2), 21.37(0), 18.04(3), 12.81(2), 10.38(2); MS HRES Calculated for C₂₇H₃₆O₃D₆ M+ 420.3511

Observed M+ 420.3524

EXAMPLE 49 1 α,25-Dihydroxy- 16-ene-20-cyclopropyl-26,27-hexadeutero-cholecalciferol

To a stirred solution of a (15',5i?)-l,5-bis-((tert-butyldimethyl)silanyloxy)-3-[2- (diphenylphosphinoyl)-eth-(Z)-ylidene]-2-methylene-cyclohexane (536 mg, 0.92 mmol) in tetrahydrofurane (7 mL) at -78⁰C was added n-BuLi (0.58 mL, 0.93 mmol). The resulting mixture was stirred for 15 min and solution of (3aR,7aR)-7a-Methyl-l-[l-(5,5,5-trideutero-4- trideuteromethyl-4-trimethylsilanyloxy-pentyl)-cyclopropyl]-3a,4, 5,6,7, 7a-hexahydro-3H-inden- 4-one (170 mg, 0.46 mmol, in tetrahydrofurane (2mL) was added dropwise. The reaction mixture was stirred at -72⁰C for 3.5 h diluted with hexane (35 mL) washed brine (30 mL) and dried over Na₂SO₄. The residue (725mg) after evaporation of the solvent was purified by FC (15g, 5% AcOEt in hexane) to give lα,3β-Di(tert-Butyl-dimethyl-silanyloxy)-25- trimethylsilanyloxy-16-ene-20-cyclopropyl-26,27-hexadeutero-cholecalciferol (302 mg, 041 mmol). To the lα,3β-Di(tert-Butyl-dimethyl-silanyloxy)-25-trimethylsilanyloxy-16-ene-20- cyclopropyl-26,27-hexadeutero-cholecalciferol (302 mg, 0.41 mmol) tetrabutylammonium fluoride (4 mL, 4 mmol, IM solution in THF) was added, at room temperature. The mixture was stirred for 15h. diluted with AcOEt (25 mL) and washed with water (5x20 mL), brine (20 rnL) and dried over Na₂SO₄. The residue (280 mg) after evaporation of the solvent was purified by FC (15g, 50% AcOEt in hexane and AcOEt) to give the titled compound (160 mg, 0.37 mmol, 80 %)

[CC]²V +15.3 c 0.34, EtOH

UV λmax (EtOH): 207nm (εl7011), 264 nm (ε 15067);

¹H NMR (CDCl₃): 6.37 (IH, d, J=I 1.3 Hz), 6.09 (IH, d, J=I 1.3 Hz), 5.33 (2H, m), 5.01 (IH, s), 4.44 (IH, m), 4.23 (IH, m), 2.80 (IH, dd, J=I 1.9, 3.2 Hz), 2.60 (IH, dd, J=13.2, 3.2 Hz), 2.38- 1.08 (2OH, m), 0.79 (3H, s ),0.66-0.24 (4H, m);

¹³C NMR (CDCl₃): 156.97(0), 147.53(0), 142.41(0), 132.94(0), 124.83(1), 124.68(1), 117.14(1), 111.60(2), 70.82(0), 70.71(1), 66.88(1), 59.55(1), 50.30(0), 45.23(2), 43.79(2), 42.90(2), 38.18(2), 35.64(2), 29.19(2), 28.71(2), 23.63(2), 22.30(2), 21.36(0), 17.91(3), 12.82(2), 10.39(2); MS HRES Calculated for C₂₈H₃₆O₃D₆ M+ 432.3510

Observed M+ 432.3517

EXAMPLE 50 1 α-fluoro-25-hydroxy- 16-ene-20-cyclopropyl-26,27-hexadeutero-cholecalciferol

To a stirred solution of a (15',5i?)-l-((tert-butyldimethyl)silanyloxy)-3-[2-(diphenylphosphinoyl)- eth-(Z)-ylidene]-5-fluoro-2-methylene-cyclohexane (433 mg, 0.92 mmol) in tetrahydrofurane (7 mL) at -78⁰C was added n-BuLi (0.58 mL, 0.93 mmol). The resulting mixture was stirred for 15 min and solution of (3aR,7aR)-7a-Methyl-l-[l-(5,5,5-trideutero-4-trideuteromethyl-4- trimethylsilanyloxy-pentyl)-cyclopropyl]-3a,4, 5,6,7, 7a-hexahydro-3H-inden-4-one (170 mg, 0.46 mmol, in tetrahydrofurane (2mL) was added dropwise. The reaction mixture was stirred at -72⁰C for 3.5h diluted with hexane (25 mL) washed brine (20 mL) and dried over Na₂SO₄. The residue (580mg) after evaporation of the solvent was purified by FC (15g, 10% AcOEt in hexane) to give lα-tert-Butyl-dimethyl-silanyloxy-3β-fluoro-25-trimethylsilanyloxy-16-ene-20- cyclopropyl-26,27-hexadeutero-cholecalciferol (260 mg, 042 mmol). To the give lα-tert-Butyl-dimethyl-silanyloxy-3β-fluoro-25-trimethylsilanyloxy-16-ene-20- cyclopropyl-26,27-hexadeutero-cholecalciferol (260 mg, 0.42 mmol) tetrabutylammonium fluoride (4 mL, 4 mmol, IM solution in THF) was added, at room temperature. The mixture was stirred for 15h. diluted with AcOEt (25 mL) and washed with water (5x20 mL), brine (20 mL) and dried over Na₂SO₄. The residue (260 mg) after evaporation of the solvent was purified by FC (1Og, 30%,50% AcOEt in hexane) to give the titled compound (140 mg, 0.32 mmol, 70 %) [CC]⁵D= +30.0 c 0.30, EtOH UV λmax (EtOH): 243nm (ε 12254), 265 nm (ε 12144);

¹H NMR (CDCl₃): 6.40 (IH, d, J=I 1.3 Hz), 6.10 (IH, d, J=I Ll Hz), 5.39 (IH, s), 5.34 (IH, m), 5.13 (IH, dm, J=50Hz), 5.11 (IH, s), 4.23 (IH, m), 2.80 (IH, m), 2.63 (IH, m), 2.38-1.08 (19H, m), 0.80 (3H, s ),0.66-0.24 (4H, m);

¹³C NMR (CDCl₃): 156.92(0), 143.06(0, d, J=I 7Hz), 142.78(0), 131.49(0), 125.48(1), 124.71(1), 117.16(1), 114.67(2, d, J=IOHz), 91.47 (1, d, J=172Hz), 70.83(0), 66.58(1, d, J=6Hz), 59.55(1), 50.35(0), 45.00(2), 43.80(2), 40.79(2, d, J=20Hz), 38.20(2), 35.68(2), 29.15(2), 28.74(2), 23.64(2), 22.32(2), 20.79(0), 17.96(3), 12.81(2), 10.41(2); MS HRES Calculated for C₂₈H₃₅FO₂D₆ M+Na 457.3359

Observed M+Na 457.3360

BIOLOGICAL EXAMPLES

BIOLOGICAL EXAMPLE 1

Inhibition of IL-8 production in human BPH cells by vitamin D compounds.

Methods

Approximately 2000 human BPH cells were placed in wells of a standard 96 well plate and stimulated for 72 hours with IL- 17 at 10 ng/ml and interferon gamma at 10 ng/ml and incubated with vitamin D compounds individually at concentrations of 1, 10 and 100 nM for 72 hours IL-8 production by the cells was measured_by conventional two-site ELISA using human IL-8 ELISA set (BD Biosciences, San Diego, CA) according to the manufacturer's instructions.

The following compounds were tested:

Calcitriol, Compound A, Compound B, Compound C, Compound D, Compound E, Compound F and Compound G. Results

Figure 1 shows a plot of IL-8 concentration with vitamin D compound concentration. The inhibitory effect of the vitamin D compounds on IL-8 is notable, and the effect can be seen to be dose related.

BIOLOGICAL EXAMPLE 2

Correlation of elevated seminal plasma IL-8 levels with sperm motility in CP and BPH patients

Methods

A patient population having chronic prostatitis category IIIA (n=9), chronic prostatitis category IIIA (n=31) and benign prostatic hyperplasia (n=23) was investigated. All patients had an abnormal International Prostate Symptom Score (IPSS >8) or a Chronic Prostatitis Symptom Index (CPSI) score >15 (Penna et al, Eur Urol, in press, 2006).

IL-8 concentration in seminal plasma was measured as per Biological Example 1. Sperm motility was measured using methods disclosed in World Health Organization Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interaction, 1992, pp. 4-45 and 1999, pp 4-33.

Results

In this patient population, we found that individuals having a reduced forward sperm motility,

(a+b <50%, WHO criteria) also have a higher seminal plasma concentration of IL-8 (Fig. IA, p<0.001) (see Fig 2A). Receiver Operating Characteristic (ROC) analysis for IL-8, according to the presence or absence of reduced forward sperm motility was performed. At 3.75 ng/mL, IL-8 discriminates between normal and pathological motility with 75% sensitivity and 74.5% specificity. The area under the ROC curve, assumed as a measure of accuracy, was 0.74±0.6, (p=0.001). Hence, IL-8 >3.75 ng/ml helps distinguishing subjects, within those with prostate diseases, showing altered sperm motility (see Fig 2B).

BIOLOGICAL EXAMPLE 3

Correlation of elevated seminal plasma IL-8 levels in males from infertile couples

Methods

Semen analysis was performed on men from infertile couples presenting to the University Clinic for Couple Infertility (University of Florence) who were asymptomatic for any prostatic diseases (n=92). IL-8 levels in seminal plasmas were quantified as per Biological Example 1. Sperm motility was measured using methods disclosed in World Health Organization Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interaction, 1992, pp. 4-45 and 1999, pp 4-33.

Results

Individuals having IL-8 > 3.75 ng/mL, also demonstrated a significantly reduced sperm forward motility (p<0.005, Fig. 3A). IL-8, at this biological threshold, predicts abnormal forward motility with 70% sensitivity and 58.3%specificity. The accuracy (equivalent to area under the curve) was 0.691±0.6, p=0.003 (Fig. 3B).

BIOLOGICAL EXAMPLE 4

Correlation of elevated seminal plasma IL-8 levels with abnormal semen parameters in males from infertile couples

Methods

Semen analysis was performed on men from infertile couples at the University Clinic for Couple Infertility (University of Florence). Seminal plasma IL-8 levels were quantified as per Biological Example 1 Sperm density, ejaculate volume, sperm morphology, and leukocyte concentration in ejaculate were measured using methods disclosed in World Health Organization Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interaction, 1992, pp. 4-45 and 1999, pp 4-33.

Results

Those males with elevated IL-8 (>3.75 ng/ml) also have reduced sperm density (p<0.01) (Fig 4A), reduced ejaculate volume (p<0.05) (Fig 4B), altered sperm morphology (p<0.005) (Fig 4C) and increased number of leucocytes in the ejaculate (p<0.01) (Fig 4D).

BIOLOGICAL EXAMPLE 5

Study of seminal plasma IL-8 levels in CP patients treated with vitamin D compound

Method We conducted a randomized, double-blind placebo controlled study in 121 patients with

CP/CPPS. The primary objective of the study was to evaluate the effect of Compound A(150 meg/die) after three months of treatment on the NIH score, a score encompassing pain, quality of life and lower urinary tract symptoms. As a secondary endpoint, we measured IL8 in the semen at baseline and at the end of the treatment. Compound A was capable to significantly reduce the IL-8 levels in the semen vs. placebo after 12 weeks.

Results Results are shown in the Table below:

Treatment Baseline Weekl2 Abs Change vs Baseline % Change vs Baseline

Weekl2 Weekl2

Placebo N 51 43 39 39

Mean 1358.10 1210.21 -160.00 -4.03

SD 570.00 550.52 523.46 43.63

Median 1311.00 979.00 -100.00 -10.45

Min 440.00 312.00 -1266.00 -62.89

Max 2922.00 2617.00 852.00 172.82

25th perc. 949.00 788.00 -462.00 -33.17

75th perc. 1725.00 1505.00 116.00 9.02

Comp. A N 56 44 44 44

Mean 1486.43 1172.57 -368.34 -19.33

SD 618.12 536.72 482.36 30.76

Median 1376.50 985.50 -358.00 -19.17

Min 468.00 386.00 -1264.00 -61.82

Max 3015.00 2599.00 604.00 89.48

25th perc. 947.50 809.50 -723.00 -42.37

75th perc. 1903.50 1394.00 12.50 1.05

The treated group experienced a greater lowering in seminal plasma IL-8 concentration than the placebo group (mean of -19.33% (treated) compared to mean of -4.03% (placebo): P=O.055).

BIOLOGICAL EXAMPLE 6

Study to investigate change in level of inflammatory markers (and in the case of TIMP-I an inhibitor of an inflammatory marker) in seminal fluid of subjects treated with placebo or Compound A.

A sandwich ELISA system was used to re-evaluate seminal plasma IL-8 level in 27 Placebo- treated and 29 Compound A- treated patients from the trial described in Biological Example 5 and to extend the analysis to other inflammatory mediators. Note that TIMP-I is an inhibitor of an inflammatory marker. Significantly reduced (p=0.002) seminal plasma IL-8 levels were observed following treatment with Compound A compared to placebo. In addition other inflammatory markers such as the chemokines CCL2/MCP-1, matrix metalloproteinase MMP2 and the soluble pattern recognition receptor PTX3 were decreased conversely the tissue inhibitor of metalloproteinase TIM-I was enhanced further demonstrating the anti- inflammatory properties of treatment with Compound A in prostatic secretion of CP/CPPS patients

In summary, Compound A is shown to have an effect in reducing levels of a range of inflammatory markers (and in the case of TIMP-I increasing the level of an inhibitor of an inflammatory marker) in prostatic secretions.

BIOLOGICAL EXAMPLE 7

In a population of234 infertile men, 78 are treated with placebo, 78 with Compound A (150 ug per day, orally) and 78 with Compound A (75 ug per day, orally) for four months. The primary objective of the study is to evaluate the effect of Compound A on the semen quality in terms of motility, the secondary objectives consist in evaluating the effect of Compound A on sperm parameters such as morphology, forward motility, conception rate, IL-8 Level, total levels of leukocytes on the semen.

References:

Baggiolini, M, Loetscher, P, Moser, B. Interleukin-8 and the chemokine family. Int J Immunopharmacol 1995;17:103-108.

Boisvert, WA, Curtiss, LK, Terkeltaub, RA. Interleukin-8 and its receptor CXCR2 in atherosclerosis. Immunol Res 2000;21 : 129-137.

Bubanovic L, Najman S., Kojic S. Immunomodulatory treatment for infertile men with antisperm antibodies. Fertility and Sterility 2004; 81(3):S7-31

Bruckert E. How frequent is unintentional childlessness in Germany? Andrologia. 1991 May-Jun;23(3):245-50.

Comhaire FH, Mahmoud AM, Depuydt CE, Zalata AA, Christophe AB. Mechanisms and effects of male genital tract infection on sperm quality and fertilizing potential: the andrologist's viewpoint. Hum Reprod Update. 1999a Sep-Oct;5(5):393- 8.

Comhaire F, Zalata A, Christophe A, Mahmoud A, Depuydt C, Dhooge W. Which efforts towards conservative treatment of male infertility will be successful? Reactive oxygen species, antioxidants, and sperm phospholipids. Andrologia. 1999b Sep;31(5):295-6.

Comhaire F, Bosnians E, Ombelet W, Punjabi U, Schoonjans F. Cytokines in semen of noormal men and of patients with andro logical diseases. 1994 Am J Reprod Immunol 31 :99-103

Dousset B, Hussenet F, Daudin M BujanL, Foliguet B, Nabet P. Seminal cytokine ncentrations, semen parameters and blood hormonal status in male infertility. Hum Reprod 1997. 12:1476- 1479

De Benedetti, F, Pignatti, P, Bernasconi, S, Gerloni, V, Matsushima, K, Caporali, R et al. Inter leukin 8 and monocyte chemoattractant protein- 1 in patients with juvenile rheumatoid arthritis. Relation to onset types, disease activity, and synovial fluid leukocytes. J Rheumatol 1999;26:425-431.

De Geyter C, De Geyter M, Behre HM, Schneider HP, Nieschlag E.

Peroxidase-positive round cells and microorganisms in human semen together with antibiotic treatment adversely influence the outcome of in- vitro fertilization and embryo transfer. Int J Androl. 1994 Jun;17(3):127-34.

Depuydt CE, Bosmans E, Zalata A, Schoonjans F, Comhaire FH.

The relation between reactive oxygen species and cytokines in andrological patients with or without male accessory gland infection. J Androl. 1996 Nov-Dec; 17(6): 699-707.

Eggert-Kruse W, Boit R, Rohr G, Aufenanger J, Hund M, Strowitzki T. Relationship of seminal plasma interleukin (IL) -8 and IL-6 with semen quality. Hum Reprod. 2001 Mar;16(3):517-28.

Estrada LS, Champion HC, Wang R, Rajasekaran M, Hellstrom WJ, Aggarwal B, Sikka SC. Effect of tumour necrosis factor-alpha (TNF-alpha) and interferon-gamma(IFN- gamma) on human sperm motility, viability and motion parameters. Int J Androl. 1997 Aug;20(4):237-42.

Forti G, Krausz C. Clinical review 100: Evaluation and treatment of the infertile couple. J Clin Endocrinol Metab. 1998 Dec;83(12):4177-88.

Friebe K, Bohring C, Skrzypek J, Krause W. Levels of Interleukin-6 and interleukin-8 in seminal fluid of men attending an andrological clinic. Andrologia, 2003, 35, 126-129

Furuya Y, Akashi T, Fuse H. Soluble Fas and IL-6 and IL-8 levels in seminal plasma of infertile men. 2003. Arch Androl 49(6):449-52 Juul S, Karmaus W, Olsen J. Regional differences in waiting time to pregnancy: pregnancy- based surveys from Denmark, France, Germany, Italy and Sweden. The European Infertility and Subfecundity Study Group. Hum Reprod. 1999 May; 14(5): 1250-4.

Koumantakis E, Metalliotakis I, Kyriakou D, FragouliiY, relakis K. Increased levels of inteleukin-8 in human seminal plasma. 1998. Andrologia. 30(6):339-43

Krausz C, Mills C, Rogers S, Tan SL, Aitken RJ. Stimulation of oxidant generation by human sperm suspensions using phorbol esters and formyl peptides: relationships with motility and fertilization in vitro.Fertil Steril. 1994 Sep;62(3):599-605.

Mahmoud AM, Comhaire FH, Christophe AB. Oral antioxidants and male infertility. Hum Reprod. 1999 Dec;14(12):3149-50.

Maegawa M, Kamada M, Irahara M, Yamamoto S, Yoshikawa S, Kasai Y, Ohmoto Y, Gima H, thaler CJ, Aono T. A repertoire of cytokines in human seminal plasma. 2002. J Reprod Immunol 54 (l-2):33-42

Matalliotakis I, Kiriakou D, Fragouli I, Sifakis F, Eliopoulos GKoumantakis E. Interleukin-6 in seminal plasma of fertile and infertile men. 1998 Arch Androl 41 :43-50

McCormack, G, Moriarty, D, O'Donoghue, DP, McCormick, PA, Sheahan, K, Baird, AW. Tissue cytokine and chemokine expression in inflammatory bowel disease. Inflamm Res 2001;50:491-495.

Motrich RD, Maccioni M, Ponce AA, Gatti GA, Oberti JP, Rivero VE. Pathogenic consequences in semen quality of an autoimmune response against the prostate gland: from animal models to human disease. J Immunol. 2006 JuI 15;177(2):957-67.

Nieschlag E and Behre HM Andrology, Male reproductive health and Dysfunction, 2^nd edition Springer Verlag, 2000

Pease, JE, Sabroe, I. The role of interleukin-8 and its receptors in inflammatory lung disease: implications for therapy. Am J Respir Med 2002; 1 : 19-25.

Penna G, Mondaini N, Amuchastegui S, Degli Innocenti S, Carini M, Giubilei G, Fibbi B, Colli E, Maggi M, Adorini L. Seminal Plasma Cytokines and Chemokines in Prostate Inflammation: Interleukin 8 as a Predictive Biomarker in Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Benign Prostatic Hyperplasia. Eur Urol. 2006 JuI 28;

Sanocka D, Jedrzejczak P, Kakol S, Fraczek M, Kurpisz M. Male genital tract inflammation: the role of selected interleukins in regulation of pro-oxidant and antioxidant enzymatic substances in seminal plasma. Jour of Andrology, 2003, 24(3)448-455

Shimoia K, Matsuzaki N, Tsutsui T, Taniguchi T, Saji F, Tanizawa O. 1993. Detection of IL-8 in seminal plasma and elevated IL-8 in seminal plasma of infertile patients with leukospermia. Fertil Steril 1993 59:885-888

Shimada, T, Terano, A. Chemokine expression in Helicobacter pylori-infected gastric mucosa. J Gastroenterol 1998;33:613-617.

World Health Organization (1992) WHO Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interaction, 3rd edn. Cambridge University Press, Cambridge, UK, pp. 4-45.

World Health Organization (1999) WHO Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interaction, 3rd edn. Cambridge University Press, Cambridge, UK, pp. 4-33.

"Comprising" Throughout the specification and the claims which follow, unless the context requires otherwise, the word 'comprise', and variations such as 'comprises' and 'comprising', will be understood to imply the inclusion of a stated integer, step, group of integers or group of steps but not to the exclusion of any other integer, step, group of integers or group of steps.

Incorporation by Reference

The contents of all references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated herein in their entireties by reference.

Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents of the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

Claims

I . A method of treatment of male sub-fertility using a vitamin D compound.

2. A method for treatment of sub-fertility in a male subject, comprising administering to a subject in need thereof an effective amount of a vitamin D compound, such that male sub-fertility is treated in said subject.

3. The method of claim 2, further comprising identifying a subject in need of treatment for male sub- fertility.

4. The method according to either claim 2 or claim 3, further comprising the step of obtaining the vitamin D compound.

5. The method of any one of claims 2 to 4, wherein the subject is a mammal.

6. The method of claim 5, wherein the subject is a human.

7. The method according to any one of claims 1 to 6, wherein the vitamin D compound is formulated in a pharmaceutical composition together with a pharmaceutically acceptable diluent or carrier.

8. The use of a vitamin D compound in the manufacture of a medicament for the treatment of male sub- fertility.

9. A pharmaceutical formulation comprising a vitamin D compound and a pharmaceutically acceptable carrier for use in the treatment of male sub- fertility.

10. A pharmaceutical formulation comprising a vitamin D compound and a pharmaceutically acceptable carrier packaged with instructions for use in the treatment of male sub- fertility.

I I. A vitamin D compound for use in the treatment of male sub- fertility.

12. A kit containing a vitamin D compound together with instructions directing administration of said compound to a subject in need of treatment for male sub-fertility thereby to treat male sub- fertility in said subject.

13. The use, method, formulation, compound or kit according to any one of claims 1 to 12, wherein the vitamin D compound is administered separately, sequentially or simultaneously in separate or combined pharmaceutical formulations with a second medicament for the treatment of male sub- fertility.

14. The use, method, formulation, compound or kit according to any one of claims 1 to 13 wherein the subject is a human suffering from prostatic disease.

15. The use, method, formulation, compound or kit according to any one of claims 1 to 13 wherein the subject is a human not suffering from prostatic disease.

16. The use, method, formulation, compound or kit according to any one of claims 1 to 13 wherein the subject is not vitamin D deficient.

17. The use, method, formulation, compound or kit according to any one of claims 1 to 13 wherein the treatment with or use of the vitamin D compound leads to an improvement in semen quality.

18. The use, method, formulation, compound or kit according to claim 17 wherein the improvement in semen quality, is evidenced by increased sperm motility.

19. The use, method, formulation, compound or kit of any one of claims 1 to 18, wherein said vitamin D compound is a compound of the formula:

wherein:

Ai is single or double bond;

A₂ is a single, double or triple bond;

Xi and X₂ are each independently H or =CH₂, provided Xi and X₂ are not both =CH₂;

Ri and R₂ are each independently OH, OC(O)Ci-C₄ alkyl, OC(O)hydroxyalkyl, OROC(O)haloalkyl, OAc; R₃, R₄ and R₅ are each independently hydrogen, Ci -C₄ alkyl, hydroxyalkyl, or haloalkyl, or R₃ and R₄ taken together with C20 form C₃-C₆ cycloalkyl; and

R₆ and R₇ are each independently Ci_₄alkyl or haloalkyl; and R₈ is H, -COCi-C₄alkyl, -COhydroxyalkyl or -COhaloalkyl; and pharmaceutically acceptable esters, salts, and prodrugs thereof.

20. The use, method, formulation, compound or kit of claim 19, wherein Ri and R₂ are OH or OC(O)Ci-C₄ alkyl.

21. The use, method, formulation, compound or kit of claim 20, wherein Ri and R₂ are OAc.

22. The use, method, formulation, compound or kit of claim 20, wherein Ri and R₂ are OH.

23. The use, method, formulation, compound or kit of any one of claims 19 to 22, wherein Xi is =CH₂ and X₂ is H.

24. The use, method, formulation, compound or kit of any one of claims 19 to 23, wherein Ai is single bond and A₂ is a single bond.

25. The use, method, formulation, compound or kit of any one of claims 19 to 24, wherein R₃ and R₄ taken together with C₂o form C₃-C₆ cycloalkyl.

26. The use, method, formulation, compound or kit of claim 25, wherein R₃ and R₄ taken together with C₂o form cyclopropyl.

27. The use, method, formulation, compound or kit of any one of claims 19 to 26, wherein R₅ is hydrogen.

28. The use, method, formulation, compound or kit of any one of claims 19 to 27, wherein R₆ and R₇ are each independently Ci_₄alkyl.

29. The use, method, formulation, compound or kit of claim 28, wherein R₆ and R₇ are each independently methyl.

30. The use, method, formulation, compound or kit of any one of claims 19 to 29, wherein R₈ is H.

31. The use, method, formulation, compound or kit of claim 19, wherein Ri and R₂ are OH or OC(O)Ci-C₄ alkyl, Xi is =CH₂ and X₂ is H, Ai is single bond, A₂ is a single bond, R3 and R₄ taken together with C₂o form C3-C6 cycloalkyl, R₅ is hydrogen, R₆ and R₇ are each independently Ci_₄alkyl, and Rs is H.

32. The use, method, formulation, compound or kit of claim 31 , wherein Ri and R₂ are OH or OAc, R3 and R₄ taken together with C₂o form cyclopropyl, and R₆ and R₇ are each methyl.

33. The use, method, formulation, compound or kit of any one of claims 1 to 18, wherein said vitamin D compo

wherein: X is H₂ or CH₂

Ri is hydrogen, hydroxy or fluorine

R₂ is hydrogen or methyl

R₃ is hydrogen or methyl provided that when R₂ or R₃ is methyl, R₃ or R₂ must be hydrogen R₄ is methyl, ethyl or trifluoromethyl

R₅ is methyl, ethyl or trifluoromethyl

A is a single or double bond

B is a single, E-double, Z-double or triple bond.

34. The use, method, formulation, compound, or kit according to claim 33, wherein each OfR₄ and R₅ is independently methyl or ethyl.

35. The use, method, formulation, compound or kit of claim 33, wherein said vitamin D compound is 1 -alpha- fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol, having the formula:

36. The use, method, formulation, compound or kit of any one of claims 1 to 18, wherein said vitamin D compound is a compound of the formula (IV):

wherein:

Xi and X₂ are H₂ or CH₂, wherein Xi and X₂ are not CH₂ at the same time;

A is a single or double bond; A₂ is a single, double or triple bond;

A3 is a single or double bond;

Ri and R₂ are hydrogen, Ci -C₄ alkyl or 4-hydroxy-4-methylpentyl, wherein Ri and R₂ are not both hydrogen;

R₅ is H₂ or oxygen, R₅ may also represent hydrogen or may be absent; R₃ is C₁-C₄ alkyl, hydroxyalkyl or haloalkyl, and

R₄ is C₁-C₄ alkyl, hydroxyalkyl or haloalkyl.

37. The use, method, formulation, compound or kit of any one of claims 1 to 18, wherein said vitamin D compound is a compound of the formula (V):

wherein:

Xi and X₂ are H₂ or CH₂, wherein Xi and X₂ are not CH₂ at the same time; A is a single or double bond; A₂ is a single, double or triple bond;

A₃ is a single or double bond;

Ri and R₂ are hydrogen, Ci -C₄ alkyl, wherein Ri and R₂ are not both hydrogen; R₅ is H₂ or oxygen, R₅ may also represent hydrogen or may be absent; R₃ is C₁-C₄ alkyl, hydroxyalkyl or haloalkyl; and R₄ is C₁-C₄ alkyl, hydroxyalkyl haloalkyl.

38. The use, method, formulation, compound or kit of any one of claims 1 to 18, wherein said vitamin D compound is a compound of the formula (VI):

wherein:

Xi is H₂ or CH₂;

A₂ is a single, a double or a triple bond;

R₃ is C₁-C₄ alkyl, hydroxyalkyl, or haloalkyl; R₄ is C₁-C₄ alkyl, hydroxyalkyl or haloalkyl; and the configuration at C₂o is R or S.

39. The use, method, formulation, compound or kit of claim 38, wherein said vitamin D compound is l,25-dihydroxy-21-(3-hydroxy-3-methylbutyl)-19-nor-cholecalciferol having the formula:

40. The use, method, formulation, compound or kit of any one of claims 1 to 18, wherein said vitamin D compound is a compound of the formula (VII):

wherein:

A is a single or double bond;

Ri and R₂ are each, independently, hydrogen, alkyl;

R₃, and R₄, are each independently alkyl, and

X is hydroxy 1 or fluoro.

41. The use, method, formulation, compound or kit of any one of claims 1 to 18, wherein said vitamin D compound is a compound of the formula (VIII):

wherein:

Ri and R₂, are each, independently, hydrogen, or alkyl;

R₃ is alkyl,

R₄ is alky; and

X is hydroxy 1 or fluoro.

42. The use, method, formulation, compound or kit of any one of claims 1 to 18, wherein said vitamin D compound is a compound of the formula (IX):

wherein:

Ai is a single or double bond; A₂ is a single, a double or a triple bond;

R₁, R₂, R3 and R₄ are each independently Ci -C₄ alkyl, Ci -C₄ deuteroalkyl, hydroxyalkyl, or haloalkyl; Rs, R₆ and R₇ are each independently hydroxyl, OC(O)Ci-C₄ alkyl, OC(O)hydroxyalkyl, or OC(O)haloalkyl; the configuration at C20 is R or S;

Xi is H₂ or CH₂; Z is hydrogen when at least one of Ri and R₂ is Ci -C₄ deuteroalkyl and at least one OfR₃ and R₄ is haloalkyl or when at least one of Ri and R₂ is haloalkyl and at least one of R3 and R₄ is Ci-C₄ deuteroalkyl; or Z is -OH, =0, -SH, or -NH₂; and pharmaceutically acceptable esters, salts, and prodrugs thereof.

43. The use, method, formulation, compound or kit of claim 42, wherein Ai is a single bond.

44. The use, method, formulation, compound or kit of either claim 32 or 43, wherein A₂ is a single bond.

45. The use, method, formulation, compound or kit of either claim 42 or 43, wherein A₂ is a triple bond.

46. The use, method, formulation, compound or kit of any one of claims 42 to 44, wherein R₁, R₂, R3, and R₄ are each independently methyl, ethyl, C1-C4 deuteroalkyl or haloalkyl.

47. The use, method, formulation, compound or kit of any one of claims 42 to 46, wherein R5 is hydroxyl.

48. The use, method, formulation, compound or kit of any one of claims 42 to 47, wherein R₆ and R₇ are each independently hydroxyl or OC(O)Ci-C₄ alkyl.

49. The use, method, formulation, compound or kit of any one of claims 42 to 48, wherein Xi is H₂.

50. The use, method, formulation, compound or kit of any one of claims 42 to 48, wherein Xi is CH₂.

51. The use, method, formulation, compound or kit of any one of claims 42 to 50, wherein Z is hydrogen or =0.

52. The use, method, formulation, compound or kit of claim 42, wherein Z is hydrogen, at least one of Ri and R₂ is Ci -C₄ deuteroalkyl and at least one Of R₃ and R₄ is haloalkyl.

53. The use, method, formulation, compound or kit of claim 42, wherein Z is hydrogen, at least one of Ri and R₂ is haloalkyl and at least one of R₃ and R₄ is Ci-C₄ deuteroalkyl.

54. The use, method, formulation, compound or kit of claim 42, wherein Z is -OH, =0, -SH, or -NH₂; and Xi is CH₂.

55. The use, method, formulation, compound or kit of claim 42, wherein Z is -OH, =0, -SH, or -NH₂; Xi is H₂; and the configuration at C₂o is S.

56. The use, method, formulation, compound or kit of claim 42, wherein Z is =0, -

SH, or -NH₂; Xi is H₂ and the configuration at C₂o is R.

57. The use, method, formulation, compound or kit of claim 42, wherein Xi is CH₂; A₂ is a single bond; R₁, R₂, R₃, and R₄ are each independently methyl or ethyl; and Z is -OH.

58. The use, method, formulation, compound or kit of claim 42, wherein Xi is CH₂; A₂ is a single bond; R₁, R₂, R₃, and R₄ are each independently methyl or ethyl; and Z is =0.

59. The use, method, formulation, compound or kit of claim 42, wherein Xi is H₂; A₂ is a single bond; R₁, R₂, R₃, and R₄ are each independently methyl or ethyl; the configuration at

C₂₀ is S; and Z is -OH.

60. The use, method, formulation, compound or kit of claim 42, wherein Xi is H₂; A₂ is a single bond; R₁, R₂, R₃, and R₄ are each independently methyl or ethyl; and Z is =0.

61. The use, method, formulation, compound or kit of claim 42, wherein Xi is H₂; A₂ is a triple bond; Ri and R₂ are each Ci-C₄ deuteroalkyl; R₃ and R₄ are each haloalkyl; and Z is hydrogen.

63. The use, method, formulation, compound or kit of claim 42, wherein Xi is CH₂;

A₂ is a triple bond; Ri and R₂ are each Ci-C₄ deuteroalkyl; R₃ and R₄ are each haloalkyl; and Z is hydrogen.

64. The use, method, formulation, compound or kit of claim 42, wherein Ri and R₂ are each deuteromethyl and R₃ and R₄ are each trifluoromethyl.

65. The use, method, formulation, compound or kit of any one of claims 1 to 18, wherein said vitamin D compo

wherein: Xi is H₂ or CH₂;

A₂ is a single, a double or a triple bond; R₁, R₂, R₃ and R₄ are each independently Ci -C₄ alkyl, hydroxyalkyl, or haloalkyl;

Z is -OH, =0, -NH₂ or -SH; and the configuration at C₂o is R or S, and pharmaceutically acceptable esters, salts, and prodrugs thereof.

66. The use, method, formulation, compound or kit of claim 65, wherein Xi is CH₂.

67. The use, method, formulation, compound or kit of either claim 65 or 66, wherein A₂ is a single bond.

68. The use, method, formulation, compound or kit of any one of claims 65 to 67, wherein R₁, R₂, R₃, and R₄ are each independently methyl or ethyl.

69. The use, method, formulation, compound or kit of any one of claims 65 to 68, wherein Z is -OH.

70. The use, method, formulation, compound or kit of claim 65, wherein Xi is CH₂; A₂ is a single bond; R₁, R₂, R₃, and R₄ are each independently methyl or ethyl; and Z is -OH.

71. The use, method, formulation, compound or kit of any one of claims 1 to 18, wherein said vitamin D compound is a compound of the formula (XI):

wherein:

Xi and Xi are each independently H₂ or =CH₂, provided Xi and Xi are not both =CH₂;

Ri and R₂ are each independently, hydroxyl, OC(O)Ci-C₄ alkyl, OC(O)hydroxyalkyl, OC(O)fluoroalkyl;

R₃ and R₄ are each independently hydrogen, Ci -C₄ alkyl, hydroxyalkyl or haloalkyl, or R3 and R₄ taken together with C₂o form C3-C6 cylcoalkyl; and

R₅ and Re are each independently C₁-C₄ alkyl or haloalkyl; and pharmaceutically acceptable esters, salts, and prodrugs thereof.

72. The use, method, formulation, compound or kit of claim 71, wherein R₃ and R₄ are each independently hydrogen, Ci-C₄ alkyl, or taken together with C₂o form C₃-C₆ cycloalkyl.

73. The use, method, formulation, compound or kit of claim 72, wherein R₃ is hydrogen and R₄ is Ci-C₄ alkyl.

74. The use, method, formulation, compound or kit of any one of claims 71 to 73, wherein R₅ and Re are each independently Ci-C₄ alkyl.

75. The use, method, formulation, compound or kit of any one of claims 71 to 73, wherein R₅ and Re are each independently haloalkyl.

76. The use, method, formulation, compound or kit of any one of claims 71 to 73, wherein R₅ and Re are each independently methyl, ethyl, fluoromethyl or trifluoromethyl.

77. The use, method, formulation, compound or kit of any one of claims 71 to 76, wherein Xi and X₂ are each H₂.

78. The use, method, formulation, compound or kit of any one of claims 71 to 77, wherein Ri and R₂ are each independently hydroxyl or OC(O)Ci-C₄ alkyl.

79. The use, method, formulation, compound or kit of any one of claims 1 to 18, wherein said vitamin D compound is 2-methylene-19-nor-20(S)-l-alpha,25-hydroxyvitamin D₃:

80. The use, method, formulation, compound or kit of any one of claims 1 to 18, wherein said vitamin D compound is a compound of the formula (XII):

wherein:

Ai is single or double bond;

A₂ is a single, double or triple bond;

Xi and X₂ are each independently H or =CH₂, provided Xi and X₂ are not both =CH₂;

Ri and R₂ are each independently H, OC(O)Ci-C₄ alkyl, OC(O)hydroxyalkyl, OC(O)haloalkyl;

R₃, R₄ and R₅ are each independently hydrogen, Ci -C₄ alkyl, hydroxyalkyl, or haloalkyl, or R₃ and R₄ taken together with C₂o form C₃-C₆ cycloalkyl; and

R₆ and R₇ are each independently Ci_₄alkyl or haloalkyl; and

R₈ is H, -COCi-C₄alkyl, -COhydroxyalkyl or -COhaloalkyl; and pharmaceutically acceptable esters, salts, and prodrugs thereof.

81. The use, method, formulation, compound or kit of claim 80, wherein R3 and R₄ are taken together with C20 to form C3-C6 cycloalkyl.

82. The use, method, formulation, compound or kit of claim 80, wherein R₃ is hydrogen and R₄ is C₁-C₄ alkyl.

83. The use, method, formulation, compound or kit of any one of claims 80 to 82, wherein R₆ and R₇ are each independently Ci_₄alkyl or haloalkyl.

84. The use, method, formulation, compound or kit of claim 83, wherein R₆ and R₇ are each independently haloalkyl.

85. The use, method, formulation, compound or kit of any one of claims 80 to 84, wherein R₈ is H or -COCi-C₄alkyl.

86. The use, method, formulation, compound or kit of any one of claims 80 to 85, wherein Ai is a single bond and A₂ is a single bond, E or Z double bond, or a triple bond.

87. The use, method, formulation, compound or kit of any one of claims 80 to 85, wherein Ai is a double bond and A₂ is a single bond, E or Z double bond, or a triple bond.

88. The use, method, formulation, compound or kit of any one of claims 80 to 87, wherein Xi and X₂ are each H.

89. The use, method, formulation, compound or kit of any one of claims 80 to 87, wherein Xi is CH₂ and X₂ is H₂.

90. The use, method, formulation, compound or kit of any one of claims 80 to 89, wherein Ri and R₂ both represent OAc.

91 8i . The use, method, formulation, compound or kit of any one of claims 80 to 90, wherein R₅ is hydrogen.

92. The use, method, formulation, compound or kit of claim 80, wherein said vitamin D compound is a compound of the formula (XIV):

93. The use, method, formulation, compound or kit of claim 80, wherein said vitamin D compound is a compound of the formula (XV):

94. The use, method, formulation, compound or kit of claim 93, wherein Xi is =CH2 and X₂ is H₂.

95. The use, method, formulation, compound or kit of claim 94, wherein Ai is a single bond, A₂ is a triple bond, Rs is H or C(O)CH₃, and R₆ and R₇ are alkyl.

96. The use, method, formulation, compound or kit of claim 94, wherein Ai is a single bond, A₂ is a single bond, Rs is H or C(O)CH₃, and R₆ and R₇ are alkyl.

97. The use, method, formulation, compound or kit of claim 94, wherein Ai is a double bond, A₂ is a single bond, Rs is H or C(O)CH₃, and R₆ and R₇ are alkyl.

98. The use, method, formulation, compound or kit of claim 93, wherein Xi and X₂ are each H₂.

99. The use, method, formulation, compound or kit of claim 98, wherein Ai is a single bond, A₂ is a triple bond, Rs is H or C(O)CH₃, and R₆ and R₇ are alkyl or haloalkyl.

100. The use, method, formulation, compound or kit of claim 98, wherein Ai is a single bond, A₂ is a double bond, Rs is H or C(O)CH₃, R₆ and R₇ are haloalkyl.

101. The use, method, formulation, compound or kit of claim 98, wherein Ai is a double bond, A₂ is a single bond, Rs is H or C(O)CH₃, R₆ and R₇ are alkyl.

102. The use, method, formulation, compound or kit of any one of claims 1 to 18, wherein said vitamin D compound is a compound of the formula (XVII):

wherein:

B is single, double, or triple bond;

Xi and X₂ are each independently H₂ or CH₂, provided Xi and X₂ are not both CH₂; and

R₄ and R₅ are each independently alkyl or haloalkyl.

103. The use, method, formulation, compound or kit of any one of claims 1 to 18, wherein said vitamin D

wherein Ai is a double bond, or single bond; A₂ is a triple bond, double bond, or single bond; Xi is =CH₂ or H₂ ; X₂ is H₂;

R^ and R₇ are each independently alkyl or haloalkyl; and

R₈ is H or C(O)CH₃.

104. The use, method, formulation, compound or kit of any one of claims 1 to 18, wherein said vitamin D compound is a compound of the formula (XIX):

wherein:

Ai is single or double bond;

A₂ is a single, double or triple bond,

Xi and X₂ are each independently H₂ or CH₂, provided Xi and X₂ are not both CH₂;

Ri and R₂ are each independently OC(O)Ci-C₄ alkyl, OC(O)hydroxy alkyl, or OC(O)haloalkyl;

R₃, R₄ and R₅ are each independently hydrogen, Ci -C₄ alkyl, hydroxyalkyl, or haloalkyl, or R₃ and R₄ taken together with C₂o form C₃-C₆ cylcoalkyl;

R₆ and R₇ are each independently haloalkyl; and

R₈ is H, OC(O)Ci-C₄ alkyl, OC(O)hydroxyalkyl, or OC(O)haloalkyl; and pharmaceutically acceptable esters, salts, and prodrugs thereof.

105. The use, method, formulation, compound or kit of any one of claims 1 to 18, wherein said vitamin D compound is a compound of the formula (XX):

wherein:

Ai is a single or double bond;

A₂ is a single, a double or a triple bond;

R₁, R₂, R₃ and R₄ are each independently alkyl, deuteroalkyl, hydroxyalkyl, or haloalkyl;

R₅ is halogen, hydroxyl, OC(O)alkyl, OC(O)hydroxyalkyl, or OC(O)haloalkyl;

R₆ is halogen, hydroxyl, OC(O)alkyl, OC(O)hydroxyalkyl, or OC(O)haloalkyl;

Xi is H₂ or CH₂;

Y is alkyl; and pharmaceutically acceptable esters, salts, and prodrugs thereof.

106. The use, method, formulation, compound or kit of claim 105, wherein said vitamin D compound is a compound of the formula (XX-a):

wherein:

A₂ is a single, a double or a triple bond;

Ri, R₂, R₃ and R₄ are each independently alkyl, hydroxyalkyl, or haloalkyl; R₅ is halogen, hydroxyl, OC(O)alkyl, OC(O)hydroxyalkyl, or OC(O)haloalkyl; R₆ is hydroxyl, OC(O)alkyl, OC(O)hydroxyalkyl, or OC(O)haloalkyl; Xi is H₂ or CH₂; and pharmaceutically acceptable esters, salts, and prodrugs thereof.

107. The use, method, formulation, compound or kit of claim 105, wherein said vitamin D compound is a compound of the formula (XX-b):

wherein:

R5 is fluoro or hydroxyl; Xi is H₂ or CH₂; and pharmaceutically acceptable esters, salts, and prodrugs thereof.

108. The use, method, formulation, compound or kit of claim 105, wherein said vitamin D compound is a compound of the formula (XX-c):

wherein:

A₂ is a single, a double or a triple bond;

R5 is fluoro or hydroxyl;

Xi is H₂ or CH₂; and pharmaceutically acceptable esters, salts, and prodrugs thereof.

109. The use, method, formulation, compound or kit of claim 105, wherein said vitamin D compound is a compound of the formula (XX-d):

wherein:

A₂ is a single, a double or a triple bond; Rs is fluoro or hydroxyl;

Xi is H₂ or CH₂; and pharmaceutically acceptable esters, salts, and prodrugs thereof.

110. The use, method, formulation, compound or kit of claim 105, wherein said vitamin D compound is a compound of the formula (XX-e):

wherein: A₂ is a single, a double or a triple bond;

R5 is fluoro or hydroxyl; Xi is H₂ or CH₂; and pharmaceutically acceptable esters, salts, and prodrugs thereof.

111. The use, method, formulation, compound or kit of claim 105, wherein said vitamin D compound is a compound of the formula (XX- f):

wherein:

A₂ is a single, a double or a triple bond; R5 is fluoro or hydroxyl;

Xi is H₂ or CH₂; and pharmaceutically acceptable esters, salts, and prodrugs thereof.

112. The use, method, formulation, compound or kit of any one of claims 1 to 18, wherein said vitamin D compound is a compound of the formula (XXII):

wherein: A is single or double bond; B is a single, double, or triple bond; X is H₂ or CH₂;

Y is hydroxyl, OC(O)Ci-C₄ alkyl, OC(O)hydroxyalkyl, OC(O)haloalkyl; or halogen; Z is hydroxyl, OC(O)Ci-C₄ alkyl, OC(O)hydroxyalkyl, or OC(O)haloalkyl; and pharmaceutically acceptable esters, salts, and prodrugs thereof.

113. The use, method, formulation, compound or kit of any one of claims 1 to 18, wherein said vitamin D compound is l,3-Di-O-acetyl-l,25-dihydroxy-20-cyclopropyl- cholecalciferol having the formula:

114. The use, method, formulation, compound or kit of any one of claims 1 to 18, wherein said vitamin D compound is l,25-dihydroxy-20,21,28-cyclopropyl-cholecalciferol having the formula:

115 The use, method, formulation, compound or kit of any one of claims 1 to 18 wherein said compound is calcitriol.

116. A method for improving fertility in a sub-fertile male subject, comprising (i) determining whether the subject has elevated seminal plasma IL-8 levels relative to male subjects of normal fertility and (ii) if so, administering to said sub-fertile subject an effective amount of a vitamin D compound, such that fertility is improved in said subject.

117. A kit comprising (i) means to determine the level of IL-8 in the seminal plasma of a sub-fertile male subject (ii) a vitamin D compound and (iii) instructions directing administration of said compound to said subject, provided said subject has elevated seminal plasma IL-8 levels relative to subjects of normal fertility, thereby to improve fertility in said sub-fertile subject.